bio-datasets/bigbio-ner-merged · Datasets at Hugging Face

answer stringlengths 1 16.1k	id stringlengths 7 56	instruction stringlengths 106 72.6k	ner_tags list	text stringlengths 5 72.4k	tokens list	types list
older is an umlsterm, people is an umlsterm, continuing education is an umlsterm, communication is an umlsterm, co - operation is an umlsterm, Internet is an umlsterm, Institutes is an umlsterm, continuing education is an umlsterm, older is an umlsterm, people is an umlsterm, training is an umlsterm, media is an umlsterm, media is an umlsterm, competence is an umlsterm, educational is an umlsterm, people is an umlsterm, communication is an umlsterm, technologies is an umlsterm, Learning is an umlsterm, Life is an umlsterm, Learning is an umlsterm, Research is an umlsterm, culture is an umlsterm, universities is an umlsterm, health is an umlsterm, educational is an umlsterm	ZfuerGerontologie+Geriatrie.00330186.eng.abstr_task1	Sentence: More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area . Instructions: please typing these entity words according to sentence: older, people, continuing education, communication, co - operation, Internet, Institutes, continuing education, older, people, training, media, media, competence, educational, people, communication, technologies, Learning, Life, Learning, Research, culture, universities, health, educational Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area .	[ "More", "and", "more", "older", "people", "interested", "in", "continuing", "education", "recognise", "the", "many", "possibilties", "for", "information", ",", "communication", "and", "co", "-", "operation", "which", "Internet", "offers", "to", "them", ".", "Institutes", "of", "continuing", "education", "and", "other", "institutions", "serving", "older", "people", "are", "required", "to", "provide", "training", "for", "this", "target", "group", "in", "order", "to", "make", "access", "to", "the", "world", "of", "the", "digital", "media", "easier", ",", "to", "support", "them", "in", "acquiring", "media", "competence", "and", "to", "design", "interesting", "virtual", "educational", "programmes", "and", "courses", ".", "In", "this", "article", ",", "the", "possibilities", "of", "showing", "people", "over", "50", "the", "way", "to", "the", "new", "communication", "technologies", "will", "be", "described", "in", "view", "of", "the", "experiences", "gained", "during", "the", "information", "campaign", "\"", "Senior", "-", "Info", "-", "Mobil", "\"", ".", "It", "will", "also", "be", "demonstrated", "based", "on", "the", "examples", "of", "the", "European", "network", "\"", "Learning", "in", "Later", "Life", "\"", "and", "other", "projects", "such", "as", "\"", "Learning", "through", "Research", "\"", "that", "virtual", "working", "groups", "and", "networks", "of", "elders", "can", "become", "a", "driving", "force", "of", "a", "new", "\"", "learning", "culture", "\"", ",", "involving", "also", "those", "who", "do", "not", "live", "near", "universities", "or", "who", "for", "health", "and", "other", "personal", "reasons", "cannot", "participate", "in", "educational", "programmes", "offered", "in", "the", "area", "." ]	[ "umlsterm" ]
older, people, continuing education, communication, co - operation, Internet, Institutes, continuing education, older, people, training, media, media, competence, educational, people, communication, technologies, Learning, Life, Learning, Research, culture, universities, health, educational	ZfuerGerontologie+Geriatrie.00330186.eng.abstr_task2	Sentence: More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area .	[ "More", "and", "more", "older", "people", "interested", "in", "continuing", "education", "recognise", "the", "many", "possibilties", "for", "information", ",", "communication", "and", "co", "-", "operation", "which", "Internet", "offers", "to", "them", ".", "Institutes", "of", "continuing", "education", "and", "other", "institutions", "serving", "older", "people", "are", "required", "to", "provide", "training", "for", "this", "target", "group", "in", "order", "to", "make", "access", "to", "the", "world", "of", "the", "digital", "media", "easier", ",", "to", "support", "them", "in", "acquiring", "media", "competence", "and", "to", "design", "interesting", "virtual", "educational", "programmes", "and", "courses", ".", "In", "this", "article", ",", "the", "possibilities", "of", "showing", "people", "over", "50", "the", "way", "to", "the", "new", "communication", "technologies", "will", "be", "described", "in", "view", "of", "the", "experiences", "gained", "during", "the", "information", "campaign", "\"", "Senior", "-", "Info", "-", "Mobil", "\"", ".", "It", "will", "also", "be", "demonstrated", "based", "on", "the", "examples", "of", "the", "European", "network", "\"", "Learning", "in", "Later", "Life", "\"", "and", "other", "projects", "such", "as", "\"", "Learning", "through", "Research", "\"", "that", "virtual", "working", "groups", "and", "networks", "of", "elders", "can", "become", "a", "driving", "force", "of", "a", "new", "\"", "learning", "culture", "\"", ",", "involving", "also", "those", "who", "do", "not", "live", "near", "universities", "or", "who", "for", "health", "and", "other", "personal", "reasons", "cannot", "participate", "in", "educational", "programmes", "offered", "in", "the", "area", "." ]	[ "umlsterm" ]
children is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, tramadol is an umlsterm, administration is an umlsterm, ward is an umlsterm, adjustment is an umlsterm, nursing staff is an umlsterm, tramadol is an umlsterm, consumption is an umlsterm, pain is an umlsterm, ten - step is an umlsterm, scales is an umlsterm, treatment is an umlsterm, therapy is an umlsterm, oxygen is an umlsterm, patients is an umlsterm, treatment is an umlsterm, Pruritus is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, procedure is an umlsterm, surgery is an umlsterm, children is an umlsterm	DerUrologeA.70360552.eng.abstr_task0	Sentence: We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children .	[ "We", "investigated", "in", "17", "children", "(", "mean", "7.1", "years", ")", "the", "continuous", "administration", "of", "tramadol", "following", "augmentation", "cystoplasty", "or", "exstrophy", "reconstruction", ".", "Mean", "duration", "of", "the", "tramadol", "administration", "on", "the", "pediatric", "ward", "was", "3.8", "+", "/-", "1.1", "days", "(", "initial", "dosage", "0.25", "mg", "/", "kg", "/", "per", "hour", ",", "dose", "adjustment", "by", "the", "nursing", "staff", ")", ".", "Mean", "tramadol", "consumption", "was", "0.21", "mg", "/", "kg", "/", "h", "on", "day", "1", "and", "was", "reduced", "to", "0.08", "mg", "/", "kg", "/", "per", "hour", "on", "day", "4", ".", "Median", "pain", "score", "(", "assessed", "with", "ten", "-", "step", "scales", ")", "was", "5", "before", "treatment", "and", "between", "2.5", "(", "day", "1", ")", "and", "0.5", "(", "day", "5", ")", "during", "therapy", ".", "Lowest", "oxygen", "saturations", "(", "mean", ")", "ranged", "from", "93.8", "%", "to", "95.2", "%", ".", "Three", "patients", "(", "17.6", "%", ")", "suffered", "from", "nausea", "/", "vomiting", "on", "3", "of", "64", "treatment", "days", "(", "4.7", "%", ")", ".", "Pruritus", "and", "extreme", "sedation", "did", "not", "occur", ".", "The", "continuous", "administration", "of", "tramadol", "is", "a", "simple", "and", "safe", "procedure", "following", "major", "urological", "surgery", "in", "children", "." ]	[ "umlsterm" ]
children is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, tramadol is an umlsterm, administration is an umlsterm, ward is an umlsterm, adjustment is an umlsterm, nursing staff is an umlsterm, tramadol is an umlsterm, consumption is an umlsterm, pain is an umlsterm, ten - step is an umlsterm, scales is an umlsterm, treatment is an umlsterm, therapy is an umlsterm, oxygen is an umlsterm, patients is an umlsterm, treatment is an umlsterm, Pruritus is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, procedure is an umlsterm, surgery is an umlsterm, children is an umlsterm	DerUrologeA.70360552.eng.abstr_task1	Sentence: We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children . Instructions: please typing these entity words according to sentence: children, administration, tramadol, tramadol, administration, ward, adjustment, nursing staff, tramadol, consumption, pain, ten - step, scales, treatment, therapy, oxygen, patients, treatment, Pruritus, administration, tramadol, procedure, surgery, children Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children .	[ "We", "investigated", "in", "17", "children", "(", "mean", "7.1", "years", ")", "the", "continuous", "administration", "of", "tramadol", "following", "augmentation", "cystoplasty", "or", "exstrophy", "reconstruction", ".", "Mean", "duration", "of", "the", "tramadol", "administration", "on", "the", "pediatric", "ward", "was", "3.8", "+", "/-", "1.1", "days", "(", "initial", "dosage", "0.25", "mg", "/", "kg", "/", "per", "hour", ",", "dose", "adjustment", "by", "the", "nursing", "staff", ")", ".", "Mean", "tramadol", "consumption", "was", "0.21", "mg", "/", "kg", "/", "h", "on", "day", "1", "and", "was", "reduced", "to", "0.08", "mg", "/", "kg", "/", "per", "hour", "on", "day", "4", ".", "Median", "pain", "score", "(", "assessed", "with", "ten", "-", "step", "scales", ")", "was", "5", "before", "treatment", "and", "between", "2.5", "(", "day", "1", ")", "and", "0.5", "(", "day", "5", ")", "during", "therapy", ".", "Lowest", "oxygen", "saturations", "(", "mean", ")", "ranged", "from", "93.8", "%", "to", "95.2", "%", ".", "Three", "patients", "(", "17.6", "%", ")", "suffered", "from", "nausea", "/", "vomiting", "on", "3", "of", "64", "treatment", "days", "(", "4.7", "%", ")", ".", "Pruritus", "and", "extreme", "sedation", "did", "not", "occur", ".", "The", "continuous", "administration", "of", "tramadol", "is", "a", "simple", "and", "safe", "procedure", "following", "major", "urological", "surgery", "in", "children", "." ]	[ "umlsterm" ]
children, administration, tramadol, tramadol, administration, ward, adjustment, nursing staff, tramadol, consumption, pain, ten - step, scales, treatment, therapy, oxygen, patients, treatment, Pruritus, administration, tramadol, procedure, surgery, children	DerUrologeA.70360552.eng.abstr_task2	Sentence: We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]	We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children .	[ "We", "investigated", "in", "17", "children", "(", "mean", "7.1", "years", ")", "the", "continuous", "administration", "of", "tramadol", "following", "augmentation", "cystoplasty", "or", "exstrophy", "reconstruction", ".", "Mean", "duration", "of", "the", "tramadol", "administration", "on", "the", "pediatric", "ward", "was", "3.8", "+", "/-", "1.1", "days", "(", "initial", "dosage", "0.25", "mg", "/", "kg", "/", "per", "hour", ",", "dose", "adjustment", "by", "the", "nursing", "staff", ")", ".", "Mean", "tramadol", "consumption", "was", "0.21", "mg", "/", "kg", "/", "h", "on", "day", "1", "and", "was", "reduced", "to", "0.08", "mg", "/", "kg", "/", "per", "hour", "on", "day", "4", ".", "Median", "pain", "score", "(", "assessed", "with", "ten", "-", "step", "scales", ")", "was", "5", "before", "treatment", "and", "between", "2.5", "(", "day", "1", ")", "and", "0.5", "(", "day", "5", ")", "during", "therapy", ".", "Lowest", "oxygen", "saturations", "(", "mean", ")", "ranged", "from", "93.8", "%", "to", "95.2", "%", ".", "Three", "patients", "(", "17.6", "%", ")", "suffered", "from", "nausea", "/", "vomiting", "on", "3", "of", "64", "treatment", "days", "(", "4.7", "%", ")", ".", "Pruritus", "and", "extreme", "sedation", "did", "not", "occur", ".", "The", "continuous", "administration", "of", "tramadol", "is", "a", "simple", "and", "safe", "procedure", "following", "major", "urological", "surgery", "in", "children", "." ]	[ "umlsterm" ]
filamentous is a Phenotype, Scopulariopsis brevicaulis is a Microorganism, cheese is a Habitat, S. brevicaulis is a Microorganism, Danish cheese is a Habitat, cheeses is a Habitat, high proteolytic activity is a Phenotype, ammonia production is a Phenotype, production of arsenical compounds is a Phenotype	109_task0	Sentence: Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype, Habitat	[ "O", "O", "O", "B-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5].	[ "Finally", ",", "the", "filamentous", "fungus", "Scopulariopsis", "brevicaulis", "was", "found", "in", "a", "high", "number", "on", "cheese", "A.", "S.", "brevicaulis", "has", "previously", "been", "found", "in", "Danish", "cheese", "[", "52", "]", ",", " ", "and", "has", "been", "subject", "to", "spoilage", "of", "cheeses", "due", "to", "its", "high", "proteolytic", " ", "activity", "resulting", "in", "ammonia", "production", "and", "its", "production", "of", " ", "arsenical", "compounds", ",", "e.g", ".", ",", "diethylarsine", ",", "which", "has", "a", "very", " ", "characteristic", "garlic", "-", "like", "odour", "[", "5", "]", "." ]	[ "Phenotype", "Microorganism", "Habitat" ]
filamentous is a Phenotype, Scopulariopsis brevicaulis is a Microorganism, cheese is a Habitat, S. brevicaulis is a Microorganism, Danish cheese is a Habitat, cheeses is a Habitat, high proteolytic activity is a Phenotype, ammonia production is a Phenotype, production of arsenical compounds is a Phenotype	109_task1	Sentence: Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5]. Instructions: please typing these entity words according to sentence: filamentous, Scopulariopsis brevicaulis, cheese, S. brevicaulis, Danish cheese, cheeses, high proteolytic activity, ammonia production, production of arsenical compounds Options: Microorganism, Phenotype, Habitat	[ "O", "O", "O", "B-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5].	[ "Finally", ",", "the", "filamentous", "fungus", "Scopulariopsis", "brevicaulis", "was", "found", "in", "a", "high", "number", "on", "cheese", "A.", "S.", "brevicaulis", "has", "previously", "been", "found", "in", "Danish", "cheese", "[", "52", "]", ",", " ", "and", "has", "been", "subject", "to", "spoilage", "of", "cheeses", "due", "to", "its", "high", "proteolytic", " ", "activity", "resulting", "in", "ammonia", "production", "and", "its", "production", "of", " ", "arsenical", "compounds", ",", "e.g", ".", ",", "diethylarsine", ",", "which", "has", "a", "very", " ", "characteristic", "garlic", "-", "like", "odour", "[", "5", "]", "." ]	[ "Phenotype", "Microorganism", "Habitat" ]
filamentous, Scopulariopsis brevicaulis, cheese, S. brevicaulis, Danish cheese, cheeses, high proteolytic activity, ammonia production, production of arsenical compounds	109_task2	Sentence: Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5]. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5].	[ "Finally", ",", "the", "filamentous", "fungus", "Scopulariopsis", "brevicaulis", "was", "found", "in", "a", "high", "number", "on", "cheese", "A.", "S.", "brevicaulis", "has", "previously", "been", "found", "in", "Danish", "cheese", "[", "52", "]", ",", " ", "and", "has", "been", "subject", "to", "spoilage", "of", "cheeses", "due", "to", "its", "high", "proteolytic", " ", "activity", "resulting", "in", "ammonia", "production", "and", "its", "production", "of", " ", "arsenical", "compounds", ",", "e.g", ".", ",", "diethylarsine", ",", "which", "has", "a", "very", " ", "characteristic", "garlic", "-", "like", "odour", "[", "5", "]", "." ]	[ "Phenotype", "Microorganism", "Habitat" ]
Surgery is an umlsterm, endoscopy is an umlsterm, surgery is an umlsterm, thoracic surgery is an umlsterm, surgery is an umlsterm, Methods is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, pressure is an umlsterm, tip is an umlsterm, laryngoscope is an umlsterm, pressures is an umlsterm, high - frequency jet ventilation is an umlsterm, lung is an umlsterm, patients is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, measurements is an umlsterm, lung is an umlsterm, laryngoscope is an umlsterm, tidal volume is an umlsterm, inspiratory is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, endoscope is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, inspiratory is an umlsterm, pressures is an umlsterm, tidal volumes is an umlsterm, endoscopy is an umlsterm, laryngoscope is an umlsterm, ventilation is an umlsterm, surgical is an umlsterm, surgical procedure is an umlsterm, CO2 is an umlsterm, laser is an umlsterm, ventilation is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, surgery is an umlsterm, microsurgery is an umlsterm, larynx is an umlsterm	DerAnaesthesist.50440048.eng.abstr_task0	Sentence: Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx .	[ "Surgery", "by", "three", "-", "dimensional", "(", "3D", ")", "endoscopy", "is", "being", "used", "routinely", "in", "abdominal", "surgery", "and", ",", "in", "special", "cases", ",", "in", "thoracic", "surgery", ";", "however", ",", "it", "has", "not", "been", "reported", "as", "being", "used", "in", "microlaryngeal", "surgery", ".", "Methods", ".", "We", "inserted", "a", "3-D", "endoscope", "into", "a", "jet", "laryngoscope", "and", "studied", "the", "pressure", "properties", "at", "the", "tip", "of", "the", "laryngoscope", "as", "well", "as", "intrapulmonary", "pressures", "while", "applying", "superimposed", "high", "-", "frequency", "jet", "ventilation", ".", "The", "studies", "were", "conducted", "initially", "using", "a", "lung", "simulator", ",", "and", "then", "in", "seven", "patients", "undergoing", "microlaryngeal", "surgery", ".", "Results", ".", "Due", "to", "the", "rather", "large", "3-D", "endoscope", ",", "the", "diameter", "of", "the", "jet", "laryngoscope", "was", "reduced", "by", "between", "25.2", "%", "and", "70.9", "%", ",", "depending", "on", "its", "size", ".", "The", "measurements", "on", "the", "lung", "simulator", "revealed", "that", "reduction", "of", "laryngoscope", "diameter", "leads", "to", "an", "increase", "in", "the", "following", "parameters", ":", "expiratory", "resistance", ",", "tidal", "volume", ",", "and", "peak", "inspiratory", "pressure", ".", "The", "mean", "FiO2", "was", "0.74", "+", "/-", "0.1", ";", "the", "mean", "paO2", "was", "169.2", "+", "/-", "80.4", "mm", "Hg", ";", "and", "the", "mean", "paCO2", "was", "40.9", "+", "/-", "2.4", "mm", "Hg", ".", "The", "mean", "airway", "pressure", "was", "19", "+", "/-", "5.3", "mm", "Hg", "prior", "to", "insertion", "of", "the", "endoscope", "and", "12.3", "+", "/-", "6.9", "mm", "Hg", "after", "insertion", ".", "The", "mean", "positive", "end", "-", "expiratory", "pressure", "values", "increased", "from", "2", "+", "/-", "0.6", "to", "3.6", "+", "/-", "2.3", "mm", "Hg", ".", "Reduction", "of", "the", "working", "pressure", "resulted", "in", "restoration", "of", "the", "initial", "inspiratory", "pressures", "and", "tidal", "volumes", ".", "Conclusions", ".", "In", "the", "clinical", "application", "of", "3-D", "endoscopy", "via", "a", "jet", "laryngoscope", ",", "it", "was", "possible", "to", "achieve", "sufficient", "ventilation", ",", "inspection", "of", "the", "surgical", "field", ",", "and", "performance", "of", "the", "surgical", "procedure", ".", "A", "CO2", "laser", "was", "used", "without", "changing", "the", "ventilation", "regime", ".", "Although", "technical", "alterations", "would", "be", "desirable", "for", "its", "application", "to", "microlaryngeal", "surgery", ",", "it", "is", "presently", "possible", "to", "safely", "use", "the", "3-D", "endoscope", "via", "the", "jet", "laryngoscope", "for", "microlaryngeal", "surgery", ",", "presenting", "the", "surgeon", "with", "new", "possibilities", "in", "voice", "-", "improving", "microsurgery", "of", "the", "larynx", "." ]	[ "umlsterm" ]
Surgery is an umlsterm, endoscopy is an umlsterm, surgery is an umlsterm, thoracic surgery is an umlsterm, surgery is an umlsterm, Methods is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, pressure is an umlsterm, tip is an umlsterm, laryngoscope is an umlsterm, pressures is an umlsterm, high - frequency jet ventilation is an umlsterm, lung is an umlsterm, patients is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, measurements is an umlsterm, lung is an umlsterm, laryngoscope is an umlsterm, tidal volume is an umlsterm, inspiratory is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, endoscope is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, inspiratory is an umlsterm, pressures is an umlsterm, tidal volumes is an umlsterm, endoscopy is an umlsterm, laryngoscope is an umlsterm, ventilation is an umlsterm, surgical is an umlsterm, surgical procedure is an umlsterm, CO2 is an umlsterm, laser is an umlsterm, ventilation is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, surgery is an umlsterm, microsurgery is an umlsterm, larynx is an umlsterm	DerAnaesthesist.50440048.eng.abstr_task1	Sentence: Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx . Instructions: please typing these entity words according to sentence: Surgery, endoscopy, surgery, thoracic surgery, surgery, Methods, endoscope, laryngoscope, pressure, tip, laryngoscope, pressures, high - frequency jet ventilation, lung, patients, surgery, endoscope, laryngoscope, measurements, lung, laryngoscope, tidal volume, inspiratory, pressure, pressure, endoscope, pressure, pressure, inspiratory, pressures, tidal volumes, endoscopy, laryngoscope, ventilation, surgical, surgical procedure, CO2, laser, ventilation, surgery, endoscope, laryngoscope, surgery, microsurgery, larynx Options: umlsterm	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx .	[ "Surgery", "by", "three", "-", "dimensional", "(", "3D", ")", "endoscopy", "is", "being", "used", "routinely", "in", "abdominal", "surgery", "and", ",", "in", "special", "cases", ",", "in", "thoracic", "surgery", ";", "however", ",", "it", "has", "not", "been", "reported", "as", "being", "used", "in", "microlaryngeal", "surgery", ".", "Methods", ".", "We", "inserted", "a", "3-D", "endoscope", "into", "a", "jet", "laryngoscope", "and", "studied", "the", "pressure", "properties", "at", "the", "tip", "of", "the", "laryngoscope", "as", "well", "as", "intrapulmonary", "pressures", "while", "applying", "superimposed", "high", "-", "frequency", "jet", "ventilation", ".", "The", "studies", "were", "conducted", "initially", "using", "a", "lung", "simulator", ",", "and", "then", "in", "seven", "patients", "undergoing", "microlaryngeal", "surgery", ".", "Results", ".", "Due", "to", "the", "rather", "large", "3-D", "endoscope", ",", "the", "diameter", "of", "the", "jet", "laryngoscope", "was", "reduced", "by", "between", "25.2", "%", "and", "70.9", "%", ",", "depending", "on", "its", "size", ".", "The", "measurements", "on", "the", "lung", "simulator", "revealed", "that", "reduction", "of", "laryngoscope", "diameter", "leads", "to", "an", "increase", "in", "the", "following", "parameters", ":", "expiratory", "resistance", ",", "tidal", "volume", ",", "and", "peak", "inspiratory", "pressure", ".", "The", "mean", "FiO2", "was", "0.74", "+", "/-", "0.1", ";", "the", "mean", "paO2", "was", "169.2", "+", "/-", "80.4", "mm", "Hg", ";", "and", "the", "mean", "paCO2", "was", "40.9", "+", "/-", "2.4", "mm", "Hg", ".", "The", "mean", "airway", "pressure", "was", "19", "+", "/-", "5.3", "mm", "Hg", "prior", "to", "insertion", "of", "the", "endoscope", "and", "12.3", "+", "/-", "6.9", "mm", "Hg", "after", "insertion", ".", "The", "mean", "positive", "end", "-", "expiratory", "pressure", "values", "increased", "from", "2", "+", "/-", "0.6", "to", "3.6", "+", "/-", "2.3", "mm", "Hg", ".", "Reduction", "of", "the", "working", "pressure", "resulted", "in", "restoration", "of", "the", "initial", "inspiratory", "pressures", "and", "tidal", "volumes", ".", "Conclusions", ".", "In", "the", "clinical", "application", "of", "3-D", "endoscopy", "via", "a", "jet", "laryngoscope", ",", "it", "was", "possible", "to", "achieve", "sufficient", "ventilation", ",", "inspection", "of", "the", "surgical", "field", ",", "and", "performance", "of", "the", "surgical", "procedure", ".", "A", "CO2", "laser", "was", "used", "without", "changing", "the", "ventilation", "regime", ".", "Although", "technical", "alterations", "would", "be", "desirable", "for", "its", "application", "to", "microlaryngeal", "surgery", ",", "it", "is", "presently", "possible", "to", "safely", "use", "the", "3-D", "endoscope", "via", "the", "jet", "laryngoscope", "for", "microlaryngeal", "surgery", ",", "presenting", "the", "surgeon", "with", "new", "possibilities", "in", "voice", "-", "improving", "microsurgery", "of", "the", "larynx", "." ]	[ "umlsterm" ]
Surgery, endoscopy, surgery, thoracic surgery, surgery, Methods, endoscope, laryngoscope, pressure, tip, laryngoscope, pressures, high - frequency jet ventilation, lung, patients, surgery, endoscope, laryngoscope, measurements, lung, laryngoscope, tidal volume, inspiratory, pressure, pressure, endoscope, pressure, pressure, inspiratory, pressures, tidal volumes, endoscopy, laryngoscope, ventilation, surgical, surgical procedure, CO2, laser, ventilation, surgery, endoscope, laryngoscope, surgery, microsurgery, larynx	DerAnaesthesist.50440048.eng.abstr_task2	Sentence: Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx . Instructions: please extract entity words from the input sentence	[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]	Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx .	[ "Surgery", "by", "three", "-", "dimensional", "(", "3D", ")", "endoscopy", "is", "being", "used", "routinely", "in", "abdominal", "surgery", "and", ",", "in", "special", "cases", ",", "in", "thoracic", "surgery", ";", "however", ",", "it", "has", "not", "been", "reported", "as", "being", "used", "in", "microlaryngeal", "surgery", ".", "Methods", ".", "We", "inserted", "a", "3-D", "endoscope", "into", "a", "jet", "laryngoscope", "and", "studied", "the", "pressure", "properties", "at", "the", "tip", "of", "the", "laryngoscope", "as", "well", "as", "intrapulmonary", "pressures", "while", "applying", "superimposed", "high", "-", "frequency", "jet", "ventilation", ".", "The", "studies", "were", "conducted", "initially", "using", "a", "lung", "simulator", ",", "and", "then", "in", "seven", "patients", "undergoing", "microlaryngeal", "surgery", ".", "Results", ".", "Due", "to", "the", "rather", "large", "3-D", "endoscope", ",", "the", "diameter", "of", "the", "jet", "laryngoscope", "was", "reduced", "by", "between", "25.2", "%", "and", "70.9", "%", ",", "depending", "on", "its", "size", ".", "The", "measurements", "on", "the", "lung", "simulator", "revealed", "that", "reduction", "of", "laryngoscope", "diameter", "leads", "to", "an", "increase", "in", "the", "following", "parameters", ":", "expiratory", "resistance", ",", "tidal", "volume", ",", "and", "peak", "inspiratory", "pressure", ".", "The", "mean", "FiO2", "was", "0.74", "+", "/-", "0.1", ";", "the", "mean", "paO2", "was", "169.2", "+", "/-", "80.4", "mm", "Hg", ";", "and", "the", "mean", "paCO2", "was", "40.9", "+", "/-", "2.4", "mm", "Hg", ".", "The", "mean", "airway", "pressure", "was", "19", "+", "/-", "5.3", "mm", "Hg", "prior", "to", "insertion", "of", "the", "endoscope", "and", "12.3", "+", "/-", "6.9", "mm", "Hg", "after", "insertion", ".", "The", "mean", "positive", "end", "-", "expiratory", "pressure", "values", "increased", "from", "2", "+", "/-", "0.6", "to", "3.6", "+", "/-", "2.3", "mm", "Hg", ".", "Reduction", "of", "the", "working", "pressure", "resulted", "in", "restoration", "of", "the", "initial", "inspiratory", "pressures", "and", "tidal", "volumes", ".", "Conclusions", ".", "In", "the", "clinical", "application", "of", "3-D", "endoscopy", "via", "a", "jet", "laryngoscope", ",", "it", "was", "possible", "to", "achieve", "sufficient", "ventilation", ",", "inspection", "of", "the", "surgical", "field", ",", "and", "performance", "of", "the", "surgical", "procedure", ".", "A", "CO2", "laser", "was", "used", "without", "changing", "the", "ventilation", "regime", ".", "Although", "technical", "alterations", "would", "be", "desirable", "for", "its", "application", "to", "microlaryngeal", "surgery", ",", "it", "is", "presently", "possible", "to", "safely", "use", "the", "3-D", "endoscope", "via", "the", "jet", "laryngoscope", "for", "microlaryngeal", "surgery", ",", "presenting", "the", "surgeon", "with", "new", "possibilities", "in", "voice", "-", "improving", "microsurgery", "of", "the", "larynx", "." ]	[ "umlsterm" ]
patients is an umlsterm, separations is an umlsterm, surgical reconstruction is an umlsterm, classification is an umlsterm, Matsen is an umlsterm, patients is an umlsterm, patient is an umlsterm, patients is an umlsterm, ligaments is an umlsterm, ligaments is an umlsterm, acromioclavicular joint is an umlsterm, polydioxanone - sulphate is an umlsterm, patients is an umlsterm, surgery is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, Calcifications is an umlsterm, ligaments is an umlsterm, range of motion is an umlsterm, complications is an umlsterm, infection is an umlsterm, infection is an umlsterm, complications is an umlsterm, redislocation is an umlsterm, patients is an umlsterm, arthritis is an umlsterm, joint is an umlsterm, postoperative is an umlsterm, treatment is an umlsterm, procedure is an umlsterm, patients is an umlsterm, complications is an umlsterm, migration is an umlsterm, metal is an umlsterm	DerUnfallchirurg.71000193.eng.abstr_task0	Sentence: From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided .	[ "From", "1986", "to", "1994", ",", "we", "treated", "79", "patients", "with", "acute", "acromioclavicular", "separations", "by", "surgical", "reconstruction", ".", "According", "to", "the", "classification", "of", "Rockwood", "and", "Matsen", ",", "65", "patients", "had", "type", "III", "lesions", ",", "1", "patient", "had", "a", "type", "IV", "lesion", "and", "13", "patients", "had", "type", "V", "lesions", ".", "Both", "the", "coracoclavicular", "ligaments", "and", "the", "ligaments", "of", "the", "acromioclavicular", "joint", "were", "reconstructed", ".", "An", "additional", "ligamentous", "augmentation", "was", "performed", "using", "completely", "resorbable", "5-", "and", "10-mm", "polydioxanone", "-", "sulphate", "bands", ".", "Fifty", "-", "five", "patients", "(", "70", "%", ")", "were", "reexamined", "1", "-", "7.5", "years", "after", "surgery", "(", "mean", "28", "months", ")", ".", "The", "results", "were", "good", "to", "excellent", "in", "50", "cases", "(", "90", "%", ")", ".", "Fifty", "-", "two", "patients", "(", "93", "%", ")", "achieved", "a", "range", "of", "motion", "with", "an", "abduction", "deficit", "of", "less", "than", "20", "°", ".", "Calcifications", "in", "the", "area", "of", "the", "coracoclavicular", "ligaments", "did", "not", "affect", "the", "final", "range", "of", "motion", ".", "Early", "complications", "consisted", "of", "a", "subcutaneous", "infection", ",", "one", "deep", "infection", ",", "and", "one", "reconstruction", "failure", ".", "Late", "complications", "consisted", "of", "a", "redislocation", "in", "2", "patients", "and", "symptomatic", "post", "-", "traumatic", "arthritis", "of", "the", "joint", "in", "3", "cases", ".", "Augmenting", "the", "reconstruction", "with", "polydioxyanone", "-", "sulphate", "bands", "allowed", "early", "functional", "postoperative", "treatment", ".", "With", "this", "procedure", ",", "patients", "do", "not", "require", "removal", "of", "the", "implant", ",", "and", "complications", "from", "breakage", "or", "migration", "of", "metal", "implants", "are", "avoided", "." ]	[ "umlsterm" ]
patients is an umlsterm, separations is an umlsterm, surgical reconstruction is an umlsterm, classification is an umlsterm, Matsen is an umlsterm, patients is an umlsterm, patient is an umlsterm, patients is an umlsterm, ligaments is an umlsterm, ligaments is an umlsterm, acromioclavicular joint is an umlsterm, polydioxanone - sulphate is an umlsterm, patients is an umlsterm, surgery is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, Calcifications is an umlsterm, ligaments is an umlsterm, range of motion is an umlsterm, complications is an umlsterm, infection is an umlsterm, infection is an umlsterm, complications is an umlsterm, redislocation is an umlsterm, patients is an umlsterm, arthritis is an umlsterm, joint is an umlsterm, postoperative is an umlsterm, treatment is an umlsterm, procedure is an umlsterm, patients is an umlsterm, complications is an umlsterm, migration is an umlsterm, metal is an umlsterm	DerUnfallchirurg.71000193.eng.abstr_task1	Sentence: From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided . Instructions: please typing these entity words according to sentence: patients, separations, surgical reconstruction, classification, Matsen, patients, patient, patients, ligaments, ligaments, acromioclavicular joint, polydioxanone - sulphate, patients, surgery, patients, range of motion, Calcifications, ligaments, range of motion, complications, infection, infection, complications, redislocation, patients, arthritis, joint, postoperative, treatment, procedure, patients, complications, migration, metal Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided .	[ "From", "1986", "to", "1994", ",", "we", "treated", "79", "patients", "with", "acute", "acromioclavicular", "separations", "by", "surgical", "reconstruction", ".", "According", "to", "the", "classification", "of", "Rockwood", "and", "Matsen", ",", "65", "patients", "had", "type", "III", "lesions", ",", "1", "patient", "had", "a", "type", "IV", "lesion", "and", "13", "patients", "had", "type", "V", "lesions", ".", "Both", "the", "coracoclavicular", "ligaments", "and", "the", "ligaments", "of", "the", "acromioclavicular", "joint", "were", "reconstructed", ".", "An", "additional", "ligamentous", "augmentation", "was", "performed", "using", "completely", "resorbable", "5-", "and", "10-mm", "polydioxanone", "-", "sulphate", "bands", ".", "Fifty", "-", "five", "patients", "(", "70", "%", ")", "were", "reexamined", "1", "-", "7.5", "years", "after", "surgery", "(", "mean", "28", "months", ")", ".", "The", "results", "were", "good", "to", "excellent", "in", "50", "cases", "(", "90", "%", ")", ".", "Fifty", "-", "two", "patients", "(", "93", "%", ")", "achieved", "a", "range", "of", "motion", "with", "an", "abduction", "deficit", "of", "less", "than", "20", "°", ".", "Calcifications", "in", "the", "area", "of", "the", "coracoclavicular", "ligaments", "did", "not", "affect", "the", "final", "range", "of", "motion", ".", "Early", "complications", "consisted", "of", "a", "subcutaneous", "infection", ",", "one", "deep", "infection", ",", "and", "one", "reconstruction", "failure", ".", "Late", "complications", "consisted", "of", "a", "redislocation", "in", "2", "patients", "and", "symptomatic", "post", "-", "traumatic", "arthritis", "of", "the", "joint", "in", "3", "cases", ".", "Augmenting", "the", "reconstruction", "with", "polydioxyanone", "-", "sulphate", "bands", "allowed", "early", "functional", "postoperative", "treatment", ".", "With", "this", "procedure", ",", "patients", "do", "not", "require", "removal", "of", "the", "implant", ",", "and", "complications", "from", "breakage", "or", "migration", "of", "metal", "implants", "are", "avoided", "." ]	[ "umlsterm" ]
patients, separations, surgical reconstruction, classification, Matsen, patients, patient, patients, ligaments, ligaments, acromioclavicular joint, polydioxanone - sulphate, patients, surgery, patients, range of motion, Calcifications, ligaments, range of motion, complications, infection, infection, complications, redislocation, patients, arthritis, joint, postoperative, treatment, procedure, patients, complications, migration, metal	DerUnfallchirurg.71000193.eng.abstr_task2	Sentence: From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]	From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided .	[ "From", "1986", "to", "1994", ",", "we", "treated", "79", "patients", "with", "acute", "acromioclavicular", "separations", "by", "surgical", "reconstruction", ".", "According", "to", "the", "classification", "of", "Rockwood", "and", "Matsen", ",", "65", "patients", "had", "type", "III", "lesions", ",", "1", "patient", "had", "a", "type", "IV", "lesion", "and", "13", "patients", "had", "type", "V", "lesions", ".", "Both", "the", "coracoclavicular", "ligaments", "and", "the", "ligaments", "of", "the", "acromioclavicular", "joint", "were", "reconstructed", ".", "An", "additional", "ligamentous", "augmentation", "was", "performed", "using", "completely", "resorbable", "5-", "and", "10-mm", "polydioxanone", "-", "sulphate", "bands", ".", "Fifty", "-", "five", "patients", "(", "70", "%", ")", "were", "reexamined", "1", "-", "7.5", "years", "after", "surgery", "(", "mean", "28", "months", ")", ".", "The", "results", "were", "good", "to", "excellent", "in", "50", "cases", "(", "90", "%", ")", ".", "Fifty", "-", "two", "patients", "(", "93", "%", ")", "achieved", "a", "range", "of", "motion", "with", "an", "abduction", "deficit", "of", "less", "than", "20", "°", ".", "Calcifications", "in", "the", "area", "of", "the", "coracoclavicular", "ligaments", "did", "not", "affect", "the", "final", "range", "of", "motion", ".", "Early", "complications", "consisted", "of", "a", "subcutaneous", "infection", ",", "one", "deep", "infection", ",", "and", "one", "reconstruction", "failure", ".", "Late", "complications", "consisted", "of", "a", "redislocation", "in", "2", "patients", "and", "symptomatic", "post", "-", "traumatic", "arthritis", "of", "the", "joint", "in", "3", "cases", ".", "Augmenting", "the", "reconstruction", "with", "polydioxyanone", "-", "sulphate", "bands", "allowed", "early", "functional", "postoperative", "treatment", ".", "With", "this", "procedure", ",", "patients", "do", "not", "require", "removal", "of", "the", "implant", ",", "and", "complications", "from", "breakage", "or", "migration", "of", "metal", "implants", "are", "avoided", "." ]	[ "umlsterm" ]
benzo(a)pyrene is a compound, CYP1A is a protein	DS.d615_task0	Sentence: Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]	Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression.	[ "Exposure", "to", "benzo(a)pyrene", "(", "BaP", ")", "by", "intraperitoneal", "injection", "increased", "biliary", "BaP", "metabolites", "and", "liver", "CYP1A", "gene", "expression", "." ]	[ "compound", "protein" ]
benzo(a)pyrene is a compound, CYP1A is a protein	DS.d615_task1	Sentence: Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression. Instructions: please typing these entity words according to sentence: benzo(a)pyrene, CYP1A Options: compound, protein	[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]	Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression.	[ "Exposure", "to", "benzo(a)pyrene", "(", "BaP", ")", "by", "intraperitoneal", "injection", "increased", "biliary", "BaP", "metabolites", "and", "liver", "CYP1A", "gene", "expression", "." ]	[ "compound", "protein" ]
benzo(a)pyrene, CYP1A	DS.d615_task2	Sentence: Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]	Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression.	[ "Exposure", "to", "benzo(a)pyrene", "(", "BaP", ")", "by", "intraperitoneal", "injection", "increased", "biliary", "BaP", "metabolites", "and", "liver", "CYP1A", "gene", "expression", "." ]	[ "compound", "protein" ]
F - actin is a protein, epidermal growth factor receptor is a protein, profilin is a protein-family	1.0alpha7.train.658_task0	Sentence: Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein	[ "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O" ]	Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56).	[ "Previous", "studies", "have", "shown", "that", " ", "F", "-", "actin", "binds", "to", "the", " ", "epidermal", "growth", "factor", "receptor", "at", "a", "site", "in", "its", "cytoplasmic", "domain", "similar", "to", "a", "peptide", "of", " ", "profilin", "(", "56", ")", "." ]	[ "protein", "protein-family" ]
F - actin is a protein, epidermal growth factor receptor is a protein, profilin is a protein-family	1.0alpha7.train.658_task1	Sentence: Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56). Instructions: please typing these entity words according to sentence: F - actin, epidermal growth factor receptor, profilin Options: protein-family, protein	[ "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O" ]	Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56).	[ "Previous", "studies", "have", "shown", "that", " ", "F", "-", "actin", "binds", "to", "the", " ", "epidermal", "growth", "factor", "receptor", "at", "a", "site", "in", "its", "cytoplasmic", "domain", "similar", "to", "a", "peptide", "of", " ", "profilin", "(", "56", ")", "." ]	[ "protein", "protein-family" ]
F - actin, epidermal growth factor receptor, profilin	1.0alpha7.train.658_task2	Sentence: Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56). Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O" ]	Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56).	[ "Previous", "studies", "have", "shown", "that", " ", "F", "-", "actin", "binds", "to", "the", " ", "epidermal", "growth", "factor", "receptor", "at", "a", "site", "in", "its", "cytoplasmic", "domain", "similar", "to", "a", "peptide", "of", " ", "profilin", "(", "56", ")", "." ]	[ "protein", "protein-family" ]
antipsychotic drugs is a Intervention_Pharmacological, cortical thickness . is a Outcome_Physical, haloperidol is a Intervention_Pharmacological, risperidone is a Intervention_Pharmacological, olanzapine is a Intervention_Pharmacological, effects of antipsychotic medication is a Outcome_Other, N=16 is a Participant_Sample-size, N=18 is a Participant_Sample-size, cortical thickness changes is a Outcome_Physical, schizophrenia spectrum is a Participant_Condition, clinical is a Outcome_Physical, 45 is a Participant_Sample-size, healthy is a Participant_Condition, cortical thickness variables . is a Outcome_Physical, changes in cortical thickness is a Outcome_Physical, gray matter cortical thickness , overall and lobes is a Outcome_Physical	56131_task0	Sentence: Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness .	[ "Effect", "of", "antipsychotic", "drugs", "on", "cortical", "thickness", ".", "A", "randomized", "controlled", "one", "-", "year", "follow", "-", "up", "study", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", ".", "BACKGROUND", "Imaging", "evidence", "indicates", "that", "brain", "alterations", "are", "primary", "to", "the", "full", "-", "blown", "onset", "of", "schizophrenia", "and", "seem", "to", "progress", "across", "time", ".", "The", "potential", "effects", "of", "antipsychotic", "medication", "on", "brain", "structure", "represent", "a", "key", "factor", "in", "understanding", "brain", "changes", "in", "psychosis", ".", "We", "aimed", "to", "investigate", "the", "effects", "of", "low", "doses", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", "on", "cortical", "thickness", ".", "METHOD", "We", "investigated", "the", "effects", "of", "risperidone", "(", "N=16", ")", ",", "olanzapine", "(", "N=18", ")", "and", "low", "doses", "of", "haloperidol", "(", "N=18", ")", "in", "cortical", "thickness", "changes", "during", "1-year", "follow", "-", "up", "period", "in", "a", "large", "and", "heterogeneous", "sample", "of", "schizophrenia", "spectrum", "patients", ".", "The", "relationship", "between", "cortical", "thickness", "changes", "and", "clinical", "and", "cognitive", "outcome", "was", "also", "assessed", ".", "A", "group", "of", "45", "healthy", "volunteers", "was", "also", "longitudinally", "evaluated", ".", "Magnetic", "resonance", "imaging", "brain", "scans", "(", "1.5", "T", ")", "were", "obtained", "and", "images", "were", "analyzed", "by", "using", "BRAINS2", ".", "RESULTS", "There", "were", "no", "significant", "effects", "of", "time", "(", "F", "(", "1,47", ")", "<", "1.66", ";", "P", ">", "0.204", ")", ",", "treatment", "group", "(", "F", "(", "2,47", ")", "<", "1.47", ";", "P", ">", "0.242", ")", "or", "group", "-", "by", "-", "time", "interaction", "(", "F", "(", "2,47", ")", "<", "1.82", ";", "P", ">", "0.174", ")", "for", "any", "of", "the", "cortical", "thickness", "variables", ".", "When", "the", "group", "of", "healthy", "controls", "was", "included", "in", "the", "analyses", ",", "it", "is", "of", "note", "that", "group", "-", "by", "-", "time", "interaction", "showed", "a", "significant", "result", "for", "the", "frontal", "lobe", "at", "trend", "level", "(", "F", "(", "3,81", ")", "=", "2.686", ";", "P=0.052", ")", ".", "After", "the", "Bonferroni", "adjustment", "for", "multiple", "comparisons", ",", "there", "were", "no", "significant", "associations", "between", "changes", "in", "cortical", "thickness", "and", "clinical", "and", "cognitive", "outcome", ".", "CONCLUSIONS", "Low", "doses", "of", "haloperidol", ",", "risperidone", ",", "and", "olanzapine", "seem", "to", "equally", "affect", "gray", "matter", "cortical", "thickness", ",", "overall", "and", "lobes", ",", "at", "the", "medium", "-", "term", "(", "1", "year", ")", ".", "The", "clinical", "effectiveness", "of", "treatments", "was", "not", "significantly", "related", "to", "changes", "in", "cortical", "thickness", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]
antipsychotic drugs is a Intervention_Pharmacological, cortical thickness . is a Outcome_Physical, haloperidol is a Intervention_Pharmacological, risperidone is a Intervention_Pharmacological, olanzapine is a Intervention_Pharmacological, effects of antipsychotic medication is a Outcome_Other, N=16 is a Participant_Sample-size, N=18 is a Participant_Sample-size, cortical thickness changes is a Outcome_Physical, schizophrenia spectrum is a Participant_Condition, clinical is a Outcome_Physical, 45 is a Participant_Sample-size, healthy is a Participant_Condition, cortical thickness variables . is a Outcome_Physical, changes in cortical thickness is a Outcome_Physical, gray matter cortical thickness , overall and lobes is a Outcome_Physical	56131_task1	Sentence: Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness . Instructions: please typing these entity words according to sentence: antipsychotic drugs, cortical thickness ., haloperidol, risperidone, olanzapine, effects of antipsychotic medication, N=16, N=18, cortical thickness changes, schizophrenia spectrum, clinical, 45, healthy, cortical thickness variables ., changes in cortical thickness, gray matter cortical thickness , overall and lobes Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness .	[ "Effect", "of", "antipsychotic", "drugs", "on", "cortical", "thickness", ".", "A", "randomized", "controlled", "one", "-", "year", "follow", "-", "up", "study", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", ".", "BACKGROUND", "Imaging", "evidence", "indicates", "that", "brain", "alterations", "are", "primary", "to", "the", "full", "-", "blown", "onset", "of", "schizophrenia", "and", "seem", "to", "progress", "across", "time", ".", "The", "potential", "effects", "of", "antipsychotic", "medication", "on", "brain", "structure", "represent", "a", "key", "factor", "in", "understanding", "brain", "changes", "in", "psychosis", ".", "We", "aimed", "to", "investigate", "the", "effects", "of", "low", "doses", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", "on", "cortical", "thickness", ".", "METHOD", "We", "investigated", "the", "effects", "of", "risperidone", "(", "N=16", ")", ",", "olanzapine", "(", "N=18", ")", "and", "low", "doses", "of", "haloperidol", "(", "N=18", ")", "in", "cortical", "thickness", "changes", "during", "1-year", "follow", "-", "up", "period", "in", "a", "large", "and", "heterogeneous", "sample", "of", "schizophrenia", "spectrum", "patients", ".", "The", "relationship", "between", "cortical", "thickness", "changes", "and", "clinical", "and", "cognitive", "outcome", "was", "also", "assessed", ".", "A", "group", "of", "45", "healthy", "volunteers", "was", "also", "longitudinally", "evaluated", ".", "Magnetic", "resonance", "imaging", "brain", "scans", "(", "1.5", "T", ")", "were", "obtained", "and", "images", "were", "analyzed", "by", "using", "BRAINS2", ".", "RESULTS", "There", "were", "no", "significant", "effects", "of", "time", "(", "F", "(", "1,47", ")", "<", "1.66", ";", "P", ">", "0.204", ")", ",", "treatment", "group", "(", "F", "(", "2,47", ")", "<", "1.47", ";", "P", ">", "0.242", ")", "or", "group", "-", "by", "-", "time", "interaction", "(", "F", "(", "2,47", ")", "<", "1.82", ";", "P", ">", "0.174", ")", "for", "any", "of", "the", "cortical", "thickness", "variables", ".", "When", "the", "group", "of", "healthy", "controls", "was", "included", "in", "the", "analyses", ",", "it", "is", "of", "note", "that", "group", "-", "by", "-", "time", "interaction", "showed", "a", "significant", "result", "for", "the", "frontal", "lobe", "at", "trend", "level", "(", "F", "(", "3,81", ")", "=", "2.686", ";", "P=0.052", ")", ".", "After", "the", "Bonferroni", "adjustment", "for", "multiple", "comparisons", ",", "there", "were", "no", "significant", "associations", "between", "changes", "in", "cortical", "thickness", "and", "clinical", "and", "cognitive", "outcome", ".", "CONCLUSIONS", "Low", "doses", "of", "haloperidol", ",", "risperidone", ",", "and", "olanzapine", "seem", "to", "equally", "affect", "gray", "matter", "cortical", "thickness", ",", "overall", "and", "lobes", ",", "at", "the", "medium", "-", "term", "(", "1", "year", ")", ".", "The", "clinical", "effectiveness", "of", "treatments", "was", "not", "significantly", "related", "to", "changes", "in", "cortical", "thickness", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]
antipsychotic drugs, cortical thickness ., haloperidol, risperidone, olanzapine, effects of antipsychotic medication, N=16, N=18, cortical thickness changes, schizophrenia spectrum, clinical, 45, healthy, cortical thickness variables ., changes in cortical thickness, gray matter cortical thickness , overall and lobes	56131_task2	Sentence: Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness .	[ "Effect", "of", "antipsychotic", "drugs", "on", "cortical", "thickness", ".", "A", "randomized", "controlled", "one", "-", "year", "follow", "-", "up", "study", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", ".", "BACKGROUND", "Imaging", "evidence", "indicates", "that", "brain", "alterations", "are", "primary", "to", "the", "full", "-", "blown", "onset", "of", "schizophrenia", "and", "seem", "to", "progress", "across", "time", ".", "The", "potential", "effects", "of", "antipsychotic", "medication", "on", "brain", "structure", "represent", "a", "key", "factor", "in", "understanding", "brain", "changes", "in", "psychosis", ".", "We", "aimed", "to", "investigate", "the", "effects", "of", "low", "doses", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", "on", "cortical", "thickness", ".", "METHOD", "We", "investigated", "the", "effects", "of", "risperidone", "(", "N=16", ")", ",", "olanzapine", "(", "N=18", ")", "and", "low", "doses", "of", "haloperidol", "(", "N=18", ")", "in", "cortical", "thickness", "changes", "during", "1-year", "follow", "-", "up", "period", "in", "a", "large", "and", "heterogeneous", "sample", "of", "schizophrenia", "spectrum", "patients", ".", "The", "relationship", "between", "cortical", "thickness", "changes", "and", "clinical", "and", "cognitive", "outcome", "was", "also", "assessed", ".", "A", "group", "of", "45", "healthy", "volunteers", "was", "also", "longitudinally", "evaluated", ".", "Magnetic", "resonance", "imaging", "brain", "scans", "(", "1.5", "T", ")", "were", "obtained", "and", "images", "were", "analyzed", "by", "using", "BRAINS2", ".", "RESULTS", "There", "were", "no", "significant", "effects", "of", "time", "(", "F", "(", "1,47", ")", "<", "1.66", ";", "P", ">", "0.204", ")", ",", "treatment", "group", "(", "F", "(", "2,47", ")", "<", "1.47", ";", "P", ">", "0.242", ")", "or", "group", "-", "by", "-", "time", "interaction", "(", "F", "(", "2,47", ")", "<", "1.82", ";", "P", ">", "0.174", ")", "for", "any", "of", "the", "cortical", "thickness", "variables", ".", "When", "the", "group", "of", "healthy", "controls", "was", "included", "in", "the", "analyses", ",", "it", "is", "of", "note", "that", "group", "-", "by", "-", "time", "interaction", "showed", "a", "significant", "result", "for", "the", "frontal", "lobe", "at", "trend", "level", "(", "F", "(", "3,81", ")", "=", "2.686", ";", "P=0.052", ")", ".", "After", "the", "Bonferroni", "adjustment", "for", "multiple", "comparisons", ",", "there", "were", "no", "significant", "associations", "between", "changes", "in", "cortical", "thickness", "and", "clinical", "and", "cognitive", "outcome", ".", "CONCLUSIONS", "Low", "doses", "of", "haloperidol", ",", "risperidone", ",", "and", "olanzapine", "seem", "to", "equally", "affect", "gray", "matter", "cortical", "thickness", ",", "overall", "and", "lobes", ",", "at", "the", "medium", "-", "term", "(", "1", "year", ")", ".", "The", "clinical", "effectiveness", "of", "treatments", "was", "not", "significantly", "related", "to", "changes", "in", "cortical", "thickness", "." ]	[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]
ponatinib is a CHEMICAL, kinase domain is a GENE-N	23430109_task0	Sentence: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.	[ "Activity", "of", "ponatinib", "against", "clinically", "-", "relevant", "AC220-resistant", "kinase", "domain", "mutants", "of", "FLT3-ITD", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
ponatinib is a CHEMICAL, kinase domain is a GENE-N	23430109_task1	Sentence: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Instructions: please typing these entity words according to sentence: ponatinib, kinase domain Options: GENE-N, CHEMICAL	[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.	[ "Activity", "of", "ponatinib", "against", "clinically", "-", "relevant", "AC220-resistant", "kinase", "domain", "mutants", "of", "FLT3-ITD", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
ponatinib, kinase domain	23430109_task2	Sentence: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Instructions: please extract entity words from the input sentence	[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]	Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.	[ "Activity", "of", "ponatinib", "against", "clinically", "-", "relevant", "AC220-resistant", "kinase", "domain", "mutants", "of", "FLT3-ITD", "." ]	[ "GENE-N", "CHEMICAL", "GENE-Y" ]
alpha(2A)-adrenoceptor is a GENE-Y, brimonidine is a CHEMICAL	11481271_task0	Sentence: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL	[ "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.	[ "Potent", "alpha(2A)-adrenoceptor", "-", "mediated", "vasoconstriction", "by", "brimonidine", "in", "porcine", "ciliary", "arteries", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
alpha(2A)-adrenoceptor is a GENE-Y, brimonidine is a CHEMICAL	11481271_task1	Sentence: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Instructions: please typing these entity words according to sentence: alpha(2A)-adrenoceptor, brimonidine Options: GENE-Y, CHEMICAL	[ "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.	[ "Potent", "alpha(2A)-adrenoceptor", "-", "mediated", "vasoconstriction", "by", "brimonidine", "in", "porcine", "ciliary", "arteries", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
alpha(2A)-adrenoceptor, brimonidine	11481271_task2	Sentence: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Instructions: please extract entity words from the input sentence	[ "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]	Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.	[ "Potent", "alpha(2A)-adrenoceptor", "-", "mediated", "vasoconstriction", "by", "brimonidine", "in", "porcine", "ciliary", "arteries", "." ]	[ "GENE-Y", "GENE-N", "CHEMICAL" ]
Active is a Qualifier, ischemia is a Condition, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention is a Scope, CCS functional class is a Measurement, IV is a Value, angina is a Condition, antiarrhythmic drug is a Drug, allergy , intolerance or contraindication is a Scope, left ventricular thrombus is a Condition, catheter ablation procedure is a Procedure, VT is a Condition, renal failure is a Condition, Creatinine clearance is a Measurement, < 15 mL / min is a Value, NYHA Functional class is a Measurement, IV is a Value, heart failure is a Condition, systemic illness is a Condition, survival is a Observation, < 1 year is a Value, ST elevation myocardial infarction or non - ST elevation MI is a Scope, < 30 days is a Temporal, pregnant is a Condition	NCT02830360_exc_task0	Sentence: Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Observation, Procedure, Scope, Measurement, Drug	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O" ]	Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant.	[ "Unable", "or", "unwilling", "to", "provide", "informed", "consent", ".", "\n", "Active", "ischemia", "(", "acute", "thrombus", "diagnosed", "by", "coronary", "angiography", ",", "or", "dynamic", "ST", "segment", "changes", "demonstrated", "on", "ECG", ")", "or", "another", "reversible", "cause", "of", "VT", "(", "e.g", ".", "drug", "-", "induced", "arrhythmia", ")", ",", "had", "recent", "acute", "coronary", "syndrome", "within", "30", "days", ",", "coronary", "revascularization", "(", "<", "90", "days", "bypass", "surgery", ",", "<", "30", "days", "percutaneous", "coronary", "intervention", ")", ",", "or", "have", "CCS", "functional", "class", "IV", "angina", ".", "Note", "that", "biomarker", "level", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "acute", "coronary", "syndrome", "or", "active", "ischemia", ".", "\n", "Are", "ineligible", "to", "take", "the", "antiarrhythmic", "drug", "to", "which", "they", "would", "be", "assigned", "due", "to", "allergy", ",", "intolerance", "or", "contraindication", "\n", "Are", "known", "to", "have", "protruding", "left", "ventricular", "thrombus", "or", "mechanical", "aortic", "and", "mitral", "valves", "\n", "Have", "had", "a", "prior", "catheter", "ablation", "procedure", "for", "VT", "\n", "Are", "in", "renal", "failure", "(", "Creatinine", "clearance", "<", "15", "mL", "/", "min", ")", ",", "have", "NYHA", "Functional", "class", "IV", "heart", "failure", ",", "or", "a", "systemic", "illness", "likely", "to", "limit", "survival", "to", "<", "1", "year", "\n", "Have", "had", "recent", "ST", "elevation", "myocardial", "infarction", "or", "non", "-", "ST", "elevation", "MI", "(", "<", "30", "days", ")", ";", "note", "that", "biomarker", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "MI", ".", "\n", "Are", "pregnant", ".", "\n" ]	[ "Scope", "Procedure", "Condition", "Measurement", "Drug", "Device", "Temporal", "Qualifier", "Value", "Observation" ]
Active is a Qualifier, ischemia is a Condition, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention is a Scope, CCS functional class is a Measurement, IV is a Value, angina is a Condition, antiarrhythmic drug is a Drug, allergy , intolerance or contraindication is a Scope, left ventricular thrombus is a Condition, catheter ablation procedure is a Procedure, VT is a Condition, renal failure is a Condition, Creatinine clearance is a Measurement, < 15 mL / min is a Value, NYHA Functional class is a Measurement, IV is a Value, heart failure is a Condition, systemic illness is a Condition, survival is a Observation, < 1 year is a Value, ST elevation myocardial infarction or non - ST elevation MI is a Scope, < 30 days is a Temporal, pregnant is a Condition	NCT02830360_exc_task1	Sentence: Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant. Instructions: please typing these entity words according to sentence: Active, ischemia, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention, CCS functional class, IV, angina, antiarrhythmic drug, allergy , intolerance or contraindication, left ventricular thrombus, catheter ablation procedure, VT, renal failure, Creatinine clearance, < 15 mL / min, NYHA Functional class, IV, heart failure, systemic illness, survival, < 1 year, ST elevation myocardial infarction or non - ST elevation MI, < 30 days, pregnant Options: Temporal, Condition, Qualifier, Value, Observation, Procedure, Scope, Measurement, Drug	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O" ]	Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant.	[ "Unable", "or", "unwilling", "to", "provide", "informed", "consent", ".", "\n", "Active", "ischemia", "(", "acute", "thrombus", "diagnosed", "by", "coronary", "angiography", ",", "or", "dynamic", "ST", "segment", "changes", "demonstrated", "on", "ECG", ")", "or", "another", "reversible", "cause", "of", "VT", "(", "e.g", ".", "drug", "-", "induced", "arrhythmia", ")", ",", "had", "recent", "acute", "coronary", "syndrome", "within", "30", "days", ",", "coronary", "revascularization", "(", "<", "90", "days", "bypass", "surgery", ",", "<", "30", "days", "percutaneous", "coronary", "intervention", ")", ",", "or", "have", "CCS", "functional", "class", "IV", "angina", ".", "Note", "that", "biomarker", "level", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "acute", "coronary", "syndrome", "or", "active", "ischemia", ".", "\n", "Are", "ineligible", "to", "take", "the", "antiarrhythmic", "drug", "to", "which", "they", "would", "be", "assigned", "due", "to", "allergy", ",", "intolerance", "or", "contraindication", "\n", "Are", "known", "to", "have", "protruding", "left", "ventricular", "thrombus", "or", "mechanical", "aortic", "and", "mitral", "valves", "\n", "Have", "had", "a", "prior", "catheter", "ablation", "procedure", "for", "VT", "\n", "Are", "in", "renal", "failure", "(", "Creatinine", "clearance", "<", "15", "mL", "/", "min", ")", ",", "have", "NYHA", "Functional", "class", "IV", "heart", "failure", ",", "or", "a", "systemic", "illness", "likely", "to", "limit", "survival", "to", "<", "1", "year", "\n", "Have", "had", "recent", "ST", "elevation", "myocardial", "infarction", "or", "non", "-", "ST", "elevation", "MI", "(", "<", "30", "days", ")", ";", "note", "that", "biomarker", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "MI", ".", "\n", "Are", "pregnant", ".", "\n" ]	[ "Scope", "Procedure", "Condition", "Measurement", "Drug", "Device", "Temporal", "Qualifier", "Value", "Observation" ]
Active, ischemia, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention, CCS functional class, IV, angina, antiarrhythmic drug, allergy , intolerance or contraindication, left ventricular thrombus, catheter ablation procedure, VT, renal failure, Creatinine clearance, < 15 mL / min, NYHA Functional class, IV, heart failure, systemic illness, survival, < 1 year, ST elevation myocardial infarction or non - ST elevation MI, < 30 days, pregnant	NCT02830360_exc_task2	Sentence: Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O" ]	Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant.	[ "Unable", "or", "unwilling", "to", "provide", "informed", "consent", ".", "\n", "Active", "ischemia", "(", "acute", "thrombus", "diagnosed", "by", "coronary", "angiography", ",", "or", "dynamic", "ST", "segment", "changes", "demonstrated", "on", "ECG", ")", "or", "another", "reversible", "cause", "of", "VT", "(", "e.g", ".", "drug", "-", "induced", "arrhythmia", ")", ",", "had", "recent", "acute", "coronary", "syndrome", "within", "30", "days", ",", "coronary", "revascularization", "(", "<", "90", "days", "bypass", "surgery", ",", "<", "30", "days", "percutaneous", "coronary", "intervention", ")", ",", "or", "have", "CCS", "functional", "class", "IV", "angina", ".", "Note", "that", "biomarker", "level", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "acute", "coronary", "syndrome", "or", "active", "ischemia", ".", "\n", "Are", "ineligible", "to", "take", "the", "antiarrhythmic", "drug", "to", "which", "they", "would", "be", "assigned", "due", "to", "allergy", ",", "intolerance", "or", "contraindication", "\n", "Are", "known", "to", "have", "protruding", "left", "ventricular", "thrombus", "or", "mechanical", "aortic", "and", "mitral", "valves", "\n", "Have", "had", "a", "prior", "catheter", "ablation", "procedure", "for", "VT", "\n", "Are", "in", "renal", "failure", "(", "Creatinine", "clearance", "<", "15", "mL", "/", "min", ")", ",", "have", "NYHA", "Functional", "class", "IV", "heart", "failure", ",", "or", "a", "systemic", "illness", "likely", "to", "limit", "survival", "to", "<", "1", "year", "\n", "Have", "had", "recent", "ST", "elevation", "myocardial", "infarction", "or", "non", "-", "ST", "elevation", "MI", "(", "<", "30", "days", ")", ";", "note", "that", "biomarker", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "MI", ".", "\n", "Are", "pregnant", ".", "\n" ]	[ "Scope", "Procedure", "Condition", "Measurement", "Drug", "Device", "Temporal", "Qualifier", "Value", "Observation" ]
renal transplant is an umlsterm, patient is an umlsterm, cyclosporin A is an umlsterm, sebaceous gland is an umlsterm, hyperplasia is an umlsterm, hyperkeratosis is an umlsterm, face is an umlsterm, limbs is an umlsterm, hyperkeratosis is an umlsterm, hair is an umlsterm, histology is an umlsterm, hyperkeratosis is an umlsterm, hair follicles is an umlsterm, hair - like is an umlsterm, hairs is an umlsterm, hairs is an umlsterm, hyperkeratosis is an umlsterm, disorders is an umlsterm, Scanning electron microscopy is an umlsterm, hair - like is an umlsterm, keratoses is an umlsterm, sebaceous glands is an umlsterm, finding is an umlsterm, observations is an umlsterm, skin is an umlsterm, side effects is an umlsterm, cyclosporin A is an umlsterm	DerHautarzt.50460841.eng.abstr_task0	Sentence: We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent .	[ "We", "report", "a", "31-year", "-", "old", "renal", "transplant", "patient", "treated", "with", "cyclosporin", "A", "who", "developed", "an", "unusual", "sebaceous", "gland", "hyperplasia", "accompanied", "by", "a", "disseminated", "follicular", "spiny", "hyperkeratosis", ".", "Those", "alterations", "were", "most", "evident", "on", "his", "face", "and", "limbs", ".", "In", "some", "locations", "hairy", "hyperkeratosis", "with", "authentic", "hair", "neogenesis", "was", "found", ".", "The", "histology", "of", "these", "alterations", "showed", "a", "marked", "hyperkeratosis", "of", "the", "hair", "follicles", "with", "formation", "of", "hair", "-", "like", "spikes", "either", "alone", "or", "in", "connection", "with", "hairs", ".", "The", "presence", "of", "true", "hairs", "distinguishes", "our", "case", "from", "the", "morphologically", "similar", "disseminated", "spiked", "hyperkeratosis", "and", "other", "spiny", "keratinization", "disorders", ".", "Scanning", "electron", "microscopy", "helped", "to", "demonstrate", "the", "hair", "-", "like", "structure", "of", "these", "keratoses", ".", "Some", "of", "the", "sebaceous", "glands", "showed", "cystic", "widening", "of", "their", "lumina", ",", "which", "were", "filled", "with", "abundant", "amorphous", "eosinophilic", "material", ",", "a", "finding", "similar", "to", "earlier", "observations", ".", "Our", "case", "demonstrates", "that", "these", "skin", "alterations", "should", "be", "classified", "as", "side", "effects", "of", "cyclosporin", "A", "and", "that", "they", "are", "apparently", "dose", "-", "dependent", "." ]	[ "umlsterm" ]
renal transplant is an umlsterm, patient is an umlsterm, cyclosporin A is an umlsterm, sebaceous gland is an umlsterm, hyperplasia is an umlsterm, hyperkeratosis is an umlsterm, face is an umlsterm, limbs is an umlsterm, hyperkeratosis is an umlsterm, hair is an umlsterm, histology is an umlsterm, hyperkeratosis is an umlsterm, hair follicles is an umlsterm, hair - like is an umlsterm, hairs is an umlsterm, hairs is an umlsterm, hyperkeratosis is an umlsterm, disorders is an umlsterm, Scanning electron microscopy is an umlsterm, hair - like is an umlsterm, keratoses is an umlsterm, sebaceous glands is an umlsterm, finding is an umlsterm, observations is an umlsterm, skin is an umlsterm, side effects is an umlsterm, cyclosporin A is an umlsterm	DerHautarzt.50460841.eng.abstr_task1	Sentence: We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent . Instructions: please typing these entity words according to sentence: renal transplant, patient, cyclosporin A, sebaceous gland, hyperplasia, hyperkeratosis, face, limbs, hyperkeratosis, hair, histology, hyperkeratosis, hair follicles, hair - like, hairs, hairs, hyperkeratosis, disorders, Scanning electron microscopy, hair - like, keratoses, sebaceous glands, finding, observations, skin, side effects, cyclosporin A Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent .	[ "We", "report", "a", "31-year", "-", "old", "renal", "transplant", "patient", "treated", "with", "cyclosporin", "A", "who", "developed", "an", "unusual", "sebaceous", "gland", "hyperplasia", "accompanied", "by", "a", "disseminated", "follicular", "spiny", "hyperkeratosis", ".", "Those", "alterations", "were", "most", "evident", "on", "his", "face", "and", "limbs", ".", "In", "some", "locations", "hairy", "hyperkeratosis", "with", "authentic", "hair", "neogenesis", "was", "found", ".", "The", "histology", "of", "these", "alterations", "showed", "a", "marked", "hyperkeratosis", "of", "the", "hair", "follicles", "with", "formation", "of", "hair", "-", "like", "spikes", "either", "alone", "or", "in", "connection", "with", "hairs", ".", "The", "presence", "of", "true", "hairs", "distinguishes", "our", "case", "from", "the", "morphologically", "similar", "disseminated", "spiked", "hyperkeratosis", "and", "other", "spiny", "keratinization", "disorders", ".", "Scanning", "electron", "microscopy", "helped", "to", "demonstrate", "the", "hair", "-", "like", "structure", "of", "these", "keratoses", ".", "Some", "of", "the", "sebaceous", "glands", "showed", "cystic", "widening", "of", "their", "lumina", ",", "which", "were", "filled", "with", "abundant", "amorphous", "eosinophilic", "material", ",", "a", "finding", "similar", "to", "earlier", "observations", ".", "Our", "case", "demonstrates", "that", "these", "skin", "alterations", "should", "be", "classified", "as", "side", "effects", "of", "cyclosporin", "A", "and", "that", "they", "are", "apparently", "dose", "-", "dependent", "." ]	[ "umlsterm" ]
renal transplant, patient, cyclosporin A, sebaceous gland, hyperplasia, hyperkeratosis, face, limbs, hyperkeratosis, hair, histology, hyperkeratosis, hair follicles, hair - like, hairs, hairs, hyperkeratosis, disorders, Scanning electron microscopy, hair - like, keratoses, sebaceous glands, finding, observations, skin, side effects, cyclosporin A	DerHautarzt.50460841.eng.abstr_task2	Sentence: We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent .	[ "We", "report", "a", "31-year", "-", "old", "renal", "transplant", "patient", "treated", "with", "cyclosporin", "A", "who", "developed", "an", "unusual", "sebaceous", "gland", "hyperplasia", "accompanied", "by", "a", "disseminated", "follicular", "spiny", "hyperkeratosis", ".", "Those", "alterations", "were", "most", "evident", "on", "his", "face", "and", "limbs", ".", "In", "some", "locations", "hairy", "hyperkeratosis", "with", "authentic", "hair", "neogenesis", "was", "found", ".", "The", "histology", "of", "these", "alterations", "showed", "a", "marked", "hyperkeratosis", "of", "the", "hair", "follicles", "with", "formation", "of", "hair", "-", "like", "spikes", "either", "alone", "or", "in", "connection", "with", "hairs", ".", "The", "presence", "of", "true", "hairs", "distinguishes", "our", "case", "from", "the", "morphologically", "similar", "disseminated", "spiked", "hyperkeratosis", "and", "other", "spiny", "keratinization", "disorders", ".", "Scanning", "electron", "microscopy", "helped", "to", "demonstrate", "the", "hair", "-", "like", "structure", "of", "these", "keratoses", ".", "Some", "of", "the", "sebaceous", "glands", "showed", "cystic", "widening", "of", "their", "lumina", ",", "which", "were", "filled", "with", "abundant", "amorphous", "eosinophilic", "material", ",", "a", "finding", "similar", "to", "earlier", "observations", ".", "Our", "case", "demonstrates", "that", "these", "skin", "alterations", "should", "be", "classified", "as", "side", "effects", "of", "cyclosporin", "A", "and", "that", "they", "are", "apparently", "dose", "-", "dependent", "." ]	[ "umlsterm" ]
Psychoanalyse is an umlsterm, Empathie is an umlsterm, Methode is an umlsterm, Arbeit is an umlsterm, Uebertragung is an umlsterm, Gegenuebertragung is an umlsterm, ichstaerkende is an umlsterm, Gegenuebertragung is an umlsterm, Kriseninterventionen is an umlsterm	Psychotherapeut.00450301.ger.abstr_task0	Sentence: Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert .	[ "Das", "interaktionelle", "Verstaendnis", "der", "Psychoanalyse", ",", "speziell", "das", "Konzept", "des", "dritten", "Punktes", "\"", "\"", "legen", "nahe", ",", "dass", "die", "Entwicklungen", "von", "Einsicht", ",", "Empathie", "und", "Beziehung", "als", "verschiedene", "Dimensionen", "des", "einen", "triangulierenden", "Prozesses", ",", "anzusehen", "sind", ",", "der", "das", "psychoanalytische", "Verstehen", "kennzeichnet", ".", "Von", "hieraus", "erscheint", "die", "psychoanalytische", "Methode", ",", "hier", "verstanden", "als", "Arbeit", "mit", "Widerstand", ",", "Uebertragung", "und", "Gegenuebertragung", ",", "nicht", "nur", "als", "ein", "Weg", "zur", "Erkenntnis", ",", "sondern", "auch", "als", "eine", "ebenso", "konfliktloesende", "wie", "ichstaerkende", "und", "damit", "speziell", "psychoanalytische", "Weise", "der", "hilfreichen", "Beziehungsbildung", ".", "Der", "Ausdruck", "\"", "Deutung", "aus", "der", "Gegenuebertragung", "\"", "bezeichnet", "eine", "Form", "psychoanalytischer", "Deutung", ",", "welche", "diesen", "Zusammenhang", "gezielt", "aufgreift", ",", "und", "dadurch", "bei", "neurotischen", "Konflikten", "auch", "fuer", "Kriseninterventionen", "genutzt", "werden", "kann", ".", "Dies", "wird", "an", "einem", "Fallbeispiel", "erlaeutert", "." ]	[ "umlsterm" ]
Psychoanalyse is an umlsterm, Empathie is an umlsterm, Methode is an umlsterm, Arbeit is an umlsterm, Uebertragung is an umlsterm, Gegenuebertragung is an umlsterm, ichstaerkende is an umlsterm, Gegenuebertragung is an umlsterm, Kriseninterventionen is an umlsterm	Psychotherapeut.00450301.ger.abstr_task1	Sentence: Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert . Instructions: please typing these entity words according to sentence: Psychoanalyse, Empathie, Methode, Arbeit, Uebertragung, Gegenuebertragung, ichstaerkende, Gegenuebertragung, Kriseninterventionen Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert .	[ "Das", "interaktionelle", "Verstaendnis", "der", "Psychoanalyse", ",", "speziell", "das", "Konzept", "des", "dritten", "Punktes", "\"", "\"", "legen", "nahe", ",", "dass", "die", "Entwicklungen", "von", "Einsicht", ",", "Empathie", "und", "Beziehung", "als", "verschiedene", "Dimensionen", "des", "einen", "triangulierenden", "Prozesses", ",", "anzusehen", "sind", ",", "der", "das", "psychoanalytische", "Verstehen", "kennzeichnet", ".", "Von", "hieraus", "erscheint", "die", "psychoanalytische", "Methode", ",", "hier", "verstanden", "als", "Arbeit", "mit", "Widerstand", ",", "Uebertragung", "und", "Gegenuebertragung", ",", "nicht", "nur", "als", "ein", "Weg", "zur", "Erkenntnis", ",", "sondern", "auch", "als", "eine", "ebenso", "konfliktloesende", "wie", "ichstaerkende", "und", "damit", "speziell", "psychoanalytische", "Weise", "der", "hilfreichen", "Beziehungsbildung", ".", "Der", "Ausdruck", "\"", "Deutung", "aus", "der", "Gegenuebertragung", "\"", "bezeichnet", "eine", "Form", "psychoanalytischer", "Deutung", ",", "welche", "diesen", "Zusammenhang", "gezielt", "aufgreift", ",", "und", "dadurch", "bei", "neurotischen", "Konflikten", "auch", "fuer", "Kriseninterventionen", "genutzt", "werden", "kann", ".", "Dies", "wird", "an", "einem", "Fallbeispiel", "erlaeutert", "." ]	[ "umlsterm" ]
Psychoanalyse, Empathie, Methode, Arbeit, Uebertragung, Gegenuebertragung, ichstaerkende, Gegenuebertragung, Kriseninterventionen	Psychotherapeut.00450301.ger.abstr_task2	Sentence: Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert .	[ "Das", "interaktionelle", "Verstaendnis", "der", "Psychoanalyse", ",", "speziell", "das", "Konzept", "des", "dritten", "Punktes", "\"", "\"", "legen", "nahe", ",", "dass", "die", "Entwicklungen", "von", "Einsicht", ",", "Empathie", "und", "Beziehung", "als", "verschiedene", "Dimensionen", "des", "einen", "triangulierenden", "Prozesses", ",", "anzusehen", "sind", ",", "der", "das", "psychoanalytische", "Verstehen", "kennzeichnet", ".", "Von", "hieraus", "erscheint", "die", "psychoanalytische", "Methode", ",", "hier", "verstanden", "als", "Arbeit", "mit", "Widerstand", ",", "Uebertragung", "und", "Gegenuebertragung", ",", "nicht", "nur", "als", "ein", "Weg", "zur", "Erkenntnis", ",", "sondern", "auch", "als", "eine", "ebenso", "konfliktloesende", "wie", "ichstaerkende", "und", "damit", "speziell", "psychoanalytische", "Weise", "der", "hilfreichen", "Beziehungsbildung", ".", "Der", "Ausdruck", "\"", "Deutung", "aus", "der", "Gegenuebertragung", "\"", "bezeichnet", "eine", "Form", "psychoanalytischer", "Deutung", ",", "welche", "diesen", "Zusammenhang", "gezielt", "aufgreift", ",", "und", "dadurch", "bei", "neurotischen", "Konflikten", "auch", "fuer", "Kriseninterventionen", "genutzt", "werden", "kann", ".", "Dies", "wird", "an", "einem", "Fallbeispiel", "erlaeutert", "." ]	[ "umlsterm" ]
Diagnostik is an umlsterm, maligner Lymphome is an umlsterm, Knochenmarkslaesionen is an umlsterm, Methoden is an umlsterm, Arbeit is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm, Patienten is an umlsterm, Knochenmarksbiopsien is an umlsterm, Lymphominfiltrate is an umlsterm, Infiltrationsgrad is an umlsterm, Durchflusszytometrie is an umlsterm, Leukaemien is an umlsterm, Lymphomen is an umlsterm, chronischen lymphatischen Leukaemie is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm	DerPathologe.00210296.ger.abstr_task0	Sentence: Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen .	[ "Bestandteil", "der", "klinischen", "Diagnostik", "beim", "Staging", "maligner", "Lymphome", ".", "Die", "Fortschritte", "der", "letzten", "Jahre", "bei", "der", "immunophaenotypischen", "Charakterisierung", "dieser", "Krankheitsentitaeten", "und", "die", "immer", "wieder", "zu", "beobachtenden", "Schwierigkeiten", "bei", "der", "Einordnung", "diskreter", "lymphoider", "Knochenmarkslaesionen", "machen", "die", "Etablierung", "weiterer", "diagnostischer", "Methoden", "wuenschenswert", ".", "Ziel", "der", "vorliegenden", "Arbeit", "ist", "die", "Evaluierung", "der", "diagnostischen", "Wertigkeit", "der", "Durchflusszytometrie", "im", "Vergleich", "zur", "herkoemmlichen", "Beckenkammbiopsie", ".", "Fuer", "die", "Untersuchung", "standen", "156", "Patienten", "mit", "insgesamt", "191", "Knochenmarksbiopsien", "bzw", ".", "Knochenmarksaspiraten", "zur", "Verfuegung", ".", "In", "der", "Auswertung", "der", "erfassten", "Daten", "ergibt", "sich", ",", "dass", "bis", "zu", "1/3", "der", "Lymphominfiltrate", "durchflusszytometrisch", "nicht", "diagnostizierbar", "sind", "und", "der", "Infiltrationsgrad", "bis", "zu", "2/3", "niedriger", "eingeschaetzt", "wird", ".", "Gute", "Ergebnisse", "sind", "mit", "der", "Durchflusszytometrie", "bei", "akuten", "Leukaemien", ",", "lymphoblastischen", "Lymphomen", ",", "Haarzellleukaemien", "sowie", "der", "chronischen", "lymphatischen", "Leukaemie", "zu", "erzielen", ".", "Insgesamt", "kommt", "der", "Durchflusszytometrie", "beim", "Lymphomstaging", "eine", "ergaenzende", "Bedeutung", "zu", ",", "kann", "aber", "die", "herkoemmliche", "Beckenkammbiopsie", "nicht", "vollstaendig", "ersetzen", "." ]	[ "umlsterm" ]
Diagnostik is an umlsterm, maligner Lymphome is an umlsterm, Knochenmarkslaesionen is an umlsterm, Methoden is an umlsterm, Arbeit is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm, Patienten is an umlsterm, Knochenmarksbiopsien is an umlsterm, Lymphominfiltrate is an umlsterm, Infiltrationsgrad is an umlsterm, Durchflusszytometrie is an umlsterm, Leukaemien is an umlsterm, Lymphomen is an umlsterm, chronischen lymphatischen Leukaemie is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm	DerPathologe.00210296.ger.abstr_task1	Sentence: Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen . Instructions: please typing these entity words according to sentence: Diagnostik, maligner Lymphome, Knochenmarkslaesionen, Methoden, Arbeit, Durchflusszytometrie, Beckenkammbiopsie, Patienten, Knochenmarksbiopsien, Lymphominfiltrate, Infiltrationsgrad, Durchflusszytometrie, Leukaemien, Lymphomen, chronischen lymphatischen Leukaemie, Durchflusszytometrie, Beckenkammbiopsie Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen .	[ "Bestandteil", "der", "klinischen", "Diagnostik", "beim", "Staging", "maligner", "Lymphome", ".", "Die", "Fortschritte", "der", "letzten", "Jahre", "bei", "der", "immunophaenotypischen", "Charakterisierung", "dieser", "Krankheitsentitaeten", "und", "die", "immer", "wieder", "zu", "beobachtenden", "Schwierigkeiten", "bei", "der", "Einordnung", "diskreter", "lymphoider", "Knochenmarkslaesionen", "machen", "die", "Etablierung", "weiterer", "diagnostischer", "Methoden", "wuenschenswert", ".", "Ziel", "der", "vorliegenden", "Arbeit", "ist", "die", "Evaluierung", "der", "diagnostischen", "Wertigkeit", "der", "Durchflusszytometrie", "im", "Vergleich", "zur", "herkoemmlichen", "Beckenkammbiopsie", ".", "Fuer", "die", "Untersuchung", "standen", "156", "Patienten", "mit", "insgesamt", "191", "Knochenmarksbiopsien", "bzw", ".", "Knochenmarksaspiraten", "zur", "Verfuegung", ".", "In", "der", "Auswertung", "der", "erfassten", "Daten", "ergibt", "sich", ",", "dass", "bis", "zu", "1/3", "der", "Lymphominfiltrate", "durchflusszytometrisch", "nicht", "diagnostizierbar", "sind", "und", "der", "Infiltrationsgrad", "bis", "zu", "2/3", "niedriger", "eingeschaetzt", "wird", ".", "Gute", "Ergebnisse", "sind", "mit", "der", "Durchflusszytometrie", "bei", "akuten", "Leukaemien", ",", "lymphoblastischen", "Lymphomen", ",", "Haarzellleukaemien", "sowie", "der", "chronischen", "lymphatischen", "Leukaemie", "zu", "erzielen", ".", "Insgesamt", "kommt", "der", "Durchflusszytometrie", "beim", "Lymphomstaging", "eine", "ergaenzende", "Bedeutung", "zu", ",", "kann", "aber", "die", "herkoemmliche", "Beckenkammbiopsie", "nicht", "vollstaendig", "ersetzen", "." ]	[ "umlsterm" ]
Diagnostik, maligner Lymphome, Knochenmarkslaesionen, Methoden, Arbeit, Durchflusszytometrie, Beckenkammbiopsie, Patienten, Knochenmarksbiopsien, Lymphominfiltrate, Infiltrationsgrad, Durchflusszytometrie, Leukaemien, Lymphomen, chronischen lymphatischen Leukaemie, Durchflusszytometrie, Beckenkammbiopsie	DerPathologe.00210296.ger.abstr_task2	Sentence: Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]	Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen .	[ "Bestandteil", "der", "klinischen", "Diagnostik", "beim", "Staging", "maligner", "Lymphome", ".", "Die", "Fortschritte", "der", "letzten", "Jahre", "bei", "der", "immunophaenotypischen", "Charakterisierung", "dieser", "Krankheitsentitaeten", "und", "die", "immer", "wieder", "zu", "beobachtenden", "Schwierigkeiten", "bei", "der", "Einordnung", "diskreter", "lymphoider", "Knochenmarkslaesionen", "machen", "die", "Etablierung", "weiterer", "diagnostischer", "Methoden", "wuenschenswert", ".", "Ziel", "der", "vorliegenden", "Arbeit", "ist", "die", "Evaluierung", "der", "diagnostischen", "Wertigkeit", "der", "Durchflusszytometrie", "im", "Vergleich", "zur", "herkoemmlichen", "Beckenkammbiopsie", ".", "Fuer", "die", "Untersuchung", "standen", "156", "Patienten", "mit", "insgesamt", "191", "Knochenmarksbiopsien", "bzw", ".", "Knochenmarksaspiraten", "zur", "Verfuegung", ".", "In", "der", "Auswertung", "der", "erfassten", "Daten", "ergibt", "sich", ",", "dass", "bis", "zu", "1/3", "der", "Lymphominfiltrate", "durchflusszytometrisch", "nicht", "diagnostizierbar", "sind", "und", "der", "Infiltrationsgrad", "bis", "zu", "2/3", "niedriger", "eingeschaetzt", "wird", ".", "Gute", "Ergebnisse", "sind", "mit", "der", "Durchflusszytometrie", "bei", "akuten", "Leukaemien", ",", "lymphoblastischen", "Lymphomen", ",", "Haarzellleukaemien", "sowie", "der", "chronischen", "lymphatischen", "Leukaemie", "zu", "erzielen", ".", "Insgesamt", "kommt", "der", "Durchflusszytometrie", "beim", "Lymphomstaging", "eine", "ergaenzende", "Bedeutung", "zu", ",", "kann", "aber", "die", "herkoemmliche", "Beckenkammbiopsie", "nicht", "vollstaendig", "ersetzen", "." ]	[ "umlsterm" ]
Pemphigus is an umlsterm, Tumor is an umlsterm, Mundschleimhaut is an umlsterm, Lippen is an umlsterm, Haut is an umlsterm, Pemphigus vulgaris is an umlsterm, Patienten is an umlsterm, Lichen planus is an umlsterm, Patienten is an umlsterm, Autoantikoerper is an umlsterm, Immunpraezipitation is an umlsterm, Proteinkomplex is an umlsterm, Akantholyse is an umlsterm, Einzelnekrosen is an umlsterm, Immunfluoreszenz is an umlsterm, Harnblase is an umlsterm, Immunfluoreszenz is an umlsterm, Antigenkomplex is an umlsterm, Antigene is an umlsterm, Pemphigus vulgaris is an umlsterm, Pemphigus is an umlsterm, Harnblasenepithel is an umlsterm, Diagnose is an umlsterm	DerHautarzt.40450827.ger.abstr_task0	Sentence: Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP .	[ "Zusammenfassung", ".", "Der", "paraneoplastische", "Pemphigus", "(", "PP", ")", "ist", "eine", "neue", "Autoimmundermatose", ",", "die", "obligat", "mit", "einem", "Tumor", "assoziiert", "ist", ".", "Klinisch", "kommt", "es", "zu", "schmerzhaften", "Erosionen", "der", "Konjunktival-", "und", "Mundschleimhaut", "unter", "Einbeziehung", "der", "Lippen", ".", "An", "der", "Haut", "finden", "sich", "polymorphe", "Veraenderungen", ",", "die", "an", "ein", "Erythema", "exsudativum", "multiforme", "(", "EEM", ")", ",", "einen", "Pemphigus", "vulgaris", "und", "bei", "manchen", "Patienten", "auch", "an", "einen", "Lichen", "planus", "pemphigoides", "erinnern", ".", "Die", "Seren", "der", "Patienten", "weisen", "Autoantikoerper", "auf", ",", "die", "in", "der", "Immunpraezipitation", "von", "Keratinozytenextrakten", "an", "einen", "distinkten", "Proteinkomplex", "binden", ".", "Dieser", "besteht", "aus", "Desmoplakin", "I", "(", "250", "kD", ")", ",", "dem", "bulloesen", "Pemphigoid", "-", "Hauptantigen", "(", "230", "kD", ")", ",", "Desmoplakin", "II", "(", "210", "kD", ")", ",", "sowie", "einem", "190-", "und", "170-kD", "-", "Protein", ",", "die", "bislang", "noch", "nicht", "naeher", "charakterisiert", "wurden", ".", "Histologisch", "finden", "sich", "Akantholyse", "Einzelnekrosen", ",", "vakuolige", "Basalzelldegenerationen", "und", ",", "in", "manchen", "Praeparaten", "lichenoide", "Infiltrate", "im", "oberen", "Korium", ".", "In", "der", "direkten", "Immunfluoreszenz", "sieht", "man", "interzellulaere", "epidermale", "Ablagerungen", "und", "granulaere", "Ablagerungen", "an", "der", "Basalmembran", ".", "Verwendet", "man", "Harnblase", "von", "Nagetieren", "als", "Substrat", "fuer", "die", "indirekte", "Immunfluoreszenz", ",", "erkennt", "man", "interzellulaere", "IgG", "-", "Ablagerungen", ".", "Anders", "als", "der", "Antigenkomplex", "des", "PP", "werden", "die", "Antigene", "des", "Pemphigus", "vulgaris", "und", "des", "Pemphigus", "foliaceus", "in", "Harnblasenepithel", "nicht", "exprimiert", ".", "Dies", "ist", "daher", "die", "einfachste", "und", "kostenguenstigste", "Untersuchungsmethode", "zur", "Diagnose", "eines", "PP", "." ]	[ "umlsterm" ]
Pemphigus is an umlsterm, Tumor is an umlsterm, Mundschleimhaut is an umlsterm, Lippen is an umlsterm, Haut is an umlsterm, Pemphigus vulgaris is an umlsterm, Patienten is an umlsterm, Lichen planus is an umlsterm, Patienten is an umlsterm, Autoantikoerper is an umlsterm, Immunpraezipitation is an umlsterm, Proteinkomplex is an umlsterm, Akantholyse is an umlsterm, Einzelnekrosen is an umlsterm, Immunfluoreszenz is an umlsterm, Harnblase is an umlsterm, Immunfluoreszenz is an umlsterm, Antigenkomplex is an umlsterm, Antigene is an umlsterm, Pemphigus vulgaris is an umlsterm, Pemphigus is an umlsterm, Harnblasenepithel is an umlsterm, Diagnose is an umlsterm	DerHautarzt.40450827.ger.abstr_task1	Sentence: Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP . Instructions: please typing these entity words according to sentence: Pemphigus, Tumor, Mundschleimhaut, Lippen, Haut, Pemphigus vulgaris, Patienten, Lichen planus, Patienten, Autoantikoerper, Immunpraezipitation, Proteinkomplex, Akantholyse, Einzelnekrosen, Immunfluoreszenz, Harnblase, Immunfluoreszenz, Antigenkomplex, Antigene, Pemphigus vulgaris, Pemphigus, Harnblasenepithel, Diagnose Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP .	[ "Zusammenfassung", ".", "Der", "paraneoplastische", "Pemphigus", "(", "PP", ")", "ist", "eine", "neue", "Autoimmundermatose", ",", "die", "obligat", "mit", "einem", "Tumor", "assoziiert", "ist", ".", "Klinisch", "kommt", "es", "zu", "schmerzhaften", "Erosionen", "der", "Konjunktival-", "und", "Mundschleimhaut", "unter", "Einbeziehung", "der", "Lippen", ".", "An", "der", "Haut", "finden", "sich", "polymorphe", "Veraenderungen", ",", "die", "an", "ein", "Erythema", "exsudativum", "multiforme", "(", "EEM", ")", ",", "einen", "Pemphigus", "vulgaris", "und", "bei", "manchen", "Patienten", "auch", "an", "einen", "Lichen", "planus", "pemphigoides", "erinnern", ".", "Die", "Seren", "der", "Patienten", "weisen", "Autoantikoerper", "auf", ",", "die", "in", "der", "Immunpraezipitation", "von", "Keratinozytenextrakten", "an", "einen", "distinkten", "Proteinkomplex", "binden", ".", "Dieser", "besteht", "aus", "Desmoplakin", "I", "(", "250", "kD", ")", ",", "dem", "bulloesen", "Pemphigoid", "-", "Hauptantigen", "(", "230", "kD", ")", ",", "Desmoplakin", "II", "(", "210", "kD", ")", ",", "sowie", "einem", "190-", "und", "170-kD", "-", "Protein", ",", "die", "bislang", "noch", "nicht", "naeher", "charakterisiert", "wurden", ".", "Histologisch", "finden", "sich", "Akantholyse", "Einzelnekrosen", ",", "vakuolige", "Basalzelldegenerationen", "und", ",", "in", "manchen", "Praeparaten", "lichenoide", "Infiltrate", "im", "oberen", "Korium", ".", "In", "der", "direkten", "Immunfluoreszenz", "sieht", "man", "interzellulaere", "epidermale", "Ablagerungen", "und", "granulaere", "Ablagerungen", "an", "der", "Basalmembran", ".", "Verwendet", "man", "Harnblase", "von", "Nagetieren", "als", "Substrat", "fuer", "die", "indirekte", "Immunfluoreszenz", ",", "erkennt", "man", "interzellulaere", "IgG", "-", "Ablagerungen", ".", "Anders", "als", "der", "Antigenkomplex", "des", "PP", "werden", "die", "Antigene", "des", "Pemphigus", "vulgaris", "und", "des", "Pemphigus", "foliaceus", "in", "Harnblasenepithel", "nicht", "exprimiert", ".", "Dies", "ist", "daher", "die", "einfachste", "und", "kostenguenstigste", "Untersuchungsmethode", "zur", "Diagnose", "eines", "PP", "." ]	[ "umlsterm" ]
Pemphigus, Tumor, Mundschleimhaut, Lippen, Haut, Pemphigus vulgaris, Patienten, Lichen planus, Patienten, Autoantikoerper, Immunpraezipitation, Proteinkomplex, Akantholyse, Einzelnekrosen, Immunfluoreszenz, Harnblase, Immunfluoreszenz, Antigenkomplex, Antigene, Pemphigus vulgaris, Pemphigus, Harnblasenepithel, Diagnose	DerHautarzt.40450827.ger.abstr_task2	Sentence: Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP .	[ "Zusammenfassung", ".", "Der", "paraneoplastische", "Pemphigus", "(", "PP", ")", "ist", "eine", "neue", "Autoimmundermatose", ",", "die", "obligat", "mit", "einem", "Tumor", "assoziiert", "ist", ".", "Klinisch", "kommt", "es", "zu", "schmerzhaften", "Erosionen", "der", "Konjunktival-", "und", "Mundschleimhaut", "unter", "Einbeziehung", "der", "Lippen", ".", "An", "der", "Haut", "finden", "sich", "polymorphe", "Veraenderungen", ",", "die", "an", "ein", "Erythema", "exsudativum", "multiforme", "(", "EEM", ")", ",", "einen", "Pemphigus", "vulgaris", "und", "bei", "manchen", "Patienten", "auch", "an", "einen", "Lichen", "planus", "pemphigoides", "erinnern", ".", "Die", "Seren", "der", "Patienten", "weisen", "Autoantikoerper", "auf", ",", "die", "in", "der", "Immunpraezipitation", "von", "Keratinozytenextrakten", "an", "einen", "distinkten", "Proteinkomplex", "binden", ".", "Dieser", "besteht", "aus", "Desmoplakin", "I", "(", "250", "kD", ")", ",", "dem", "bulloesen", "Pemphigoid", "-", "Hauptantigen", "(", "230", "kD", ")", ",", "Desmoplakin", "II", "(", "210", "kD", ")", ",", "sowie", "einem", "190-", "und", "170-kD", "-", "Protein", ",", "die", "bislang", "noch", "nicht", "naeher", "charakterisiert", "wurden", ".", "Histologisch", "finden", "sich", "Akantholyse", "Einzelnekrosen", ",", "vakuolige", "Basalzelldegenerationen", "und", ",", "in", "manchen", "Praeparaten", "lichenoide", "Infiltrate", "im", "oberen", "Korium", ".", "In", "der", "direkten", "Immunfluoreszenz", "sieht", "man", "interzellulaere", "epidermale", "Ablagerungen", "und", "granulaere", "Ablagerungen", "an", "der", "Basalmembran", ".", "Verwendet", "man", "Harnblase", "von", "Nagetieren", "als", "Substrat", "fuer", "die", "indirekte", "Immunfluoreszenz", ",", "erkennt", "man", "interzellulaere", "IgG", "-", "Ablagerungen", ".", "Anders", "als", "der", "Antigenkomplex", "des", "PP", "werden", "die", "Antigene", "des", "Pemphigus", "vulgaris", "und", "des", "Pemphigus", "foliaceus", "in", "Harnblasenepithel", "nicht", "exprimiert", ".", "Dies", "ist", "daher", "die", "einfachste", "und", "kostenguenstigste", "Untersuchungsmethode", "zur", "Diagnose", "eines", "PP", "." ]	[ "umlsterm" ]
Tumoren is an umlsterm, Routinediagnostik is an umlsterm, Diagnosestellung is an umlsterm, malignen Melanoms is an umlsterm, Naevus is an umlsterm, Tumorparameter is an umlsterm, malignen Melanomen is an umlsterm, Diagnostik is an umlsterm, malignen Melanomen is an umlsterm	DerHautarzt.70480720.ger.abstr_task0	Sentence: Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst .	[ "Die", "Begutachtung", "melanozytaerer", "Tumoren", "repraesentiert", "einen", "der", "wichtigsten", "und", "vordringlichsten", "Aspekte", "der", "Routinediagnostik", "in", "der", "Dermatohistopathologie", ".", "Fuer", "die", "Diagnosestellung", "eines", "malignen", "Melanoms", "oder", "eines", "differentialdiagnostisch", "in", "Frage", "kommenden", "melanozytaeren", "Naevus", "sind", "einheitliche", "und", "reproduzierbare", "histologische", "Kriterien", "zu", "fordern", ".", "Die", "prognostisch", "relevanten", "und", "fuer", "das", "therapeutische", "Vorgehen", "wichtigen", "Tumorparameter", "muessen", "bei", "malignen", "Melanomen", "im", "histopathologischen", "Befundbericht", "vollstaendig", "und", "einheitlich", "erfasst", "werden", ".", "Die", "Empfehlungen", "der", "Arbeitsgruppe", "zur", "histopathologischen", "Diagnostik", "bei", "malignen", "Melanomen", "sind", "nachfolgend", "zusammengefasst", "." ]	[ "umlsterm" ]
Tumoren is an umlsterm, Routinediagnostik is an umlsterm, Diagnosestellung is an umlsterm, malignen Melanoms is an umlsterm, Naevus is an umlsterm, Tumorparameter is an umlsterm, malignen Melanomen is an umlsterm, Diagnostik is an umlsterm, malignen Melanomen is an umlsterm	DerHautarzt.70480720.ger.abstr_task1	Sentence: Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst . Instructions: please typing these entity words according to sentence: Tumoren, Routinediagnostik, Diagnosestellung, malignen Melanoms, Naevus, Tumorparameter, malignen Melanomen, Diagnostik, malignen Melanomen Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst .	[ "Die", "Begutachtung", "melanozytaerer", "Tumoren", "repraesentiert", "einen", "der", "wichtigsten", "und", "vordringlichsten", "Aspekte", "der", "Routinediagnostik", "in", "der", "Dermatohistopathologie", ".", "Fuer", "die", "Diagnosestellung", "eines", "malignen", "Melanoms", "oder", "eines", "differentialdiagnostisch", "in", "Frage", "kommenden", "melanozytaeren", "Naevus", "sind", "einheitliche", "und", "reproduzierbare", "histologische", "Kriterien", "zu", "fordern", ".", "Die", "prognostisch", "relevanten", "und", "fuer", "das", "therapeutische", "Vorgehen", "wichtigen", "Tumorparameter", "muessen", "bei", "malignen", "Melanomen", "im", "histopathologischen", "Befundbericht", "vollstaendig", "und", "einheitlich", "erfasst", "werden", ".", "Die", "Empfehlungen", "der", "Arbeitsgruppe", "zur", "histopathologischen", "Diagnostik", "bei", "malignen", "Melanomen", "sind", "nachfolgend", "zusammengefasst", "." ]	[ "umlsterm" ]
Tumoren, Routinediagnostik, Diagnosestellung, malignen Melanoms, Naevus, Tumorparameter, malignen Melanomen, Diagnostik, malignen Melanomen	DerHautarzt.70480720.ger.abstr_task2	Sentence: Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]	Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst .	[ "Die", "Begutachtung", "melanozytaerer", "Tumoren", "repraesentiert", "einen", "der", "wichtigsten", "und", "vordringlichsten", "Aspekte", "der", "Routinediagnostik", "in", "der", "Dermatohistopathologie", ".", "Fuer", "die", "Diagnosestellung", "eines", "malignen", "Melanoms", "oder", "eines", "differentialdiagnostisch", "in", "Frage", "kommenden", "melanozytaeren", "Naevus", "sind", "einheitliche", "und", "reproduzierbare", "histologische", "Kriterien", "zu", "fordern", ".", "Die", "prognostisch", "relevanten", "und", "fuer", "das", "therapeutische", "Vorgehen", "wichtigen", "Tumorparameter", "muessen", "bei", "malignen", "Melanomen", "im", "histopathologischen", "Befundbericht", "vollstaendig", "und", "einheitlich", "erfasst", "werden", ".", "Die", "Empfehlungen", "der", "Arbeitsgruppe", "zur", "histopathologischen", "Diagnostik", "bei", "malignen", "Melanomen", "sind", "nachfolgend", "zusammengefasst", "." ]	[ "umlsterm" ]
ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells is a Protein, ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, ICSAT is a Protein, ICSBP is a Protein, ICSAT is a Protein, tax is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, IRF-1 is a Protein, IRF-2 is a Protein, ICSBP is a Protein, ICSAT is a Protein, IRF-2 is a Protein, ICSBP is a Protein	588_task0	Sentence: A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes.	[ "A", "novel", "interferon", "regulatory", "factor", "family", "transcription", "factor", ",", "ICSAT", "/", "Pip", "/", "LSIRF", ",", "that", "negatively", "regulates", "the", "activity", "of", "interferon", "-", "regulated", "genes", ".", "\n", "We", "have", "isolated", "a", "novel", "cDNA", "clone", "encoding", "interferon", "(", "IFN", ")", "consensus", "sequence", "-", "binding", "protein", "in", "adult", "T", "-", "cell", "leukemia", "cell", "line", "or", "activated", "T", "cells", "(", "ICSAT", ")", ";", "this", "protein", "is", "the", "human", "homolog", "of", "the", "recently", "cloned", "Pip", "/", "LSIRF", ".", "ICSAT", "is", "structurally", "most", "closely", "related", "to", "the", "previously", "cloned", "ICSBP", ",", "a", "member", "of", "the", "IFN", "regulatory", "factor", "(", "IRF", ")", "family", "of", "proteins", "that", "binds", "to", "interferon", "consensus", "sequences", "(", "ICSs", ")", "found", "in", "many", "promoters", "of", "the", "IFN", "-", "regulated", "genes", ".", "Among", "T", "-", "cell", "lines", "investigated", ",", "ICSAT", "was", "abundantly", "expressed", "in", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-infected", "T", "cells", ".", "When", "the", "HTLV-1", "tax", "gene", "was", "expressed", "or", "phorbol", "myristake", "acetate", "-", "A23187", "stimulation", "was", "used", ",", "ICSAT", "expression", "was", "induced", "in", "Jurkat", "cells", "which", "otherwise", "do", "not", "express", "ICSAT", ".", "When", "the", "binding", "of", "ICSAT", "to", "four", "different", "ICSs", "was", "tested", ",", "the", "relative", "differences", "in", "binding", "affinities", "for", "those", "ICSs", "were", "determined", ".", "To", "study", "the", "functional", "role", "of", "ICSAT", ",", "we", "performed", "cotransfection", "experiments", "with", "the", "human", "embryonal", "carcinoma", "cell", "line", "N", "-", "Tera2", ".", "ICSAT", "was", "demonstrated", "to", "possess", "repressive", "function", "over", "the", "gene", "activation", "induced", "by", "IFN", "stimulation", "or", "by", "IRF-1", "cotransfection", ".", "Such", "repressive", "function", "is", "similar", "to", "that", "seen", "in", "IRF-2", "or", "ICSBP", ".", "However", ",", "we", "have", "found", "that", "ICSAT", "has", "a", "different", "repressive", "effect", "from", "that", "of", "IRF-2", "or", "ICSBP", "in", "some", "IFN", "-", "responsive", "reporter", "constructs", ".", "These", "results", "suggest", "that", "a", "novel", "mechanism", "of", "gene", "regulation", "by", "\"", "differential", "repression", "\"", "is", "used", "by", "multiple", "members", "of", "repressor", "proteins", "with", "different", "repressive", "effects", "on", "the", "IFN", "-", "responsive", "genes", "." ]	[ "Protein" ]
ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells is a Protein, ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, ICSAT is a Protein, ICSBP is a Protein, ICSAT is a Protein, tax is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, IRF-1 is a Protein, IRF-2 is a Protein, ICSBP is a Protein, ICSAT is a Protein, IRF-2 is a Protein, ICSBP is a Protein	588_task1	Sentence: A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes. Instructions: please typing these entity words according to sentence: ICSAT, Pip, LSIRF, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells, ICSAT, Pip, LSIRF, ICSAT, ICSBP, ICSAT, tax, ICSAT, ICSAT, ICSAT, ICSAT, ICSAT, IRF-1, IRF-2, ICSBP, ICSAT, IRF-2, ICSBP Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes.	[ "A", "novel", "interferon", "regulatory", "factor", "family", "transcription", "factor", ",", "ICSAT", "/", "Pip", "/", "LSIRF", ",", "that", "negatively", "regulates", "the", "activity", "of", "interferon", "-", "regulated", "genes", ".", "\n", "We", "have", "isolated", "a", "novel", "cDNA", "clone", "encoding", "interferon", "(", "IFN", ")", "consensus", "sequence", "-", "binding", "protein", "in", "adult", "T", "-", "cell", "leukemia", "cell", "line", "or", "activated", "T", "cells", "(", "ICSAT", ")", ";", "this", "protein", "is", "the", "human", "homolog", "of", "the", "recently", "cloned", "Pip", "/", "LSIRF", ".", "ICSAT", "is", "structurally", "most", "closely", "related", "to", "the", "previously", "cloned", "ICSBP", ",", "a", "member", "of", "the", "IFN", "regulatory", "factor", "(", "IRF", ")", "family", "of", "proteins", "that", "binds", "to", "interferon", "consensus", "sequences", "(", "ICSs", ")", "found", "in", "many", "promoters", "of", "the", "IFN", "-", "regulated", "genes", ".", "Among", "T", "-", "cell", "lines", "investigated", ",", "ICSAT", "was", "abundantly", "expressed", "in", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-infected", "T", "cells", ".", "When", "the", "HTLV-1", "tax", "gene", "was", "expressed", "or", "phorbol", "myristake", "acetate", "-", "A23187", "stimulation", "was", "used", ",", "ICSAT", "expression", "was", "induced", "in", "Jurkat", "cells", "which", "otherwise", "do", "not", "express", "ICSAT", ".", "When", "the", "binding", "of", "ICSAT", "to", "four", "different", "ICSs", "was", "tested", ",", "the", "relative", "differences", "in", "binding", "affinities", "for", "those", "ICSs", "were", "determined", ".", "To", "study", "the", "functional", "role", "of", "ICSAT", ",", "we", "performed", "cotransfection", "experiments", "with", "the", "human", "embryonal", "carcinoma", "cell", "line", "N", "-", "Tera2", ".", "ICSAT", "was", "demonstrated", "to", "possess", "repressive", "function", "over", "the", "gene", "activation", "induced", "by", "IFN", "stimulation", "or", "by", "IRF-1", "cotransfection", ".", "Such", "repressive", "function", "is", "similar", "to", "that", "seen", "in", "IRF-2", "or", "ICSBP", ".", "However", ",", "we", "have", "found", "that", "ICSAT", "has", "a", "different", "repressive", "effect", "from", "that", "of", "IRF-2", "or", "ICSBP", "in", "some", "IFN", "-", "responsive", "reporter", "constructs", ".", "These", "results", "suggest", "that", "a", "novel", "mechanism", "of", "gene", "regulation", "by", "\"", "differential", "repression", "\"", "is", "used", "by", "multiple", "members", "of", "repressor", "proteins", "with", "different", "repressive", "effects", "on", "the", "IFN", "-", "responsive", "genes", "." ]	[ "Protein" ]
ICSAT, Pip, LSIRF, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells, ICSAT, Pip, LSIRF, ICSAT, ICSBP, ICSAT, tax, ICSAT, ICSAT, ICSAT, ICSAT, ICSAT, IRF-1, IRF-2, ICSBP, ICSAT, IRF-2, ICSBP	588_task2	Sentence: A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes.	[ "A", "novel", "interferon", "regulatory", "factor", "family", "transcription", "factor", ",", "ICSAT", "/", "Pip", "/", "LSIRF", ",", "that", "negatively", "regulates", "the", "activity", "of", "interferon", "-", "regulated", "genes", ".", "\n", "We", "have", "isolated", "a", "novel", "cDNA", "clone", "encoding", "interferon", "(", "IFN", ")", "consensus", "sequence", "-", "binding", "protein", "in", "adult", "T", "-", "cell", "leukemia", "cell", "line", "or", "activated", "T", "cells", "(", "ICSAT", ")", ";", "this", "protein", "is", "the", "human", "homolog", "of", "the", "recently", "cloned", "Pip", "/", "LSIRF", ".", "ICSAT", "is", "structurally", "most", "closely", "related", "to", "the", "previously", "cloned", "ICSBP", ",", "a", "member", "of", "the", "IFN", "regulatory", "factor", "(", "IRF", ")", "family", "of", "proteins", "that", "binds", "to", "interferon", "consensus", "sequences", "(", "ICSs", ")", "found", "in", "many", "promoters", "of", "the", "IFN", "-", "regulated", "genes", ".", "Among", "T", "-", "cell", "lines", "investigated", ",", "ICSAT", "was", "abundantly", "expressed", "in", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-infected", "T", "cells", ".", "When", "the", "HTLV-1", "tax", "gene", "was", "expressed", "or", "phorbol", "myristake", "acetate", "-", "A23187", "stimulation", "was", "used", ",", "ICSAT", "expression", "was", "induced", "in", "Jurkat", "cells", "which", "otherwise", "do", "not", "express", "ICSAT", ".", "When", "the", "binding", "of", "ICSAT", "to", "four", "different", "ICSs", "was", "tested", ",", "the", "relative", "differences", "in", "binding", "affinities", "for", "those", "ICSs", "were", "determined", ".", "To", "study", "the", "functional", "role", "of", "ICSAT", ",", "we", "performed", "cotransfection", "experiments", "with", "the", "human", "embryonal", "carcinoma", "cell", "line", "N", "-", "Tera2", ".", "ICSAT", "was", "demonstrated", "to", "possess", "repressive", "function", "over", "the", "gene", "activation", "induced", "by", "IFN", "stimulation", "or", "by", "IRF-1", "cotransfection", ".", "Such", "repressive", "function", "is", "similar", "to", "that", "seen", "in", "IRF-2", "or", "ICSBP", ".", "However", ",", "we", "have", "found", "that", "ICSAT", "has", "a", "different", "repressive", "effect", "from", "that", "of", "IRF-2", "or", "ICSBP", "in", "some", "IFN", "-", "responsive", "reporter", "constructs", ".", "These", "results", "suggest", "that", "a", "novel", "mechanism", "of", "gene", "regulation", "by", "\"", "differential", "repression", "\"", "is", "used", "by", "multiple", "members", "of", "repressor", "proteins", "with", "different", "repressive", "effects", "on", "the", "IFN", "-", "responsive", "genes", "." ]	[ "Protein" ]
cyclosporin A is a Intervention_Pharmacological, methotrexate is a Intervention_Pharmacological, rheumatoid arthritis . is a Participant_Condition, feasibility and outcome is a Outcome_Other, cyclosporin A ( CSA ) is a Intervention_Pharmacological, methotrexate ( MTX ) is a Intervention_Pharmacological, nonerosive RA is a Participant_Condition, MTX in combination is a Intervention_Pharmacological, single - agent is a Intervention_Physical, Safety , clinical efficacy is a Outcome_Other, survival on treatment is a Outcome_Mortality, radiographic progression is a Outcome_Physical, 7 of the 57 patients is a Participant_Sample-size, adverse events is a Outcome_Adverse-effects, damage score and number of eroded joints is a Outcome_Physical, early RA is a Participant_Condition	8646_task0	Sentence: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA .	[ "Step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "or", "methotrexate", "as", "maintenance", "therapy", "in", "early", "rheumatoid", "arthritis", ".", "OBJECTIVE", "To", "evaluate", "the", "feasibility", "and", "outcome", "of", "the", "step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "(", "CSA", ")", "or", "methotrexate", "(", "MTX", ")", "as", "maintenance", "therapy", "following", "6", "months", "treatment", "with", "these", "2", "agents", "in", "combination", "in", "early", ",", "nonerosive", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Fifty", "-", "seven", "patients", "younger", "than", "65", "years", "with", "early", ",", "nonerosive", "RA", "were", "first", "treated", "with", "CSA", "and", "MTX", "in", "combination", "for", "6", "months", ".", "They", "were", "then", "randomly", "stepped", "down", "to", "single", "-", "agent", "maintenance", "treatment", "for", "another", "18", "months", ".", "Safety", ",", "clinical", "efficacy", ",", "survival", "on", "treatment", ",", "and", "radiographic", "progression", "were", "evaluated", ".", "RESULTS", "When", "being", "treated", "with", "combination", "therapy", ",", "7", "of", "the", "57", "patients", "(", "12.3", "%", ")", "withdrew", "because", "of", "adverse", "events", ".", "Of", "the", "remaining", "50", "patients", ",", "42", "(", "84.0", "%", ")", "were", "American", "College", "of", "Rheumatology", "(", "ACR", ")", "20", "%", "responders", ",", "30", "(", "60.0", "%", ")", "were", "ACR", "50", "%", "responders", ",", "and", "23", "(", "46.0", "%", ")", "were", "ACR", "70", "%", "responders", ".", "At", "month", "6", ",", "22", "patients", "were", "randomized", "to", "CSA", "and", "27", "to", "MTX", ".", "During", "this", "trial", "period", ",", "the", "treatment", "was", "discontinued", "by", "16", "patients", "taking", "CSA", "(", "mainly", "because", "of", "loss", "of", "efficacy", ")", "and", "by", "4", "taking", "MTX", ".", "At", "month", "24", ",", "the", "probability", "(", "+", "/-", "SEM", ")", "of", "survival", "on", "treatment", "was", "0.273", "+", "/-", "0.09", "for", "CSA", "and", "0.852", "+", "/-", "0.07", "for", "MTX", ".", "Of", "the", "6", "CSA", "patients", "who", "completed", "the", "trial", ",", "4", "(", "66.7", "%", ")", "were", "ACR", "20", "%", "responders", ",", "and", "3", "(", "50", "%", ")", "were", "both", "ACR", "50", "%", "and", "ACR", "70", "%", "responders", ".", "Of", "the", "23", "completers", "in", "the", "MTX", "arm", ",", "21", "(", "91.3", "%", ")", "were", "ACR", "20", "%", "responders", ",", "18", "(", "78.3", "%", ")", "were", "ACR", "50", "%", ",", "and", "10", "(", "43.5", "%", ")", "were", "ACR", "70", "%", "responders", ".", "The", "treatment", "was", "not", "responsible", "for", "severe", "adverse", "events", ".", "Radiography", "showed", "a", "slow", "progression", "in", "the", "damage", "score", "and", "number", "of", "eroded", "joints", "in", "both", "treatment", "groups", ".", "CONCLUSION", "Stepping", "down", "to", "single", "agent", "maintenance", "therapy", "following", "6", "months", "of", "combination", "treatment", "with", "CSA", "and", "MTX", "in", "early", "RA", "was", "only", "successful", "with", "MTX", ".", "Because", "this", "treatment", "did", "not", "prevent", "some", "radiographic", "progression", ",", "other", "approaches", "(", "e.g", ".", ",", "step", "-", "up", "approach", ")", "may", "be", "more", "appropriate", "in", "early", "RA", "." ]	[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size", "Outcome_Adverse-effects", "Intervention_Physical" ]
cyclosporin A is a Intervention_Pharmacological, methotrexate is a Intervention_Pharmacological, rheumatoid arthritis . is a Participant_Condition, feasibility and outcome is a Outcome_Other, cyclosporin A ( CSA ) is a Intervention_Pharmacological, methotrexate ( MTX ) is a Intervention_Pharmacological, nonerosive RA is a Participant_Condition, MTX in combination is a Intervention_Pharmacological, single - agent is a Intervention_Physical, Safety , clinical efficacy is a Outcome_Other, survival on treatment is a Outcome_Mortality, radiographic progression is a Outcome_Physical, 7 of the 57 patients is a Participant_Sample-size, adverse events is a Outcome_Adverse-effects, damage score and number of eroded joints is a Outcome_Physical, early RA is a Participant_Condition	8646_task1	Sentence: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA . Instructions: please typing these entity words according to sentence: cyclosporin A, methotrexate, rheumatoid arthritis ., feasibility and outcome, cyclosporin A ( CSA ), methotrexate ( MTX ), nonerosive RA, MTX in combination, single - agent, Safety , clinical efficacy, survival on treatment, radiographic progression, 7 of the 57 patients, adverse events, damage score and number of eroded joints, early RA Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA .	[ "Step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "or", "methotrexate", "as", "maintenance", "therapy", "in", "early", "rheumatoid", "arthritis", ".", "OBJECTIVE", "To", "evaluate", "the", "feasibility", "and", "outcome", "of", "the", "step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "(", "CSA", ")", "or", "methotrexate", "(", "MTX", ")", "as", "maintenance", "therapy", "following", "6", "months", "treatment", "with", "these", "2", "agents", "in", "combination", "in", "early", ",", "nonerosive", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Fifty", "-", "seven", "patients", "younger", "than", "65", "years", "with", "early", ",", "nonerosive", "RA", "were", "first", "treated", "with", "CSA", "and", "MTX", "in", "combination", "for", "6", "months", ".", "They", "were", "then", "randomly", "stepped", "down", "to", "single", "-", "agent", "maintenance", "treatment", "for", "another", "18", "months", ".", "Safety", ",", "clinical", "efficacy", ",", "survival", "on", "treatment", ",", "and", "radiographic", "progression", "were", "evaluated", ".", "RESULTS", "When", "being", "treated", "with", "combination", "therapy", ",", "7", "of", "the", "57", "patients", "(", "12.3", "%", ")", "withdrew", "because", "of", "adverse", "events", ".", "Of", "the", "remaining", "50", "patients", ",", "42", "(", "84.0", "%", ")", "were", "American", "College", "of", "Rheumatology", "(", "ACR", ")", "20", "%", "responders", ",", "30", "(", "60.0", "%", ")", "were", "ACR", "50", "%", "responders", ",", "and", "23", "(", "46.0", "%", ")", "were", "ACR", "70", "%", "responders", ".", "At", "month", "6", ",", "22", "patients", "were", "randomized", "to", "CSA", "and", "27", "to", "MTX", ".", "During", "this", "trial", "period", ",", "the", "treatment", "was", "discontinued", "by", "16", "patients", "taking", "CSA", "(", "mainly", "because", "of", "loss", "of", "efficacy", ")", "and", "by", "4", "taking", "MTX", ".", "At", "month", "24", ",", "the", "probability", "(", "+", "/-", "SEM", ")", "of", "survival", "on", "treatment", "was", "0.273", "+", "/-", "0.09", "for", "CSA", "and", "0.852", "+", "/-", "0.07", "for", "MTX", ".", "Of", "the", "6", "CSA", "patients", "who", "completed", "the", "trial", ",", "4", "(", "66.7", "%", ")", "were", "ACR", "20", "%", "responders", ",", "and", "3", "(", "50", "%", ")", "were", "both", "ACR", "50", "%", "and", "ACR", "70", "%", "responders", ".", "Of", "the", "23", "completers", "in", "the", "MTX", "arm", ",", "21", "(", "91.3", "%", ")", "were", "ACR", "20", "%", "responders", ",", "18", "(", "78.3", "%", ")", "were", "ACR", "50", "%", ",", "and", "10", "(", "43.5", "%", ")", "were", "ACR", "70", "%", "responders", ".", "The", "treatment", "was", "not", "responsible", "for", "severe", "adverse", "events", ".", "Radiography", "showed", "a", "slow", "progression", "in", "the", "damage", "score", "and", "number", "of", "eroded", "joints", "in", "both", "treatment", "groups", ".", "CONCLUSION", "Stepping", "down", "to", "single", "agent", "maintenance", "therapy", "following", "6", "months", "of", "combination", "treatment", "with", "CSA", "and", "MTX", "in", "early", "RA", "was", "only", "successful", "with", "MTX", ".", "Because", "this", "treatment", "did", "not", "prevent", "some", "radiographic", "progression", ",", "other", "approaches", "(", "e.g", ".", ",", "step", "-", "up", "approach", ")", "may", "be", "more", "appropriate", "in", "early", "RA", "." ]	[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size", "Outcome_Adverse-effects", "Intervention_Physical" ]
cyclosporin A, methotrexate, rheumatoid arthritis ., feasibility and outcome, cyclosporin A ( CSA ), methotrexate ( MTX ), nonerosive RA, MTX in combination, single - agent, Safety , clinical efficacy, survival on treatment, radiographic progression, 7 of the 57 patients, adverse events, damage score and number of eroded joints, early RA	8646_task2	Sentence: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA .	[ "Step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "or", "methotrexate", "as", "maintenance", "therapy", "in", "early", "rheumatoid", "arthritis", ".", "OBJECTIVE", "To", "evaluate", "the", "feasibility", "and", "outcome", "of", "the", "step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "(", "CSA", ")", "or", "methotrexate", "(", "MTX", ")", "as", "maintenance", "therapy", "following", "6", "months", "treatment", "with", "these", "2", "agents", "in", "combination", "in", "early", ",", "nonerosive", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Fifty", "-", "seven", "patients", "younger", "than", "65", "years", "with", "early", ",", "nonerosive", "RA", "were", "first", "treated", "with", "CSA", "and", "MTX", "in", "combination", "for", "6", "months", ".", "They", "were", "then", "randomly", "stepped", "down", "to", "single", "-", "agent", "maintenance", "treatment", "for", "another", "18", "months", ".", "Safety", ",", "clinical", "efficacy", ",", "survival", "on", "treatment", ",", "and", "radiographic", "progression", "were", "evaluated", ".", "RESULTS", "When", "being", "treated", "with", "combination", "therapy", ",", "7", "of", "the", "57", "patients", "(", "12.3", "%", ")", "withdrew", "because", "of", "adverse", "events", ".", "Of", "the", "remaining", "50", "patients", ",", "42", "(", "84.0", "%", ")", "were", "American", "College", "of", "Rheumatology", "(", "ACR", ")", "20", "%", "responders", ",", "30", "(", "60.0", "%", ")", "were", "ACR", "50", "%", "responders", ",", "and", "23", "(", "46.0", "%", ")", "were", "ACR", "70", "%", "responders", ".", "At", "month", "6", ",", "22", "patients", "were", "randomized", "to", "CSA", "and", "27", "to", "MTX", ".", "During", "this", "trial", "period", ",", "the", "treatment", "was", "discontinued", "by", "16", "patients", "taking", "CSA", "(", "mainly", "because", "of", "loss", "of", "efficacy", ")", "and", "by", "4", "taking", "MTX", ".", "At", "month", "24", ",", "the", "probability", "(", "+", "/-", "SEM", ")", "of", "survival", "on", "treatment", "was", "0.273", "+", "/-", "0.09", "for", "CSA", "and", "0.852", "+", "/-", "0.07", "for", "MTX", ".", "Of", "the", "6", "CSA", "patients", "who", "completed", "the", "trial", ",", "4", "(", "66.7", "%", ")", "were", "ACR", "20", "%", "responders", ",", "and", "3", "(", "50", "%", ")", "were", "both", "ACR", "50", "%", "and", "ACR", "70", "%", "responders", ".", "Of", "the", "23", "completers", "in", "the", "MTX", "arm", ",", "21", "(", "91.3", "%", ")", "were", "ACR", "20", "%", "responders", ",", "18", "(", "78.3", "%", ")", "were", "ACR", "50", "%", ",", "and", "10", "(", "43.5", "%", ")", "were", "ACR", "70", "%", "responders", ".", "The", "treatment", "was", "not", "responsible", "for", "severe", "adverse", "events", ".", "Radiography", "showed", "a", "slow", "progression", "in", "the", "damage", "score", "and", "number", "of", "eroded", "joints", "in", "both", "treatment", "groups", ".", "CONCLUSION", "Stepping", "down", "to", "single", "agent", "maintenance", "therapy", "following", "6", "months", "of", "combination", "treatment", "with", "CSA", "and", "MTX", "in", "early", "RA", "was", "only", "successful", "with", "MTX", ".", "Because", "this", "treatment", "did", "not", "prevent", "some", "radiographic", "progression", ",", "other", "approaches", "(", "e.g", ".", ",", "step", "-", "up", "approach", ")", "may", "be", "more", "appropriate", "in", "early", "RA", "." ]	[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size", "Outcome_Adverse-effects", "Intervention_Physical" ]
Xabi is a NOMBRE_SUJETO_ASISTENCIA, Ibarra Izaguirre is a NOMBRE_SUJETO_ASISTENCIA, 3762723 is a ID_SUJETO_ASISTENCIA, 43 57823189 63 is a ID_ASEGURAMIENTO, Villabona is a TERRITORIO, 20150 is a TERRITORIO, 19/05/1961 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 21/09/2013 is a FECHAS, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, 20 20 54816 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, arantxa.ambg@gmail.com is a CORREO_ELECTRONICO	380_task0	Sentence: Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com	[ "Nombre", ":", " ", "Xabi", ".", "\n", "Apellidos", ":", "Ibarra", "Izaguirre", ".", "\n", "NHC", ":", " ", "3762723", ".", "\n", "NASS", ":", "43", "57823189", "63", ".", "\n", "Domicilio", ":", "Calle", "el", "buen", "pastor", "66", ",", "1C.", "\n", "Localidad/", "Provincia", ":", "Villabona", ".", "\n", "CP", ":", "20150", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "19/05/1961", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/09/2013", ".", "\n", "Médico", ":", "Arantxa", "Andújar", "Mateos", "NºCol", ":", "20", "20", "54816", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "52", "años", ",", "240", "kg", "de", "peso", "e", "IMC", "de", "74", "kg", "/", "m2", ",", "que", "ingresó", "en", "el", "hospital", "con", "diagnóstico", "de", "ictus", "isquémico", ".", "Como", "antecedentes", "patológicos", "de", "interés", ",", "el", "paciente", "presentó", "en", "el", "pasado", "un", "tromboembolismo", "venoso", "profundo", ",", "razón", "por", "la", "cual", "le", "fue", "prescrita", "terapia", "anticoagulante", "domiciliaria", "con", "Rivaroxabán", ".", "\n", "Desde", "el", "Servicio", "de", "Urgencias", "se", "plantea", "la", "posibilidad", "de", "realizar", "al", "paciente", "un", "tratamiento", "fibrinolítico", "con", "alteplasa", ".", "Sin", "embargo", ",", "tras", "la", "exploración", "se", "desestimó", "dicha", "intervención", ",", "ya", "que", "el", "paciente", "se", "encontraba", "en", "estado", "límite", "del", "intervalo", "temporal", ",", "presentaba", "23", "puntos", "en", "la", "escala", "NIHSS", "(", "National", "Institute", "of", "Health", "Stroke", "Scale", ")", "y", "se", "desconocía", "la", "hora", "de", "la", "última", "toma", "de", "Rivaroxabán", ".", "\n", "Tras", "su", "ingreso", "en", "UCI", "para", "monitorización", "y", "vigilancia", "neurológica", ",", "se", "decidió", "iniciar", "tratamiento", "con", "enoxaparina", "como", "terapia", "anticoagulante", ".", "Para", "ello", ",", "el", "Servicio", "de", "Medicina", "Intensiva", "se", "puso", "en", "contacto", "con", "el", "Servicio", "de", "Farmacia", "con", "el", "fin", "de", "conocer", "la", "posología", "más", "adecuada", "dada", "la", "situación", "de", "obesidad", "extrema2", "(", "IMC", ">", "40", "kg", "/", "m2", ")", ".", "\n", "Por", "razones", "de", "seguridad", ",", "dada", "la", "escasez", "de", "datos", "al", "respecto", ",", "se", "decidió", "iniciar", "el", "tratamiento", "a", "dosis", "de", "0,7", "mg", "/", "kg/12", "h", "vía", "subcutánea", "(", "enoxaparina", "160", "mg/12", "h", ")", "para", "evitar", "sangrados", "y", "por", "ser", "la", "dosis", "máxima", "evaluada", "en", "diversos", "ensayos", "clínicos3", "-", "5", ".", "Además", ",", "se", "estableció", "la", "monitorización", "del", "factor", "anti", "-", "Xa", "para", "establecer", "la", "dosis", "final6", ".", "\n", "Transcurridas", "cuatro", "horas", "de", "la", "administración", "de", "la", "tercera", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "en", "sangre", "obtenida", "fue", "de", "0,37", "UI", "/", "mL.", "Al", "encontrarse", "entre", "0,35", "-", "0,49", "UI", "/", "mL", "se", "procedió", "a", "incrementar", "≈10", "%", "la", "dosis", "(", "170", "mg/12", "h", ")", ".", "Cuatro", "horas", "después", "de", "la", "siguiente", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "fue", "0,59", "UI", "/", "mL", ",", "y", "a", "las", "24", "horas", "de", "0,48", "UI", "/", "mL.", "A", "la", "vista", "de", "ese", "resultado", ",", "se", "incrementó", "la", "dosis", ",", "llegando", "a", "180", "mg/12", "h.", "Finalmente", ",", "la", "siguiente", "determinación", "obtuvo", "un", "valor", "de", "0,84", "UI", "/", "mL", ",", "situándonos", "dentro", "del", "rango", "terapéutico", "y", "fijando", "la", "dosis", "óptima", "para", "nuestro", "paciente", "en", "0,75", "mg", "/", "kg/12", "h.", "\n", "Remitido", "por", ":", "Dra", ".", "Arantxa", "Andújar", "Mateos", "Correo", "electrónico", ":", "arantxa.ambg@gmail.com", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Xabi is a NOMBRE_SUJETO_ASISTENCIA, Ibarra Izaguirre is a NOMBRE_SUJETO_ASISTENCIA, 3762723 is a ID_SUJETO_ASISTENCIA, 43 57823189 63 is a ID_ASEGURAMIENTO, Villabona is a TERRITORIO, 20150 is a TERRITORIO, 19/05/1961 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 21/09/2013 is a FECHAS, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, 20 20 54816 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, arantxa.ambg@gmail.com is a CORREO_ELECTRONICO	380_task1	Sentence: Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com Instructions: please typing these entity words according to sentence: Xabi, Ibarra Izaguirre, 3762723, 43 57823189 63, Villabona, 20150, 19/05/1961, España, 52 años, 21/09/2013, Arantxa Andújar Mateos, 20 20 54816, Varón, 52 años, Arantxa Andújar Mateos, arantxa.ambg@gmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com	[ "Nombre", ":", " ", "Xabi", ".", "\n", "Apellidos", ":", "Ibarra", "Izaguirre", ".", "\n", "NHC", ":", " ", "3762723", ".", "\n", "NASS", ":", "43", "57823189", "63", ".", "\n", "Domicilio", ":", "Calle", "el", "buen", "pastor", "66", ",", "1C.", "\n", "Localidad/", "Provincia", ":", "Villabona", ".", "\n", "CP", ":", "20150", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "19/05/1961", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/09/2013", ".", "\n", "Médico", ":", "Arantxa", "Andújar", "Mateos", "NºCol", ":", "20", "20", "54816", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "52", "años", ",", "240", "kg", "de", "peso", "e", "IMC", "de", "74", "kg", "/", "m2", ",", "que", "ingresó", "en", "el", "hospital", "con", "diagnóstico", "de", "ictus", "isquémico", ".", "Como", "antecedentes", "patológicos", "de", "interés", ",", "el", "paciente", "presentó", "en", "el", "pasado", "un", "tromboembolismo", "venoso", "profundo", ",", "razón", "por", "la", "cual", "le", "fue", "prescrita", "terapia", "anticoagulante", "domiciliaria", "con", "Rivaroxabán", ".", "\n", "Desde", "el", "Servicio", "de", "Urgencias", "se", "plantea", "la", "posibilidad", "de", "realizar", "al", "paciente", "un", "tratamiento", "fibrinolítico", "con", "alteplasa", ".", "Sin", "embargo", ",", "tras", "la", "exploración", "se", "desestimó", "dicha", "intervención", ",", "ya", "que", "el", "paciente", "se", "encontraba", "en", "estado", "límite", "del", "intervalo", "temporal", ",", "presentaba", "23", "puntos", "en", "la", "escala", "NIHSS", "(", "National", "Institute", "of", "Health", "Stroke", "Scale", ")", "y", "se", "desconocía", "la", "hora", "de", "la", "última", "toma", "de", "Rivaroxabán", ".", "\n", "Tras", "su", "ingreso", "en", "UCI", "para", "monitorización", "y", "vigilancia", "neurológica", ",", "se", "decidió", "iniciar", "tratamiento", "con", "enoxaparina", "como", "terapia", "anticoagulante", ".", "Para", "ello", ",", "el", "Servicio", "de", "Medicina", "Intensiva", "se", "puso", "en", "contacto", "con", "el", "Servicio", "de", "Farmacia", "con", "el", "fin", "de", "conocer", "la", "posología", "más", "adecuada", "dada", "la", "situación", "de", "obesidad", "extrema2", "(", "IMC", ">", "40", "kg", "/", "m2", ")", ".", "\n", "Por", "razones", "de", "seguridad", ",", "dada", "la", "escasez", "de", "datos", "al", "respecto", ",", "se", "decidió", "iniciar", "el", "tratamiento", "a", "dosis", "de", "0,7", "mg", "/", "kg/12", "h", "vía", "subcutánea", "(", "enoxaparina", "160", "mg/12", "h", ")", "para", "evitar", "sangrados", "y", "por", "ser", "la", "dosis", "máxima", "evaluada", "en", "diversos", "ensayos", "clínicos3", "-", "5", ".", "Además", ",", "se", "estableció", "la", "monitorización", "del", "factor", "anti", "-", "Xa", "para", "establecer", "la", "dosis", "final6", ".", "\n", "Transcurridas", "cuatro", "horas", "de", "la", "administración", "de", "la", "tercera", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "en", "sangre", "obtenida", "fue", "de", "0,37", "UI", "/", "mL.", "Al", "encontrarse", "entre", "0,35", "-", "0,49", "UI", "/", "mL", "se", "procedió", "a", "incrementar", "≈10", "%", "la", "dosis", "(", "170", "mg/12", "h", ")", ".", "Cuatro", "horas", "después", "de", "la", "siguiente", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "fue", "0,59", "UI", "/", "mL", ",", "y", "a", "las", "24", "horas", "de", "0,48", "UI", "/", "mL.", "A", "la", "vista", "de", "ese", "resultado", ",", "se", "incrementó", "la", "dosis", ",", "llegando", "a", "180", "mg/12", "h.", "Finalmente", ",", "la", "siguiente", "determinación", "obtuvo", "un", "valor", "de", "0,84", "UI", "/", "mL", ",", "situándonos", "dentro", "del", "rango", "terapéutico", "y", "fijando", "la", "dosis", "óptima", "para", "nuestro", "paciente", "en", "0,75", "mg", "/", "kg/12", "h.", "\n", "Remitido", "por", ":", "Dra", ".", "Arantxa", "Andújar", "Mateos", "Correo", "electrónico", ":", "arantxa.ambg@gmail.com", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Xabi, Ibarra Izaguirre, 3762723, 43 57823189 63, Villabona, 20150, 19/05/1961, España, 52 años, 21/09/2013, Arantxa Andújar Mateos, 20 20 54816, Varón, 52 años, Arantxa Andújar Mateos, arantxa.ambg@gmail.com	380_task2	Sentence: Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]	Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com	[ "Nombre", ":", " ", "Xabi", ".", "\n", "Apellidos", ":", "Ibarra", "Izaguirre", ".", "\n", "NHC", ":", " ", "3762723", ".", "\n", "NASS", ":", "43", "57823189", "63", ".", "\n", "Domicilio", ":", "Calle", "el", "buen", "pastor", "66", ",", "1C.", "\n", "Localidad/", "Provincia", ":", "Villabona", ".", "\n", "CP", ":", "20150", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "19/05/1961", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/09/2013", ".", "\n", "Médico", ":", "Arantxa", "Andújar", "Mateos", "NºCol", ":", "20", "20", "54816", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "52", "años", ",", "240", "kg", "de", "peso", "e", "IMC", "de", "74", "kg", "/", "m2", ",", "que", "ingresó", "en", "el", "hospital", "con", "diagnóstico", "de", "ictus", "isquémico", ".", "Como", "antecedentes", "patológicos", "de", "interés", ",", "el", "paciente", "presentó", "en", "el", "pasado", "un", "tromboembolismo", "venoso", "profundo", ",", "razón", "por", "la", "cual", "le", "fue", "prescrita", "terapia", "anticoagulante", "domiciliaria", "con", "Rivaroxabán", ".", "\n", "Desde", "el", "Servicio", "de", "Urgencias", "se", "plantea", "la", "posibilidad", "de", "realizar", "al", "paciente", "un", "tratamiento", "fibrinolítico", "con", "alteplasa", ".", "Sin", "embargo", ",", "tras", "la", "exploración", "se", "desestimó", "dicha", "intervención", ",", "ya", "que", "el", "paciente", "se", "encontraba", "en", "estado", "límite", "del", "intervalo", "temporal", ",", "presentaba", "23", "puntos", "en", "la", "escala", "NIHSS", "(", "National", "Institute", "of", "Health", "Stroke", "Scale", ")", "y", "se", "desconocía", "la", "hora", "de", "la", "última", "toma", "de", "Rivaroxabán", ".", "\n", "Tras", "su", "ingreso", "en", "UCI", "para", "monitorización", "y", "vigilancia", "neurológica", ",", "se", "decidió", "iniciar", "tratamiento", "con", "enoxaparina", "como", "terapia", "anticoagulante", ".", "Para", "ello", ",", "el", "Servicio", "de", "Medicina", "Intensiva", "se", "puso", "en", "contacto", "con", "el", "Servicio", "de", "Farmacia", "con", "el", "fin", "de", "conocer", "la", "posología", "más", "adecuada", "dada", "la", "situación", "de", "obesidad", "extrema2", "(", "IMC", ">", "40", "kg", "/", "m2", ")", ".", "\n", "Por", "razones", "de", "seguridad", ",", "dada", "la", "escasez", "de", "datos", "al", "respecto", ",", "se", "decidió", "iniciar", "el", "tratamiento", "a", "dosis", "de", "0,7", "mg", "/", "kg/12", "h", "vía", "subcutánea", "(", "enoxaparina", "160", "mg/12", "h", ")", "para", "evitar", "sangrados", "y", "por", "ser", "la", "dosis", "máxima", "evaluada", "en", "diversos", "ensayos", "clínicos3", "-", "5", ".", "Además", ",", "se", "estableció", "la", "monitorización", "del", "factor", "anti", "-", "Xa", "para", "establecer", "la", "dosis", "final6", ".", "\n", "Transcurridas", "cuatro", "horas", "de", "la", "administración", "de", "la", "tercera", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "en", "sangre", "obtenida", "fue", "de", "0,37", "UI", "/", "mL.", "Al", "encontrarse", "entre", "0,35", "-", "0,49", "UI", "/", "mL", "se", "procedió", "a", "incrementar", "≈10", "%", "la", "dosis", "(", "170", "mg/12", "h", ")", ".", "Cuatro", "horas", "después", "de", "la", "siguiente", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "fue", "0,59", "UI", "/", "mL", ",", "y", "a", "las", "24", "horas", "de", "0,48", "UI", "/", "mL.", "A", "la", "vista", "de", "ese", "resultado", ",", "se", "incrementó", "la", "dosis", ",", "llegando", "a", "180", "mg/12", "h.", "Finalmente", ",", "la", "siguiente", "determinación", "obtuvo", "un", "valor", "de", "0,84", "UI", "/", "mL", ",", "situándonos", "dentro", "del", "rango", "terapéutico", "y", "fijando", "la", "dosis", "óptima", "para", "nuestro", "paciente", "en", "0,75", "mg", "/", "kg/12", "h.", "\n", "Remitido", "por", ":", "Dra", ".", "Arantxa", "Andújar", "Mateos", "Correo", "electrónico", ":", "arantxa.ambg@gmail.com", "\n" ]	[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]
Fazialisparese is an umlsterm, Therapiemassnahmen is an umlsterm, Uhrglasverbands is an umlsterm, Operationsmethode is an umlsterm, Patienten is an umlsterm, Goldimplantation is an umlsterm, Gesichtsbereich is an umlsterm, Goldimplantation is an umlsterm, Gesichtsfeldes is an umlsterm, Patienten is an umlsterm, Fazialisparese is an umlsterm, Goldimplantation is an umlsterm, Komplikationen is an umlsterm, Goldimplantats is an umlsterm, Goldimplantats is an umlsterm, Ausbildung is an umlsterm, Patienten is an umlsterm, Astigmatismus is an umlsterm, Goldimplantation is an umlsterm	HNO.90470262.ger.abstr_task0	Sentence: Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen .	[ "Die", "periphere", "Fazialisparese", "geht", "oft", "mit", "unvollstaendigem", "Lidschluss", "einher", "und", "kann", "zu", "einer", "Keratopathie", "unterschiedlichen", "Schweregrades", "bis", "hin", "zum", "Hornhautulkus", "fuehren", ".", "Die", "konservativen", "Therapiemassnahmen", "sind", "unbefriedigend", ",", "zudem", "stellt", "das", "Tragen", "eines", "Uhrglasverbands", "eine", "erhebliche", "kosmetische", "Beeintraechtigung", "dar", ".", "Zur", "Verbesserung", "des", "Lidschlusses", "gilt", "als", "klassische", "Operationsmethode", "die", "Tarsorrhapie", ",", "welche", "jedoch", "fuer", "den", "Patienten", "sowohl", "funktionelle", "als", "auch", "aesthetische", "Nachteile", "mit", "sich", "bringt", ".", "Als", "operative", "Alternative", "kommt", "die", "Goldimplantation", "zur", "Beschwerung", "des", "Oberlids", "zur", "Anwendung", ",", "ggf", ".", "in", "Kombination", "mit", "weiteren", "rehabilitativen", "Eingriffen", "im", "Gesichtsbereich", ".", "Durch", "die", "Goldimplantation", "wird", "ein", "kompletter", "Lidschluss", "ohne", "Beeintraechtigung", "des", "Gesichtsfeldes", "und", "ohne", "stoerenden", "kosmetischen", "Nebeneffekt", "ermoeglicht", ".", "Von", "Mai", "1994", "bis", "Januar", "1997", "wurden", "an", "der", "HNO", "-", "Klinik", "der", "Martin", "-", "Luther", "-", "Universitaet", "Halle", "-", "Wittenberg", "29", "Patienten", "mit", "peripherer", "Fazialisparese", "und", "Lagophthalmus", "mit", "einer", "Goldimplantation", "ins", "Oberlid", "versorgt", ".", "In", "allen", "Faellen", "war", "der", "Lidschluss", "postoperativ", "ausreichend", ",", "und", "es", "kam", "zu", "einer", "statistisch", "signifikanten", "Verminderung", "des", "Lagophthalmus", "und", "Verbesserung", "der", "Keratopathie", "mit", "Visusanstieg", ".", "Als", "Komplikationen", "wurden", "beobachtet", ":", "mechanische", "Ptosis", "(", "n=5", ")", ",", "deutliche", "Konturierung", "des", "Goldimplantats", "(", "n=5", ")", ",", "eine", "Extrusion", "des", "Goldimplantats", "(", "n=1", ")", "und", "ueberraschenderweise", "in", "mehreren", "Faellen", "die", "Ausbildung", "eines", "geringgradigen", "Hornhautastigmatismus", "(", "n=7", ")", ".", "Bei", "allen", "Patienten", "konnte", "der", "Astigmatismus", "durch", "das", "Anpassen", "von", "Zylinderglaesern", "korrigiert", "werden", ".", "Bei", "insgesamt", "sehr", "guten", "funktionellen", "Ergebnissen", "ist", "die", "Goldimplantation", "der", "aesthetisch", "stoerenden", "Tarsorrhapie", "ueberlegen", "." ]	[ "umlsterm" ]
Fazialisparese is an umlsterm, Therapiemassnahmen is an umlsterm, Uhrglasverbands is an umlsterm, Operationsmethode is an umlsterm, Patienten is an umlsterm, Goldimplantation is an umlsterm, Gesichtsbereich is an umlsterm, Goldimplantation is an umlsterm, Gesichtsfeldes is an umlsterm, Patienten is an umlsterm, Fazialisparese is an umlsterm, Goldimplantation is an umlsterm, Komplikationen is an umlsterm, Goldimplantats is an umlsterm, Goldimplantats is an umlsterm, Ausbildung is an umlsterm, Patienten is an umlsterm, Astigmatismus is an umlsterm, Goldimplantation is an umlsterm	HNO.90470262.ger.abstr_task1	Sentence: Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen . Instructions: please typing these entity words according to sentence: Fazialisparese, Therapiemassnahmen, Uhrglasverbands, Operationsmethode, Patienten, Goldimplantation, Gesichtsbereich, Goldimplantation, Gesichtsfeldes, Patienten, Fazialisparese, Goldimplantation, Komplikationen, Goldimplantats, Goldimplantats, Ausbildung, Patienten, Astigmatismus, Goldimplantation Options: umlsterm	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen .	[ "Die", "periphere", "Fazialisparese", "geht", "oft", "mit", "unvollstaendigem", "Lidschluss", "einher", "und", "kann", "zu", "einer", "Keratopathie", "unterschiedlichen", "Schweregrades", "bis", "hin", "zum", "Hornhautulkus", "fuehren", ".", "Die", "konservativen", "Therapiemassnahmen", "sind", "unbefriedigend", ",", "zudem", "stellt", "das", "Tragen", "eines", "Uhrglasverbands", "eine", "erhebliche", "kosmetische", "Beeintraechtigung", "dar", ".", "Zur", "Verbesserung", "des", "Lidschlusses", "gilt", "als", "klassische", "Operationsmethode", "die", "Tarsorrhapie", ",", "welche", "jedoch", "fuer", "den", "Patienten", "sowohl", "funktionelle", "als", "auch", "aesthetische", "Nachteile", "mit", "sich", "bringt", ".", "Als", "operative", "Alternative", "kommt", "die", "Goldimplantation", "zur", "Beschwerung", "des", "Oberlids", "zur", "Anwendung", ",", "ggf", ".", "in", "Kombination", "mit", "weiteren", "rehabilitativen", "Eingriffen", "im", "Gesichtsbereich", ".", "Durch", "die", "Goldimplantation", "wird", "ein", "kompletter", "Lidschluss", "ohne", "Beeintraechtigung", "des", "Gesichtsfeldes", "und", "ohne", "stoerenden", "kosmetischen", "Nebeneffekt", "ermoeglicht", ".", "Von", "Mai", "1994", "bis", "Januar", "1997", "wurden", "an", "der", "HNO", "-", "Klinik", "der", "Martin", "-", "Luther", "-", "Universitaet", "Halle", "-", "Wittenberg", "29", "Patienten", "mit", "peripherer", "Fazialisparese", "und", "Lagophthalmus", "mit", "einer", "Goldimplantation", "ins", "Oberlid", "versorgt", ".", "In", "allen", "Faellen", "war", "der", "Lidschluss", "postoperativ", "ausreichend", ",", "und", "es", "kam", "zu", "einer", "statistisch", "signifikanten", "Verminderung", "des", "Lagophthalmus", "und", "Verbesserung", "der", "Keratopathie", "mit", "Visusanstieg", ".", "Als", "Komplikationen", "wurden", "beobachtet", ":", "mechanische", "Ptosis", "(", "n=5", ")", ",", "deutliche", "Konturierung", "des", "Goldimplantats", "(", "n=5", ")", ",", "eine", "Extrusion", "des", "Goldimplantats", "(", "n=1", ")", "und", "ueberraschenderweise", "in", "mehreren", "Faellen", "die", "Ausbildung", "eines", "geringgradigen", "Hornhautastigmatismus", "(", "n=7", ")", ".", "Bei", "allen", "Patienten", "konnte", "der", "Astigmatismus", "durch", "das", "Anpassen", "von", "Zylinderglaesern", "korrigiert", "werden", ".", "Bei", "insgesamt", "sehr", "guten", "funktionellen", "Ergebnissen", "ist", "die", "Goldimplantation", "der", "aesthetisch", "stoerenden", "Tarsorrhapie", "ueberlegen", "." ]	[ "umlsterm" ]
Fazialisparese, Therapiemassnahmen, Uhrglasverbands, Operationsmethode, Patienten, Goldimplantation, Gesichtsbereich, Goldimplantation, Gesichtsfeldes, Patienten, Fazialisparese, Goldimplantation, Komplikationen, Goldimplantats, Goldimplantats, Ausbildung, Patienten, Astigmatismus, Goldimplantation	HNO.90470262.ger.abstr_task2	Sentence: Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen . Instructions: please extract entity words from the input sentence	[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]	Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen .	[ "Die", "periphere", "Fazialisparese", "geht", "oft", "mit", "unvollstaendigem", "Lidschluss", "einher", "und", "kann", "zu", "einer", "Keratopathie", "unterschiedlichen", "Schweregrades", "bis", "hin", "zum", "Hornhautulkus", "fuehren", ".", "Die", "konservativen", "Therapiemassnahmen", "sind", "unbefriedigend", ",", "zudem", "stellt", "das", "Tragen", "eines", "Uhrglasverbands", "eine", "erhebliche", "kosmetische", "Beeintraechtigung", "dar", ".", "Zur", "Verbesserung", "des", "Lidschlusses", "gilt", "als", "klassische", "Operationsmethode", "die", "Tarsorrhapie", ",", "welche", "jedoch", "fuer", "den", "Patienten", "sowohl", "funktionelle", "als", "auch", "aesthetische", "Nachteile", "mit", "sich", "bringt", ".", "Als", "operative", "Alternative", "kommt", "die", "Goldimplantation", "zur", "Beschwerung", "des", "Oberlids", "zur", "Anwendung", ",", "ggf", ".", "in", "Kombination", "mit", "weiteren", "rehabilitativen", "Eingriffen", "im", "Gesichtsbereich", ".", "Durch", "die", "Goldimplantation", "wird", "ein", "kompletter", "Lidschluss", "ohne", "Beeintraechtigung", "des", "Gesichtsfeldes", "und", "ohne", "stoerenden", "kosmetischen", "Nebeneffekt", "ermoeglicht", ".", "Von", "Mai", "1994", "bis", "Januar", "1997", "wurden", "an", "der", "HNO", "-", "Klinik", "der", "Martin", "-", "Luther", "-", "Universitaet", "Halle", "-", "Wittenberg", "29", "Patienten", "mit", "peripherer", "Fazialisparese", "und", "Lagophthalmus", "mit", "einer", "Goldimplantation", "ins", "Oberlid", "versorgt", ".", "In", "allen", "Faellen", "war", "der", "Lidschluss", "postoperativ", "ausreichend", ",", "und", "es", "kam", "zu", "einer", "statistisch", "signifikanten", "Verminderung", "des", "Lagophthalmus", "und", "Verbesserung", "der", "Keratopathie", "mit", "Visusanstieg", ".", "Als", "Komplikationen", "wurden", "beobachtet", ":", "mechanische", "Ptosis", "(", "n=5", ")", ",", "deutliche", "Konturierung", "des", "Goldimplantats", "(", "n=5", ")", ",", "eine", "Extrusion", "des", "Goldimplantats", "(", "n=1", ")", "und", "ueberraschenderweise", "in", "mehreren", "Faellen", "die", "Ausbildung", "eines", "geringgradigen", "Hornhautastigmatismus", "(", "n=7", ")", ".", "Bei", "allen", "Patienten", "konnte", "der", "Astigmatismus", "durch", "das", "Anpassen", "von", "Zylinderglaesern", "korrigiert", "werden", ".", "Bei", "insgesamt", "sehr", "guten", "funktionellen", "Ergebnissen", "ist", "die", "Goldimplantation", "der", "aesthetisch", "stoerenden", "Tarsorrhapie", "ueberlegen", "." ]	[ "umlsterm" ]
Less than 30 yrs is a Value, age is a Person, > 65 yrs is a Value, age is a Person, significant co - morbidities is a Scope, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia is a Scope	NCT02437084_exc_task0	Sentence: Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Value	[ "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia.	[ "Less", "than", "30", "yrs", "of", "age", "or", ">", "65", "yrs", "of", "age", "\n", "Any", "significant", "co", "-", "morbidities", ",", "such", "as", "active", "heart", ",", "kidney", ",", "or", "liver", "diseases", ",", "accelerated", "or", "malignant", "hypertension", ",", "heart", "failure", ",", "severe", "anemia", ".", "\n" ]	[ "Scope", "Value", "Condition", "Qualifier", "Person" ]
Less than 30 yrs is a Value, age is a Person, > 65 yrs is a Value, age is a Person, significant co - morbidities is a Scope, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia is a Scope	NCT02437084_exc_task1	Sentence: Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia. Instructions: please typing these entity words according to sentence: Less than 30 yrs, age, > 65 yrs, age, significant co - morbidities, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia Options: Scope, Person, Value	[ "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia.	[ "Less", "than", "30", "yrs", "of", "age", "or", ">", "65", "yrs", "of", "age", "\n", "Any", "significant", "co", "-", "morbidities", ",", "such", "as", "active", "heart", ",", "kidney", ",", "or", "liver", "diseases", ",", "accelerated", "or", "malignant", "hypertension", ",", "heart", "failure", ",", "severe", "anemia", ".", "\n" ]	[ "Scope", "Value", "Condition", "Qualifier", "Person" ]
Less than 30 yrs, age, > 65 yrs, age, significant co - morbidities, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia	NCT02437084_exc_task2	Sentence: Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia. Instructions: please extract entity words from the input sentence	[ "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]	Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia.	[ "Less", "than", "30", "yrs", "of", "age", "or", ">", "65", "yrs", "of", "age", "\n", "Any", "significant", "co", "-", "morbidities", ",", "such", "as", "active", "heart", ",", "kidney", ",", "or", "liver", "diseases", ",", "accelerated", "or", "malignant", "hypertension", ",", "heart", "failure", ",", "severe", "anemia", ".", "\n" ]	[ "Scope", "Value", "Condition", "Qualifier", "Person" ]
Myokardinfarktregister is an umlsterm, Deutschland is an umlsterm, Register is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Dokumentation is an umlsterm, Infarkttherapie is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Krankenhaeusern is an umlsterm, Patienten is an umlsterm, maennlich is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, ASS is an umlsterm, ACE - Hemmer is an umlsterm, Gesamtmortalitaet is an umlsterm, Gesamtmortalitaet is an umlsterm, Krankenhaeusern is an umlsterm, Gebrauch is an umlsterm, Therapie is an umlsterm, Krankenhaeusern is an umlsterm	ZfuerKardiologie.90880857.ger.abstr_task0	Sentence: Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit .	[ "Das", "Myokardinfarktregister", "in", "Deutschland", "(", "MIR", ")", "ist", "ein", "multizentrisch", "und", "prospektiv", "angelegtes", "Register", "von", "konsekutiv", "eingeschlossenen", ",", "unselektierten", "Patienten", "mit", "akutem", "Myokardinfarkt", ".", "Ziel", "des", "MIR", "ist", "eine", "Dokumentation", "der", "Entscheidungs-", "und", "Verordnungspraxis", "einer", "optimierten", "Infarkttherapie", ",", "bestehend", "aus", "rekanalisierender", "Therapie", ",", "ASS", "Betablocker", "und", "ACE", "-", "Hemmer", "-", "Gabe", ".", ",", "Von", "12/96", "-", "5/98", "wurden", "bundesweit", "14598", "Patienten", "mit", "akutem", "Myokardinfarkt", "in", "217", "Krankenhaeusern", "eingeschlossen", ".", "Von", "diesen", "nahmen", "68", "Kliniken", "aus", "den", "neuen", "Bundeslaendern", "teil", ".", "65", "%", "der", "Patienten", "waren", "maennlich", ",", "das", "mittlere", "Alter", "betrug", "67", "Jahre", ".", "Die", "Praehospitalzeit", "lag", "im", "Median", "bei", "195", "min", ",", "das", "Erst", "-", "EKG", "war", "bei", "66", "%", "der", "Patienten", "diagnostisch", ".", "Eine", "rekanalisierende", "Therapie", "erhielten", "46,1", "%", "der", "Patienten", "(", "hospitale", "Thrombolyse", "36,2", "%", ";", "Primaer", "-", "PTCA", "9,9", "%", ")", ".", "Als", "Begleitmedikation", "in", "der", "Akutphase", "wurden", "verordnet", ":", "ASS", "bei", "90,3", "%", ",", "Betablocker", "bei", "53,8", "%", "und", "ACE", "-", "Hemmer", "bei", "52,5", "%", ".", "Die", "intrahospitale", "Gesamtmortalitaet", "betrug", "15,4", "%", ".", "Im", "Vergleich", "zeigte", "sich", "in", "kardiologischen", "Fachabteilungen", "eine", "niedrigere", "Gesamtmortalitaet", "(", "13,8", "%", ")", "gegenueber", "den", "Krankenhaeusern", "der", "Regelversorgung", "(", "16,1", "%", ")", ".", "Als", "moegliche", "Gruende", "fanden", "sich", "der", "haeufigere", "Gebrauch", "einer", "rekanalisierenden", "Therapie", "in", "Krankenhaeusern", "mit", "kardiologischer", "Fachabteilung", "(", "54,3", "%", "versus", "42,3", "%", ";", "p", "0,001", ")", "und", "das", "Vorhandensein", "eines", "Katheterlabors", "mit", "PTCA", "-", "Moeglichkeit", "." ]	[ "umlsterm" ]
Myokardinfarktregister is an umlsterm, Deutschland is an umlsterm, Register is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Dokumentation is an umlsterm, Infarkttherapie is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Krankenhaeusern is an umlsterm, Patienten is an umlsterm, maennlich is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, ASS is an umlsterm, ACE - Hemmer is an umlsterm, Gesamtmortalitaet is an umlsterm, Gesamtmortalitaet is an umlsterm, Krankenhaeusern is an umlsterm, Gebrauch is an umlsterm, Therapie is an umlsterm, Krankenhaeusern is an umlsterm	ZfuerKardiologie.90880857.ger.abstr_task1	Sentence: Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit . Instructions: please typing these entity words according to sentence: Myokardinfarktregister, Deutschland, Register, Patienten, Myokardinfarkt, Dokumentation, Infarkttherapie, Therapie, Patienten, Myokardinfarkt, Krankenhaeusern, Patienten, maennlich, Patienten, Therapie, Patienten, ASS, ACE - Hemmer, Gesamtmortalitaet, Gesamtmortalitaet, Krankenhaeusern, Gebrauch, Therapie, Krankenhaeusern Options: umlsterm	[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit .	[ "Das", "Myokardinfarktregister", "in", "Deutschland", "(", "MIR", ")", "ist", "ein", "multizentrisch", "und", "prospektiv", "angelegtes", "Register", "von", "konsekutiv", "eingeschlossenen", ",", "unselektierten", "Patienten", "mit", "akutem", "Myokardinfarkt", ".", "Ziel", "des", "MIR", "ist", "eine", "Dokumentation", "der", "Entscheidungs-", "und", "Verordnungspraxis", "einer", "optimierten", "Infarkttherapie", ",", "bestehend", "aus", "rekanalisierender", "Therapie", ",", "ASS", "Betablocker", "und", "ACE", "-", "Hemmer", "-", "Gabe", ".", ",", "Von", "12/96", "-", "5/98", "wurden", "bundesweit", "14598", "Patienten", "mit", "akutem", "Myokardinfarkt", "in", "217", "Krankenhaeusern", "eingeschlossen", ".", "Von", "diesen", "nahmen", "68", "Kliniken", "aus", "den", "neuen", "Bundeslaendern", "teil", ".", "65", "%", "der", "Patienten", "waren", "maennlich", ",", "das", "mittlere", "Alter", "betrug", "67", "Jahre", ".", "Die", "Praehospitalzeit", "lag", "im", "Median", "bei", "195", "min", ",", "das", "Erst", "-", "EKG", "war", "bei", "66", "%", "der", "Patienten", "diagnostisch", ".", "Eine", "rekanalisierende", "Therapie", "erhielten", "46,1", "%", "der", "Patienten", "(", "hospitale", "Thrombolyse", "36,2", "%", ";", "Primaer", "-", "PTCA", "9,9", "%", ")", ".", "Als", "Begleitmedikation", "in", "der", "Akutphase", "wurden", "verordnet", ":", "ASS", "bei", "90,3", "%", ",", "Betablocker", "bei", "53,8", "%", "und", "ACE", "-", "Hemmer", "bei", "52,5", "%", ".", "Die", "intrahospitale", "Gesamtmortalitaet", "betrug", "15,4", "%", ".", "Im", "Vergleich", "zeigte", "sich", "in", "kardiologischen", "Fachabteilungen", "eine", "niedrigere", "Gesamtmortalitaet", "(", "13,8", "%", ")", "gegenueber", "den", "Krankenhaeusern", "der", "Regelversorgung", "(", "16,1", "%", ")", ".", "Als", "moegliche", "Gruende", "fanden", "sich", "der", "haeufigere", "Gebrauch", "einer", "rekanalisierenden", "Therapie", "in", "Krankenhaeusern", "mit", "kardiologischer", "Fachabteilung", "(", "54,3", "%", "versus", "42,3", "%", ";", "p", "0,001", ")", "und", "das", "Vorhandensein", "eines", "Katheterlabors", "mit", "PTCA", "-", "Moeglichkeit", "." ]	[ "umlsterm" ]
Myokardinfarktregister, Deutschland, Register, Patienten, Myokardinfarkt, Dokumentation, Infarkttherapie, Therapie, Patienten, Myokardinfarkt, Krankenhaeusern, Patienten, maennlich, Patienten, Therapie, Patienten, ASS, ACE - Hemmer, Gesamtmortalitaet, Gesamtmortalitaet, Krankenhaeusern, Gebrauch, Therapie, Krankenhaeusern	ZfuerKardiologie.90880857.ger.abstr_task2	Sentence: Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit .	[ "Das", "Myokardinfarktregister", "in", "Deutschland", "(", "MIR", ")", "ist", "ein", "multizentrisch", "und", "prospektiv", "angelegtes", "Register", "von", "konsekutiv", "eingeschlossenen", ",", "unselektierten", "Patienten", "mit", "akutem", "Myokardinfarkt", ".", "Ziel", "des", "MIR", "ist", "eine", "Dokumentation", "der", "Entscheidungs-", "und", "Verordnungspraxis", "einer", "optimierten", "Infarkttherapie", ",", "bestehend", "aus", "rekanalisierender", "Therapie", ",", "ASS", "Betablocker", "und", "ACE", "-", "Hemmer", "-", "Gabe", ".", ",", "Von", "12/96", "-", "5/98", "wurden", "bundesweit", "14598", "Patienten", "mit", "akutem", "Myokardinfarkt", "in", "217", "Krankenhaeusern", "eingeschlossen", ".", "Von", "diesen", "nahmen", "68", "Kliniken", "aus", "den", "neuen", "Bundeslaendern", "teil", ".", "65", "%", "der", "Patienten", "waren", "maennlich", ",", "das", "mittlere", "Alter", "betrug", "67", "Jahre", ".", "Die", "Praehospitalzeit", "lag", "im", "Median", "bei", "195", "min", ",", "das", "Erst", "-", "EKG", "war", "bei", "66", "%", "der", "Patienten", "diagnostisch", ".", "Eine", "rekanalisierende", "Therapie", "erhielten", "46,1", "%", "der", "Patienten", "(", "hospitale", "Thrombolyse", "36,2", "%", ";", "Primaer", "-", "PTCA", "9,9", "%", ")", ".", "Als", "Begleitmedikation", "in", "der", "Akutphase", "wurden", "verordnet", ":", "ASS", "bei", "90,3", "%", ",", "Betablocker", "bei", "53,8", "%", "und", "ACE", "-", "Hemmer", "bei", "52,5", "%", ".", "Die", "intrahospitale", "Gesamtmortalitaet", "betrug", "15,4", "%", ".", "Im", "Vergleich", "zeigte", "sich", "in", "kardiologischen", "Fachabteilungen", "eine", "niedrigere", "Gesamtmortalitaet", "(", "13,8", "%", ")", "gegenueber", "den", "Krankenhaeusern", "der", "Regelversorgung", "(", "16,1", "%", ")", ".", "Als", "moegliche", "Gruende", "fanden", "sich", "der", "haeufigere", "Gebrauch", "einer", "rekanalisierenden", "Therapie", "in", "Krankenhaeusern", "mit", "kardiologischer", "Fachabteilung", "(", "54,3", "%", "versus", "42,3", "%", ";", "p", "0,001", ")", "und", "das", "Vorhandensein", "eines", "Katheterlabors", "mit", "PTCA", "-", "Moeglichkeit", "." ]	[ "umlsterm" ]
11beta - hydroxysteroid dehydrogenase type 2 is a Protein, mineralocorticoid ( MC ) receptor is a Protein, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein	15_task0	Sentence: Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side.	[ "Progesterone", "metabolism", "in", "the", "human", "kidney", "and", "inhibition", "of", "11beta", "-", "hydroxysteroid", "dehydrogenase", "type", "2", "by", "progesterone", "and", "its", "metabolites", ".", "\n", "Progesterone", "binds", "with", "high", "affinity", "to", "the", "mineralocorticoid", "(", "MC", ")", "receptor", ",", "but", "confers", "only", "very", "low", "agonistic", "MC", "activity", ".", "Therefore", ",", "progesterone", "is", "a", "potent", "MC", "antagonist", "in", "vitro", ".", "Although", "progesterone", "reaches", "up", "to", "100", "times", "higher", "plasma", "levels", "in", "late", "pregnancy", "than", "aldosterone", ",", "the", "in", "vivo", "MC", "antagonistic", "effect", "of", "progesterone", "seems", "to", "be", "relatively", "weak", ".", "One", "explanation", "for", "this", "phenomenon", "could", "be", "local", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", ",", "similar", "to", "the", "inactivation", "of", "cortisol", "to", "cortisone", "by", "the", "11beta", "-", "hydroxysteroid", "dehydrogenase", "(", "11beta", "-", "HSD", ")", "type", "2", ".", "We", "studied", "the", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", "in", "vitro", "and", "found", "reduction", "to", "20alpha", "-", "dihydro", "(", "DH)-progesterone", "as", "the", "main", "metabolite", ".", "Ring", "-", "A", "reduction", "to", "5alpha", "-", "DH", "-", "progesterone", ",", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", ",", "and", "3beta,5alpha", "-", "tetrahydro", "(", "TH)-progesterone", "was", "also", "documented", ".", "We", "further", "showed", "for", "the", "first", "time", "that", "17-hydroxylation", "of", "progesterone", "(", "17alpha", "-", "OH", "-", "progesterone", ",", "17alpha", "-", "OH", ",", "20alpha", "-", "DH", "-", "progesterone", ")", ",", "normally", "localized", "in", "the", "adrenals", "and", "the", "gonads", ",", "occurs", "in", "the", "human", "adult", "kidney", ".", "We", "found", "no", "formation", "of", "deoxycorticosterone", "from", "progesterone", "in", "the", "human", "adult", "kidney", ".", "Using", "human", "kidney", "cortex", "microsomes", ",", "we", "tested", "the", "inhibitory", "potency", "of", "progesterone", "and", "its", "metabolites", "on", "the", "11beta", "-", "HSD", "type", "2", ".", "The", "most", "potent", "inhibitor", "was", "progesterone", "itself", "(", "IC50", "=", "4.8", "x", "10(-8", ")", "mol", "/", "L", ")", ",", "followed", "by", "5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "=", "2.4", "x", "10(-7", ")", "mol", "/", "L", ")", ",", "20alpha", "-", "DH", "-", "progesterone", ",", "3beta,5alpha", "-", "TH", "-", "progesterone", ",", "17alpha", "-", "OH", "-", "progesterone", ",", "and", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "between", "7.7", "x", "10(-7", ")", "mol", "/", "L", "and", "1.3", "x", "10(-6", ")", "mol", "/", "L", ")", ".", "The", "least", "potent", "inhibitor", "was", "17alpha", "-", "OH,20alpha", "-", "DH", "-", "progesterone", ".", "In", "addition", "to", "progesterone", "metabolism", "by", "the", "kidney", ",", "the", "inhibition", "of", "11beta", "-", "HSD", "type", "2", "by", "progesterone", "and", "its", "metabolites", "could", "be", "a", "second", "explanation", "for", "the", "weak", "MC", "-", "antagonist", "activity", "of", "progesterone", "in", "vivo", ".", "Inhibition", "of", "11beta", "-", "HSD", "type", "2", "leads", "to", "an", "increase", "of", "intracellular", "cortisol", "in", "a", "way", "that", "the", "local", "equilibrium", "between", "the", "MC", "agonist", "cortisol", "and", "the", "antagonist", "progesterone", "is", "shifted", "to", "the", "agonist", "side", ".", "\n" ]	[ "Protein" ]
11beta - hydroxysteroid dehydrogenase type 2 is a Protein, mineralocorticoid ( MC ) receptor is a Protein, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein	15_task1	Sentence: Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side. Instructions: please typing these entity words according to sentence: 11beta - hydroxysteroid dehydrogenase type 2, mineralocorticoid ( MC ) receptor, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2, 11beta - HSD type 2, 11beta - HSD type 2, 11beta - HSD type 2 Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side.	[ "Progesterone", "metabolism", "in", "the", "human", "kidney", "and", "inhibition", "of", "11beta", "-", "hydroxysteroid", "dehydrogenase", "type", "2", "by", "progesterone", "and", "its", "metabolites", ".", "\n", "Progesterone", "binds", "with", "high", "affinity", "to", "the", "mineralocorticoid", "(", "MC", ")", "receptor", ",", "but", "confers", "only", "very", "low", "agonistic", "MC", "activity", ".", "Therefore", ",", "progesterone", "is", "a", "potent", "MC", "antagonist", "in", "vitro", ".", "Although", "progesterone", "reaches", "up", "to", "100", "times", "higher", "plasma", "levels", "in", "late", "pregnancy", "than", "aldosterone", ",", "the", "in", "vivo", "MC", "antagonistic", "effect", "of", "progesterone", "seems", "to", "be", "relatively", "weak", ".", "One", "explanation", "for", "this", "phenomenon", "could", "be", "local", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", ",", "similar", "to", "the", "inactivation", "of", "cortisol", "to", "cortisone", "by", "the", "11beta", "-", "hydroxysteroid", "dehydrogenase", "(", "11beta", "-", "HSD", ")", "type", "2", ".", "We", "studied", "the", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", "in", "vitro", "and", "found", "reduction", "to", "20alpha", "-", "dihydro", "(", "DH)-progesterone", "as", "the", "main", "metabolite", ".", "Ring", "-", "A", "reduction", "to", "5alpha", "-", "DH", "-", "progesterone", ",", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", ",", "and", "3beta,5alpha", "-", "tetrahydro", "(", "TH)-progesterone", "was", "also", "documented", ".", "We", "further", "showed", "for", "the", "first", "time", "that", "17-hydroxylation", "of", "progesterone", "(", "17alpha", "-", "OH", "-", "progesterone", ",", "17alpha", "-", "OH", ",", "20alpha", "-", "DH", "-", "progesterone", ")", ",", "normally", "localized", "in", "the", "adrenals", "and", "the", "gonads", ",", "occurs", "in", "the", "human", "adult", "kidney", ".", "We", "found", "no", "formation", "of", "deoxycorticosterone", "from", "progesterone", "in", "the", "human", "adult", "kidney", ".", "Using", "human", "kidney", "cortex", "microsomes", ",", "we", "tested", "the", "inhibitory", "potency", "of", "progesterone", "and", "its", "metabolites", "on", "the", "11beta", "-", "HSD", "type", "2", ".", "The", "most", "potent", "inhibitor", "was", "progesterone", "itself", "(", "IC50", "=", "4.8", "x", "10(-8", ")", "mol", "/", "L", ")", ",", "followed", "by", "5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "=", "2.4", "x", "10(-7", ")", "mol", "/", "L", ")", ",", "20alpha", "-", "DH", "-", "progesterone", ",", "3beta,5alpha", "-", "TH", "-", "progesterone", ",", "17alpha", "-", "OH", "-", "progesterone", ",", "and", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "between", "7.7", "x", "10(-7", ")", "mol", "/", "L", "and", "1.3", "x", "10(-6", ")", "mol", "/", "L", ")", ".", "The", "least", "potent", "inhibitor", "was", "17alpha", "-", "OH,20alpha", "-", "DH", "-", "progesterone", ".", "In", "addition", "to", "progesterone", "metabolism", "by", "the", "kidney", ",", "the", "inhibition", "of", "11beta", "-", "HSD", "type", "2", "by", "progesterone", "and", "its", "metabolites", "could", "be", "a", "second", "explanation", "for", "the", "weak", "MC", "-", "antagonist", "activity", "of", "progesterone", "in", "vivo", ".", "Inhibition", "of", "11beta", "-", "HSD", "type", "2", "leads", "to", "an", "increase", "of", "intracellular", "cortisol", "in", "a", "way", "that", "the", "local", "equilibrium", "between", "the", "MC", "agonist", "cortisol", "and", "the", "antagonist", "progesterone", "is", "shifted", "to", "the", "agonist", "side", ".", "\n" ]	[ "Protein" ]
11beta - hydroxysteroid dehydrogenase type 2, mineralocorticoid ( MC ) receptor, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2, 11beta - HSD type 2, 11beta - HSD type 2, 11beta - HSD type 2	15_task2	Sentence: Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side.	[ "Progesterone", "metabolism", "in", "the", "human", "kidney", "and", "inhibition", "of", "11beta", "-", "hydroxysteroid", "dehydrogenase", "type", "2", "by", "progesterone", "and", "its", "metabolites", ".", "\n", "Progesterone", "binds", "with", "high", "affinity", "to", "the", "mineralocorticoid", "(", "MC", ")", "receptor", ",", "but", "confers", "only", "very", "low", "agonistic", "MC", "activity", ".", "Therefore", ",", "progesterone", "is", "a", "potent", "MC", "antagonist", "in", "vitro", ".", "Although", "progesterone", "reaches", "up", "to", "100", "times", "higher", "plasma", "levels", "in", "late", "pregnancy", "than", "aldosterone", ",", "the", "in", "vivo", "MC", "antagonistic", "effect", "of", "progesterone", "seems", "to", "be", "relatively", "weak", ".", "One", "explanation", "for", "this", "phenomenon", "could", "be", "local", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", ",", "similar", "to", "the", "inactivation", "of", "cortisol", "to", "cortisone", "by", "the", "11beta", "-", "hydroxysteroid", "dehydrogenase", "(", "11beta", "-", "HSD", ")", "type", "2", ".", "We", "studied", "the", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", "in", "vitro", "and", "found", "reduction", "to", "20alpha", "-", "dihydro", "(", "DH)-progesterone", "as", "the", "main", "metabolite", ".", "Ring", "-", "A", "reduction", "to", "5alpha", "-", "DH", "-", "progesterone", ",", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", ",", "and", "3beta,5alpha", "-", "tetrahydro", "(", "TH)-progesterone", "was", "also", "documented", ".", "We", "further", "showed", "for", "the", "first", "time", "that", "17-hydroxylation", "of", "progesterone", "(", "17alpha", "-", "OH", "-", "progesterone", ",", "17alpha", "-", "OH", ",", "20alpha", "-", "DH", "-", "progesterone", ")", ",", "normally", "localized", "in", "the", "adrenals", "and", "the", "gonads", ",", "occurs", "in", "the", "human", "adult", "kidney", ".", "We", "found", "no", "formation", "of", "deoxycorticosterone", "from", "progesterone", "in", "the", "human", "adult", "kidney", ".", "Using", "human", "kidney", "cortex", "microsomes", ",", "we", "tested", "the", "inhibitory", "potency", "of", "progesterone", "and", "its", "metabolites", "on", "the", "11beta", "-", "HSD", "type", "2", ".", "The", "most", "potent", "inhibitor", "was", "progesterone", "itself", "(", "IC50", "=", "4.8", "x", "10(-8", ")", "mol", "/", "L", ")", ",", "followed", "by", "5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "=", "2.4", "x", "10(-7", ")", "mol", "/", "L", ")", ",", "20alpha", "-", "DH", "-", "progesterone", ",", "3beta,5alpha", "-", "TH", "-", "progesterone", ",", "17alpha", "-", "OH", "-", "progesterone", ",", "and", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "between", "7.7", "x", "10(-7", ")", "mol", "/", "L", "and", "1.3", "x", "10(-6", ")", "mol", "/", "L", ")", ".", "The", "least", "potent", "inhibitor", "was", "17alpha", "-", "OH,20alpha", "-", "DH", "-", "progesterone", ".", "In", "addition", "to", "progesterone", "metabolism", "by", "the", "kidney", ",", "the", "inhibition", "of", "11beta", "-", "HSD", "type", "2", "by", "progesterone", "and", "its", "metabolites", "could", "be", "a", "second", "explanation", "for", "the", "weak", "MC", "-", "antagonist", "activity", "of", "progesterone", "in", "vivo", ".", "Inhibition", "of", "11beta", "-", "HSD", "type", "2", "leads", "to", "an", "increase", "of", "intracellular", "cortisol", "in", "a", "way", "that", "the", "local", "equilibrium", "between", "the", "MC", "agonist", "cortisol", "and", "the", "antagonist", "progesterone", "is", "shifted", "to", "the", "agonist", "side", ".", "\n" ]	[ "Protein" ]
Klassifizierung is an umlsterm, perforierender Keratoplastik is an umlsterm, Klassifizierung is an umlsterm, Klassifizierung is an umlsterm	DerOpthalmologe.80950741.ger.abstr_task0	Sentence: Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren .	[ "Hintergrund", ":", "Die", "semiquantitative", "Klassifizierung", "der", "Hornhauttopographie", "nach", "perforierender", "Keratoplastik", "bietet", "die", "Moeglichkeit", ",", "neben", "dem", "keratometrischen", "oder", "topographischen", "Astigmatismusbetrag", "gebuendelt", "Information", "ueber", "die", "flaechige", "Brechkraftentwicklung", "der", "Hornhaut", "zu", "erhalten", ".", "Ziel", "der", "Studie", "war", ",", "den", "subjektiven", "semiquantitativen", "Prozess", "der", "Klassifizierung", "auf", "der", "Basis", "von", "Fourier", "-", "Koeffizienten", "zu", "objektivieren", "und", "mit", "der", "subjektiven", "Klassifizierung", "zu", "korrelieren", "." ]	[ "umlsterm" ]
Klassifizierung is an umlsterm, perforierender Keratoplastik is an umlsterm, Klassifizierung is an umlsterm, Klassifizierung is an umlsterm	DerOpthalmologe.80950741.ger.abstr_task1	Sentence: Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren . Instructions: please typing these entity words according to sentence: Klassifizierung, perforierender Keratoplastik, Klassifizierung, Klassifizierung Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren .	[ "Hintergrund", ":", "Die", "semiquantitative", "Klassifizierung", "der", "Hornhauttopographie", "nach", "perforierender", "Keratoplastik", "bietet", "die", "Moeglichkeit", ",", "neben", "dem", "keratometrischen", "oder", "topographischen", "Astigmatismusbetrag", "gebuendelt", "Information", "ueber", "die", "flaechige", "Brechkraftentwicklung", "der", "Hornhaut", "zu", "erhalten", ".", "Ziel", "der", "Studie", "war", ",", "den", "subjektiven", "semiquantitativen", "Prozess", "der", "Klassifizierung", "auf", "der", "Basis", "von", "Fourier", "-", "Koeffizienten", "zu", "objektivieren", "und", "mit", "der", "subjektiven", "Klassifizierung", "zu", "korrelieren", "." ]	[ "umlsterm" ]
Klassifizierung, perforierender Keratoplastik, Klassifizierung, Klassifizierung	DerOpthalmologe.80950741.ger.abstr_task2	Sentence: Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]	Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren .	[ "Hintergrund", ":", "Die", "semiquantitative", "Klassifizierung", "der", "Hornhauttopographie", "nach", "perforierender", "Keratoplastik", "bietet", "die", "Moeglichkeit", ",", "neben", "dem", "keratometrischen", "oder", "topographischen", "Astigmatismusbetrag", "gebuendelt", "Information", "ueber", "die", "flaechige", "Brechkraftentwicklung", "der", "Hornhaut", "zu", "erhalten", ".", "Ziel", "der", "Studie", "war", ",", "den", "subjektiven", "semiquantitativen", "Prozess", "der", "Klassifizierung", "auf", "der", "Basis", "von", "Fourier", "-", "Koeffizienten", "zu", "objektivieren", "und", "mit", "der", "subjektiven", "Klassifizierung", "zu", "korrelieren", "." ]	[ "umlsterm" ]
iliac crest bone graft harvesting is a Procedure, neurological deficits or peripheral neuropathy is a Scope, sciatic nerve is a Qualifier, Local infection is a Condition, Contraindication is a Condition, regional anesthesia is a Procedure, bleeding diathesis , coagulopathy is a Scope, Chronic pain is a Condition, oxycodone or equivalent is a Scope, Allergy is a Condition, local anesthetics is a Procedure, Pregnancy is a Condition	NCT02707874_exc_task0	Sentence: Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition, Procedure, Qualifier	[ "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O" ]	Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent	[ "Patients", "who", "undergo", "iliac", "crest", "bone", "graft", "harvesting", "as", "part", "of", "their", "surgery", "\n", "Preexisting", "neurological", "deficits", "or", "peripheral", "neuropathy", "in", "the", "distribution", "of", "the", "sciatic", "nerve", "\n", "Local", "infection", "\n", "Contraindication", "to", "regional", "anesthesia", "e.g", ".", "bleeding", "diathesis", ",", "coagulopathy", "\n", "Chronic", "pain", "disorders", "\n", "History", "of", "use", "of", "over", "30", "mg", "oxycodone", "or", "equivalent", "per", "day", "\n", "Allergy", "to", "local", "anesthetics", "\n", "History", "of", "significant", "psychiatric", "conditions", "that", "may", "affect", "patient", "assessment", "\n", "Pregnancy", "\n", "Inability", "to", "provide", "informed", "consent", "\n" ]	[ "Scope", "Procedure", "Condition", "Qualifier", "Multiplier", "Drug" ]
iliac crest bone graft harvesting is a Procedure, neurological deficits or peripheral neuropathy is a Scope, sciatic nerve is a Qualifier, Local infection is a Condition, Contraindication is a Condition, regional anesthesia is a Procedure, bleeding diathesis , coagulopathy is a Scope, Chronic pain is a Condition, oxycodone or equivalent is a Scope, Allergy is a Condition, local anesthetics is a Procedure, Pregnancy is a Condition	NCT02707874_exc_task1	Sentence: Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent Instructions: please typing these entity words according to sentence: iliac crest bone graft harvesting, neurological deficits or peripheral neuropathy, sciatic nerve, Local infection, Contraindication, regional anesthesia, bleeding diathesis , coagulopathy, Chronic pain, oxycodone or equivalent, Allergy, local anesthetics, Pregnancy Options: Scope, Condition, Procedure, Qualifier	[ "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O" ]	Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent	[ "Patients", "who", "undergo", "iliac", "crest", "bone", "graft", "harvesting", "as", "part", "of", "their", "surgery", "\n", "Preexisting", "neurological", "deficits", "or", "peripheral", "neuropathy", "in", "the", "distribution", "of", "the", "sciatic", "nerve", "\n", "Local", "infection", "\n", "Contraindication", "to", "regional", "anesthesia", "e.g", ".", "bleeding", "diathesis", ",", "coagulopathy", "\n", "Chronic", "pain", "disorders", "\n", "History", "of", "use", "of", "over", "30", "mg", "oxycodone", "or", "equivalent", "per", "day", "\n", "Allergy", "to", "local", "anesthetics", "\n", "History", "of", "significant", "psychiatric", "conditions", "that", "may", "affect", "patient", "assessment", "\n", "Pregnancy", "\n", "Inability", "to", "provide", "informed", "consent", "\n" ]	[ "Scope", "Procedure", "Condition", "Qualifier", "Multiplier", "Drug" ]
iliac crest bone graft harvesting, neurological deficits or peripheral neuropathy, sciatic nerve, Local infection, Contraindication, regional anesthesia, bleeding diathesis , coagulopathy, Chronic pain, oxycodone or equivalent, Allergy, local anesthetics, Pregnancy	NCT02707874_exc_task2	Sentence: Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O" ]	Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent	[ "Patients", "who", "undergo", "iliac", "crest", "bone", "graft", "harvesting", "as", "part", "of", "their", "surgery", "\n", "Preexisting", "neurological", "deficits", "or", "peripheral", "neuropathy", "in", "the", "distribution", "of", "the", "sciatic", "nerve", "\n", "Local", "infection", "\n", "Contraindication", "to", "regional", "anesthesia", "e.g", ".", "bleeding", "diathesis", ",", "coagulopathy", "\n", "Chronic", "pain", "disorders", "\n", "History", "of", "use", "of", "over", "30", "mg", "oxycodone", "or", "equivalent", "per", "day", "\n", "Allergy", "to", "local", "anesthetics", "\n", "History", "of", "significant", "psychiatric", "conditions", "that", "may", "affect", "patient", "assessment", "\n", "Pregnancy", "\n", "Inability", "to", "provide", "informed", "consent", "\n" ]	[ "Scope", "Procedure", "Condition", "Qualifier", "Multiplier", "Drug" ]
ECG is an umlsterm, ventricular tachycardia is an umlsterm, axis is an umlsterm, right is an umlsterm, bundle branch block is an umlsterm, echocardiogram is an umlsterm, heart is an umlsterm, verapamil is an umlsterm, tachycardia is an umlsterm, antiarrhythmic agents is an umlsterm, Sinus is an umlsterm, ECG is an umlsterm, findings is an umlsterm, verapamil - sensitive is an umlsterm, ventricular tachycardia is an umlsterm, children is an umlsterm	MonatsschriftKinderheilkunde.91471086.eng.abstr_task0	Sentence: The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children .	[ "The", "ECG", "of", "a", "15-year", "-", "old", "boy", "hospitalized", "for", "rhythm", "disturbances", "showed", "a", "sustained", "ventricular", "tachycardia", "(", "beat", "rate", "170", "to", "180/", "min", ")", "with", "left", "axis", "deviation", "and", "complete", "right", "bundle", "branch", "block", ".", "His", "echocardiogram", "showed", "a", "structurally", "normal", "heart", "with", "diminished", "left", "ventricular", "performance", ".", "Intravenous", "application", "of", "verapamil", "led", "to", "prompt", "termination", "of", "the", "tachycardia", ",", "after", "previous", "attempts", "with", "various", "other", "antiarrhythmic", "agents", "had", "failed", ".", "Sinus", "rhythm", "remained", "stable", ".", "ECG", "and", "echocardiographic", "changes", "returned", "to", "normal", ".", "Course", "and", "findings", "are", "characteristic", "of", "verapamil", "-", "sensitive", "idiopathic", "left", "ventricular", "tachycardia", ",", "an", "entity", "which", "so", "far", "has", "only", "rarely", "been", "observed", "in", "children", "." ]	[ "umlsterm" ]
ECG is an umlsterm, ventricular tachycardia is an umlsterm, axis is an umlsterm, right is an umlsterm, bundle branch block is an umlsterm, echocardiogram is an umlsterm, heart is an umlsterm, verapamil is an umlsterm, tachycardia is an umlsterm, antiarrhythmic agents is an umlsterm, Sinus is an umlsterm, ECG is an umlsterm, findings is an umlsterm, verapamil - sensitive is an umlsterm, ventricular tachycardia is an umlsterm, children is an umlsterm	MonatsschriftKinderheilkunde.91471086.eng.abstr_task1	Sentence: The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children . Instructions: please typing these entity words according to sentence: ECG, ventricular tachycardia, axis, right, bundle branch block, echocardiogram, heart, verapamil, tachycardia, antiarrhythmic agents, Sinus, ECG, findings, verapamil - sensitive, ventricular tachycardia, children Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children .	[ "The", "ECG", "of", "a", "15-year", "-", "old", "boy", "hospitalized", "for", "rhythm", "disturbances", "showed", "a", "sustained", "ventricular", "tachycardia", "(", "beat", "rate", "170", "to", "180/", "min", ")", "with", "left", "axis", "deviation", "and", "complete", "right", "bundle", "branch", "block", ".", "His", "echocardiogram", "showed", "a", "structurally", "normal", "heart", "with", "diminished", "left", "ventricular", "performance", ".", "Intravenous", "application", "of", "verapamil", "led", "to", "prompt", "termination", "of", "the", "tachycardia", ",", "after", "previous", "attempts", "with", "various", "other", "antiarrhythmic", "agents", "had", "failed", ".", "Sinus", "rhythm", "remained", "stable", ".", "ECG", "and", "echocardiographic", "changes", "returned", "to", "normal", ".", "Course", "and", "findings", "are", "characteristic", "of", "verapamil", "-", "sensitive", "idiopathic", "left", "ventricular", "tachycardia", ",", "an", "entity", "which", "so", "far", "has", "only", "rarely", "been", "observed", "in", "children", "." ]	[ "umlsterm" ]
ECG, ventricular tachycardia, axis, right, bundle branch block, echocardiogram, heart, verapamil, tachycardia, antiarrhythmic agents, Sinus, ECG, findings, verapamil - sensitive, ventricular tachycardia, children	MonatsschriftKinderheilkunde.91471086.eng.abstr_task2	Sentence: The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children .	[ "The", "ECG", "of", "a", "15-year", "-", "old", "boy", "hospitalized", "for", "rhythm", "disturbances", "showed", "a", "sustained", "ventricular", "tachycardia", "(", "beat", "rate", "170", "to", "180/", "min", ")", "with", "left", "axis", "deviation", "and", "complete", "right", "bundle", "branch", "block", ".", "His", "echocardiogram", "showed", "a", "structurally", "normal", "heart", "with", "diminished", "left", "ventricular", "performance", ".", "Intravenous", "application", "of", "verapamil", "led", "to", "prompt", "termination", "of", "the", "tachycardia", ",", "after", "previous", "attempts", "with", "various", "other", "antiarrhythmic", "agents", "had", "failed", ".", "Sinus", "rhythm", "remained", "stable", ".", "ECG", "and", "echocardiographic", "changes", "returned", "to", "normal", ".", "Course", "and", "findings", "are", "characteristic", "of", "verapamil", "-", "sensitive", "idiopathic", "left", "ventricular", "tachycardia", ",", "an", "entity", "which", "so", "far", "has", "only", "rarely", "been", "observed", "in", "children", "." ]	[ "umlsterm" ]
alendronate is a compound, alkaline phosphatase is a protein, osteocalcin is a protein, CD44 is a protein	DS.d653_task0	Sentence: Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis.	[ "Osteogenic", "differentiation", "was", "enhanced", "after", "treatment", "with", "alendronate", "as", "confirmed", "by", "Alizarin", "Red", "S", "staining", ",", "elevated", "alkaline", "phosphatase", "activity", "and", "osteocalcin", "mRNA", "expression", ",", "a", "greater", "calcium", "peak", "by", "energy", "-", "dispersive", "xray", "spectrophotometry", ",", "and", "by", "immunofluorescence", "staining", "against", "CD44", "by", "flow", "cytometric", "analysis", "." ]	[ "protein", "compound" ]
alendronate is a compound, alkaline phosphatase is a protein, osteocalcin is a protein, CD44 is a protein	DS.d653_task1	Sentence: Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis. Instructions: please typing these entity words according to sentence: alendronate, alkaline phosphatase, osteocalcin, CD44 Options: compound, protein	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis.	[ "Osteogenic", "differentiation", "was", "enhanced", "after", "treatment", "with", "alendronate", "as", "confirmed", "by", "Alizarin", "Red", "S", "staining", ",", "elevated", "alkaline", "phosphatase", "activity", "and", "osteocalcin", "mRNA", "expression", ",", "a", "greater", "calcium", "peak", "by", "energy", "-", "dispersive", "xray", "spectrophotometry", ",", "and", "by", "immunofluorescence", "staining", "against", "CD44", "by", "flow", "cytometric", "analysis", "." ]	[ "protein", "compound" ]
alendronate, alkaline phosphatase, osteocalcin, CD44	DS.d653_task2	Sentence: Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]	Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis.	[ "Osteogenic", "differentiation", "was", "enhanced", "after", "treatment", "with", "alendronate", "as", "confirmed", "by", "Alizarin", "Red", "S", "staining", ",", "elevated", "alkaline", "phosphatase", "activity", "and", "osteocalcin", "mRNA", "expression", ",", "a", "greater", "calcium", "peak", "by", "energy", "-", "dispersive", "xray", "spectrophotometry", ",", "and", "by", "immunofluorescence", "staining", "against", "CD44", "by", "flow", "cytometric", "analysis", "." ]	[ "protein", "compound" ]
contrast is an umlsterm, myopia is an umlsterm, technique is an umlsterm, astigmatism is an umlsterm, techniques is an umlsterm, standard is an umlsterm	DerOpthalmologe.80950677.eng.abstr_task0	Sentence: Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) .	[ "Background", ":", "In", "contrast", "to", "the", "correction", "of", "simple", "myopia", "there", "is", "no", "widely", "accepted", "technique", "for", "the", "correction", "of", "myopic", "astigmatism", ".", "Currently", "two", "techniques", "are", "available", ":", "the", "photoastigmatic", "refractive", "keratectomy", "(", "PARK", ")", "and", "the", "combination", "of", "arcuate", "keratotomies", "with", "standard", "PRK", "(", "PRK", "-", "T", ")", "." ]	[ "umlsterm" ]
contrast is an umlsterm, myopia is an umlsterm, technique is an umlsterm, astigmatism is an umlsterm, techniques is an umlsterm, standard is an umlsterm	DerOpthalmologe.80950677.eng.abstr_task1	Sentence: Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) . Instructions: please typing these entity words according to sentence: contrast, myopia, technique, astigmatism, techniques, standard Options: umlsterm	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) .	[ "Background", ":", "In", "contrast", "to", "the", "correction", "of", "simple", "myopia", "there", "is", "no", "widely", "accepted", "technique", "for", "the", "correction", "of", "myopic", "astigmatism", ".", "Currently", "two", "techniques", "are", "available", ":", "the", "photoastigmatic", "refractive", "keratectomy", "(", "PARK", ")", "and", "the", "combination", "of", "arcuate", "keratotomies", "with", "standard", "PRK", "(", "PRK", "-", "T", ")", "." ]	[ "umlsterm" ]
contrast, myopia, technique, astigmatism, techniques, standard	DerOpthalmologe.80950677.eng.abstr_task2	Sentence: Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]	Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) .	[ "Background", ":", "In", "contrast", "to", "the", "correction", "of", "simple", "myopia", "there", "is", "no", "widely", "accepted", "technique", "for", "the", "correction", "of", "myopic", "astigmatism", ".", "Currently", "two", "techniques", "are", "available", ":", "the", "photoastigmatic", "refractive", "keratectomy", "(", "PARK", ")", "and", "the", "combination", "of", "arcuate", "keratotomies", "with", "standard", "PRK", "(", "PRK", "-", "T", ")", "." ]	[ "umlsterm" ]
head is an umlsterm, pancreas is an umlsterm, procedure is an umlsterm, patients is an umlsterm, pain is an umlsterm, inflammation is an umlsterm, head is an umlsterm, pancreas is an umlsterm, bile duct obstruction is an umlsterm, pancreatic duct is an umlsterm, retropancreatic is an umlsterm, vessels is an umlsterm, patients is an umlsterm, operation is an umlsterm, operation is an umlsterm, need is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, patient is an umlsterm, relaparotomy is an umlsterm, bowel obstruction is an umlsterm, hospital is an umlsterm, patients is an umlsterm, diabetes is an umlsterm, head is an umlsterm, pancreas is an umlsterm, surgery is an umlsterm, procedure is an umlsterm, complications is an umlsterm, pancreatitis is an umlsterm, pain is an umlsterm, patients is an umlsterm	DerChirurg.70680364.eng.abstr_task0	Sentence: Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients .	[ "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "was", "developed", "25", "years", "ago", "by", "Beger", ".", "This", "procedure", "is", "indicated", "in", "patients", "suffering", "from", "chronic", "pain", "in", "combination", "with", "inflammation", "of", "the", "head", "of", "the", "pancreas", ",", "common", "bile", "duct", "obstruction", ",", "pancreatic", "duct", "obstruction", "and", "/", "or", "obstruction", "of", "the", "retropancreatic", "vessels", ".", "At", "the", "Inselspital", "in", "Berne", ",", "74", "patients", "underwent", "this", "operation", "between", "1993", "and", "1996", ".", "The", "median", "length", "of", "the", "operation", "was", "380", "min", ",", "with", "the", "need", "for", "transfusion", "in", "a", "median", "of", "0", "units", "(", "0", "-", "6", ")", ".", "There", "was", "no", "postoperative", "mortality", ".", "Total", "postoperative", "morbidity", "was", "13", "%", ".", "One", "patient", "needed", "relaparotomy", "on", "day", "17", "for", "small", "bowel", "obstruction", ".", "Median", "length", "of", "hospital", "stay", "was", "11", "days", ".", "Postoperatively", ",", "two", "patients", "developed", "diabetes", ".", "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "represents", "an", "organ", "-", "preserving", "principle", "of", "surgery", ".", "This", "procedure", "treats", "the", "complications", "of", "chronic", "pancreatitis", "and", "provides", "long", "-", "term", "pain", "relief", "in", "more", "than", "80", "%", "of", "patients", "." ]	[ "umlsterm" ]
head is an umlsterm, pancreas is an umlsterm, procedure is an umlsterm, patients is an umlsterm, pain is an umlsterm, inflammation is an umlsterm, head is an umlsterm, pancreas is an umlsterm, bile duct obstruction is an umlsterm, pancreatic duct is an umlsterm, retropancreatic is an umlsterm, vessels is an umlsterm, patients is an umlsterm, operation is an umlsterm, operation is an umlsterm, need is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, patient is an umlsterm, relaparotomy is an umlsterm, bowel obstruction is an umlsterm, hospital is an umlsterm, patients is an umlsterm, diabetes is an umlsterm, head is an umlsterm, pancreas is an umlsterm, surgery is an umlsterm, procedure is an umlsterm, complications is an umlsterm, pancreatitis is an umlsterm, pain is an umlsterm, patients is an umlsterm	DerChirurg.70680364.eng.abstr_task1	Sentence: Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients . Instructions: please typing these entity words according to sentence: head, pancreas, procedure, patients, pain, inflammation, head, pancreas, bile duct obstruction, pancreatic duct, retropancreatic, vessels, patients, operation, operation, need, postoperative, mortality, postoperative, morbidity, patient, relaparotomy, bowel obstruction, hospital, patients, diabetes, head, pancreas, surgery, procedure, complications, pancreatitis, pain, patients Options: umlsterm	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients .	[ "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "was", "developed", "25", "years", "ago", "by", "Beger", ".", "This", "procedure", "is", "indicated", "in", "patients", "suffering", "from", "chronic", "pain", "in", "combination", "with", "inflammation", "of", "the", "head", "of", "the", "pancreas", ",", "common", "bile", "duct", "obstruction", ",", "pancreatic", "duct", "obstruction", "and", "/", "or", "obstruction", "of", "the", "retropancreatic", "vessels", ".", "At", "the", "Inselspital", "in", "Berne", ",", "74", "patients", "underwent", "this", "operation", "between", "1993", "and", "1996", ".", "The", "median", "length", "of", "the", "operation", "was", "380", "min", ",", "with", "the", "need", "for", "transfusion", "in", "a", "median", "of", "0", "units", "(", "0", "-", "6", ")", ".", "There", "was", "no", "postoperative", "mortality", ".", "Total", "postoperative", "morbidity", "was", "13", "%", ".", "One", "patient", "needed", "relaparotomy", "on", "day", "17", "for", "small", "bowel", "obstruction", ".", "Median", "length", "of", "hospital", "stay", "was", "11", "days", ".", "Postoperatively", ",", "two", "patients", "developed", "diabetes", ".", "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "represents", "an", "organ", "-", "preserving", "principle", "of", "surgery", ".", "This", "procedure", "treats", "the", "complications", "of", "chronic", "pancreatitis", "and", "provides", "long", "-", "term", "pain", "relief", "in", "more", "than", "80", "%", "of", "patients", "." ]	[ "umlsterm" ]
head, pancreas, procedure, patients, pain, inflammation, head, pancreas, bile duct obstruction, pancreatic duct, retropancreatic, vessels, patients, operation, operation, need, postoperative, mortality, postoperative, morbidity, patient, relaparotomy, bowel obstruction, hospital, patients, diabetes, head, pancreas, surgery, procedure, complications, pancreatitis, pain, patients	DerChirurg.70680364.eng.abstr_task2	Sentence: Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]	Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients .	[ "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "was", "developed", "25", "years", "ago", "by", "Beger", ".", "This", "procedure", "is", "indicated", "in", "patients", "suffering", "from", "chronic", "pain", "in", "combination", "with", "inflammation", "of", "the", "head", "of", "the", "pancreas", ",", "common", "bile", "duct", "obstruction", ",", "pancreatic", "duct", "obstruction", "and", "/", "or", "obstruction", "of", "the", "retropancreatic", "vessels", ".", "At", "the", "Inselspital", "in", "Berne", ",", "74", "patients", "underwent", "this", "operation", "between", "1993", "and", "1996", ".", "The", "median", "length", "of", "the", "operation", "was", "380", "min", ",", "with", "the", "need", "for", "transfusion", "in", "a", "median", "of", "0", "units", "(", "0", "-", "6", ")", ".", "There", "was", "no", "postoperative", "mortality", ".", "Total", "postoperative", "morbidity", "was", "13", "%", ".", "One", "patient", "needed", "relaparotomy", "on", "day", "17", "for", "small", "bowel", "obstruction", ".", "Median", "length", "of", "hospital", "stay", "was", "11", "days", ".", "Postoperatively", ",", "two", "patients", "developed", "diabetes", ".", "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "represents", "an", "organ", "-", "preserving", "principle", "of", "surgery", ".", "This", "procedure", "treats", "the", "complications", "of", "chronic", "pancreatitis", "and", "provides", "long", "-", "term", "pain", "relief", "in", "more", "than", "80", "%", "of", "patients", "." ]	[ "umlsterm" ]
prostatectomy is an umlsterm, postoperative is an umlsterm, disorder is an umlsterm, technique is an umlsterm, erections is an umlsterm, sexual intercourse is an umlsterm, nerves is an umlsterm, injuries is an umlsterm, erectile dysfunction is an umlsterm, Alprostadil is an umlsterm, self - injection is an umlsterm, drugs is an umlsterm, administration is an umlsterm, alprostadil is an umlsterm, drug is an umlsterm, Sildenafil is an umlsterm, patients is an umlsterm, erections is an umlsterm, prostatectomy is an umlsterm, pressure is an umlsterm, devices is an umlsterm, penile prosthesis is an umlsterm, N. suralis is an umlsterm, transplantation is an umlsterm, prostatectomy is an umlsterm, erection is an umlsterm, future is an umlsterm	Reproduktionsmedizin.00160279.eng.abstr_task0	Sentence: Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future .	[ "Erectile", "failure", "after", "radical", "prostatectomy", "is", "a", "common", "postoperative", "disorder", ".", "However", ",", "nerve", "-", "sparing", "technique", "provides", "in", "about", "50", "-", "60", "%", "erections", "sufficient", "for", "sexual", "intercourse", ".", "Damage", "to", "the", "cavernous", "nerves", "or", "vascular", "injuries", "are", "responsible", "for", "erectile", "dysfunction", ".", "Alprostadil", "is", "most", "commonly", "used", "for", "self", "-", "injection", "monotherapy", "or", "in", "combination", "with", "other", "vasoactive", "drugs", ".", "Intraurethral", "administration", "of", "alprostadil", "failed", "to", "reproduce", "promising", "early", "results", ".", "The", "oral", "drug", "Sildenafil", "showed", "to", "be", "effective", "in", "patients", "with", "partial", "erections", ",", "however", ",", "it", "failed", "to", "work", "after", "non", "nerve", "-", "sparing", "radical", "prostatectomy", ".", "Negative", "pressure", "devices", "and", "penile", "prosthesis", "can", "be", "considered", "as", "alternative", "therpeutic", "options", ".", "Autologous", "N.", "suralis", "transplantation", "during", "radical", "prostatectomy", "might", "further", "improve", "erection", "rates", "in", "the", "near", "future", "." ]	[ "umlsterm" ]
prostatectomy is an umlsterm, postoperative is an umlsterm, disorder is an umlsterm, technique is an umlsterm, erections is an umlsterm, sexual intercourse is an umlsterm, nerves is an umlsterm, injuries is an umlsterm, erectile dysfunction is an umlsterm, Alprostadil is an umlsterm, self - injection is an umlsterm, drugs is an umlsterm, administration is an umlsterm, alprostadil is an umlsterm, drug is an umlsterm, Sildenafil is an umlsterm, patients is an umlsterm, erections is an umlsterm, prostatectomy is an umlsterm, pressure is an umlsterm, devices is an umlsterm, penile prosthesis is an umlsterm, N. suralis is an umlsterm, transplantation is an umlsterm, prostatectomy is an umlsterm, erection is an umlsterm, future is an umlsterm	Reproduktionsmedizin.00160279.eng.abstr_task1	Sentence: Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future . Instructions: please typing these entity words according to sentence: prostatectomy, postoperative, disorder, technique, erections, sexual intercourse, nerves, injuries, erectile dysfunction, Alprostadil, self - injection, drugs, administration, alprostadil, drug, Sildenafil, patients, erections, prostatectomy, pressure, devices, penile prosthesis, N. suralis, transplantation, prostatectomy, erection, future Options: umlsterm	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future .	[ "Erectile", "failure", "after", "radical", "prostatectomy", "is", "a", "common", "postoperative", "disorder", ".", "However", ",", "nerve", "-", "sparing", "technique", "provides", "in", "about", "50", "-", "60", "%", "erections", "sufficient", "for", "sexual", "intercourse", ".", "Damage", "to", "the", "cavernous", "nerves", "or", "vascular", "injuries", "are", "responsible", "for", "erectile", "dysfunction", ".", "Alprostadil", "is", "most", "commonly", "used", "for", "self", "-", "injection", "monotherapy", "or", "in", "combination", "with", "other", "vasoactive", "drugs", ".", "Intraurethral", "administration", "of", "alprostadil", "failed", "to", "reproduce", "promising", "early", "results", ".", "The", "oral", "drug", "Sildenafil", "showed", "to", "be", "effective", "in", "patients", "with", "partial", "erections", ",", "however", ",", "it", "failed", "to", "work", "after", "non", "nerve", "-", "sparing", "radical", "prostatectomy", ".", "Negative", "pressure", "devices", "and", "penile", "prosthesis", "can", "be", "considered", "as", "alternative", "therpeutic", "options", ".", "Autologous", "N.", "suralis", "transplantation", "during", "radical", "prostatectomy", "might", "further", "improve", "erection", "rates", "in", "the", "near", "future", "." ]	[ "umlsterm" ]
prostatectomy, postoperative, disorder, technique, erections, sexual intercourse, nerves, injuries, erectile dysfunction, Alprostadil, self - injection, drugs, administration, alprostadil, drug, Sildenafil, patients, erections, prostatectomy, pressure, devices, penile prosthesis, N. suralis, transplantation, prostatectomy, erection, future	Reproduktionsmedizin.00160279.eng.abstr_task2	Sentence: Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future . Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]	Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future .	[ "Erectile", "failure", "after", "radical", "prostatectomy", "is", "a", "common", "postoperative", "disorder", ".", "However", ",", "nerve", "-", "sparing", "technique", "provides", "in", "about", "50", "-", "60", "%", "erections", "sufficient", "for", "sexual", "intercourse", ".", "Damage", "to", "the", "cavernous", "nerves", "or", "vascular", "injuries", "are", "responsible", "for", "erectile", "dysfunction", ".", "Alprostadil", "is", "most", "commonly", "used", "for", "self", "-", "injection", "monotherapy", "or", "in", "combination", "with", "other", "vasoactive", "drugs", ".", "Intraurethral", "administration", "of", "alprostadil", "failed", "to", "reproduce", "promising", "early", "results", ".", "The", "oral", "drug", "Sildenafil", "showed", "to", "be", "effective", "in", "patients", "with", "partial", "erections", ",", "however", ",", "it", "failed", "to", "work", "after", "non", "nerve", "-", "sparing", "radical", "prostatectomy", ".", "Negative", "pressure", "devices", "and", "penile", "prosthesis", "can", "be", "considered", "as", "alternative", "therpeutic", "options", ".", "Autologous", "N.", "suralis", "transplantation", "during", "radical", "prostatectomy", "might", "further", "improve", "erection", "rates", "in", "the", "near", "future", "." ]	[ "umlsterm" ]
tyrosinase is a Protein, tyrosine hydroxylase is a Protein, tyrosinase is a Protein, Tyrosine hydroxylase is a Protein	46_task0	Sentence: Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule.	[ "Hydroxylating", "activity", "of", "frog", "epidermis", "tyrosinase", ".", "\n", "Trypsin", "activated", "in", "a", "similar", "way", "both", "the", "tyrosine", "hydroxylase", "and", "the", "dopa", "-", "oxidasa", "activities", "of", "frog", "epidermis", "tyrosinase", ".", "Several", "electron", "donors", "reduced", "or", "eliminated", "the", "lag", "period", "for", "the", "hydroxylating", "enzyme", ".", "4", "x", "10(-5", ")", "M", "dopa", "was", "particularly", "effective", ",", "but", "without", "affecting", "the", "stationary", "activity", "after", "lag", "period", ".", "Tyrosine", "hydroxylase", "had", "KM", "=", "2.6", "X", "10(-3", ")", "M", "for", "tyrosine", "and", "2", "x", "10(-3", ")", "M", "dopa", "was", "a", "competitive", "inhibitor", "with", "Ki", "=", "5", "x", "10(-4", ")", "M.", "The", "enzyme", "was", "inactivated", "during", "its", "actuation", ".", "Data", "on", "thermal", "denaturation", "were", "similar", "to", "other", "obtained", "from", "dopa", "oxidase", ".", "Our", "results", "tend", "to", "confirm", "our", "previous", "hypothesis", "that", "the", "activatory", "process", "of", "the", "enzyme", "is", "accompanied", "by", "a", "spatial", "unfolding", "of", "the", "enzyme", "molecule", ".", "\n" ]	[ "Protein" ]
tyrosinase is a Protein, tyrosine hydroxylase is a Protein, tyrosinase is a Protein, Tyrosine hydroxylase is a Protein	46_task1	Sentence: Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule. Instructions: please typing these entity words according to sentence: tyrosinase, tyrosine hydroxylase, tyrosinase, Tyrosine hydroxylase Options: Protein	[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule.	[ "Hydroxylating", "activity", "of", "frog", "epidermis", "tyrosinase", ".", "\n", "Trypsin", "activated", "in", "a", "similar", "way", "both", "the", "tyrosine", "hydroxylase", "and", "the", "dopa", "-", "oxidasa", "activities", "of", "frog", "epidermis", "tyrosinase", ".", "Several", "electron", "donors", "reduced", "or", "eliminated", "the", "lag", "period", "for", "the", "hydroxylating", "enzyme", ".", "4", "x", "10(-5", ")", "M", "dopa", "was", "particularly", "effective", ",", "but", "without", "affecting", "the", "stationary", "activity", "after", "lag", "period", ".", "Tyrosine", "hydroxylase", "had", "KM", "=", "2.6", "X", "10(-3", ")", "M", "for", "tyrosine", "and", "2", "x", "10(-3", ")", "M", "dopa", "was", "a", "competitive", "inhibitor", "with", "Ki", "=", "5", "x", "10(-4", ")", "M.", "The", "enzyme", "was", "inactivated", "during", "its", "actuation", ".", "Data", "on", "thermal", "denaturation", "were", "similar", "to", "other", "obtained", "from", "dopa", "oxidase", ".", "Our", "results", "tend", "to", "confirm", "our", "previous", "hypothesis", "that", "the", "activatory", "process", "of", "the", "enzyme", "is", "accompanied", "by", "a", "spatial", "unfolding", "of", "the", "enzyme", "molecule", ".", "\n" ]	[ "Protein" ]
tyrosinase, tyrosine hydroxylase, tyrosinase, Tyrosine hydroxylase	46_task2	Sentence: Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule.	[ "Hydroxylating", "activity", "of", "frog", "epidermis", "tyrosinase", ".", "\n", "Trypsin", "activated", "in", "a", "similar", "way", "both", "the", "tyrosine", "hydroxylase", "and", "the", "dopa", "-", "oxidasa", "activities", "of", "frog", "epidermis", "tyrosinase", ".", "Several", "electron", "donors", "reduced", "or", "eliminated", "the", "lag", "period", "for", "the", "hydroxylating", "enzyme", ".", "4", "x", "10(-5", ")", "M", "dopa", "was", "particularly", "effective", ",", "but", "without", "affecting", "the", "stationary", "activity", "after", "lag", "period", ".", "Tyrosine", "hydroxylase", "had", "KM", "=", "2.6", "X", "10(-3", ")", "M", "for", "tyrosine", "and", "2", "x", "10(-3", ")", "M", "dopa", "was", "a", "competitive", "inhibitor", "with", "Ki", "=", "5", "x", "10(-4", ")", "M.", "The", "enzyme", "was", "inactivated", "during", "its", "actuation", ".", "Data", "on", "thermal", "denaturation", "were", "similar", "to", "other", "obtained", "from", "dopa", "oxidase", ".", "Our", "results", "tend", "to", "confirm", "our", "previous", "hypothesis", "that", "the", "activatory", "process", "of", "the", "enzyme", "is", "accompanied", "by", "a", "spatial", "unfolding", "of", "the", "enzyme", "molecule", ".", "\n" ]	[ "Protein" ]
ubiquitin is a Protein, ubiquitin is a Protein	313_task0	Sentence: Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination.	[ "Biochemical", "and", "biophysical", "analyses", "of", "Ras", "modification", "by", "ubiquitin", ".", "\n", "Ras", "proteins", "are", "small", "GTPases", "that", "play", "key", "roles", "in", "the", "regulation", "of", "several", "cellular", "processes", "such", "as", "growth", ",", "differentiation", ",", "and", "transformation", ".", "Although", "Ras", "signaling", "was", "thought", "to", "occur", "uniformly", "on", "the", "inner", "leaflet", "of", "the", "plasma", "membrane", ",", "a", "growing", "body", "of", "evidence", "indicates", "that", "Ras", "activation", "happens", "dynamically", "within", "defined", "plasma", "membrane", "microdomains", "and", "at", "other", "specific", "intracellular", "compartments", ",", "thus", "ensuring", "the", "generation", "of", "distinct", "signal", "outputs", ".", "Yet", "the", "mechanisms", "that", "control", "the", "spatiotemporal", "segregation", "of", "Ras", "proteins", "remain", "poorly", "characterized", ".", "We", "have", "recently", "shown", "that", "the", "differential", "modification", "of", "Ras", "proteins", "by", "ubiquitination", "is", "a", "crucial", "factor", "that", "controls", "Ras", "intracellular", "trafficking", "and", "signaling", "potential", ".", "To", "better", "understand", "the", "process", "of", "Ras", "ubiquitination", ",", "it", "is", "important", "to", "establish", "assays", "that", "not", "only", "provide", "information", "about", "the", "nature", "of", "the", "ubiquitin", "modification", "involved", ",", "but", "also", "enable", "the", "monitoring", "of", "the", "dynamics", "of", "this", "process", ".", "In", "this", "chapter", ",", "we", "will", "describe", "biochemical", "and", "biophysical", "methodologies", ",", "namely", "immunoprecipitation", ",", "nickel", "-", "chelate", "affinity", "chromatography", ",", "and", "bioluminescence", "resonance", "energy", "transfer", "(", "BRET", ")", ",", "for", "monitoring", "the", "ubiquitination", "of", "Ras", "proteins", ".", "Although", "the", "description", "focuses", "on", "Ras", ",", "the", "assays", "described", "can", "in", "principle", "be", "applied", "to", "the", "study", "of", "a", "range", "of", "proteins", "of", "interest", "that", "may", "be", "subject", "to", "ubiquitination", ",", "and", "the", "use", "of", "the", "different", "methods", "in", "parallel", "should", "provide", "new", "insights", "into", "the", "nature", "and", "dynamics", "of", "protein", "ubiquitination", ".", "\n" ]	[ "Protein" ]
ubiquitin is a Protein, ubiquitin is a Protein	313_task1	Sentence: Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination. Instructions: please typing these entity words according to sentence: ubiquitin, ubiquitin Options: Protein	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination.	[ "Biochemical", "and", "biophysical", "analyses", "of", "Ras", "modification", "by", "ubiquitin", ".", "\n", "Ras", "proteins", "are", "small", "GTPases", "that", "play", "key", "roles", "in", "the", "regulation", "of", "several", "cellular", "processes", "such", "as", "growth", ",", "differentiation", ",", "and", "transformation", ".", "Although", "Ras", "signaling", "was", "thought", "to", "occur", "uniformly", "on", "the", "inner", "leaflet", "of", "the", "plasma", "membrane", ",", "a", "growing", "body", "of", "evidence", "indicates", "that", "Ras", "activation", "happens", "dynamically", "within", "defined", "plasma", "membrane", "microdomains", "and", "at", "other", "specific", "intracellular", "compartments", ",", "thus", "ensuring", "the", "generation", "of", "distinct", "signal", "outputs", ".", "Yet", "the", "mechanisms", "that", "control", "the", "spatiotemporal", "segregation", "of", "Ras", "proteins", "remain", "poorly", "characterized", ".", "We", "have", "recently", "shown", "that", "the", "differential", "modification", "of", "Ras", "proteins", "by", "ubiquitination", "is", "a", "crucial", "factor", "that", "controls", "Ras", "intracellular", "trafficking", "and", "signaling", "potential", ".", "To", "better", "understand", "the", "process", "of", "Ras", "ubiquitination", ",", "it", "is", "important", "to", "establish", "assays", "that", "not", "only", "provide", "information", "about", "the", "nature", "of", "the", "ubiquitin", "modification", "involved", ",", "but", "also", "enable", "the", "monitoring", "of", "the", "dynamics", "of", "this", "process", ".", "In", "this", "chapter", ",", "we", "will", "describe", "biochemical", "and", "biophysical", "methodologies", ",", "namely", "immunoprecipitation", ",", "nickel", "-", "chelate", "affinity", "chromatography", ",", "and", "bioluminescence", "resonance", "energy", "transfer", "(", "BRET", ")", ",", "for", "monitoring", "the", "ubiquitination", "of", "Ras", "proteins", ".", "Although", "the", "description", "focuses", "on", "Ras", ",", "the", "assays", "described", "can", "in", "principle", "be", "applied", "to", "the", "study", "of", "a", "range", "of", "proteins", "of", "interest", "that", "may", "be", "subject", "to", "ubiquitination", ",", "and", "the", "use", "of", "the", "different", "methods", "in", "parallel", "should", "provide", "new", "insights", "into", "the", "nature", "and", "dynamics", "of", "protein", "ubiquitination", ".", "\n" ]	[ "Protein" ]
ubiquitin, ubiquitin	313_task2	Sentence: Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination. Instructions: please extract entity words from the input sentence	[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]	Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination.	[ "Biochemical", "and", "biophysical", "analyses", "of", "Ras", "modification", "by", "ubiquitin", ".", "\n", "Ras", "proteins", "are", "small", "GTPases", "that", "play", "key", "roles", "in", "the", "regulation", "of", "several", "cellular", "processes", "such", "as", "growth", ",", "differentiation", ",", "and", "transformation", ".", "Although", "Ras", "signaling", "was", "thought", "to", "occur", "uniformly", "on", "the", "inner", "leaflet", "of", "the", "plasma", "membrane", ",", "a", "growing", "body", "of", "evidence", "indicates", "that", "Ras", "activation", "happens", "dynamically", "within", "defined", "plasma", "membrane", "microdomains", "and", "at", "other", "specific", "intracellular", "compartments", ",", "thus", "ensuring", "the", "generation", "of", "distinct", "signal", "outputs", ".", "Yet", "the", "mechanisms", "that", "control", "the", "spatiotemporal", "segregation", "of", "Ras", "proteins", "remain", "poorly", "characterized", ".", "We", "have", "recently", "shown", "that", "the", "differential", "modification", "of", "Ras", "proteins", "by", "ubiquitination", "is", "a", "crucial", "factor", "that", "controls", "Ras", "intracellular", "trafficking", "and", "signaling", "potential", ".", "To", "better", "understand", "the", "process", "of", "Ras", "ubiquitination", ",", "it", "is", "important", "to", "establish", "assays", "that", "not", "only", "provide", "information", "about", "the", "nature", "of", "the", "ubiquitin", "modification", "involved", ",", "but", "also", "enable", "the", "monitoring", "of", "the", "dynamics", "of", "this", "process", ".", "In", "this", "chapter", ",", "we", "will", "describe", "biochemical", "and", "biophysical", "methodologies", ",", "namely", "immunoprecipitation", ",", "nickel", "-", "chelate", "affinity", "chromatography", ",", "and", "bioluminescence", "resonance", "energy", "transfer", "(", "BRET", ")", ",", "for", "monitoring", "the", "ubiquitination", "of", "Ras", "proteins", ".", "Although", "the", "description", "focuses", "on", "Ras", ",", "the", "assays", "described", "can", "in", "principle", "be", "applied", "to", "the", "study", "of", "a", "range", "of", "proteins", "of", "interest", "that", "may", "be", "subject", "to", "ubiquitination", ",", "and", "the", "use", "of", "the", "different", "methods", "in", "parallel", "should", "provide", "new", "insights", "into", "the", "nature", "and", "dynamics", "of", "protein", "ubiquitination", ".", "\n" ]	[ "Protein" ]
interactions is an umlsterm, agonists is an umlsterm, anaesthetics is an umlsterm, analgesics is an umlsterm, local anaesthetics is an umlsterm, pain therapy is an umlsterm, Laboratory is an umlsterm, animal is an umlsterm, research is an umlsterm, drug interactions is an umlsterm, molecular biology is an umlsterm, drug therapies is an umlsterm, local anaesthetic is an umlsterm, agonists is an umlsterm, peripheral nerve is an umlsterm, interaction is an umlsterm, local anaesthetics is an umlsterm, work is an umlsterm, interactions is an umlsterm, agonists is an umlsterm, opioids is an umlsterm, role is an umlsterm, spinal cord is an umlsterm	DerSchmerz.60100014.eng.abstr_task0	Sentence: The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]	The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception .	[ "The", "interactions", "of", "2-adrenoceptor", "agonists", "with", "anaesthetics", ",", "analgesics", "and", "local", "anaesthetics", "are", "not", "only", "of", "practical", "importance", "in", "many", "areas", "of", "anaesthesia", "and", "pain", "therapy", ",", "but", "also", "of", "significant", "theoretical", "interest", ".", "Laboratory", "investigations", "and", "animal", "research", "allow", "us", "to", "study", "the", "pharmacological", "mechanisms", "of", "these", "drug", "interactions", "by", "using", "the", "tools", "of", "molecular", "biology", ".", "This", "may", "lead", "to", "the", "establishment", "of", "a", "scientific", "basis", "allowing", "the", "definition", "of", "rational", "drug", "therapies", ".", "In", "the", "first", "part", "of", "this", "overview", ",", "recent", "data", "on", "local", "anaesthetic", "effects", "of", "2-adrenoceptor", "agonists", "on", "peripheral", "nerve", "conduction", "and", "their", "interaction", "with", "local", "anaesthetics", "are", "presented", ".", "Some", "important", "experimental", "work", "focusing", "on", "additive", "and", "synergistic", "spinal", "interactions", "of", "2-adrenoceptor", "agonists", "with", "opioids", "and", "some", "other", "agents", "are", "then", "discussed", ".", "Finally", ",", "there", "is", "a", "brief", "reference", "to", "the", "central", "role", "of", "the", "spinal", "cord", "in", "mediating", "and", "controlling", "nociception", "." ]	[ "umlsterm" ]
interactions is an umlsterm, agonists is an umlsterm, anaesthetics is an umlsterm, analgesics is an umlsterm, local anaesthetics is an umlsterm, pain therapy is an umlsterm, Laboratory is an umlsterm, animal is an umlsterm, research is an umlsterm, drug interactions is an umlsterm, molecular biology is an umlsterm, drug therapies is an umlsterm, local anaesthetic is an umlsterm, agonists is an umlsterm, peripheral nerve is an umlsterm, interaction is an umlsterm, local anaesthetics is an umlsterm, work is an umlsterm, interactions is an umlsterm, agonists is an umlsterm, opioids is an umlsterm, role is an umlsterm, spinal cord is an umlsterm	DerSchmerz.60100014.eng.abstr_task1	Sentence: The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception . Instructions: please typing these entity words according to sentence: interactions, agonists, anaesthetics, analgesics, local anaesthetics, pain therapy, Laboratory, animal, research, drug interactions, molecular biology, drug therapies, local anaesthetic, agonists, peripheral nerve, interaction, local anaesthetics, work, interactions, agonists, opioids, role, spinal cord Options: umlsterm	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]	The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception .	[ "The", "interactions", "of", "2-adrenoceptor", "agonists", "with", "anaesthetics", ",", "analgesics", "and", "local", "anaesthetics", "are", "not", "only", "of", "practical", "importance", "in", "many", "areas", "of", "anaesthesia", "and", "pain", "therapy", ",", "but", "also", "of", "significant", "theoretical", "interest", ".", "Laboratory", "investigations", "and", "animal", "research", "allow", "us", "to", "study", "the", "pharmacological", "mechanisms", "of", "these", "drug", "interactions", "by", "using", "the", "tools", "of", "molecular", "biology", ".", "This", "may", "lead", "to", "the", "establishment", "of", "a", "scientific", "basis", "allowing", "the", "definition", "of", "rational", "drug", "therapies", ".", "In", "the", "first", "part", "of", "this", "overview", ",", "recent", "data", "on", "local", "anaesthetic", "effects", "of", "2-adrenoceptor", "agonists", "on", "peripheral", "nerve", "conduction", "and", "their", "interaction", "with", "local", "anaesthetics", "are", "presented", ".", "Some", "important", "experimental", "work", "focusing", "on", "additive", "and", "synergistic", "spinal", "interactions", "of", "2-adrenoceptor", "agonists", "with", "opioids", "and", "some", "other", "agents", "are", "then", "discussed", ".", "Finally", ",", "there", "is", "a", "brief", "reference", "to", "the", "central", "role", "of", "the", "spinal", "cord", "in", "mediating", "and", "controlling", "nociception", "." ]	[ "umlsterm" ]
interactions, agonists, anaesthetics, analgesics, local anaesthetics, pain therapy, Laboratory, animal, research, drug interactions, molecular biology, drug therapies, local anaesthetic, agonists, peripheral nerve, interaction, local anaesthetics, work, interactions, agonists, opioids, role, spinal cord	DerSchmerz.60100014.eng.abstr_task2	Sentence: The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception . Instructions: please extract entity words from the input sentence	[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]	The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception .	[ "The", "interactions", "of", "2-adrenoceptor", "agonists", "with", "anaesthetics", ",", "analgesics", "and", "local", "anaesthetics", "are", "not", "only", "of", "practical", "importance", "in", "many", "areas", "of", "anaesthesia", "and", "pain", "therapy", ",", "but", "also", "of", "significant", "theoretical", "interest", ".", "Laboratory", "investigations", "and", "animal", "research", "allow", "us", "to", "study", "the", "pharmacological", "mechanisms", "of", "these", "drug", "interactions", "by", "using", "the", "tools", "of", "molecular", "biology", ".", "This", "may", "lead", "to", "the", "establishment", "of", "a", "scientific", "basis", "allowing", "the", "definition", "of", "rational", "drug", "therapies", ".", "In", "the", "first", "part", "of", "this", "overview", ",", "recent", "data", "on", "local", "anaesthetic", "effects", "of", "2-adrenoceptor", "agonists", "on", "peripheral", "nerve", "conduction", "and", "their", "interaction", "with", "local", "anaesthetics", "are", "presented", ".", "Some", "important", "experimental", "work", "focusing", "on", "additive", "and", "synergistic", "spinal", "interactions", "of", "2-adrenoceptor", "agonists", "with", "opioids", "and", "some", "other", "agents", "are", "then", "discussed", ".", "Finally", ",", "there", "is", "a", "brief", "reference", "to", "the", "central", "role", "of", "the", "spinal", "cord", "in", "mediating", "and", "controlling", "nociception", "." ]	[ "umlsterm" ]
clozapine is a CHEMICAL, 5-hydroxytryptamine1C is a GENE-N, 5-hydroxytryptamine2 is a GENE-N	1403790_task0	Sentence: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]	The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.	[ "The", "discriminative", "stimulus", "effects", "of", "clozapine", "in", "pigeons", ":", "involvement", "of", "5-hydroxytryptamine1C", "and", "5-hydroxytryptamine2", "receptors", "." ]	[ "CHEMICAL", "GENE-N" ]
clozapine is a CHEMICAL, 5-hydroxytryptamine1C is a GENE-N, 5-hydroxytryptamine2 is a GENE-N	1403790_task1	Sentence: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Instructions: please typing these entity words according to sentence: clozapine, 5-hydroxytryptamine1C, 5-hydroxytryptamine2 Options: GENE-N, CHEMICAL	[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]	The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.	[ "The", "discriminative", "stimulus", "effects", "of", "clozapine", "in", "pigeons", ":", "involvement", "of", "5-hydroxytryptamine1C", "and", "5-hydroxytryptamine2", "receptors", "." ]	[ "CHEMICAL", "GENE-N" ]

older is an umlsterm, people is an umlsterm, continuing education is an umlsterm, communication is an umlsterm, co - operation is an umlsterm, Internet is an umlsterm, Institutes is an umlsterm, continuing education is an umlsterm, older is an umlsterm, people is an umlsterm, training is an umlsterm, media is an umlsterm, media is an umlsterm, competence is an umlsterm, educational is an umlsterm, people is an umlsterm, communication is an umlsterm, technologies is an umlsterm, Learning is an umlsterm, Life is an umlsterm, Learning is an umlsterm, Research is an umlsterm, culture is an umlsterm, universities is an umlsterm, health is an umlsterm, educational is an umlsterm

ZfuerGerontologie+Geriatrie.00330186.eng.abstr_task1

Sentence: More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area . Instructions: please typing these entity words according to sentence: older, people, continuing education, communication, co - operation, Internet, Institutes, continuing education, older, people, training, media, media, competence, educational, people, communication, technologies, Learning, Life, Learning, Research, culture, universities, health, educational Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area .

[ "More", "and", "more", "older", "people", "interested", "in", "continuing", "education", "recognise", "the", "many", "possibilties", "for", "information", ",", "communication", "and", "co", "-", "operation", "which", "Internet", "offers", "to", "them", ".", "Institutes", "of", "continuing", "education", "and", "other", "institutions", "serving", "older", "people", "are", "required", "to", "provide", "training", "for", "this", "target", "group", "in", "order", "to", "make", "access", "to", "the", "world", "of", "the", "digital", "media", "easier", ",", "to", "support", "them", "in", "acquiring", "media", "competence", "and", "to", "design", "interesting", "virtual", "educational", "programmes", "and", "courses", ".", "In", "this", "article", ",", "the", "possibilities", "of", "showing", "people", "over", "50", "the", "way", "to", "the", "new", "communication", "technologies", "will", "be", "described", "in", "view", "of", "the", "experiences", "gained", "during", "the", "information", "campaign", "\"", "Senior", "-", "Info", "-", "Mobil", "\"", ".", "It", "will", "also", "be", "demonstrated", "based", "on", "the", "examples", "of", "the", "European", "network", "\"", "Learning", "in", "Later", "Life", "\"", "and", "other", "projects", "such", "as", "\"", "Learning", "through", "Research", "\"", "that", "virtual", "working", "groups", "and", "networks", "of", "elders", "can", "become", "a", "driving", "force", "of", "a", "new", "\"", "learning", "culture", "\"", ",", "involving", "also", "those", "who", "do", "not", "live", "near", "universities", "or", "who", "for", "health", "and", "other", "personal", "reasons", "cannot", "participate", "in", "educational", "programmes", "offered", "in", "the", "area", "." ]

[ "umlsterm" ]

older, people, continuing education, communication, co - operation, Internet, Institutes, continuing education, older, people, training, media, media, competence, educational, people, communication, technologies, Learning, Life, Learning, Research, culture, universities, health, educational

ZfuerGerontologie+Geriatrie.00330186.eng.abstr_task2

Sentence: More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

More and more older people interested in continuing education recognise the many possibilties for information , communication and co-operation which Internet offers to them . Institutes of continuing education and other institutions serving older people are required to provide training for this target group in order to make access to the world of the digital media easier , to support them in acquiring media competence and to design interesting virtual educational programmes and courses . In this article , the possibilities of showing people over 50 the way to the new communication technologies will be described in view of the experiences gained during the information campaign " Senior-Info-Mobil " . It will also be demonstrated based on the examples of the European network " Learning in Later Life " and other projects such as " Learning through Research " that virtual working groups and networks of elders can become a driving force of a new " learning culture " , involving also those who do not live near universities or who for health and other personal reasons cannot participate in educational programmes offered in the area .

[ "More", "and", "more", "older", "people", "interested", "in", "continuing", "education", "recognise", "the", "many", "possibilties", "for", "information", ",", "communication", "and", "co", "-", "operation", "which", "Internet", "offers", "to", "them", ".", "Institutes", "of", "continuing", "education", "and", "other", "institutions", "serving", "older", "people", "are", "required", "to", "provide", "training", "for", "this", "target", "group", "in", "order", "to", "make", "access", "to", "the", "world", "of", "the", "digital", "media", "easier", ",", "to", "support", "them", "in", "acquiring", "media", "competence", "and", "to", "design", "interesting", "virtual", "educational", "programmes", "and", "courses", ".", "In", "this", "article", ",", "the", "possibilities", "of", "showing", "people", "over", "50", "the", "way", "to", "the", "new", "communication", "technologies", "will", "be", "described", "in", "view", "of", "the", "experiences", "gained", "during", "the", "information", "campaign", "\"", "Senior", "-", "Info", "-", "Mobil", "\"", ".", "It", "will", "also", "be", "demonstrated", "based", "on", "the", "examples", "of", "the", "European", "network", "\"", "Learning", "in", "Later", "Life", "\"", "and", "other", "projects", "such", "as", "\"", "Learning", "through", "Research", "\"", "that", "virtual", "working", "groups", "and", "networks", "of", "elders", "can", "become", "a", "driving", "force", "of", "a", "new", "\"", "learning", "culture", "\"", ",", "involving", "also", "those", "who", "do", "not", "live", "near", "universities", "or", "who", "for", "health", "and", "other", "personal", "reasons", "cannot", "participate", "in", "educational", "programmes", "offered", "in", "the", "area", "." ]

[ "umlsterm" ]

children is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, tramadol is an umlsterm, administration is an umlsterm, ward is an umlsterm, adjustment is an umlsterm, nursing staff is an umlsterm, tramadol is an umlsterm, consumption is an umlsterm, pain is an umlsterm, ten - step is an umlsterm, scales is an umlsterm, treatment is an umlsterm, therapy is an umlsterm, oxygen is an umlsterm, patients is an umlsterm, treatment is an umlsterm, Pruritus is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, procedure is an umlsterm, surgery is an umlsterm, children is an umlsterm

DerUrologeA.70360552.eng.abstr_task0

Sentence: We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children .

[ "We", "investigated", "in", "17", "children", "(", "mean", "7.1", "years", ")", "the", "continuous", "administration", "of", "tramadol", "following", "augmentation", "cystoplasty", "or", "exstrophy", "reconstruction", ".", "Mean", "duration", "of", "the", "tramadol", "administration", "on", "the", "pediatric", "ward", "was", "3.8", "+", "/-", "1.1", "days", "(", "initial", "dosage", "0.25", "mg", "/", "kg", "/", "per", "hour", ",", "dose", "adjustment", "by", "the", "nursing", "staff", ")", ".", "Mean", "tramadol", "consumption", "was", "0.21", "mg", "/", "kg", "/", "h", "on", "day", "1", "and", "was", "reduced", "to", "0.08", "mg", "/", "kg", "/", "per", "hour", "on", "day", "4", ".", "Median", "pain", "score", "(", "assessed", "with", "ten", "-", "step", "scales", ")", "was", "5", "before", "treatment", "and", "between", "2.5", "(", "day", "1", ")", "and", "0.5", "(", "day", "5", ")", "during", "therapy", ".", "Lowest", "oxygen", "saturations", "(", "mean", ")", "ranged", "from", "93.8", "%", "to", "95.2", "%", ".", "Three", "patients", "(", "17.6", "%", ")", "suffered", "from", "nausea", "/", "vomiting", "on", "3", "of", "64", "treatment", "days", "(", "4.7", "%", ")", ".", "Pruritus", "and", "extreme", "sedation", "did", "not", "occur", ".", "The", "continuous", "administration", "of", "tramadol", "is", "a", "simple", "and", "safe", "procedure", "following", "major", "urological", "surgery", "in", "children", "." ]

[ "umlsterm" ]

children is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, tramadol is an umlsterm, administration is an umlsterm, ward is an umlsterm, adjustment is an umlsterm, nursing staff is an umlsterm, tramadol is an umlsterm, consumption is an umlsterm, pain is an umlsterm, ten - step is an umlsterm, scales is an umlsterm, treatment is an umlsterm, therapy is an umlsterm, oxygen is an umlsterm, patients is an umlsterm, treatment is an umlsterm, Pruritus is an umlsterm, administration is an umlsterm, tramadol is an umlsterm, procedure is an umlsterm, surgery is an umlsterm, children is an umlsterm

DerUrologeA.70360552.eng.abstr_task1

Sentence: We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children . Instructions: please typing these entity words according to sentence: children, administration, tramadol, tramadol, administration, ward, adjustment, nursing staff, tramadol, consumption, pain, ten - step, scales, treatment, therapy, oxygen, patients, treatment, Pruritus, administration, tramadol, procedure, surgery, children Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children .

[ "We", "investigated", "in", "17", "children", "(", "mean", "7.1", "years", ")", "the", "continuous", "administration", "of", "tramadol", "following", "augmentation", "cystoplasty", "or", "exstrophy", "reconstruction", ".", "Mean", "duration", "of", "the", "tramadol", "administration", "on", "the", "pediatric", "ward", "was", "3.8", "+", "/-", "1.1", "days", "(", "initial", "dosage", "0.25", "mg", "/", "kg", "/", "per", "hour", ",", "dose", "adjustment", "by", "the", "nursing", "staff", ")", ".", "Mean", "tramadol", "consumption", "was", "0.21", "mg", "/", "kg", "/", "h", "on", "day", "1", "and", "was", "reduced", "to", "0.08", "mg", "/", "kg", "/", "per", "hour", "on", "day", "4", ".", "Median", "pain", "score", "(", "assessed", "with", "ten", "-", "step", "scales", ")", "was", "5", "before", "treatment", "and", "between", "2.5", "(", "day", "1", ")", "and", "0.5", "(", "day", "5", ")", "during", "therapy", ".", "Lowest", "oxygen", "saturations", "(", "mean", ")", "ranged", "from", "93.8", "%", "to", "95.2", "%", ".", "Three", "patients", "(", "17.6", "%", ")", "suffered", "from", "nausea", "/", "vomiting", "on", "3", "of", "64", "treatment", "days", "(", "4.7", "%", ")", ".", "Pruritus", "and", "extreme", "sedation", "did", "not", "occur", ".", "The", "continuous", "administration", "of", "tramadol", "is", "a", "simple", "and", "safe", "procedure", "following", "major", "urological", "surgery", "in", "children", "." ]

[ "umlsterm" ]

children, administration, tramadol, tramadol, administration, ward, adjustment, nursing staff, tramadol, consumption, pain, ten - step, scales, treatment, therapy, oxygen, patients, treatment, Pruritus, administration, tramadol, procedure, surgery, children

DerUrologeA.70360552.eng.abstr_task2

Sentence: We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O" ]

We investigated in 17 children ( mean 7.1 years ) the continuous administration of tramadol following augmentation cystoplasty or exstrophy reconstruction . Mean duration of the tramadol administration on the pediatric ward was 3.8 +/- 1.1 days ( initial dosage 0.25 mg/kg/per hour , dose adjustment by the nursing staff ) . Mean tramadol consumption was 0.21 mg/kg/h on day 1 and was reduced to 0.08 mg/kg/per hour on day 4. Median pain score ( assessed with ten-step scales ) was 5 before treatment and between 2.5 ( day 1 ) and 0.5 ( day 5 ) during therapy . Lowest oxygen saturations ( mean ) ranged from 93.8 % to 95.2 % . Three patients ( 17.6 % ) suffered from nausea/vomiting on 3 of 64 treatment days ( 4.7 % ) . Pruritus and extreme sedation did not occur . The continuous administration of tramadol is a simple and safe procedure following major urological surgery in children .

[ "We", "investigated", "in", "17", "children", "(", "mean", "7.1", "years", ")", "the", "continuous", "administration", "of", "tramadol", "following", "augmentation", "cystoplasty", "or", "exstrophy", "reconstruction", ".", "Mean", "duration", "of", "the", "tramadol", "administration", "on", "the", "pediatric", "ward", "was", "3.8", "+", "/-", "1.1", "days", "(", "initial", "dosage", "0.25", "mg", "/", "kg", "/", "per", "hour", ",", "dose", "adjustment", "by", "the", "nursing", "staff", ")", ".", "Mean", "tramadol", "consumption", "was", "0.21", "mg", "/", "kg", "/", "h", "on", "day", "1", "and", "was", "reduced", "to", "0.08", "mg", "/", "kg", "/", "per", "hour", "on", "day", "4", ".", "Median", "pain", "score", "(", "assessed", "with", "ten", "-", "step", "scales", ")", "was", "5", "before", "treatment", "and", "between", "2.5", "(", "day", "1", ")", "and", "0.5", "(", "day", "5", ")", "during", "therapy", ".", "Lowest", "oxygen", "saturations", "(", "mean", ")", "ranged", "from", "93.8", "%", "to", "95.2", "%", ".", "Three", "patients", "(", "17.6", "%", ")", "suffered", "from", "nausea", "/", "vomiting", "on", "3", "of", "64", "treatment", "days", "(", "4.7", "%", ")", ".", "Pruritus", "and", "extreme", "sedation", "did", "not", "occur", ".", "The", "continuous", "administration", "of", "tramadol", "is", "a", "simple", "and", "safe", "procedure", "following", "major", "urological", "surgery", "in", "children", "." ]

[ "umlsterm" ]

filamentous is a Phenotype, Scopulariopsis brevicaulis is a Microorganism, cheese is a Habitat, S. brevicaulis is a Microorganism, Danish cheese is a Habitat, cheeses is a Habitat, high proteolytic activity is a Phenotype, ammonia production is a Phenotype, production of arsenical compounds is a Phenotype

109_task0

Sentence: Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5]. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Microorganism, Phenotype, Habitat

[ "O", "O", "O", "B-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5].

[ "Finally", ",", "the", "filamentous", "fungus", "Scopulariopsis", "brevicaulis", "was", "found", "in", "a", "high", "number", "on", "cheese", "A.", "S.", "brevicaulis", "has", "previously", "been", "found", "in", "Danish", "cheese", "[", "52", "]", ",", " ", "and", "has", "been", "subject", "to", "spoilage", "of", "cheeses", "due", "to", "its", "high", "proteolytic", " ", "activity", "resulting", "in", "ammonia", "production", "and", "its", "production", "of", " ", "arsenical", "compounds", ",", "e.g", ".", ",", "diethylarsine", ",", "which", "has", "a", "very", " ", "characteristic", "garlic", "-", "like", "odour", "[", "5", "]", "." ]

[ "Phenotype", "Microorganism", "Habitat" ]

filamentous is a Phenotype, Scopulariopsis brevicaulis is a Microorganism, cheese is a Habitat, S. brevicaulis is a Microorganism, Danish cheese is a Habitat, cheeses is a Habitat, high proteolytic activity is a Phenotype, ammonia production is a Phenotype, production of arsenical compounds is a Phenotype

109_task1

Sentence: Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5]. Instructions: please typing these entity words according to sentence: filamentous, Scopulariopsis brevicaulis, cheese, S. brevicaulis, Danish cheese, cheeses, high proteolytic activity, ammonia production, production of arsenical compounds Options: Microorganism, Phenotype, Habitat

[ "O", "O", "O", "B-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5].

[ "Finally", ",", "the", "filamentous", "fungus", "Scopulariopsis", "brevicaulis", "was", "found", "in", "a", "high", "number", "on", "cheese", "A.", "S.", "brevicaulis", "has", "previously", "been", "found", "in", "Danish", "cheese", "[", "52", "]", ",", " ", "and", "has", "been", "subject", "to", "spoilage", "of", "cheeses", "due", "to", "its", "high", "proteolytic", " ", "activity", "resulting", "in", "ammonia", "production", "and", "its", "production", "of", " ", "arsenical", "compounds", ",", "e.g", ".", ",", "diethylarsine", ",", "which", "has", "a", "very", " ", "characteristic", "garlic", "-", "like", "odour", "[", "5", "]", "." ]

[ "Phenotype", "Microorganism", "Habitat" ]

filamentous, Scopulariopsis brevicaulis, cheese, S. brevicaulis, Danish cheese, cheeses, high proteolytic activity, ammonia production, production of arsenical compounds

109_task2

Sentence: Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5]. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Phenotype", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "B-Microorganism", "I-Microorganism", "O", "O", "O", "O", "O", "B-Habitat", "I-Habitat", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Habitat", "O", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "O", "O", "B-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "I-Phenotype", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Finally, the filamentous fungus Scopulariopsis brevicaulis was found in a high number on cheese A. S. brevicaulis has previously been found in Danish cheese [52], and has been subject to spoilage of cheeses due to its high proteolytic activity resulting in ammonia production and its production of arsenical compounds, e.g., diethylarsine, which has a very characteristic garlic-like odour [5].

[ "Finally", ",", "the", "filamentous", "fungus", "Scopulariopsis", "brevicaulis", "was", "found", "in", "a", "high", "number", "on", "cheese", "A.", "S.", "brevicaulis", "has", "previously", "been", "found", "in", "Danish", "cheese", "[", "52", "]", ",", " ", "and", "has", "been", "subject", "to", "spoilage", "of", "cheeses", "due", "to", "its", "high", "proteolytic", " ", "activity", "resulting", "in", "ammonia", "production", "and", "its", "production", "of", " ", "arsenical", "compounds", ",", "e.g", ".", ",", "diethylarsine", ",", "which", "has", "a", "very", " ", "characteristic", "garlic", "-", "like", "odour", "[", "5", "]", "." ]

[ "Phenotype", "Microorganism", "Habitat" ]

Surgery is an umlsterm, endoscopy is an umlsterm, surgery is an umlsterm, thoracic surgery is an umlsterm, surgery is an umlsterm, Methods is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, pressure is an umlsterm, tip is an umlsterm, laryngoscope is an umlsterm, pressures is an umlsterm, high - frequency jet ventilation is an umlsterm, lung is an umlsterm, patients is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, measurements is an umlsterm, lung is an umlsterm, laryngoscope is an umlsterm, tidal volume is an umlsterm, inspiratory is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, endoscope is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, inspiratory is an umlsterm, pressures is an umlsterm, tidal volumes is an umlsterm, endoscopy is an umlsterm, laryngoscope is an umlsterm, ventilation is an umlsterm, surgical is an umlsterm, surgical procedure is an umlsterm, CO2 is an umlsterm, laser is an umlsterm, ventilation is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, surgery is an umlsterm, microsurgery is an umlsterm, larynx is an umlsterm

DerAnaesthesist.50440048.eng.abstr_task0

Sentence: Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx .

[ "Surgery", "by", "three", "-", "dimensional", "(", "3D", ")", "endoscopy", "is", "being", "used", "routinely", "in", "abdominal", "surgery", "and", ",", "in", "special", "cases", ",", "in", "thoracic", "surgery", ";", "however", ",", "it", "has", "not", "been", "reported", "as", "being", "used", "in", "microlaryngeal", "surgery", ".", "Methods", ".", "We", "inserted", "a", "3-D", "endoscope", "into", "a", "jet", "laryngoscope", "and", "studied", "the", "pressure", "properties", "at", "the", "tip", "of", "the", "laryngoscope", "as", "well", "as", "intrapulmonary", "pressures", "while", "applying", "superimposed", "high", "-", "frequency", "jet", "ventilation", ".", "The", "studies", "were", "conducted", "initially", "using", "a", "lung", "simulator", ",", "and", "then", "in", "seven", "patients", "undergoing", "microlaryngeal", "surgery", ".", "Results", ".", "Due", "to", "the", "rather", "large", "3-D", "endoscope", ",", "the", "diameter", "of", "the", "jet", "laryngoscope", "was", "reduced", "by", "between", "25.2", "%", "and", "70.9", "%", ",", "depending", "on", "its", "size", ".", "The", "measurements", "on", "the", "lung", "simulator", "revealed", "that", "reduction", "of", "laryngoscope", "diameter", "leads", "to", "an", "increase", "in", "the", "following", "parameters", ":", "expiratory", "resistance", ",", "tidal", "volume", ",", "and", "peak", "inspiratory", "pressure", ".", "The", "mean", "FiO2", "was", "0.74", "+", "/-", "0.1", ";", "the", "mean", "paO2", "was", "169.2", "+", "/-", "80.4", "mm", "Hg", ";", "and", "the", "mean", "paCO2", "was", "40.9", "+", "/-", "2.4", "mm", "Hg", ".", "The", "mean", "airway", "pressure", "was", "19", "+", "/-", "5.3", "mm", "Hg", "prior", "to", "insertion", "of", "the", "endoscope", "and", "12.3", "+", "/-", "6.9", "mm", "Hg", "after", "insertion", ".", "The", "mean", "positive", "end", "-", "expiratory", "pressure", "values", "increased", "from", "2", "+", "/-", "0.6", "to", "3.6", "+", "/-", "2.3", "mm", "Hg", ".", "Reduction", "of", "the", "working", "pressure", "resulted", "in", "restoration", "of", "the", "initial", "inspiratory", "pressures", "and", "tidal", "volumes", ".", "Conclusions", ".", "In", "the", "clinical", "application", "of", "3-D", "endoscopy", "via", "a", "jet", "laryngoscope", ",", "it", "was", "possible", "to", "achieve", "sufficient", "ventilation", ",", "inspection", "of", "the", "surgical", "field", ",", "and", "performance", "of", "the", "surgical", "procedure", ".", "A", "CO2", "laser", "was", "used", "without", "changing", "the", "ventilation", "regime", ".", "Although", "technical", "alterations", "would", "be", "desirable", "for", "its", "application", "to", "microlaryngeal", "surgery", ",", "it", "is", "presently", "possible", "to", "safely", "use", "the", "3-D", "endoscope", "via", "the", "jet", "laryngoscope", "for", "microlaryngeal", "surgery", ",", "presenting", "the", "surgeon", "with", "new", "possibilities", "in", "voice", "-", "improving", "microsurgery", "of", "the", "larynx", "." ]

[ "umlsterm" ]

Surgery is an umlsterm, endoscopy is an umlsterm, surgery is an umlsterm, thoracic surgery is an umlsterm, surgery is an umlsterm, Methods is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, pressure is an umlsterm, tip is an umlsterm, laryngoscope is an umlsterm, pressures is an umlsterm, high - frequency jet ventilation is an umlsterm, lung is an umlsterm, patients is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, measurements is an umlsterm, lung is an umlsterm, laryngoscope is an umlsterm, tidal volume is an umlsterm, inspiratory is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, endoscope is an umlsterm, pressure is an umlsterm, pressure is an umlsterm, inspiratory is an umlsterm, pressures is an umlsterm, tidal volumes is an umlsterm, endoscopy is an umlsterm, laryngoscope is an umlsterm, ventilation is an umlsterm, surgical is an umlsterm, surgical procedure is an umlsterm, CO2 is an umlsterm, laser is an umlsterm, ventilation is an umlsterm, surgery is an umlsterm, endoscope is an umlsterm, laryngoscope is an umlsterm, surgery is an umlsterm, microsurgery is an umlsterm, larynx is an umlsterm

DerAnaesthesist.50440048.eng.abstr_task1

Sentence: Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx . Instructions: please typing these entity words according to sentence: Surgery, endoscopy, surgery, thoracic surgery, surgery, Methods, endoscope, laryngoscope, pressure, tip, laryngoscope, pressures, high - frequency jet ventilation, lung, patients, surgery, endoscope, laryngoscope, measurements, lung, laryngoscope, tidal volume, inspiratory, pressure, pressure, endoscope, pressure, pressure, inspiratory, pressures, tidal volumes, endoscopy, laryngoscope, ventilation, surgical, surgical procedure, CO2, laser, ventilation, surgery, endoscope, laryngoscope, surgery, microsurgery, larynx Options: umlsterm

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx .

[ "Surgery", "by", "three", "-", "dimensional", "(", "3D", ")", "endoscopy", "is", "being", "used", "routinely", "in", "abdominal", "surgery", "and", ",", "in", "special", "cases", ",", "in", "thoracic", "surgery", ";", "however", ",", "it", "has", "not", "been", "reported", "as", "being", "used", "in", "microlaryngeal", "surgery", ".", "Methods", ".", "We", "inserted", "a", "3-D", "endoscope", "into", "a", "jet", "laryngoscope", "and", "studied", "the", "pressure", "properties", "at", "the", "tip", "of", "the", "laryngoscope", "as", "well", "as", "intrapulmonary", "pressures", "while", "applying", "superimposed", "high", "-", "frequency", "jet", "ventilation", ".", "The", "studies", "were", "conducted", "initially", "using", "a", "lung", "simulator", ",", "and", "then", "in", "seven", "patients", "undergoing", "microlaryngeal", "surgery", ".", "Results", ".", "Due", "to", "the", "rather", "large", "3-D", "endoscope", ",", "the", "diameter", "of", "the", "jet", "laryngoscope", "was", "reduced", "by", "between", "25.2", "%", "and", "70.9", "%", ",", "depending", "on", "its", "size", ".", "The", "measurements", "on", "the", "lung", "simulator", "revealed", "that", "reduction", "of", "laryngoscope", "diameter", "leads", "to", "an", "increase", "in", "the", "following", "parameters", ":", "expiratory", "resistance", ",", "tidal", "volume", ",", "and", "peak", "inspiratory", "pressure", ".", "The", "mean", "FiO2", "was", "0.74", "+", "/-", "0.1", ";", "the", "mean", "paO2", "was", "169.2", "+", "/-", "80.4", "mm", "Hg", ";", "and", "the", "mean", "paCO2", "was", "40.9", "+", "/-", "2.4", "mm", "Hg", ".", "The", "mean", "airway", "pressure", "was", "19", "+", "/-", "5.3", "mm", "Hg", "prior", "to", "insertion", "of", "the", "endoscope", "and", "12.3", "+", "/-", "6.9", "mm", "Hg", "after", "insertion", ".", "The", "mean", "positive", "end", "-", "expiratory", "pressure", "values", "increased", "from", "2", "+", "/-", "0.6", "to", "3.6", "+", "/-", "2.3", "mm", "Hg", ".", "Reduction", "of", "the", "working", "pressure", "resulted", "in", "restoration", "of", "the", "initial", "inspiratory", "pressures", "and", "tidal", "volumes", ".", "Conclusions", ".", "In", "the", "clinical", "application", "of", "3-D", "endoscopy", "via", "a", "jet", "laryngoscope", ",", "it", "was", "possible", "to", "achieve", "sufficient", "ventilation", ",", "inspection", "of", "the", "surgical", "field", ",", "and", "performance", "of", "the", "surgical", "procedure", ".", "A", "CO2", "laser", "was", "used", "without", "changing", "the", "ventilation", "regime", ".", "Although", "technical", "alterations", "would", "be", "desirable", "for", "its", "application", "to", "microlaryngeal", "surgery", ",", "it", "is", "presently", "possible", "to", "safely", "use", "the", "3-D", "endoscope", "via", "the", "jet", "laryngoscope", "for", "microlaryngeal", "surgery", ",", "presenting", "the", "surgeon", "with", "new", "possibilities", "in", "voice", "-", "improving", "microsurgery", "of", "the", "larynx", "." ]

[ "umlsterm" ]

Surgery, endoscopy, surgery, thoracic surgery, surgery, Methods, endoscope, laryngoscope, pressure, tip, laryngoscope, pressures, high - frequency jet ventilation, lung, patients, surgery, endoscope, laryngoscope, measurements, lung, laryngoscope, tidal volume, inspiratory, pressure, pressure, endoscope, pressure, pressure, inspiratory, pressures, tidal volumes, endoscopy, laryngoscope, ventilation, surgical, surgical procedure, CO2, laser, ventilation, surgery, endoscope, laryngoscope, surgery, microsurgery, larynx

DerAnaesthesist.50440048.eng.abstr_task2

Sentence: Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx . Instructions: please extract entity words from the input sentence

[ "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O" ]

Surgery by three-dimensional ( 3D ) endoscopy is being used routinely in abdominal surgery and , in special cases , in thoracic surgery ; however , it has not been reported as being used in microlaryngeal surgery . Methods . We inserted a 3-D endoscope into a jet laryngoscope and studied the pressure properties at the tip of the laryngoscope as well as intrapulmonary pressures while applying superimposed high-frequency jet ventilation . The studies were conducted initially using a lung simulator , and then in seven patients undergoing microlaryngeal surgery . Results . Due to the rather large 3-D endoscope , the diameter of the jet laryngoscope was reduced by between 25.2% and 70.9% , depending on its size . The measurements on the lung simulator revealed that reduction of laryngoscope diameter leads to an increase in the following parameters : expiratory resistance , tidal volume , and peak inspiratory pressure . The mean FiO2 was 0.74 +/- 0.1 ; the mean paO2 was 169.2 +/- 80.4 mm Hg ; and the mean paCO2 was 40.9 +/- 2.4 mm Hg. The mean airway pressure was 19 +/- 5.3 mm Hg prior to insertion of the endoscope and 12.3 +/- 6.9 mm Hg after insertion . The mean positive end-expiratory pressure values increased from 2 +/- 0.6 to 3.6 +/- 2.3 mm Hg. Reduction of the working pressure resulted in restoration of the initial inspiratory pressures and tidal volumes . Conclusions . In the clinical application of 3-D endoscopy via a jet laryngoscope , it was possible to achieve sufficient ventilation , inspection of the surgical field , and performance of the surgical procedure . A CO2 laser was used without changing the ventilation regime . Although technical alterations would be desirable for its application to microlaryngeal surgery , it is presently possible to safely use the 3-D endoscope via the jet laryngoscope for microlaryngeal surgery , presenting the surgeon with new possibilities in voice-improving microsurgery of the larynx .

[ "Surgery", "by", "three", "-", "dimensional", "(", "3D", ")", "endoscopy", "is", "being", "used", "routinely", "in", "abdominal", "surgery", "and", ",", "in", "special", "cases", ",", "in", "thoracic", "surgery", ";", "however", ",", "it", "has", "not", "been", "reported", "as", "being", "used", "in", "microlaryngeal", "surgery", ".", "Methods", ".", "We", "inserted", "a", "3-D", "endoscope", "into", "a", "jet", "laryngoscope", "and", "studied", "the", "pressure", "properties", "at", "the", "tip", "of", "the", "laryngoscope", "as", "well", "as", "intrapulmonary", "pressures", "while", "applying", "superimposed", "high", "-", "frequency", "jet", "ventilation", ".", "The", "studies", "were", "conducted", "initially", "using", "a", "lung", "simulator", ",", "and", "then", "in", "seven", "patients", "undergoing", "microlaryngeal", "surgery", ".", "Results", ".", "Due", "to", "the", "rather", "large", "3-D", "endoscope", ",", "the", "diameter", "of", "the", "jet", "laryngoscope", "was", "reduced", "by", "between", "25.2", "%", "and", "70.9", "%", ",", "depending", "on", "its", "size", ".", "The", "measurements", "on", "the", "lung", "simulator", "revealed", "that", "reduction", "of", "laryngoscope", "diameter", "leads", "to", "an", "increase", "in", "the", "following", "parameters", ":", "expiratory", "resistance", ",", "tidal", "volume", ",", "and", "peak", "inspiratory", "pressure", ".", "The", "mean", "FiO2", "was", "0.74", "+", "/-", "0.1", ";", "the", "mean", "paO2", "was", "169.2", "+", "/-", "80.4", "mm", "Hg", ";", "and", "the", "mean", "paCO2", "was", "40.9", "+", "/-", "2.4", "mm", "Hg", ".", "The", "mean", "airway", "pressure", "was", "19", "+", "/-", "5.3", "mm", "Hg", "prior", "to", "insertion", "of", "the", "endoscope", "and", "12.3", "+", "/-", "6.9", "mm", "Hg", "after", "insertion", ".", "The", "mean", "positive", "end", "-", "expiratory", "pressure", "values", "increased", "from", "2", "+", "/-", "0.6", "to", "3.6", "+", "/-", "2.3", "mm", "Hg", ".", "Reduction", "of", "the", "working", "pressure", "resulted", "in", "restoration", "of", "the", "initial", "inspiratory", "pressures", "and", "tidal", "volumes", ".", "Conclusions", ".", "In", "the", "clinical", "application", "of", "3-D", "endoscopy", "via", "a", "jet", "laryngoscope", ",", "it", "was", "possible", "to", "achieve", "sufficient", "ventilation", ",", "inspection", "of", "the", "surgical", "field", ",", "and", "performance", "of", "the", "surgical", "procedure", ".", "A", "CO2", "laser", "was", "used", "without", "changing", "the", "ventilation", "regime", ".", "Although", "technical", "alterations", "would", "be", "desirable", "for", "its", "application", "to", "microlaryngeal", "surgery", ",", "it", "is", "presently", "possible", "to", "safely", "use", "the", "3-D", "endoscope", "via", "the", "jet", "laryngoscope", "for", "microlaryngeal", "surgery", ",", "presenting", "the", "surgeon", "with", "new", "possibilities", "in", "voice", "-", "improving", "microsurgery", "of", "the", "larynx", "." ]

[ "umlsterm" ]

patients is an umlsterm, separations is an umlsterm, surgical reconstruction is an umlsterm, classification is an umlsterm, Matsen is an umlsterm, patients is an umlsterm, patient is an umlsterm, patients is an umlsterm, ligaments is an umlsterm, ligaments is an umlsterm, acromioclavicular joint is an umlsterm, polydioxanone - sulphate is an umlsterm, patients is an umlsterm, surgery is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, Calcifications is an umlsterm, ligaments is an umlsterm, range of motion is an umlsterm, complications is an umlsterm, infection is an umlsterm, infection is an umlsterm, complications is an umlsterm, redislocation is an umlsterm, patients is an umlsterm, arthritis is an umlsterm, joint is an umlsterm, postoperative is an umlsterm, treatment is an umlsterm, procedure is an umlsterm, patients is an umlsterm, complications is an umlsterm, migration is an umlsterm, metal is an umlsterm

DerUnfallchirurg.71000193.eng.abstr_task0

Sentence: From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided .

[ "From", "1986", "to", "1994", ",", "we", "treated", "79", "patients", "with", "acute", "acromioclavicular", "separations", "by", "surgical", "reconstruction", ".", "According", "to", "the", "classification", "of", "Rockwood", "and", "Matsen", ",", "65", "patients", "had", "type", "III", "lesions", ",", "1", "patient", "had", "a", "type", "IV", "lesion", "and", "13", "patients", "had", "type", "V", "lesions", ".", "Both", "the", "coracoclavicular", "ligaments", "and", "the", "ligaments", "of", "the", "acromioclavicular", "joint", "were", "reconstructed", ".", "An", "additional", "ligamentous", "augmentation", "was", "performed", "using", "completely", "resorbable", "5-", "and", "10-mm", "polydioxanone", "-", "sulphate", "bands", ".", "Fifty", "-", "five", "patients", "(", "70", "%", ")", "were", "reexamined", "1", "-", "7.5", "years", "after", "surgery", "(", "mean", "28", "months", ")", ".", "The", "results", "were", "good", "to", "excellent", "in", "50", "cases", "(", "90", "%", ")", ".", "Fifty", "-", "two", "patients", "(", "93", "%", ")", "achieved", "a", "range", "of", "motion", "with", "an", "abduction", "deficit", "of", "less", "than", "20", "°", ".", "Calcifications", "in", "the", "area", "of", "the", "coracoclavicular", "ligaments", "did", "not", "affect", "the", "final", "range", "of", "motion", ".", "Early", "complications", "consisted", "of", "a", "subcutaneous", "infection", ",", "one", "deep", "infection", ",", "and", "one", "reconstruction", "failure", ".", "Late", "complications", "consisted", "of", "a", "redislocation", "in", "2", "patients", "and", "symptomatic", "post", "-", "traumatic", "arthritis", "of", "the", "joint", "in", "3", "cases", ".", "Augmenting", "the", "reconstruction", "with", "polydioxyanone", "-", "sulphate", "bands", "allowed", "early", "functional", "postoperative", "treatment", ".", "With", "this", "procedure", ",", "patients", "do", "not", "require", "removal", "of", "the", "implant", ",", "and", "complications", "from", "breakage", "or", "migration", "of", "metal", "implants", "are", "avoided", "." ]

[ "umlsterm" ]

patients is an umlsterm, separations is an umlsterm, surgical reconstruction is an umlsterm, classification is an umlsterm, Matsen is an umlsterm, patients is an umlsterm, patient is an umlsterm, patients is an umlsterm, ligaments is an umlsterm, ligaments is an umlsterm, acromioclavicular joint is an umlsterm, polydioxanone - sulphate is an umlsterm, patients is an umlsterm, surgery is an umlsterm, patients is an umlsterm, range of motion is an umlsterm, Calcifications is an umlsterm, ligaments is an umlsterm, range of motion is an umlsterm, complications is an umlsterm, infection is an umlsterm, infection is an umlsterm, complications is an umlsterm, redislocation is an umlsterm, patients is an umlsterm, arthritis is an umlsterm, joint is an umlsterm, postoperative is an umlsterm, treatment is an umlsterm, procedure is an umlsterm, patients is an umlsterm, complications is an umlsterm, migration is an umlsterm, metal is an umlsterm

DerUnfallchirurg.71000193.eng.abstr_task1

Sentence: From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided . Instructions: please typing these entity words according to sentence: patients, separations, surgical reconstruction, classification, Matsen, patients, patient, patients, ligaments, ligaments, acromioclavicular joint, polydioxanone - sulphate, patients, surgery, patients, range of motion, Calcifications, ligaments, range of motion, complications, infection, infection, complications, redislocation, patients, arthritis, joint, postoperative, treatment, procedure, patients, complications, migration, metal Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided .

[ "From", "1986", "to", "1994", ",", "we", "treated", "79", "patients", "with", "acute", "acromioclavicular", "separations", "by", "surgical", "reconstruction", ".", "According", "to", "the", "classification", "of", "Rockwood", "and", "Matsen", ",", "65", "patients", "had", "type", "III", "lesions", ",", "1", "patient", "had", "a", "type", "IV", "lesion", "and", "13", "patients", "had", "type", "V", "lesions", ".", "Both", "the", "coracoclavicular", "ligaments", "and", "the", "ligaments", "of", "the", "acromioclavicular", "joint", "were", "reconstructed", ".", "An", "additional", "ligamentous", "augmentation", "was", "performed", "using", "completely", "resorbable", "5-", "and", "10-mm", "polydioxanone", "-", "sulphate", "bands", ".", "Fifty", "-", "five", "patients", "(", "70", "%", ")", "were", "reexamined", "1", "-", "7.5", "years", "after", "surgery", "(", "mean", "28", "months", ")", ".", "The", "results", "were", "good", "to", "excellent", "in", "50", "cases", "(", "90", "%", ")", ".", "Fifty", "-", "two", "patients", "(", "93", "%", ")", "achieved", "a", "range", "of", "motion", "with", "an", "abduction", "deficit", "of", "less", "than", "20", "°", ".", "Calcifications", "in", "the", "area", "of", "the", "coracoclavicular", "ligaments", "did", "not", "affect", "the", "final", "range", "of", "motion", ".", "Early", "complications", "consisted", "of", "a", "subcutaneous", "infection", ",", "one", "deep", "infection", ",", "and", "one", "reconstruction", "failure", ".", "Late", "complications", "consisted", "of", "a", "redislocation", "in", "2", "patients", "and", "symptomatic", "post", "-", "traumatic", "arthritis", "of", "the", "joint", "in", "3", "cases", ".", "Augmenting", "the", "reconstruction", "with", "polydioxyanone", "-", "sulphate", "bands", "allowed", "early", "functional", "postoperative", "treatment", ".", "With", "this", "procedure", ",", "patients", "do", "not", "require", "removal", "of", "the", "implant", ",", "and", "complications", "from", "breakage", "or", "migration", "of", "metal", "implants", "are", "avoided", "." ]

[ "umlsterm" ]

patients, separations, surgical reconstruction, classification, Matsen, patients, patient, patients, ligaments, ligaments, acromioclavicular joint, polydioxanone - sulphate, patients, surgery, patients, range of motion, Calcifications, ligaments, range of motion, complications, infection, infection, complications, redislocation, patients, arthritis, joint, postoperative, treatment, procedure, patients, complications, migration, metal

DerUnfallchirurg.71000193.eng.abstr_task2

Sentence: From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O" ]

From 1986 to 1994 , we treated 79 patients with acute acromioclavicular separations by surgical reconstruction . According to the classification of Rockwood and Matsen , 65 patients had type III lesions , 1 patient had a type IV lesion and 13 patients had type V lesions . Both the coracoclavicular ligaments and the ligaments of the acromioclavicular joint were reconstructed . An additional ligamentous augmentation was performed using completely resorbable 5- and 10-mm polydioxanone-sulphate bands . Fifty-five patients ( 70% ) were reexamined 1 - 7.5 years after surgery ( mean 28 months ) . The results were good to excellent in 50 cases ( 90% ) . Fifty-two patients ( 93% ) achieved a range of motion with an abduction deficit of less than 20 ° . Calcifications in the area of the coracoclavicular ligaments did not affect the final range of motion . Early complications consisted of a subcutaneous infection , one deep infection , and one reconstruction failure . Late complications consisted of a redislocation in 2 patients and symptomatic post-traumatic arthritis of the joint in 3 cases . Augmenting the reconstruction with polydioxyanone-sulphate bands allowed early functional postoperative treatment . With this procedure , patients do not require removal of the implant , and complications from breakage or migration of metal implants are avoided .

[ "From", "1986", "to", "1994", ",", "we", "treated", "79", "patients", "with", "acute", "acromioclavicular", "separations", "by", "surgical", "reconstruction", ".", "According", "to", "the", "classification", "of", "Rockwood", "and", "Matsen", ",", "65", "patients", "had", "type", "III", "lesions", ",", "1", "patient", "had", "a", "type", "IV", "lesion", "and", "13", "patients", "had", "type", "V", "lesions", ".", "Both", "the", "coracoclavicular", "ligaments", "and", "the", "ligaments", "of", "the", "acromioclavicular", "joint", "were", "reconstructed", ".", "An", "additional", "ligamentous", "augmentation", "was", "performed", "using", "completely", "resorbable", "5-", "and", "10-mm", "polydioxanone", "-", "sulphate", "bands", ".", "Fifty", "-", "five", "patients", "(", "70", "%", ")", "were", "reexamined", "1", "-", "7.5", "years", "after", "surgery", "(", "mean", "28", "months", ")", ".", "The", "results", "were", "good", "to", "excellent", "in", "50", "cases", "(", "90", "%", ")", ".", "Fifty", "-", "two", "patients", "(", "93", "%", ")", "achieved", "a", "range", "of", "motion", "with", "an", "abduction", "deficit", "of", "less", "than", "20", "°", ".", "Calcifications", "in", "the", "area", "of", "the", "coracoclavicular", "ligaments", "did", "not", "affect", "the", "final", "range", "of", "motion", ".", "Early", "complications", "consisted", "of", "a", "subcutaneous", "infection", ",", "one", "deep", "infection", ",", "and", "one", "reconstruction", "failure", ".", "Late", "complications", "consisted", "of", "a", "redislocation", "in", "2", "patients", "and", "symptomatic", "post", "-", "traumatic", "arthritis", "of", "the", "joint", "in", "3", "cases", ".", "Augmenting", "the", "reconstruction", "with", "polydioxyanone", "-", "sulphate", "bands", "allowed", "early", "functional", "postoperative", "treatment", ".", "With", "this", "procedure", ",", "patients", "do", "not", "require", "removal", "of", "the", "implant", ",", "and", "complications", "from", "breakage", "or", "migration", "of", "metal", "implants", "are", "avoided", "." ]

[ "umlsterm" ]

benzo(a)pyrene is a compound, CYP1A is a protein

DS.d615_task0

Sentence: Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]

Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression.

[ "Exposure", "to", "benzo(a)pyrene", "(", "BaP", ")", "by", "intraperitoneal", "injection", "increased", "biliary", "BaP", "metabolites", "and", "liver", "CYP1A", "gene", "expression", "." ]

[ "compound", "protein" ]

benzo(a)pyrene is a compound, CYP1A is a protein

DS.d615_task1

Sentence: Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression. Instructions: please typing these entity words according to sentence: benzo(a)pyrene, CYP1A Options: compound, protein

[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]

Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression.

[ "Exposure", "to", "benzo(a)pyrene", "(", "BaP", ")", "by", "intraperitoneal", "injection", "increased", "biliary", "BaP", "metabolites", "and", "liver", "CYP1A", "gene", "expression", "." ]

[ "compound", "protein" ]

benzo(a)pyrene, CYP1A

DS.d615_task2

Sentence: Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O" ]

Exposure to benzo(a)pyrene (BaP) by intraperitoneal injection increased biliary BaP metabolites and liver CYP1A gene expression.

[ "Exposure", "to", "benzo(a)pyrene", "(", "BaP", ")", "by", "intraperitoneal", "injection", "increased", "biliary", "BaP", "metabolites", "and", "liver", "CYP1A", "gene", "expression", "." ]

[ "compound", "protein" ]

F - actin is a protein, epidermal growth factor receptor is a protein, profilin is a protein-family

1.0alpha7.train.658_task0

Sentence: Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56). Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: protein-family, protein

[ "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O" ]

Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56).

[ "Previous", "studies", "have", "shown", "that", " ", "F", "-", "actin", "binds", "to", "the", " ", "epidermal", "growth", "factor", "receptor", "at", "a", "site", "in", "its", "cytoplasmic", "domain", "similar", "to", "a", "peptide", "of", " ", "profilin", "(", "56", ")", "." ]

[ "protein", "protein-family" ]

F - actin is a protein, epidermal growth factor receptor is a protein, profilin is a protein-family

1.0alpha7.train.658_task1

Sentence: Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56). Instructions: please typing these entity words according to sentence: F - actin, epidermal growth factor receptor, profilin Options: protein-family, protein

[ "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O" ]

Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56).

[ "Previous", "studies", "have", "shown", "that", " ", "F", "-", "actin", "binds", "to", "the", " ", "epidermal", "growth", "factor", "receptor", "at", "a", "site", "in", "its", "cytoplasmic", "domain", "similar", "to", "a", "peptide", "of", " ", "profilin", "(", "56", ")", "." ]

[ "protein", "protein-family" ]

F - actin, epidermal growth factor receptor, profilin

1.0alpha7.train.658_task2

Sentence: Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56). Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "O", "O", "O", "O", "B-protein", "I-protein", "I-protein", "I-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein-family", "O", "O", "O", "O" ]

Previous studies have shown that F-actin binds to the epidermal growth factor receptor at a site in its cytoplasmic domain similar to a peptide of profilin ( 56).

[ "Previous", "studies", "have", "shown", "that", " ", "F", "-", "actin", "binds", "to", "the", " ", "epidermal", "growth", "factor", "receptor", "at", "a", "site", "in", "its", "cytoplasmic", "domain", "similar", "to", "a", "peptide", "of", " ", "profilin", "(", "56", ")", "." ]

[ "protein", "protein-family" ]

antipsychotic drugs is a Intervention_Pharmacological, cortical thickness . is a Outcome_Physical, haloperidol is a Intervention_Pharmacological, risperidone is a Intervention_Pharmacological, olanzapine is a Intervention_Pharmacological, effects of antipsychotic medication is a Outcome_Other, N=16 is a Participant_Sample-size, N=18 is a Participant_Sample-size, cortical thickness changes is a Outcome_Physical, schizophrenia spectrum is a Participant_Condition, clinical is a Outcome_Physical, 45 is a Participant_Sample-size, healthy is a Participant_Condition, cortical thickness variables . is a Outcome_Physical, changes in cortical thickness is a Outcome_Physical, gray matter cortical thickness , overall and lobes is a Outcome_Physical

56131_task0

Sentence: Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness .

[ "Effect", "of", "antipsychotic", "drugs", "on", "cortical", "thickness", ".", "A", "randomized", "controlled", "one", "-", "year", "follow", "-", "up", "study", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", ".", "BACKGROUND", "Imaging", "evidence", "indicates", "that", "brain", "alterations", "are", "primary", "to", "the", "full", "-", "blown", "onset", "of", "schizophrenia", "and", "seem", "to", "progress", "across", "time", ".", "The", "potential", "effects", "of", "antipsychotic", "medication", "on", "brain", "structure", "represent", "a", "key", "factor", "in", "understanding", "brain", "changes", "in", "psychosis", ".", "We", "aimed", "to", "investigate", "the", "effects", "of", "low", "doses", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", "on", "cortical", "thickness", ".", "METHOD", "We", "investigated", "the", "effects", "of", "risperidone", "(", "N=16", ")", ",", "olanzapine", "(", "N=18", ")", "and", "low", "doses", "of", "haloperidol", "(", "N=18", ")", "in", "cortical", "thickness", "changes", "during", "1-year", "follow", "-", "up", "period", "in", "a", "large", "and", "heterogeneous", "sample", "of", "schizophrenia", "spectrum", "patients", ".", "The", "relationship", "between", "cortical", "thickness", "changes", "and", "clinical", "and", "cognitive", "outcome", "was", "also", "assessed", ".", "A", "group", "of", "45", "healthy", "volunteers", "was", "also", "longitudinally", "evaluated", ".", "Magnetic", "resonance", "imaging", "brain", "scans", "(", "1.5", "T", ")", "were", "obtained", "and", "images", "were", "analyzed", "by", "using", "BRAINS2", ".", "RESULTS", "There", "were", "no", "significant", "effects", "of", "time", "(", "F", "(", "1,47", ")", "<", "1.66", ";", "P", ">", "0.204", ")", ",", "treatment", "group", "(", "F", "(", "2,47", ")", "<", "1.47", ";", "P", ">", "0.242", ")", "or", "group", "-", "by", "-", "time", "interaction", "(", "F", "(", "2,47", ")", "<", "1.82", ";", "P", ">", "0.174", ")", "for", "any", "of", "the", "cortical", "thickness", "variables", ".", "When", "the", "group", "of", "healthy", "controls", "was", "included", "in", "the", "analyses", ",", "it", "is", "of", "note", "that", "group", "-", "by", "-", "time", "interaction", "showed", "a", "significant", "result", "for", "the", "frontal", "lobe", "at", "trend", "level", "(", "F", "(", "3,81", ")", "=", "2.686", ";", "P=0.052", ")", ".", "After", "the", "Bonferroni", "adjustment", "for", "multiple", "comparisons", ",", "there", "were", "no", "significant", "associations", "between", "changes", "in", "cortical", "thickness", "and", "clinical", "and", "cognitive", "outcome", ".", "CONCLUSIONS", "Low", "doses", "of", "haloperidol", ",", "risperidone", ",", "and", "olanzapine", "seem", "to", "equally", "affect", "gray", "matter", "cortical", "thickness", ",", "overall", "and", "lobes", ",", "at", "the", "medium", "-", "term", "(", "1", "year", ")", ".", "The", "clinical", "effectiveness", "of", "treatments", "was", "not", "significantly", "related", "to", "changes", "in", "cortical", "thickness", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]

antipsychotic drugs is a Intervention_Pharmacological, cortical thickness . is a Outcome_Physical, haloperidol is a Intervention_Pharmacological, risperidone is a Intervention_Pharmacological, olanzapine is a Intervention_Pharmacological, effects of antipsychotic medication is a Outcome_Other, N=16 is a Participant_Sample-size, N=18 is a Participant_Sample-size, cortical thickness changes is a Outcome_Physical, schizophrenia spectrum is a Participant_Condition, clinical is a Outcome_Physical, 45 is a Participant_Sample-size, healthy is a Participant_Condition, cortical thickness variables . is a Outcome_Physical, changes in cortical thickness is a Outcome_Physical, gray matter cortical thickness , overall and lobes is a Outcome_Physical

56131_task1

Sentence: Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness . Instructions: please typing these entity words according to sentence: antipsychotic drugs, cortical thickness ., haloperidol, risperidone, olanzapine, effects of antipsychotic medication, N=16, N=18, cortical thickness changes, schizophrenia spectrum, clinical, 45, healthy, cortical thickness variables ., changes in cortical thickness, gray matter cortical thickness , overall and lobes Options: Intervention_Pharmacological, Participant_Condition, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness .

[ "Effect", "of", "antipsychotic", "drugs", "on", "cortical", "thickness", ".", "A", "randomized", "controlled", "one", "-", "year", "follow", "-", "up", "study", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", ".", "BACKGROUND", "Imaging", "evidence", "indicates", "that", "brain", "alterations", "are", "primary", "to", "the", "full", "-", "blown", "onset", "of", "schizophrenia", "and", "seem", "to", "progress", "across", "time", ".", "The", "potential", "effects", "of", "antipsychotic", "medication", "on", "brain", "structure", "represent", "a", "key", "factor", "in", "understanding", "brain", "changes", "in", "psychosis", ".", "We", "aimed", "to", "investigate", "the", "effects", "of", "low", "doses", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", "on", "cortical", "thickness", ".", "METHOD", "We", "investigated", "the", "effects", "of", "risperidone", "(", "N=16", ")", ",", "olanzapine", "(", "N=18", ")", "and", "low", "doses", "of", "haloperidol", "(", "N=18", ")", "in", "cortical", "thickness", "changes", "during", "1-year", "follow", "-", "up", "period", "in", "a", "large", "and", "heterogeneous", "sample", "of", "schizophrenia", "spectrum", "patients", ".", "The", "relationship", "between", "cortical", "thickness", "changes", "and", "clinical", "and", "cognitive", "outcome", "was", "also", "assessed", ".", "A", "group", "of", "45", "healthy", "volunteers", "was", "also", "longitudinally", "evaluated", ".", "Magnetic", "resonance", "imaging", "brain", "scans", "(", "1.5", "T", ")", "were", "obtained", "and", "images", "were", "analyzed", "by", "using", "BRAINS2", ".", "RESULTS", "There", "were", "no", "significant", "effects", "of", "time", "(", "F", "(", "1,47", ")", "<", "1.66", ";", "P", ">", "0.204", ")", ",", "treatment", "group", "(", "F", "(", "2,47", ")", "<", "1.47", ";", "P", ">", "0.242", ")", "or", "group", "-", "by", "-", "time", "interaction", "(", "F", "(", "2,47", ")", "<", "1.82", ";", "P", ">", "0.174", ")", "for", "any", "of", "the", "cortical", "thickness", "variables", ".", "When", "the", "group", "of", "healthy", "controls", "was", "included", "in", "the", "analyses", ",", "it", "is", "of", "note", "that", "group", "-", "by", "-", "time", "interaction", "showed", "a", "significant", "result", "for", "the", "frontal", "lobe", "at", "trend", "level", "(", "F", "(", "3,81", ")", "=", "2.686", ";", "P=0.052", ")", ".", "After", "the", "Bonferroni", "adjustment", "for", "multiple", "comparisons", ",", "there", "were", "no", "significant", "associations", "between", "changes", "in", "cortical", "thickness", "and", "clinical", "and", "cognitive", "outcome", ".", "CONCLUSIONS", "Low", "doses", "of", "haloperidol", ",", "risperidone", ",", "and", "olanzapine", "seem", "to", "equally", "affect", "gray", "matter", "cortical", "thickness", ",", "overall", "and", "lobes", ",", "at", "the", "medium", "-", "term", "(", "1", "year", ")", ".", "The", "clinical", "effectiveness", "of", "treatments", "was", "not", "significantly", "related", "to", "changes", "in", "cortical", "thickness", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]

antipsychotic drugs, cortical thickness ., haloperidol, risperidone, olanzapine, effects of antipsychotic medication, N=16, N=18, cortical thickness changes, schizophrenia spectrum, clinical, 45, healthy, cortical thickness variables ., changes in cortical thickness, gray matter cortical thickness , overall and lobes

56131_task2

Sentence: Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "B-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "B-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Effect of antipsychotic drugs on cortical thickness . A randomized controlled one-year follow-up study of haloperidol , risperidone and olanzapine . BACKGROUND Imaging evidence indicates that brain alterations are primary to the full-blown onset of schizophrenia and seem to progress across time . The potential effects of antipsychotic medication on brain structure represent a key factor in understanding brain changes in psychosis . We aimed to investigate the effects of low doses of haloperidol , risperidone and olanzapine on cortical thickness . METHOD We investigated the effects of risperidone ( N=16 ) , olanzapine ( N=18 ) and low doses of haloperidol ( N=18 ) in cortical thickness changes during 1-year follow-up period in a large and heterogeneous sample of schizophrenia spectrum patients . The relationship between cortical thickness changes and clinical and cognitive outcome was also assessed . A group of 45 healthy volunteers was also longitudinally evaluated . Magnetic resonance imaging brain scans ( 1.5T ) were obtained and images were analyzed by using BRAINS2 . RESULTS There were no significant effects of time ( F ( 1,47 ) < 1.66 ; P > 0.204 ) , treatment group ( F ( 2,47 ) < 1.47 ; P > 0.242 ) or group-by-time interaction ( F ( 2,47 ) < 1.82 ; P > 0.174 ) for any of the cortical thickness variables . When the group of healthy controls was included in the analyses , it is of note that group-by-time interaction showed a significant result for the frontal lobe at trend level ( F ( 3,81 ) =2.686 ; P=0.052 ) . After the Bonferroni adjustment for multiple comparisons , there were no significant associations between changes in cortical thickness and clinical and cognitive outcome . CONCLUSIONS Low doses of haloperidol , risperidone , and olanzapine seem to equally affect gray matter cortical thickness , overall and lobes , at the medium-term ( 1 year ) . The clinical effectiveness of treatments was not significantly related to changes in cortical thickness .

[ "Effect", "of", "antipsychotic", "drugs", "on", "cortical", "thickness", ".", "A", "randomized", "controlled", "one", "-", "year", "follow", "-", "up", "study", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", ".", "BACKGROUND", "Imaging", "evidence", "indicates", "that", "brain", "alterations", "are", "primary", "to", "the", "full", "-", "blown", "onset", "of", "schizophrenia", "and", "seem", "to", "progress", "across", "time", ".", "The", "potential", "effects", "of", "antipsychotic", "medication", "on", "brain", "structure", "represent", "a", "key", "factor", "in", "understanding", "brain", "changes", "in", "psychosis", ".", "We", "aimed", "to", "investigate", "the", "effects", "of", "low", "doses", "of", "haloperidol", ",", "risperidone", "and", "olanzapine", "on", "cortical", "thickness", ".", "METHOD", "We", "investigated", "the", "effects", "of", "risperidone", "(", "N=16", ")", ",", "olanzapine", "(", "N=18", ")", "and", "low", "doses", "of", "haloperidol", "(", "N=18", ")", "in", "cortical", "thickness", "changes", "during", "1-year", "follow", "-", "up", "period", "in", "a", "large", "and", "heterogeneous", "sample", "of", "schizophrenia", "spectrum", "patients", ".", "The", "relationship", "between", "cortical", "thickness", "changes", "and", "clinical", "and", "cognitive", "outcome", "was", "also", "assessed", ".", "A", "group", "of", "45", "healthy", "volunteers", "was", "also", "longitudinally", "evaluated", ".", "Magnetic", "resonance", "imaging", "brain", "scans", "(", "1.5", "T", ")", "were", "obtained", "and", "images", "were", "analyzed", "by", "using", "BRAINS2", ".", "RESULTS", "There", "were", "no", "significant", "effects", "of", "time", "(", "F", "(", "1,47", ")", "<", "1.66", ";", "P", ">", "0.204", ")", ",", "treatment", "group", "(", "F", "(", "2,47", ")", "<", "1.47", ";", "P", ">", "0.242", ")", "or", "group", "-", "by", "-", "time", "interaction", "(", "F", "(", "2,47", ")", "<", "1.82", ";", "P", ">", "0.174", ")", "for", "any", "of", "the", "cortical", "thickness", "variables", ".", "When", "the", "group", "of", "healthy", "controls", "was", "included", "in", "the", "analyses", ",", "it", "is", "of", "note", "that", "group", "-", "by", "-", "time", "interaction", "showed", "a", "significant", "result", "for", "the", "frontal", "lobe", "at", "trend", "level", "(", "F", "(", "3,81", ")", "=", "2.686", ";", "P=0.052", ")", ".", "After", "the", "Bonferroni", "adjustment", "for", "multiple", "comparisons", ",", "there", "were", "no", "significant", "associations", "between", "changes", "in", "cortical", "thickness", "and", "clinical", "and", "cognitive", "outcome", ".", "CONCLUSIONS", "Low", "doses", "of", "haloperidol", ",", "risperidone", ",", "and", "olanzapine", "seem", "to", "equally", "affect", "gray", "matter", "cortical", "thickness", ",", "overall", "and", "lobes", ",", "at", "the", "medium", "-", "term", "(", "1", "year", ")", ".", "The", "clinical", "effectiveness", "of", "treatments", "was", "not", "significantly", "related", "to", "changes", "in", "cortical", "thickness", "." ]

[ "Outcome_Physical", "Outcome_Other", "Intervention_Pharmacological", "Participant_Condition", "Participant_Sample-size" ]

ponatinib is a CHEMICAL, kinase domain is a GENE-N

23430109_task0

Sentence: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

[ "Activity", "of", "ponatinib", "against", "clinically", "-", "relevant", "AC220-resistant", "kinase", "domain", "mutants", "of", "FLT3-ITD", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

ponatinib is a CHEMICAL, kinase domain is a GENE-N

23430109_task1

Sentence: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Instructions: please typing these entity words according to sentence: ponatinib, kinase domain Options: GENE-N, CHEMICAL

[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

[ "Activity", "of", "ponatinib", "against", "clinically", "-", "relevant", "AC220-resistant", "kinase", "domain", "mutants", "of", "FLT3-ITD", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

ponatinib, kinase domain

23430109_task2

Sentence: Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. Instructions: please extract entity words from the input sentence

[ "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "I-GENE-N", "O", "O", "O", "O" ]

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

[ "Activity", "of", "ponatinib", "against", "clinically", "-", "relevant", "AC220-resistant", "kinase", "domain", "mutants", "of", "FLT3-ITD", "." ]

[ "GENE-N", "CHEMICAL", "GENE-Y" ]

alpha(2A)-adrenoceptor is a GENE-Y, brimonidine is a CHEMICAL

11481271_task0

Sentence: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-Y, CHEMICAL

[ "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]

Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.

[ "Potent", "alpha(2A)-adrenoceptor", "-", "mediated", "vasoconstriction", "by", "brimonidine", "in", "porcine", "ciliary", "arteries", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

alpha(2A)-adrenoceptor is a GENE-Y, brimonidine is a CHEMICAL

11481271_task1

Sentence: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Instructions: please typing these entity words according to sentence: alpha(2A)-adrenoceptor, brimonidine Options: GENE-Y, CHEMICAL

[ "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]

Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.

[ "Potent", "alpha(2A)-adrenoceptor", "-", "mediated", "vasoconstriction", "by", "brimonidine", "in", "porcine", "ciliary", "arteries", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

alpha(2A)-adrenoceptor, brimonidine

11481271_task2

Sentence: Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Instructions: please extract entity words from the input sentence

[ "O", "B-GENE-Y", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O" ]

Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries.

[ "Potent", "alpha(2A)-adrenoceptor", "-", "mediated", "vasoconstriction", "by", "brimonidine", "in", "porcine", "ciliary", "arteries", "." ]

[ "GENE-Y", "GENE-N", "CHEMICAL" ]

Active is a Qualifier, ischemia is a Condition, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention is a Scope, CCS functional class is a Measurement, IV is a Value, angina is a Condition, antiarrhythmic drug is a Drug, allergy , intolerance or contraindication is a Scope, left ventricular thrombus is a Condition, catheter ablation procedure is a Procedure, VT is a Condition, renal failure is a Condition, Creatinine clearance is a Measurement, < 15 mL / min is a Value, NYHA Functional class is a Measurement, IV is a Value, heart failure is a Condition, systemic illness is a Condition, survival is a Observation, < 1 year is a Value, ST elevation myocardial infarction or non - ST elevation MI is a Scope, < 30 days is a Temporal, pregnant is a Condition

NCT02830360_exc_task0

Sentence: Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Temporal, Condition, Qualifier, Value, Observation, Procedure, Scope, Measurement, Drug

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O" ]

Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant.

[ "Unable", "or", "unwilling", "to", "provide", "informed", "consent", ".", "\n", "Active", "ischemia", "(", "acute", "thrombus", "diagnosed", "by", "coronary", "angiography", ",", "or", "dynamic", "ST", "segment", "changes", "demonstrated", "on", "ECG", ")", "or", "another", "reversible", "cause", "of", "VT", "(", "e.g", ".", "drug", "-", "induced", "arrhythmia", ")", ",", "had", "recent", "acute", "coronary", "syndrome", "within", "30", "days", ",", "coronary", "revascularization", "(", "<", "90", "days", "bypass", "surgery", ",", "<", "30", "days", "percutaneous", "coronary", "intervention", ")", ",", "or", "have", "CCS", "functional", "class", "IV", "angina", ".", "Note", "that", "biomarker", "level", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "acute", "coronary", "syndrome", "or", "active", "ischemia", ".", "\n", "Are", "ineligible", "to", "take", "the", "antiarrhythmic", "drug", "to", "which", "they", "would", "be", "assigned", "due", "to", "allergy", ",", "intolerance", "or", "contraindication", "\n", "Are", "known", "to", "have", "protruding", "left", "ventricular", "thrombus", "or", "mechanical", "aortic", "and", "mitral", "valves", "\n", "Have", "had", "a", "prior", "catheter", "ablation", "procedure", "for", "VT", "\n", "Are", "in", "renal", "failure", "(", "Creatinine", "clearance", "<", "15", "mL", "/", "min", ")", ",", "have", "NYHA", "Functional", "class", "IV", "heart", "failure", ",", "or", "a", "systemic", "illness", "likely", "to", "limit", "survival", "to", "<", "1", "year", "\n", "Have", "had", "recent", "ST", "elevation", "myocardial", "infarction", "or", "non", "-", "ST", "elevation", "MI", "(", "<", "30", "days", ")", ";", "note", "that", "biomarker", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "MI", ".", "\n", "Are", "pregnant", ".", "\n" ]

[ "Scope", "Procedure", "Condition", "Measurement", "Drug", "Device", "Temporal", "Qualifier", "Value", "Observation" ]

Active is a Qualifier, ischemia is a Condition, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention is a Scope, CCS functional class is a Measurement, IV is a Value, angina is a Condition, antiarrhythmic drug is a Drug, allergy , intolerance or contraindication is a Scope, left ventricular thrombus is a Condition, catheter ablation procedure is a Procedure, VT is a Condition, renal failure is a Condition, Creatinine clearance is a Measurement, < 15 mL / min is a Value, NYHA Functional class is a Measurement, IV is a Value, heart failure is a Condition, systemic illness is a Condition, survival is a Observation, < 1 year is a Value, ST elevation myocardial infarction or non - ST elevation MI is a Scope, < 30 days is a Temporal, pregnant is a Condition

NCT02830360_exc_task1

Sentence: Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant. Instructions: please typing these entity words according to sentence: Active, ischemia, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention, CCS functional class, IV, angina, antiarrhythmic drug, allergy , intolerance or contraindication, left ventricular thrombus, catheter ablation procedure, VT, renal failure, Creatinine clearance, < 15 mL / min, NYHA Functional class, IV, heart failure, systemic illness, survival, < 1 year, ST elevation myocardial infarction or non - ST elevation MI, < 30 days, pregnant Options: Temporal, Condition, Qualifier, Value, Observation, Procedure, Scope, Measurement, Drug

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O" ]

Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant.

[ "Unable", "or", "unwilling", "to", "provide", "informed", "consent", ".", "\n", "Active", "ischemia", "(", "acute", "thrombus", "diagnosed", "by", "coronary", "angiography", ",", "or", "dynamic", "ST", "segment", "changes", "demonstrated", "on", "ECG", ")", "or", "another", "reversible", "cause", "of", "VT", "(", "e.g", ".", "drug", "-", "induced", "arrhythmia", ")", ",", "had", "recent", "acute", "coronary", "syndrome", "within", "30", "days", ",", "coronary", "revascularization", "(", "<", "90", "days", "bypass", "surgery", ",", "<", "30", "days", "percutaneous", "coronary", "intervention", ")", ",", "or", "have", "CCS", "functional", "class", "IV", "angina", ".", "Note", "that", "biomarker", "level", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "acute", "coronary", "syndrome", "or", "active", "ischemia", ".", "\n", "Are", "ineligible", "to", "take", "the", "antiarrhythmic", "drug", "to", "which", "they", "would", "be", "assigned", "due", "to", "allergy", ",", "intolerance", "or", "contraindication", "\n", "Are", "known", "to", "have", "protruding", "left", "ventricular", "thrombus", "or", "mechanical", "aortic", "and", "mitral", "valves", "\n", "Have", "had", "a", "prior", "catheter", "ablation", "procedure", "for", "VT", "\n", "Are", "in", "renal", "failure", "(", "Creatinine", "clearance", "<", "15", "mL", "/", "min", ")", ",", "have", "NYHA", "Functional", "class", "IV", "heart", "failure", ",", "or", "a", "systemic", "illness", "likely", "to", "limit", "survival", "to", "<", "1", "year", "\n", "Have", "had", "recent", "ST", "elevation", "myocardial", "infarction", "or", "non", "-", "ST", "elevation", "MI", "(", "<", "30", "days", ")", ";", "note", "that", "biomarker", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "MI", ".", "\n", "Are", "pregnant", ".", "\n" ]

[ "Scope", "Procedure", "Condition", "Measurement", "Drug", "Device", "Temporal", "Qualifier", "Value", "Observation" ]

Active, ischemia, acute thrombus diagnosed by coronary angiography , or dynamic ST segment changes demonstrated on ECG ) or another reversible cause of VT ( e.g . drug - induced arrhythmia ) , had recent acute coronary syndrome within 30 days , coronary revascularization ( < 90 days bypass surgery , < 30 days percutaneous coronary intervention, CCS functional class, IV, angina, antiarrhythmic drug, allergy , intolerance or contraindication, left ventricular thrombus, catheter ablation procedure, VT, renal failure, Creatinine clearance, < 15 mL / min, NYHA Functional class, IV, heart failure, systemic illness, survival, < 1 year, ST elevation myocardial infarction or non - ST elevation MI, < 30 days, pregnant

NCT02830360_exc_task2

Sentence: Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Qualifier", "B-Condition", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Drug", "I-Drug", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "O", "B-Condition", "I-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "O", "B-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "B-Measurement", "I-Measurement", "B-Value", "I-Value", "I-Value", "I-Value", "I-Value", "O", "O", "O", "B-Measurement", "I-Measurement", "I-Measurement", "B-Value", "B-Condition", "I-Condition", "O", "O", "O", "B-Condition", "I-Condition", "O", "O", "O", "B-Observation", "O", "B-Value", "I-Value", "I-Value", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Temporal", "I-Temporal", "I-Temporal", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O" ]

Unable or unwilling to provide informed consent. Active ischemia (acute thrombus diagnosed by coronary angiography, or dynamic ST segment changes demonstrated on ECG) or another reversible cause of VT (e.g. drug-induced arrhythmia), had recent acute coronary syndrome within 30 days, coronary revascularization (<90 days bypass surgery, <30 days percutaneous coronary intervention), or have CCS functional class IV angina. Note that biomarker level elevation alone after ventricular arrhythmias does not denote acute coronary syndrome or active ischemia. Are ineligible to take the antiarrhythmic drug to which they would be assigned due to allergy, intolerance or contraindication Are known to have protruding left ventricular thrombus or mechanical aortic and mitral valves Have had a prior catheter ablation procedure for VT Are in renal failure (Creatinine clearance <15 mL/min), have NYHA Functional class IV heart failure, or a systemic illness likely to limit survival to <1 year Have had recent ST elevation myocardial infarction or non-ST elevation MI (< 30 days); note that biomarker elevation alone after ventricular arrhythmias does not denote MI. Are pregnant.

[ "Unable", "or", "unwilling", "to", "provide", "informed", "consent", ".", "\n", "Active", "ischemia", "(", "acute", "thrombus", "diagnosed", "by", "coronary", "angiography", ",", "or", "dynamic", "ST", "segment", "changes", "demonstrated", "on", "ECG", ")", "or", "another", "reversible", "cause", "of", "VT", "(", "e.g", ".", "drug", "-", "induced", "arrhythmia", ")", ",", "had", "recent", "acute", "coronary", "syndrome", "within", "30", "days", ",", "coronary", "revascularization", "(", "<", "90", "days", "bypass", "surgery", ",", "<", "30", "days", "percutaneous", "coronary", "intervention", ")", ",", "or", "have", "CCS", "functional", "class", "IV", "angina", ".", "Note", "that", "biomarker", "level", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "acute", "coronary", "syndrome", "or", "active", "ischemia", ".", "\n", "Are", "ineligible", "to", "take", "the", "antiarrhythmic", "drug", "to", "which", "they", "would", "be", "assigned", "due", "to", "allergy", ",", "intolerance", "or", "contraindication", "\n", "Are", "known", "to", "have", "protruding", "left", "ventricular", "thrombus", "or", "mechanical", "aortic", "and", "mitral", "valves", "\n", "Have", "had", "a", "prior", "catheter", "ablation", "procedure", "for", "VT", "\n", "Are", "in", "renal", "failure", "(", "Creatinine", "clearance", "<", "15", "mL", "/", "min", ")", ",", "have", "NYHA", "Functional", "class", "IV", "heart", "failure", ",", "or", "a", "systemic", "illness", "likely", "to", "limit", "survival", "to", "<", "1", "year", "\n", "Have", "had", "recent", "ST", "elevation", "myocardial", "infarction", "or", "non", "-", "ST", "elevation", "MI", "(", "<", "30", "days", ")", ";", "note", "that", "biomarker", "elevation", "alone", "after", "ventricular", "arrhythmias", "does", "not", "denote", "MI", ".", "\n", "Are", "pregnant", ".", "\n" ]

[ "Scope", "Procedure", "Condition", "Measurement", "Drug", "Device", "Temporal", "Qualifier", "Value", "Observation" ]

renal transplant is an umlsterm, patient is an umlsterm, cyclosporin A is an umlsterm, sebaceous gland is an umlsterm, hyperplasia is an umlsterm, hyperkeratosis is an umlsterm, face is an umlsterm, limbs is an umlsterm, hyperkeratosis is an umlsterm, hair is an umlsterm, histology is an umlsterm, hyperkeratosis is an umlsterm, hair follicles is an umlsterm, hair - like is an umlsterm, hairs is an umlsterm, hairs is an umlsterm, hyperkeratosis is an umlsterm, disorders is an umlsterm, Scanning electron microscopy is an umlsterm, hair - like is an umlsterm, keratoses is an umlsterm, sebaceous glands is an umlsterm, finding is an umlsterm, observations is an umlsterm, skin is an umlsterm, side effects is an umlsterm, cyclosporin A is an umlsterm

DerHautarzt.50460841.eng.abstr_task0

Sentence: We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent .

[ "We", "report", "a", "31-year", "-", "old", "renal", "transplant", "patient", "treated", "with", "cyclosporin", "A", "who", "developed", "an", "unusual", "sebaceous", "gland", "hyperplasia", "accompanied", "by", "a", "disseminated", "follicular", "spiny", "hyperkeratosis", ".", "Those", "alterations", "were", "most", "evident", "on", "his", "face", "and", "limbs", ".", "In", "some", "locations", "hairy", "hyperkeratosis", "with", "authentic", "hair", "neogenesis", "was", "found", ".", "The", "histology", "of", "these", "alterations", "showed", "a", "marked", "hyperkeratosis", "of", "the", "hair", "follicles", "with", "formation", "of", "hair", "-", "like", "spikes", "either", "alone", "or", "in", "connection", "with", "hairs", ".", "The", "presence", "of", "true", "hairs", "distinguishes", "our", "case", "from", "the", "morphologically", "similar", "disseminated", "spiked", "hyperkeratosis", "and", "other", "spiny", "keratinization", "disorders", ".", "Scanning", "electron", "microscopy", "helped", "to", "demonstrate", "the", "hair", "-", "like", "structure", "of", "these", "keratoses", ".", "Some", "of", "the", "sebaceous", "glands", "showed", "cystic", "widening", "of", "their", "lumina", ",", "which", "were", "filled", "with", "abundant", "amorphous", "eosinophilic", "material", ",", "a", "finding", "similar", "to", "earlier", "observations", ".", "Our", "case", "demonstrates", "that", "these", "skin", "alterations", "should", "be", "classified", "as", "side", "effects", "of", "cyclosporin", "A", "and", "that", "they", "are", "apparently", "dose", "-", "dependent", "." ]

[ "umlsterm" ]

renal transplant is an umlsterm, patient is an umlsterm, cyclosporin A is an umlsterm, sebaceous gland is an umlsterm, hyperplasia is an umlsterm, hyperkeratosis is an umlsterm, face is an umlsterm, limbs is an umlsterm, hyperkeratosis is an umlsterm, hair is an umlsterm, histology is an umlsterm, hyperkeratosis is an umlsterm, hair follicles is an umlsterm, hair - like is an umlsterm, hairs is an umlsterm, hairs is an umlsterm, hyperkeratosis is an umlsterm, disorders is an umlsterm, Scanning electron microscopy is an umlsterm, hair - like is an umlsterm, keratoses is an umlsterm, sebaceous glands is an umlsterm, finding is an umlsterm, observations is an umlsterm, skin is an umlsterm, side effects is an umlsterm, cyclosporin A is an umlsterm

DerHautarzt.50460841.eng.abstr_task1

Sentence: We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent . Instructions: please typing these entity words according to sentence: renal transplant, patient, cyclosporin A, sebaceous gland, hyperplasia, hyperkeratosis, face, limbs, hyperkeratosis, hair, histology, hyperkeratosis, hair follicles, hair - like, hairs, hairs, hyperkeratosis, disorders, Scanning electron microscopy, hair - like, keratoses, sebaceous glands, finding, observations, skin, side effects, cyclosporin A Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent .

[ "We", "report", "a", "31-year", "-", "old", "renal", "transplant", "patient", "treated", "with", "cyclosporin", "A", "who", "developed", "an", "unusual", "sebaceous", "gland", "hyperplasia", "accompanied", "by", "a", "disseminated", "follicular", "spiny", "hyperkeratosis", ".", "Those", "alterations", "were", "most", "evident", "on", "his", "face", "and", "limbs", ".", "In", "some", "locations", "hairy", "hyperkeratosis", "with", "authentic", "hair", "neogenesis", "was", "found", ".", "The", "histology", "of", "these", "alterations", "showed", "a", "marked", "hyperkeratosis", "of", "the", "hair", "follicles", "with", "formation", "of", "hair", "-", "like", "spikes", "either", "alone", "or", "in", "connection", "with", "hairs", ".", "The", "presence", "of", "true", "hairs", "distinguishes", "our", "case", "from", "the", "morphologically", "similar", "disseminated", "spiked", "hyperkeratosis", "and", "other", "spiny", "keratinization", "disorders", ".", "Scanning", "electron", "microscopy", "helped", "to", "demonstrate", "the", "hair", "-", "like", "structure", "of", "these", "keratoses", ".", "Some", "of", "the", "sebaceous", "glands", "showed", "cystic", "widening", "of", "their", "lumina", ",", "which", "were", "filled", "with", "abundant", "amorphous", "eosinophilic", "material", ",", "a", "finding", "similar", "to", "earlier", "observations", ".", "Our", "case", "demonstrates", "that", "these", "skin", "alterations", "should", "be", "classified", "as", "side", "effects", "of", "cyclosporin", "A", "and", "that", "they", "are", "apparently", "dose", "-", "dependent", "." ]

[ "umlsterm" ]

renal transplant, patient, cyclosporin A, sebaceous gland, hyperplasia, hyperkeratosis, face, limbs, hyperkeratosis, hair, histology, hyperkeratosis, hair follicles, hair - like, hairs, hairs, hyperkeratosis, disorders, Scanning electron microscopy, hair - like, keratoses, sebaceous glands, finding, observations, skin, side effects, cyclosporin A

DerHautarzt.50460841.eng.abstr_task2

Sentence: We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

We report a 31-year-old renal transplant patient treated with cyclosporin A who developed an unusual sebaceous gland hyperplasia accompanied by a disseminated follicular spiny hyperkeratosis . Those alterations were most evident on his face and limbs . In some locations hairy hyperkeratosis with authentic hair neogenesis was found . The histology of these alterations showed a marked hyperkeratosis of the hair follicles with formation of hair-like spikes either alone or in connection with hairs . The presence of true hairs distinguishes our case from the morphologically similar disseminated spiked hyperkeratosis and other spiny keratinization disorders . Scanning electron microscopy helped to demonstrate the hair-like structure of these keratoses . Some of the sebaceous glands showed cystic widening of their lumina , which were filled with abundant amorphous eosinophilic material , a finding similar to earlier observations . Our case demonstrates that these skin alterations should be classified as side effects of cyclosporin A and that they are apparently dose-dependent .

[ "We", "report", "a", "31-year", "-", "old", "renal", "transplant", "patient", "treated", "with", "cyclosporin", "A", "who", "developed", "an", "unusual", "sebaceous", "gland", "hyperplasia", "accompanied", "by", "a", "disseminated", "follicular", "spiny", "hyperkeratosis", ".", "Those", "alterations", "were", "most", "evident", "on", "his", "face", "and", "limbs", ".", "In", "some", "locations", "hairy", "hyperkeratosis", "with", "authentic", "hair", "neogenesis", "was", "found", ".", "The", "histology", "of", "these", "alterations", "showed", "a", "marked", "hyperkeratosis", "of", "the", "hair", "follicles", "with", "formation", "of", "hair", "-", "like", "spikes", "either", "alone", "or", "in", "connection", "with", "hairs", ".", "The", "presence", "of", "true", "hairs", "distinguishes", "our", "case", "from", "the", "morphologically", "similar", "disseminated", "spiked", "hyperkeratosis", "and", "other", "spiny", "keratinization", "disorders", ".", "Scanning", "electron", "microscopy", "helped", "to", "demonstrate", "the", "hair", "-", "like", "structure", "of", "these", "keratoses", ".", "Some", "of", "the", "sebaceous", "glands", "showed", "cystic", "widening", "of", "their", "lumina", ",", "which", "were", "filled", "with", "abundant", "amorphous", "eosinophilic", "material", ",", "a", "finding", "similar", "to", "earlier", "observations", ".", "Our", "case", "demonstrates", "that", "these", "skin", "alterations", "should", "be", "classified", "as", "side", "effects", "of", "cyclosporin", "A", "and", "that", "they", "are", "apparently", "dose", "-", "dependent", "." ]

[ "umlsterm" ]

Psychoanalyse is an umlsterm, Empathie is an umlsterm, Methode is an umlsterm, Arbeit is an umlsterm, Uebertragung is an umlsterm, Gegenuebertragung is an umlsterm, ichstaerkende is an umlsterm, Gegenuebertragung is an umlsterm, Kriseninterventionen is an umlsterm

Psychotherapeut.00450301.ger.abstr_task0

Sentence: Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert .

[ "Das", "interaktionelle", "Verstaendnis", "der", "Psychoanalyse", ",", "speziell", "das", "Konzept", "des", "dritten", "Punktes", "\"", "\"", "legen", "nahe", ",", "dass", "die", "Entwicklungen", "von", "Einsicht", ",", "Empathie", "und", "Beziehung", "als", "verschiedene", "Dimensionen", "des", "einen", "triangulierenden", "Prozesses", ",", "anzusehen", "sind", ",", "der", "das", "psychoanalytische", "Verstehen", "kennzeichnet", ".", "Von", "hieraus", "erscheint", "die", "psychoanalytische", "Methode", ",", "hier", "verstanden", "als", "Arbeit", "mit", "Widerstand", ",", "Uebertragung", "und", "Gegenuebertragung", ",", "nicht", "nur", "als", "ein", "Weg", "zur", "Erkenntnis", ",", "sondern", "auch", "als", "eine", "ebenso", "konfliktloesende", "wie", "ichstaerkende", "und", "damit", "speziell", "psychoanalytische", "Weise", "der", "hilfreichen", "Beziehungsbildung", ".", "Der", "Ausdruck", "\"", "Deutung", "aus", "der", "Gegenuebertragung", "\"", "bezeichnet", "eine", "Form", "psychoanalytischer", "Deutung", ",", "welche", "diesen", "Zusammenhang", "gezielt", "aufgreift", ",", "und", "dadurch", "bei", "neurotischen", "Konflikten", "auch", "fuer", "Kriseninterventionen", "genutzt", "werden", "kann", ".", "Dies", "wird", "an", "einem", "Fallbeispiel", "erlaeutert", "." ]

[ "umlsterm" ]

Psychoanalyse is an umlsterm, Empathie is an umlsterm, Methode is an umlsterm, Arbeit is an umlsterm, Uebertragung is an umlsterm, Gegenuebertragung is an umlsterm, ichstaerkende is an umlsterm, Gegenuebertragung is an umlsterm, Kriseninterventionen is an umlsterm

Psychotherapeut.00450301.ger.abstr_task1

Sentence: Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert . Instructions: please typing these entity words according to sentence: Psychoanalyse, Empathie, Methode, Arbeit, Uebertragung, Gegenuebertragung, ichstaerkende, Gegenuebertragung, Kriseninterventionen Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert .

[ "Das", "interaktionelle", "Verstaendnis", "der", "Psychoanalyse", ",", "speziell", "das", "Konzept", "des", "dritten", "Punktes", "\"", "\"", "legen", "nahe", ",", "dass", "die", "Entwicklungen", "von", "Einsicht", ",", "Empathie", "und", "Beziehung", "als", "verschiedene", "Dimensionen", "des", "einen", "triangulierenden", "Prozesses", ",", "anzusehen", "sind", ",", "der", "das", "psychoanalytische", "Verstehen", "kennzeichnet", ".", "Von", "hieraus", "erscheint", "die", "psychoanalytische", "Methode", ",", "hier", "verstanden", "als", "Arbeit", "mit", "Widerstand", ",", "Uebertragung", "und", "Gegenuebertragung", ",", "nicht", "nur", "als", "ein", "Weg", "zur", "Erkenntnis", ",", "sondern", "auch", "als", "eine", "ebenso", "konfliktloesende", "wie", "ichstaerkende", "und", "damit", "speziell", "psychoanalytische", "Weise", "der", "hilfreichen", "Beziehungsbildung", ".", "Der", "Ausdruck", "\"", "Deutung", "aus", "der", "Gegenuebertragung", "\"", "bezeichnet", "eine", "Form", "psychoanalytischer", "Deutung", ",", "welche", "diesen", "Zusammenhang", "gezielt", "aufgreift", ",", "und", "dadurch", "bei", "neurotischen", "Konflikten", "auch", "fuer", "Kriseninterventionen", "genutzt", "werden", "kann", ".", "Dies", "wird", "an", "einem", "Fallbeispiel", "erlaeutert", "." ]

[ "umlsterm" ]

Psychoanalyse, Empathie, Methode, Arbeit, Uebertragung, Gegenuebertragung, ichstaerkende, Gegenuebertragung, Kriseninterventionen

Psychotherapeut.00450301.ger.abstr_task2

Sentence: Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das interaktionelle Verstaendnis der Psychoanalyse , speziell das Konzept des dritten Punktes " " legen nahe , dass die Entwicklungen von Einsicht , Empathie und Beziehung als verschiedene Dimensionen des einen triangulierenden Prozesses , anzusehen sind , der das psychoanalytische Verstehen kennzeichnet . Von hieraus erscheint die psychoanalytische Methode , hier verstanden als Arbeit mit Widerstand , Uebertragung und Gegenuebertragung , nicht nur als ein Weg zur Erkenntnis , sondern auch als eine ebenso konfliktloesende wie ichstaerkende und damit speziell psychoanalytische Weise der hilfreichen Beziehungsbildung . Der Ausdruck " Deutung aus der Gegenuebertragung " bezeichnet eine Form psychoanalytischer Deutung , welche diesen Zusammenhang gezielt aufgreift , und dadurch bei neurotischen Konflikten auch fuer Kriseninterventionen genutzt werden kann . Dies wird an einem Fallbeispiel erlaeutert .

[ "Das", "interaktionelle", "Verstaendnis", "der", "Psychoanalyse", ",", "speziell", "das", "Konzept", "des", "dritten", "Punktes", "\"", "\"", "legen", "nahe", ",", "dass", "die", "Entwicklungen", "von", "Einsicht", ",", "Empathie", "und", "Beziehung", "als", "verschiedene", "Dimensionen", "des", "einen", "triangulierenden", "Prozesses", ",", "anzusehen", "sind", ",", "der", "das", "psychoanalytische", "Verstehen", "kennzeichnet", ".", "Von", "hieraus", "erscheint", "die", "psychoanalytische", "Methode", ",", "hier", "verstanden", "als", "Arbeit", "mit", "Widerstand", ",", "Uebertragung", "und", "Gegenuebertragung", ",", "nicht", "nur", "als", "ein", "Weg", "zur", "Erkenntnis", ",", "sondern", "auch", "als", "eine", "ebenso", "konfliktloesende", "wie", "ichstaerkende", "und", "damit", "speziell", "psychoanalytische", "Weise", "der", "hilfreichen", "Beziehungsbildung", ".", "Der", "Ausdruck", "\"", "Deutung", "aus", "der", "Gegenuebertragung", "\"", "bezeichnet", "eine", "Form", "psychoanalytischer", "Deutung", ",", "welche", "diesen", "Zusammenhang", "gezielt", "aufgreift", ",", "und", "dadurch", "bei", "neurotischen", "Konflikten", "auch", "fuer", "Kriseninterventionen", "genutzt", "werden", "kann", ".", "Dies", "wird", "an", "einem", "Fallbeispiel", "erlaeutert", "." ]

[ "umlsterm" ]

Diagnostik is an umlsterm, maligner Lymphome is an umlsterm, Knochenmarkslaesionen is an umlsterm, Methoden is an umlsterm, Arbeit is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm, Patienten is an umlsterm, Knochenmarksbiopsien is an umlsterm, Lymphominfiltrate is an umlsterm, Infiltrationsgrad is an umlsterm, Durchflusszytometrie is an umlsterm, Leukaemien is an umlsterm, Lymphomen is an umlsterm, chronischen lymphatischen Leukaemie is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm

DerPathologe.00210296.ger.abstr_task0

Sentence: Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen .

[ "Bestandteil", "der", "klinischen", "Diagnostik", "beim", "Staging", "maligner", "Lymphome", ".", "Die", "Fortschritte", "der", "letzten", "Jahre", "bei", "der", "immunophaenotypischen", "Charakterisierung", "dieser", "Krankheitsentitaeten", "und", "die", "immer", "wieder", "zu", "beobachtenden", "Schwierigkeiten", "bei", "der", "Einordnung", "diskreter", "lymphoider", "Knochenmarkslaesionen", "machen", "die", "Etablierung", "weiterer", "diagnostischer", "Methoden", "wuenschenswert", ".", "Ziel", "der", "vorliegenden", "Arbeit", "ist", "die", "Evaluierung", "der", "diagnostischen", "Wertigkeit", "der", "Durchflusszytometrie", "im", "Vergleich", "zur", "herkoemmlichen", "Beckenkammbiopsie", ".", "Fuer", "die", "Untersuchung", "standen", "156", "Patienten", "mit", "insgesamt", "191", "Knochenmarksbiopsien", "bzw", ".", "Knochenmarksaspiraten", "zur", "Verfuegung", ".", "In", "der", "Auswertung", "der", "erfassten", "Daten", "ergibt", "sich", ",", "dass", "bis", "zu", "1/3", "der", "Lymphominfiltrate", "durchflusszytometrisch", "nicht", "diagnostizierbar", "sind", "und", "der", "Infiltrationsgrad", "bis", "zu", "2/3", "niedriger", "eingeschaetzt", "wird", ".", "Gute", "Ergebnisse", "sind", "mit", "der", "Durchflusszytometrie", "bei", "akuten", "Leukaemien", ",", "lymphoblastischen", "Lymphomen", ",", "Haarzellleukaemien", "sowie", "der", "chronischen", "lymphatischen", "Leukaemie", "zu", "erzielen", ".", "Insgesamt", "kommt", "der", "Durchflusszytometrie", "beim", "Lymphomstaging", "eine", "ergaenzende", "Bedeutung", "zu", ",", "kann", "aber", "die", "herkoemmliche", "Beckenkammbiopsie", "nicht", "vollstaendig", "ersetzen", "." ]

[ "umlsterm" ]

Diagnostik is an umlsterm, maligner Lymphome is an umlsterm, Knochenmarkslaesionen is an umlsterm, Methoden is an umlsterm, Arbeit is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm, Patienten is an umlsterm, Knochenmarksbiopsien is an umlsterm, Lymphominfiltrate is an umlsterm, Infiltrationsgrad is an umlsterm, Durchflusszytometrie is an umlsterm, Leukaemien is an umlsterm, Lymphomen is an umlsterm, chronischen lymphatischen Leukaemie is an umlsterm, Durchflusszytometrie is an umlsterm, Beckenkammbiopsie is an umlsterm

DerPathologe.00210296.ger.abstr_task1

Sentence: Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen . Instructions: please typing these entity words according to sentence: Diagnostik, maligner Lymphome, Knochenmarkslaesionen, Methoden, Arbeit, Durchflusszytometrie, Beckenkammbiopsie, Patienten, Knochenmarksbiopsien, Lymphominfiltrate, Infiltrationsgrad, Durchflusszytometrie, Leukaemien, Lymphomen, chronischen lymphatischen Leukaemie, Durchflusszytometrie, Beckenkammbiopsie Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen .

[ "Bestandteil", "der", "klinischen", "Diagnostik", "beim", "Staging", "maligner", "Lymphome", ".", "Die", "Fortschritte", "der", "letzten", "Jahre", "bei", "der", "immunophaenotypischen", "Charakterisierung", "dieser", "Krankheitsentitaeten", "und", "die", "immer", "wieder", "zu", "beobachtenden", "Schwierigkeiten", "bei", "der", "Einordnung", "diskreter", "lymphoider", "Knochenmarkslaesionen", "machen", "die", "Etablierung", "weiterer", "diagnostischer", "Methoden", "wuenschenswert", ".", "Ziel", "der", "vorliegenden", "Arbeit", "ist", "die", "Evaluierung", "der", "diagnostischen", "Wertigkeit", "der", "Durchflusszytometrie", "im", "Vergleich", "zur", "herkoemmlichen", "Beckenkammbiopsie", ".", "Fuer", "die", "Untersuchung", "standen", "156", "Patienten", "mit", "insgesamt", "191", "Knochenmarksbiopsien", "bzw", ".", "Knochenmarksaspiraten", "zur", "Verfuegung", ".", "In", "der", "Auswertung", "der", "erfassten", "Daten", "ergibt", "sich", ",", "dass", "bis", "zu", "1/3", "der", "Lymphominfiltrate", "durchflusszytometrisch", "nicht", "diagnostizierbar", "sind", "und", "der", "Infiltrationsgrad", "bis", "zu", "2/3", "niedriger", "eingeschaetzt", "wird", ".", "Gute", "Ergebnisse", "sind", "mit", "der", "Durchflusszytometrie", "bei", "akuten", "Leukaemien", ",", "lymphoblastischen", "Lymphomen", ",", "Haarzellleukaemien", "sowie", "der", "chronischen", "lymphatischen", "Leukaemie", "zu", "erzielen", ".", "Insgesamt", "kommt", "der", "Durchflusszytometrie", "beim", "Lymphomstaging", "eine", "ergaenzende", "Bedeutung", "zu", ",", "kann", "aber", "die", "herkoemmliche", "Beckenkammbiopsie", "nicht", "vollstaendig", "ersetzen", "." ]

[ "umlsterm" ]

Diagnostik, maligner Lymphome, Knochenmarkslaesionen, Methoden, Arbeit, Durchflusszytometrie, Beckenkammbiopsie, Patienten, Knochenmarksbiopsien, Lymphominfiltrate, Infiltrationsgrad, Durchflusszytometrie, Leukaemien, Lymphomen, chronischen lymphatischen Leukaemie, Durchflusszytometrie, Beckenkammbiopsie

DerPathologe.00210296.ger.abstr_task2

Sentence: Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O" ]

Bestandteil der klinischen Diagnostik beim Staging maligner Lymphome . Die Fortschritte der letzten Jahre bei der immunophaenotypischen Charakterisierung dieser Krankheitsentitaeten und die immer wieder zu beobachtenden Schwierigkeiten bei der Einordnung diskreter lymphoider Knochenmarkslaesionen machen die Etablierung weiterer diagnostischer Methoden wuenschenswert . Ziel der vorliegenden Arbeit ist die Evaluierung der diagnostischen Wertigkeit der Durchflusszytometrie im Vergleich zur herkoemmlichen Beckenkammbiopsie . Fuer die Untersuchung standen 156 Patienten mit insgesamt 191 Knochenmarksbiopsien bzw. Knochenmarksaspiraten zur Verfuegung . In der Auswertung der erfassten Daten ergibt sich , dass bis zu 1/3 der Lymphominfiltrate durchflusszytometrisch nicht diagnostizierbar sind und der Infiltrationsgrad bis zu 2/3 niedriger eingeschaetzt wird . Gute Ergebnisse sind mit der Durchflusszytometrie bei akuten Leukaemien , lymphoblastischen Lymphomen , Haarzellleukaemien sowie der chronischen lymphatischen Leukaemie zu erzielen . Insgesamt kommt der Durchflusszytometrie beim Lymphomstaging eine ergaenzende Bedeutung zu , kann aber die herkoemmliche Beckenkammbiopsie nicht vollstaendig ersetzen .

[ "Bestandteil", "der", "klinischen", "Diagnostik", "beim", "Staging", "maligner", "Lymphome", ".", "Die", "Fortschritte", "der", "letzten", "Jahre", "bei", "der", "immunophaenotypischen", "Charakterisierung", "dieser", "Krankheitsentitaeten", "und", "die", "immer", "wieder", "zu", "beobachtenden", "Schwierigkeiten", "bei", "der", "Einordnung", "diskreter", "lymphoider", "Knochenmarkslaesionen", "machen", "die", "Etablierung", "weiterer", "diagnostischer", "Methoden", "wuenschenswert", ".", "Ziel", "der", "vorliegenden", "Arbeit", "ist", "die", "Evaluierung", "der", "diagnostischen", "Wertigkeit", "der", "Durchflusszytometrie", "im", "Vergleich", "zur", "herkoemmlichen", "Beckenkammbiopsie", ".", "Fuer", "die", "Untersuchung", "standen", "156", "Patienten", "mit", "insgesamt", "191", "Knochenmarksbiopsien", "bzw", ".", "Knochenmarksaspiraten", "zur", "Verfuegung", ".", "In", "der", "Auswertung", "der", "erfassten", "Daten", "ergibt", "sich", ",", "dass", "bis", "zu", "1/3", "der", "Lymphominfiltrate", "durchflusszytometrisch", "nicht", "diagnostizierbar", "sind", "und", "der", "Infiltrationsgrad", "bis", "zu", "2/3", "niedriger", "eingeschaetzt", "wird", ".", "Gute", "Ergebnisse", "sind", "mit", "der", "Durchflusszytometrie", "bei", "akuten", "Leukaemien", ",", "lymphoblastischen", "Lymphomen", ",", "Haarzellleukaemien", "sowie", "der", "chronischen", "lymphatischen", "Leukaemie", "zu", "erzielen", ".", "Insgesamt", "kommt", "der", "Durchflusszytometrie", "beim", "Lymphomstaging", "eine", "ergaenzende", "Bedeutung", "zu", ",", "kann", "aber", "die", "herkoemmliche", "Beckenkammbiopsie", "nicht", "vollstaendig", "ersetzen", "." ]

[ "umlsterm" ]

Pemphigus is an umlsterm, Tumor is an umlsterm, Mundschleimhaut is an umlsterm, Lippen is an umlsterm, Haut is an umlsterm, Pemphigus vulgaris is an umlsterm, Patienten is an umlsterm, Lichen planus is an umlsterm, Patienten is an umlsterm, Autoantikoerper is an umlsterm, Immunpraezipitation is an umlsterm, Proteinkomplex is an umlsterm, Akantholyse is an umlsterm, Einzelnekrosen is an umlsterm, Immunfluoreszenz is an umlsterm, Harnblase is an umlsterm, Immunfluoreszenz is an umlsterm, Antigenkomplex is an umlsterm, Antigene is an umlsterm, Pemphigus vulgaris is an umlsterm, Pemphigus is an umlsterm, Harnblasenepithel is an umlsterm, Diagnose is an umlsterm

DerHautarzt.40450827.ger.abstr_task0

Sentence: Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP .

[ "Zusammenfassung", ".", "Der", "paraneoplastische", "Pemphigus", "(", "PP", ")", "ist", "eine", "neue", "Autoimmundermatose", ",", "die", "obligat", "mit", "einem", "Tumor", "assoziiert", "ist", ".", "Klinisch", "kommt", "es", "zu", "schmerzhaften", "Erosionen", "der", "Konjunktival-", "und", "Mundschleimhaut", "unter", "Einbeziehung", "der", "Lippen", ".", "An", "der", "Haut", "finden", "sich", "polymorphe", "Veraenderungen", ",", "die", "an", "ein", "Erythema", "exsudativum", "multiforme", "(", "EEM", ")", ",", "einen", "Pemphigus", "vulgaris", "und", "bei", "manchen", "Patienten", "auch", "an", "einen", "Lichen", "planus", "pemphigoides", "erinnern", ".", "Die", "Seren", "der", "Patienten", "weisen", "Autoantikoerper", "auf", ",", "die", "in", "der", "Immunpraezipitation", "von", "Keratinozytenextrakten", "an", "einen", "distinkten", "Proteinkomplex", "binden", ".", "Dieser", "besteht", "aus", "Desmoplakin", "I", "(", "250", "kD", ")", ",", "dem", "bulloesen", "Pemphigoid", "-", "Hauptantigen", "(", "230", "kD", ")", ",", "Desmoplakin", "II", "(", "210", "kD", ")", ",", "sowie", "einem", "190-", "und", "170-kD", "-", "Protein", ",", "die", "bislang", "noch", "nicht", "naeher", "charakterisiert", "wurden", ".", "Histologisch", "finden", "sich", "Akantholyse", "Einzelnekrosen", ",", "vakuolige", "Basalzelldegenerationen", "und", ",", "in", "manchen", "Praeparaten", "lichenoide", "Infiltrate", "im", "oberen", "Korium", ".", "In", "der", "direkten", "Immunfluoreszenz", "sieht", "man", "interzellulaere", "epidermale", "Ablagerungen", "und", "granulaere", "Ablagerungen", "an", "der", "Basalmembran", ".", "Verwendet", "man", "Harnblase", "von", "Nagetieren", "als", "Substrat", "fuer", "die", "indirekte", "Immunfluoreszenz", ",", "erkennt", "man", "interzellulaere", "IgG", "-", "Ablagerungen", ".", "Anders", "als", "der", "Antigenkomplex", "des", "PP", "werden", "die", "Antigene", "des", "Pemphigus", "vulgaris", "und", "des", "Pemphigus", "foliaceus", "in", "Harnblasenepithel", "nicht", "exprimiert", ".", "Dies", "ist", "daher", "die", "einfachste", "und", "kostenguenstigste", "Untersuchungsmethode", "zur", "Diagnose", "eines", "PP", "." ]

[ "umlsterm" ]

Pemphigus is an umlsterm, Tumor is an umlsterm, Mundschleimhaut is an umlsterm, Lippen is an umlsterm, Haut is an umlsterm, Pemphigus vulgaris is an umlsterm, Patienten is an umlsterm, Lichen planus is an umlsterm, Patienten is an umlsterm, Autoantikoerper is an umlsterm, Immunpraezipitation is an umlsterm, Proteinkomplex is an umlsterm, Akantholyse is an umlsterm, Einzelnekrosen is an umlsterm, Immunfluoreszenz is an umlsterm, Harnblase is an umlsterm, Immunfluoreszenz is an umlsterm, Antigenkomplex is an umlsterm, Antigene is an umlsterm, Pemphigus vulgaris is an umlsterm, Pemphigus is an umlsterm, Harnblasenepithel is an umlsterm, Diagnose is an umlsterm

DerHautarzt.40450827.ger.abstr_task1

Sentence: Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP . Instructions: please typing these entity words according to sentence: Pemphigus, Tumor, Mundschleimhaut, Lippen, Haut, Pemphigus vulgaris, Patienten, Lichen planus, Patienten, Autoantikoerper, Immunpraezipitation, Proteinkomplex, Akantholyse, Einzelnekrosen, Immunfluoreszenz, Harnblase, Immunfluoreszenz, Antigenkomplex, Antigene, Pemphigus vulgaris, Pemphigus, Harnblasenepithel, Diagnose Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP .

[ "Zusammenfassung", ".", "Der", "paraneoplastische", "Pemphigus", "(", "PP", ")", "ist", "eine", "neue", "Autoimmundermatose", ",", "die", "obligat", "mit", "einem", "Tumor", "assoziiert", "ist", ".", "Klinisch", "kommt", "es", "zu", "schmerzhaften", "Erosionen", "der", "Konjunktival-", "und", "Mundschleimhaut", "unter", "Einbeziehung", "der", "Lippen", ".", "An", "der", "Haut", "finden", "sich", "polymorphe", "Veraenderungen", ",", "die", "an", "ein", "Erythema", "exsudativum", "multiforme", "(", "EEM", ")", ",", "einen", "Pemphigus", "vulgaris", "und", "bei", "manchen", "Patienten", "auch", "an", "einen", "Lichen", "planus", "pemphigoides", "erinnern", ".", "Die", "Seren", "der", "Patienten", "weisen", "Autoantikoerper", "auf", ",", "die", "in", "der", "Immunpraezipitation", "von", "Keratinozytenextrakten", "an", "einen", "distinkten", "Proteinkomplex", "binden", ".", "Dieser", "besteht", "aus", "Desmoplakin", "I", "(", "250", "kD", ")", ",", "dem", "bulloesen", "Pemphigoid", "-", "Hauptantigen", "(", "230", "kD", ")", ",", "Desmoplakin", "II", "(", "210", "kD", ")", ",", "sowie", "einem", "190-", "und", "170-kD", "-", "Protein", ",", "die", "bislang", "noch", "nicht", "naeher", "charakterisiert", "wurden", ".", "Histologisch", "finden", "sich", "Akantholyse", "Einzelnekrosen", ",", "vakuolige", "Basalzelldegenerationen", "und", ",", "in", "manchen", "Praeparaten", "lichenoide", "Infiltrate", "im", "oberen", "Korium", ".", "In", "der", "direkten", "Immunfluoreszenz", "sieht", "man", "interzellulaere", "epidermale", "Ablagerungen", "und", "granulaere", "Ablagerungen", "an", "der", "Basalmembran", ".", "Verwendet", "man", "Harnblase", "von", "Nagetieren", "als", "Substrat", "fuer", "die", "indirekte", "Immunfluoreszenz", ",", "erkennt", "man", "interzellulaere", "IgG", "-", "Ablagerungen", ".", "Anders", "als", "der", "Antigenkomplex", "des", "PP", "werden", "die", "Antigene", "des", "Pemphigus", "vulgaris", "und", "des", "Pemphigus", "foliaceus", "in", "Harnblasenepithel", "nicht", "exprimiert", ".", "Dies", "ist", "daher", "die", "einfachste", "und", "kostenguenstigste", "Untersuchungsmethode", "zur", "Diagnose", "eines", "PP", "." ]

[ "umlsterm" ]

Pemphigus, Tumor, Mundschleimhaut, Lippen, Haut, Pemphigus vulgaris, Patienten, Lichen planus, Patienten, Autoantikoerper, Immunpraezipitation, Proteinkomplex, Akantholyse, Einzelnekrosen, Immunfluoreszenz, Harnblase, Immunfluoreszenz, Antigenkomplex, Antigene, Pemphigus vulgaris, Pemphigus, Harnblasenepithel, Diagnose

DerHautarzt.40450827.ger.abstr_task2

Sentence: Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Zusammenfassung . Der paraneoplastische Pemphigus ( PP ) ist eine neue Autoimmundermatose , die obligat mit einem Tumor assoziiert ist . Klinisch kommt es zu schmerzhaften Erosionen der Konjunktival- und Mundschleimhaut unter Einbeziehung der Lippen . An der Haut finden sich polymorphe Veraenderungen , die an ein Erythema exsudativum multiforme ( EEM ) , einen Pemphigus vulgaris und bei manchen Patienten auch an einen Lichen planus pemphigoides erinnern . Die Seren der Patienten weisen Autoantikoerper auf , die in der Immunpraezipitation von Keratinozytenextrakten an einen distinkten Proteinkomplex binden . Dieser besteht aus Desmoplakin I ( 250 kD ) , dem bulloesen Pemphigoid-Hauptantigen ( 230 kD ) , Desmoplakin II ( 210 kD ) , sowie einem 190- und 170-kD-Protein, die bislang noch nicht naeher charakterisiert wurden . Histologisch finden sich Akantholyse Einzelnekrosen , vakuolige Basalzelldegenerationen und , in manchen Praeparaten lichenoide Infiltrate im oberen Korium . In der direkten Immunfluoreszenz sieht man interzellulaere epidermale Ablagerungen und granulaere Ablagerungen an der Basalmembran . Verwendet man Harnblase von Nagetieren als Substrat fuer die indirekte Immunfluoreszenz , erkennt man interzellulaere IgG-Ablagerungen . Anders als der Antigenkomplex des PP werden die Antigene des Pemphigus vulgaris und des Pemphigus foliaceus in Harnblasenepithel nicht exprimiert . Dies ist daher die einfachste und kostenguenstigste Untersuchungsmethode zur Diagnose eines PP .

[ "Zusammenfassung", ".", "Der", "paraneoplastische", "Pemphigus", "(", "PP", ")", "ist", "eine", "neue", "Autoimmundermatose", ",", "die", "obligat", "mit", "einem", "Tumor", "assoziiert", "ist", ".", "Klinisch", "kommt", "es", "zu", "schmerzhaften", "Erosionen", "der", "Konjunktival-", "und", "Mundschleimhaut", "unter", "Einbeziehung", "der", "Lippen", ".", "An", "der", "Haut", "finden", "sich", "polymorphe", "Veraenderungen", ",", "die", "an", "ein", "Erythema", "exsudativum", "multiforme", "(", "EEM", ")", ",", "einen", "Pemphigus", "vulgaris", "und", "bei", "manchen", "Patienten", "auch", "an", "einen", "Lichen", "planus", "pemphigoides", "erinnern", ".", "Die", "Seren", "der", "Patienten", "weisen", "Autoantikoerper", "auf", ",", "die", "in", "der", "Immunpraezipitation", "von", "Keratinozytenextrakten", "an", "einen", "distinkten", "Proteinkomplex", "binden", ".", "Dieser", "besteht", "aus", "Desmoplakin", "I", "(", "250", "kD", ")", ",", "dem", "bulloesen", "Pemphigoid", "-", "Hauptantigen", "(", "230", "kD", ")", ",", "Desmoplakin", "II", "(", "210", "kD", ")", ",", "sowie", "einem", "190-", "und", "170-kD", "-", "Protein", ",", "die", "bislang", "noch", "nicht", "naeher", "charakterisiert", "wurden", ".", "Histologisch", "finden", "sich", "Akantholyse", "Einzelnekrosen", ",", "vakuolige", "Basalzelldegenerationen", "und", ",", "in", "manchen", "Praeparaten", "lichenoide", "Infiltrate", "im", "oberen", "Korium", ".", "In", "der", "direkten", "Immunfluoreszenz", "sieht", "man", "interzellulaere", "epidermale", "Ablagerungen", "und", "granulaere", "Ablagerungen", "an", "der", "Basalmembran", ".", "Verwendet", "man", "Harnblase", "von", "Nagetieren", "als", "Substrat", "fuer", "die", "indirekte", "Immunfluoreszenz", ",", "erkennt", "man", "interzellulaere", "IgG", "-", "Ablagerungen", ".", "Anders", "als", "der", "Antigenkomplex", "des", "PP", "werden", "die", "Antigene", "des", "Pemphigus", "vulgaris", "und", "des", "Pemphigus", "foliaceus", "in", "Harnblasenepithel", "nicht", "exprimiert", ".", "Dies", "ist", "daher", "die", "einfachste", "und", "kostenguenstigste", "Untersuchungsmethode", "zur", "Diagnose", "eines", "PP", "." ]

[ "umlsterm" ]

Tumoren is an umlsterm, Routinediagnostik is an umlsterm, Diagnosestellung is an umlsterm, malignen Melanoms is an umlsterm, Naevus is an umlsterm, Tumorparameter is an umlsterm, malignen Melanomen is an umlsterm, Diagnostik is an umlsterm, malignen Melanomen is an umlsterm

DerHautarzt.70480720.ger.abstr_task0

Sentence: Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst .

[ "Die", "Begutachtung", "melanozytaerer", "Tumoren", "repraesentiert", "einen", "der", "wichtigsten", "und", "vordringlichsten", "Aspekte", "der", "Routinediagnostik", "in", "der", "Dermatohistopathologie", ".", "Fuer", "die", "Diagnosestellung", "eines", "malignen", "Melanoms", "oder", "eines", "differentialdiagnostisch", "in", "Frage", "kommenden", "melanozytaeren", "Naevus", "sind", "einheitliche", "und", "reproduzierbare", "histologische", "Kriterien", "zu", "fordern", ".", "Die", "prognostisch", "relevanten", "und", "fuer", "das", "therapeutische", "Vorgehen", "wichtigen", "Tumorparameter", "muessen", "bei", "malignen", "Melanomen", "im", "histopathologischen", "Befundbericht", "vollstaendig", "und", "einheitlich", "erfasst", "werden", ".", "Die", "Empfehlungen", "der", "Arbeitsgruppe", "zur", "histopathologischen", "Diagnostik", "bei", "malignen", "Melanomen", "sind", "nachfolgend", "zusammengefasst", "." ]

[ "umlsterm" ]

Tumoren is an umlsterm, Routinediagnostik is an umlsterm, Diagnosestellung is an umlsterm, malignen Melanoms is an umlsterm, Naevus is an umlsterm, Tumorparameter is an umlsterm, malignen Melanomen is an umlsterm, Diagnostik is an umlsterm, malignen Melanomen is an umlsterm

DerHautarzt.70480720.ger.abstr_task1

Sentence: Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst . Instructions: please typing these entity words according to sentence: Tumoren, Routinediagnostik, Diagnosestellung, malignen Melanoms, Naevus, Tumorparameter, malignen Melanomen, Diagnostik, malignen Melanomen Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst .

[ "Die", "Begutachtung", "melanozytaerer", "Tumoren", "repraesentiert", "einen", "der", "wichtigsten", "und", "vordringlichsten", "Aspekte", "der", "Routinediagnostik", "in", "der", "Dermatohistopathologie", ".", "Fuer", "die", "Diagnosestellung", "eines", "malignen", "Melanoms", "oder", "eines", "differentialdiagnostisch", "in", "Frage", "kommenden", "melanozytaeren", "Naevus", "sind", "einheitliche", "und", "reproduzierbare", "histologische", "Kriterien", "zu", "fordern", ".", "Die", "prognostisch", "relevanten", "und", "fuer", "das", "therapeutische", "Vorgehen", "wichtigen", "Tumorparameter", "muessen", "bei", "malignen", "Melanomen", "im", "histopathologischen", "Befundbericht", "vollstaendig", "und", "einheitlich", "erfasst", "werden", ".", "Die", "Empfehlungen", "der", "Arbeitsgruppe", "zur", "histopathologischen", "Diagnostik", "bei", "malignen", "Melanomen", "sind", "nachfolgend", "zusammengefasst", "." ]

[ "umlsterm" ]

Tumoren, Routinediagnostik, Diagnosestellung, malignen Melanoms, Naevus, Tumorparameter, malignen Melanomen, Diagnostik, malignen Melanomen

DerHautarzt.70480720.ger.abstr_task2

Sentence: Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O" ]

Die Begutachtung melanozytaerer Tumoren repraesentiert einen der wichtigsten und vordringlichsten Aspekte der Routinediagnostik in der Dermatohistopathologie . Fuer die Diagnosestellung eines malignen Melanoms oder eines differentialdiagnostisch in Frage kommenden melanozytaeren Naevus sind einheitliche und reproduzierbare histologische Kriterien zu fordern . Die prognostisch relevanten und fuer das therapeutische Vorgehen wichtigen Tumorparameter muessen bei malignen Melanomen im histopathologischen Befundbericht vollstaendig und einheitlich erfasst werden . Die Empfehlungen der Arbeitsgruppe zur histopathologischen Diagnostik bei malignen Melanomen sind nachfolgend zusammengefasst .

[ "Die", "Begutachtung", "melanozytaerer", "Tumoren", "repraesentiert", "einen", "der", "wichtigsten", "und", "vordringlichsten", "Aspekte", "der", "Routinediagnostik", "in", "der", "Dermatohistopathologie", ".", "Fuer", "die", "Diagnosestellung", "eines", "malignen", "Melanoms", "oder", "eines", "differentialdiagnostisch", "in", "Frage", "kommenden", "melanozytaeren", "Naevus", "sind", "einheitliche", "und", "reproduzierbare", "histologische", "Kriterien", "zu", "fordern", ".", "Die", "prognostisch", "relevanten", "und", "fuer", "das", "therapeutische", "Vorgehen", "wichtigen", "Tumorparameter", "muessen", "bei", "malignen", "Melanomen", "im", "histopathologischen", "Befundbericht", "vollstaendig", "und", "einheitlich", "erfasst", "werden", ".", "Die", "Empfehlungen", "der", "Arbeitsgruppe", "zur", "histopathologischen", "Diagnostik", "bei", "malignen", "Melanomen", "sind", "nachfolgend", "zusammengefasst", "." ]

[ "umlsterm" ]

ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells is a Protein, ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, ICSAT is a Protein, ICSBP is a Protein, ICSAT is a Protein, tax is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, IRF-1 is a Protein, IRF-2 is a Protein, ICSBP is a Protein, ICSAT is a Protein, IRF-2 is a Protein, ICSBP is a Protein

588_task0

Sentence: A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes.

[ "A", "novel", "interferon", "regulatory", "factor", "family", "transcription", "factor", ",", "ICSAT", "/", "Pip", "/", "LSIRF", ",", "that", "negatively", "regulates", "the", "activity", "of", "interferon", "-", "regulated", "genes", ".", "\n", "We", "have", "isolated", "a", "novel", "cDNA", "clone", "encoding", "interferon", "(", "IFN", ")", "consensus", "sequence", "-", "binding", "protein", "in", "adult", "T", "-", "cell", "leukemia", "cell", "line", "or", "activated", "T", "cells", "(", "ICSAT", ")", ";", "this", "protein", "is", "the", "human", "homolog", "of", "the", "recently", "cloned", "Pip", "/", "LSIRF", ".", "ICSAT", "is", "structurally", "most", "closely", "related", "to", "the", "previously", "cloned", "ICSBP", ",", "a", "member", "of", "the", "IFN", "regulatory", "factor", "(", "IRF", ")", "family", "of", "proteins", "that", "binds", "to", "interferon", "consensus", "sequences", "(", "ICSs", ")", "found", "in", "many", "promoters", "of", "the", "IFN", "-", "regulated", "genes", ".", "Among", "T", "-", "cell", "lines", "investigated", ",", "ICSAT", "was", "abundantly", "expressed", "in", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-infected", "T", "cells", ".", "When", "the", "HTLV-1", "tax", "gene", "was", "expressed", "or", "phorbol", "myristake", "acetate", "-", "A23187", "stimulation", "was", "used", ",", "ICSAT", "expression", "was", "induced", "in", "Jurkat", "cells", "which", "otherwise", "do", "not", "express", "ICSAT", ".", "When", "the", "binding", "of", "ICSAT", "to", "four", "different", "ICSs", "was", "tested", ",", "the", "relative", "differences", "in", "binding", "affinities", "for", "those", "ICSs", "were", "determined", ".", "To", "study", "the", "functional", "role", "of", "ICSAT", ",", "we", "performed", "cotransfection", "experiments", "with", "the", "human", "embryonal", "carcinoma", "cell", "line", "N", "-", "Tera2", ".", "ICSAT", "was", "demonstrated", "to", "possess", "repressive", "function", "over", "the", "gene", "activation", "induced", "by", "IFN", "stimulation", "or", "by", "IRF-1", "cotransfection", ".", "Such", "repressive", "function", "is", "similar", "to", "that", "seen", "in", "IRF-2", "or", "ICSBP", ".", "However", ",", "we", "have", "found", "that", "ICSAT", "has", "a", "different", "repressive", "effect", "from", "that", "of", "IRF-2", "or", "ICSBP", "in", "some", "IFN", "-", "responsive", "reporter", "constructs", ".", "These", "results", "suggest", "that", "a", "novel", "mechanism", "of", "gene", "regulation", "by", "\"", "differential", "repression", "\"", "is", "used", "by", "multiple", "members", "of", "repressor", "proteins", "with", "different", "repressive", "effects", "on", "the", "IFN", "-", "responsive", "genes", "." ]

[ "Protein" ]

ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells is a Protein, ICSAT is a Protein, Pip is a Protein, LSIRF is a Protein, ICSAT is a Protein, ICSBP is a Protein, ICSAT is a Protein, tax is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, ICSAT is a Protein, IRF-1 is a Protein, IRF-2 is a Protein, ICSBP is a Protein, ICSAT is a Protein, IRF-2 is a Protein, ICSBP is a Protein

588_task1

Sentence: A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes. Instructions: please typing these entity words according to sentence: ICSAT, Pip, LSIRF, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells, ICSAT, Pip, LSIRF, ICSAT, ICSBP, ICSAT, tax, ICSAT, ICSAT, ICSAT, ICSAT, ICSAT, IRF-1, IRF-2, ICSBP, ICSAT, IRF-2, ICSBP Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes.

[ "A", "novel", "interferon", "regulatory", "factor", "family", "transcription", "factor", ",", "ICSAT", "/", "Pip", "/", "LSIRF", ",", "that", "negatively", "regulates", "the", "activity", "of", "interferon", "-", "regulated", "genes", ".", "\n", "We", "have", "isolated", "a", "novel", "cDNA", "clone", "encoding", "interferon", "(", "IFN", ")", "consensus", "sequence", "-", "binding", "protein", "in", "adult", "T", "-", "cell", "leukemia", "cell", "line", "or", "activated", "T", "cells", "(", "ICSAT", ")", ";", "this", "protein", "is", "the", "human", "homolog", "of", "the", "recently", "cloned", "Pip", "/", "LSIRF", ".", "ICSAT", "is", "structurally", "most", "closely", "related", "to", "the", "previously", "cloned", "ICSBP", ",", "a", "member", "of", "the", "IFN", "regulatory", "factor", "(", "IRF", ")", "family", "of", "proteins", "that", "binds", "to", "interferon", "consensus", "sequences", "(", "ICSs", ")", "found", "in", "many", "promoters", "of", "the", "IFN", "-", "regulated", "genes", ".", "Among", "T", "-", "cell", "lines", "investigated", ",", "ICSAT", "was", "abundantly", "expressed", "in", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-infected", "T", "cells", ".", "When", "the", "HTLV-1", "tax", "gene", "was", "expressed", "or", "phorbol", "myristake", "acetate", "-", "A23187", "stimulation", "was", "used", ",", "ICSAT", "expression", "was", "induced", "in", "Jurkat", "cells", "which", "otherwise", "do", "not", "express", "ICSAT", ".", "When", "the", "binding", "of", "ICSAT", "to", "four", "different", "ICSs", "was", "tested", ",", "the", "relative", "differences", "in", "binding", "affinities", "for", "those", "ICSs", "were", "determined", ".", "To", "study", "the", "functional", "role", "of", "ICSAT", ",", "we", "performed", "cotransfection", "experiments", "with", "the", "human", "embryonal", "carcinoma", "cell", "line", "N", "-", "Tera2", ".", "ICSAT", "was", "demonstrated", "to", "possess", "repressive", "function", "over", "the", "gene", "activation", "induced", "by", "IFN", "stimulation", "or", "by", "IRF-1", "cotransfection", ".", "Such", "repressive", "function", "is", "similar", "to", "that", "seen", "in", "IRF-2", "or", "ICSBP", ".", "However", ",", "we", "have", "found", "that", "ICSAT", "has", "a", "different", "repressive", "effect", "from", "that", "of", "IRF-2", "or", "ICSBP", "in", "some", "IFN", "-", "responsive", "reporter", "constructs", ".", "These", "results", "suggest", "that", "a", "novel", "mechanism", "of", "gene", "regulation", "by", "\"", "differential", "repression", "\"", "is", "used", "by", "multiple", "members", "of", "repressor", "proteins", "with", "different", "repressive", "effects", "on", "the", "IFN", "-", "responsive", "genes", "." ]

[ "Protein" ]

ICSAT, Pip, LSIRF, interferon ( IFN ) consensus sequence - binding protein in adult T - cell leukemia cell line or activated T cells, ICSAT, Pip, LSIRF, ICSAT, ICSBP, ICSAT, tax, ICSAT, ICSAT, ICSAT, ICSAT, ICSAT, IRF-1, IRF-2, ICSBP, ICSAT, IRF-2, ICSBP

588_task2

Sentence: A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

A novel interferon regulatory factor family transcription factor, ICSAT/Pip/LSIRF, that negatively regulates the activity of interferon-regulated genes. We have isolated a novel cDNA clone encoding interferon (IFN) consensus sequence-binding protein in adult T-cell leukemia cell line or activated T cells (ICSAT); this protein is the human homolog of the recently cloned Pip/LSIRF. ICSAT is structurally most closely related to the previously cloned ICSBP, a member of the IFN regulatory factor (IRF) family of proteins that binds to interferon consensus sequences (ICSs) found in many promoters of the IFN-regulated genes. Among T-cell lines investigated, ICSAT was abundantly expressed in human T-cell leukemia virus type 1 (HTLV-1)-infected T cells. When the HTLV-1 tax gene was expressed or phorbol myristake acetate-A23187 stimulation was used, ICSAT expression was induced in Jurkat cells which otherwise do not express ICSAT. When the binding of ICSAT to four different ICSs was tested, the relative differences in binding affinities for those ICSs were determined. To study the functional role of ICSAT, we performed cotransfection experiments with the human embryonal carcinoma cell line N-Tera2. ICSAT was demonstrated to possess repressive function over the gene activation induced by IFN stimulation or by IRF-1 cotransfection. Such repressive function is similar to that seen in IRF-2 or ICSBP. However, we have found that ICSAT has a different repressive effect from that of IRF-2 or ICSBP in some IFN-responsive reporter constructs. These results suggest that a novel mechanism of gene regulation by "differential repression" is used by multiple members of repressor proteins with different repressive effects on the IFN-responsive genes.

[ "A", "novel", "interferon", "regulatory", "factor", "family", "transcription", "factor", ",", "ICSAT", "/", "Pip", "/", "LSIRF", ",", "that", "negatively", "regulates", "the", "activity", "of", "interferon", "-", "regulated", "genes", ".", "\n", "We", "have", "isolated", "a", "novel", "cDNA", "clone", "encoding", "interferon", "(", "IFN", ")", "consensus", "sequence", "-", "binding", "protein", "in", "adult", "T", "-", "cell", "leukemia", "cell", "line", "or", "activated", "T", "cells", "(", "ICSAT", ")", ";", "this", "protein", "is", "the", "human", "homolog", "of", "the", "recently", "cloned", "Pip", "/", "LSIRF", ".", "ICSAT", "is", "structurally", "most", "closely", "related", "to", "the", "previously", "cloned", "ICSBP", ",", "a", "member", "of", "the", "IFN", "regulatory", "factor", "(", "IRF", ")", "family", "of", "proteins", "that", "binds", "to", "interferon", "consensus", "sequences", "(", "ICSs", ")", "found", "in", "many", "promoters", "of", "the", "IFN", "-", "regulated", "genes", ".", "Among", "T", "-", "cell", "lines", "investigated", ",", "ICSAT", "was", "abundantly", "expressed", "in", "human", "T", "-", "cell", "leukemia", "virus", "type", "1", "(", "HTLV-1)-infected", "T", "cells", ".", "When", "the", "HTLV-1", "tax", "gene", "was", "expressed", "or", "phorbol", "myristake", "acetate", "-", "A23187", "stimulation", "was", "used", ",", "ICSAT", "expression", "was", "induced", "in", "Jurkat", "cells", "which", "otherwise", "do", "not", "express", "ICSAT", ".", "When", "the", "binding", "of", "ICSAT", "to", "four", "different", "ICSs", "was", "tested", ",", "the", "relative", "differences", "in", "binding", "affinities", "for", "those", "ICSs", "were", "determined", ".", "To", "study", "the", "functional", "role", "of", "ICSAT", ",", "we", "performed", "cotransfection", "experiments", "with", "the", "human", "embryonal", "carcinoma", "cell", "line", "N", "-", "Tera2", ".", "ICSAT", "was", "demonstrated", "to", "possess", "repressive", "function", "over", "the", "gene", "activation", "induced", "by", "IFN", "stimulation", "or", "by", "IRF-1", "cotransfection", ".", "Such", "repressive", "function", "is", "similar", "to", "that", "seen", "in", "IRF-2", "or", "ICSBP", ".", "However", ",", "we", "have", "found", "that", "ICSAT", "has", "a", "different", "repressive", "effect", "from", "that", "of", "IRF-2", "or", "ICSBP", "in", "some", "IFN", "-", "responsive", "reporter", "constructs", ".", "These", "results", "suggest", "that", "a", "novel", "mechanism", "of", "gene", "regulation", "by", "\"", "differential", "repression", "\"", "is", "used", "by", "multiple", "members", "of", "repressor", "proteins", "with", "different", "repressive", "effects", "on", "the", "IFN", "-", "responsive", "genes", "." ]

[ "Protein" ]

cyclosporin A is a Intervention_Pharmacological, methotrexate is a Intervention_Pharmacological, rheumatoid arthritis . is a Participant_Condition, feasibility and outcome is a Outcome_Other, cyclosporin A ( CSA ) is a Intervention_Pharmacological, methotrexate ( MTX ) is a Intervention_Pharmacological, nonerosive RA is a Participant_Condition, MTX in combination is a Intervention_Pharmacological, single - agent is a Intervention_Physical, Safety , clinical efficacy is a Outcome_Other, survival on treatment is a Outcome_Mortality, radiographic progression is a Outcome_Physical, 7 of the 57 patients is a Participant_Sample-size, adverse events is a Outcome_Adverse-effects, damage score and number of eroded joints is a Outcome_Physical, early RA is a Participant_Condition

8646_task0

Sentence: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA .

[ "Step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "or", "methotrexate", "as", "maintenance", "therapy", "in", "early", "rheumatoid", "arthritis", ".", "OBJECTIVE", "To", "evaluate", "the", "feasibility", "and", "outcome", "of", "the", "step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "(", "CSA", ")", "or", "methotrexate", "(", "MTX", ")", "as", "maintenance", "therapy", "following", "6", "months", "treatment", "with", "these", "2", "agents", "in", "combination", "in", "early", ",", "nonerosive", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Fifty", "-", "seven", "patients", "younger", "than", "65", "years", "with", "early", ",", "nonerosive", "RA", "were", "first", "treated", "with", "CSA", "and", "MTX", "in", "combination", "for", "6", "months", ".", "They", "were", "then", "randomly", "stepped", "down", "to", "single", "-", "agent", "maintenance", "treatment", "for", "another", "18", "months", ".", "Safety", ",", "clinical", "efficacy", ",", "survival", "on", "treatment", ",", "and", "radiographic", "progression", "were", "evaluated", ".", "RESULTS", "When", "being", "treated", "with", "combination", "therapy", ",", "7", "of", "the", "57", "patients", "(", "12.3", "%", ")", "withdrew", "because", "of", "adverse", "events", ".", "Of", "the", "remaining", "50", "patients", ",", "42", "(", "84.0", "%", ")", "were", "American", "College", "of", "Rheumatology", "(", "ACR", ")", "20", "%", "responders", ",", "30", "(", "60.0", "%", ")", "were", "ACR", "50", "%", "responders", ",", "and", "23", "(", "46.0", "%", ")", "were", "ACR", "70", "%", "responders", ".", "At", "month", "6", ",", "22", "patients", "were", "randomized", "to", "CSA", "and", "27", "to", "MTX", ".", "During", "this", "trial", "period", ",", "the", "treatment", "was", "discontinued", "by", "16", "patients", "taking", "CSA", "(", "mainly", "because", "of", "loss", "of", "efficacy", ")", "and", "by", "4", "taking", "MTX", ".", "At", "month", "24", ",", "the", "probability", "(", "+", "/-", "SEM", ")", "of", "survival", "on", "treatment", "was", "0.273", "+", "/-", "0.09", "for", "CSA", "and", "0.852", "+", "/-", "0.07", "for", "MTX", ".", "Of", "the", "6", "CSA", "patients", "who", "completed", "the", "trial", ",", "4", "(", "66.7", "%", ")", "were", "ACR", "20", "%", "responders", ",", "and", "3", "(", "50", "%", ")", "were", "both", "ACR", "50", "%", "and", "ACR", "70", "%", "responders", ".", "Of", "the", "23", "completers", "in", "the", "MTX", "arm", ",", "21", "(", "91.3", "%", ")", "were", "ACR", "20", "%", "responders", ",", "18", "(", "78.3", "%", ")", "were", "ACR", "50", "%", ",", "and", "10", "(", "43.5", "%", ")", "were", "ACR", "70", "%", "responders", ".", "The", "treatment", "was", "not", "responsible", "for", "severe", "adverse", "events", ".", "Radiography", "showed", "a", "slow", "progression", "in", "the", "damage", "score", "and", "number", "of", "eroded", "joints", "in", "both", "treatment", "groups", ".", "CONCLUSION", "Stepping", "down", "to", "single", "agent", "maintenance", "therapy", "following", "6", "months", "of", "combination", "treatment", "with", "CSA", "and", "MTX", "in", "early", "RA", "was", "only", "successful", "with", "MTX", ".", "Because", "this", "treatment", "did", "not", "prevent", "some", "radiographic", "progression", ",", "other", "approaches", "(", "e.g", ".", ",", "step", "-", "up", "approach", ")", "may", "be", "more", "appropriate", "in", "early", "RA", "." ]

[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size", "Outcome_Adverse-effects", "Intervention_Physical" ]

cyclosporin A is a Intervention_Pharmacological, methotrexate is a Intervention_Pharmacological, rheumatoid arthritis . is a Participant_Condition, feasibility and outcome is a Outcome_Other, cyclosporin A ( CSA ) is a Intervention_Pharmacological, methotrexate ( MTX ) is a Intervention_Pharmacological, nonerosive RA is a Participant_Condition, MTX in combination is a Intervention_Pharmacological, single - agent is a Intervention_Physical, Safety , clinical efficacy is a Outcome_Other, survival on treatment is a Outcome_Mortality, radiographic progression is a Outcome_Physical, 7 of the 57 patients is a Participant_Sample-size, adverse events is a Outcome_Adverse-effects, damage score and number of eroded joints is a Outcome_Physical, early RA is a Participant_Condition

8646_task1

Sentence: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA . Instructions: please typing these entity words according to sentence: cyclosporin A, methotrexate, rheumatoid arthritis ., feasibility and outcome, cyclosporin A ( CSA ), methotrexate ( MTX ), nonerosive RA, MTX in combination, single - agent, Safety , clinical efficacy, survival on treatment, radiographic progression, 7 of the 57 patients, adverse events, damage score and number of eroded joints, early RA Options: Intervention_Pharmacological, Outcome_Adverse-effects, Intervention_Physical, Participant_Condition, Outcome_Mortality, Outcome_Physical, Participant_Sample-size, Outcome_Other

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA .

[ "Step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "or", "methotrexate", "as", "maintenance", "therapy", "in", "early", "rheumatoid", "arthritis", ".", "OBJECTIVE", "To", "evaluate", "the", "feasibility", "and", "outcome", "of", "the", "step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "(", "CSA", ")", "or", "methotrexate", "(", "MTX", ")", "as", "maintenance", "therapy", "following", "6", "months", "treatment", "with", "these", "2", "agents", "in", "combination", "in", "early", ",", "nonerosive", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Fifty", "-", "seven", "patients", "younger", "than", "65", "years", "with", "early", ",", "nonerosive", "RA", "were", "first", "treated", "with", "CSA", "and", "MTX", "in", "combination", "for", "6", "months", ".", "They", "were", "then", "randomly", "stepped", "down", "to", "single", "-", "agent", "maintenance", "treatment", "for", "another", "18", "months", ".", "Safety", ",", "clinical", "efficacy", ",", "survival", "on", "treatment", ",", "and", "radiographic", "progression", "were", "evaluated", ".", "RESULTS", "When", "being", "treated", "with", "combination", "therapy", ",", "7", "of", "the", "57", "patients", "(", "12.3", "%", ")", "withdrew", "because", "of", "adverse", "events", ".", "Of", "the", "remaining", "50", "patients", ",", "42", "(", "84.0", "%", ")", "were", "American", "College", "of", "Rheumatology", "(", "ACR", ")", "20", "%", "responders", ",", "30", "(", "60.0", "%", ")", "were", "ACR", "50", "%", "responders", ",", "and", "23", "(", "46.0", "%", ")", "were", "ACR", "70", "%", "responders", ".", "At", "month", "6", ",", "22", "patients", "were", "randomized", "to", "CSA", "and", "27", "to", "MTX", ".", "During", "this", "trial", "period", ",", "the", "treatment", "was", "discontinued", "by", "16", "patients", "taking", "CSA", "(", "mainly", "because", "of", "loss", "of", "efficacy", ")", "and", "by", "4", "taking", "MTX", ".", "At", "month", "24", ",", "the", "probability", "(", "+", "/-", "SEM", ")", "of", "survival", "on", "treatment", "was", "0.273", "+", "/-", "0.09", "for", "CSA", "and", "0.852", "+", "/-", "0.07", "for", "MTX", ".", "Of", "the", "6", "CSA", "patients", "who", "completed", "the", "trial", ",", "4", "(", "66.7", "%", ")", "were", "ACR", "20", "%", "responders", ",", "and", "3", "(", "50", "%", ")", "were", "both", "ACR", "50", "%", "and", "ACR", "70", "%", "responders", ".", "Of", "the", "23", "completers", "in", "the", "MTX", "arm", ",", "21", "(", "91.3", "%", ")", "were", "ACR", "20", "%", "responders", ",", "18", "(", "78.3", "%", ")", "were", "ACR", "50", "%", ",", "and", "10", "(", "43.5", "%", ")", "were", "ACR", "70", "%", "responders", ".", "The", "treatment", "was", "not", "responsible", "for", "severe", "adverse", "events", ".", "Radiography", "showed", "a", "slow", "progression", "in", "the", "damage", "score", "and", "number", "of", "eroded", "joints", "in", "both", "treatment", "groups", ".", "CONCLUSION", "Stepping", "down", "to", "single", "agent", "maintenance", "therapy", "following", "6", "months", "of", "combination", "treatment", "with", "CSA", "and", "MTX", "in", "early", "RA", "was", "only", "successful", "with", "MTX", ".", "Because", "this", "treatment", "did", "not", "prevent", "some", "radiographic", "progression", ",", "other", "approaches", "(", "e.g", ".", ",", "step", "-", "up", "approach", ")", "may", "be", "more", "appropriate", "in", "early", "RA", "." ]

[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size", "Outcome_Adverse-effects", "Intervention_Physical" ]

cyclosporin A, methotrexate, rheumatoid arthritis ., feasibility and outcome, cyclosporin A ( CSA ), methotrexate ( MTX ), nonerosive RA, MTX in combination, single - agent, Safety , clinical efficacy, survival on treatment, radiographic progression, 7 of the 57 patients, adverse events, damage score and number of eroded joints, early RA

8646_task2

Sentence: Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "B-Intervention_Pharmacological", "I-Intervention_Pharmacological", "I-Intervention_Pharmacological", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Intervention_Physical", "I-Intervention_Physical", "I-Intervention_Physical", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "I-Outcome_Other", "O", "B-Outcome_Mortality", "I-Outcome_Mortality", "I-Outcome_Mortality", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "I-Participant_Sample-size", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Adverse-effects", "I-Outcome_Adverse-effects", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "I-Outcome_Physical", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Participant_Condition", "I-Participant_Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Step-down approach using either cyclosporin A or methotrexate as maintenance therapy in early rheumatoid arthritis . OBJECTIVE To evaluate the feasibility and outcome of the step-down approach using either cyclosporin A ( CSA ) or methotrexate ( MTX ) as maintenance therapy following 6 months treatment with these 2 agents in combination in early , nonerosive rheumatoid arthritis ( RA ) . METHODS Fifty-seven patients younger than 65 years with early , nonerosive RA were first treated with CSA and MTX in combination for 6 months . They were then randomly stepped down to single-agent maintenance treatment for another 18 months . Safety , clinical efficacy , survival on treatment , and radiographic progression were evaluated . RESULTS When being treated with combination therapy , 7 of the 57 patients ( 12.3 % ) withdrew because of adverse events . Of the remaining 50 patients , 42 ( 84.0 % ) were American College of Rheumatology ( ACR ) 20 % responders , 30 ( 60.0 % ) were ACR 50 % responders , and 23 ( 46.0 % ) were ACR 70 % responders . At month 6 , 22 patients were randomized to CSA and 27 to MTX . During this trial period , the treatment was discontinued by 16 patients taking CSA ( mainly because of loss of efficacy ) and by 4 taking MTX . At month 24 , the probability ( +/- SEM ) of survival on treatment was 0.273 +/- 0.09 for CSA and 0.852 +/- 0.07 for MTX . Of the 6 CSA patients who completed the trial , 4 ( 66.7 % ) were ACR 20 % responders , and 3 ( 50 % ) were both ACR 50 % and ACR 70 % responders . Of the 23 completers in the MTX arm , 21 ( 91.3 % ) were ACR 20 % responders , 18 ( 78.3 % ) were ACR 50 % , and 10 ( 43.5 % ) were ACR 70 % responders . The treatment was not responsible for severe adverse events . Radiography showed a slow progression in the damage score and number of eroded joints in both treatment groups . CONCLUSION Stepping down to single agent maintenance therapy following 6 months of combination treatment with CSA and MTX in early RA was only successful with MTX . Because this treatment did not prevent some radiographic progression , other approaches ( e.g. , step-up approach ) may be more appropriate in early RA .

[ "Step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "or", "methotrexate", "as", "maintenance", "therapy", "in", "early", "rheumatoid", "arthritis", ".", "OBJECTIVE", "To", "evaluate", "the", "feasibility", "and", "outcome", "of", "the", "step", "-", "down", "approach", "using", "either", "cyclosporin", "A", "(", "CSA", ")", "or", "methotrexate", "(", "MTX", ")", "as", "maintenance", "therapy", "following", "6", "months", "treatment", "with", "these", "2", "agents", "in", "combination", "in", "early", ",", "nonerosive", "rheumatoid", "arthritis", "(", "RA", ")", ".", "METHODS", "Fifty", "-", "seven", "patients", "younger", "than", "65", "years", "with", "early", ",", "nonerosive", "RA", "were", "first", "treated", "with", "CSA", "and", "MTX", "in", "combination", "for", "6", "months", ".", "They", "were", "then", "randomly", "stepped", "down", "to", "single", "-", "agent", "maintenance", "treatment", "for", "another", "18", "months", ".", "Safety", ",", "clinical", "efficacy", ",", "survival", "on", "treatment", ",", "and", "radiographic", "progression", "were", "evaluated", ".", "RESULTS", "When", "being", "treated", "with", "combination", "therapy", ",", "7", "of", "the", "57", "patients", "(", "12.3", "%", ")", "withdrew", "because", "of", "adverse", "events", ".", "Of", "the", "remaining", "50", "patients", ",", "42", "(", "84.0", "%", ")", "were", "American", "College", "of", "Rheumatology", "(", "ACR", ")", "20", "%", "responders", ",", "30", "(", "60.0", "%", ")", "were", "ACR", "50", "%", "responders", ",", "and", "23", "(", "46.0", "%", ")", "were", "ACR", "70", "%", "responders", ".", "At", "month", "6", ",", "22", "patients", "were", "randomized", "to", "CSA", "and", "27", "to", "MTX", ".", "During", "this", "trial", "period", ",", "the", "treatment", "was", "discontinued", "by", "16", "patients", "taking", "CSA", "(", "mainly", "because", "of", "loss", "of", "efficacy", ")", "and", "by", "4", "taking", "MTX", ".", "At", "month", "24", ",", "the", "probability", "(", "+", "/-", "SEM", ")", "of", "survival", "on", "treatment", "was", "0.273", "+", "/-", "0.09", "for", "CSA", "and", "0.852", "+", "/-", "0.07", "for", "MTX", ".", "Of", "the", "6", "CSA", "patients", "who", "completed", "the", "trial", ",", "4", "(", "66.7", "%", ")", "were", "ACR", "20", "%", "responders", ",", "and", "3", "(", "50", "%", ")", "were", "both", "ACR", "50", "%", "and", "ACR", "70", "%", "responders", ".", "Of", "the", "23", "completers", "in", "the", "MTX", "arm", ",", "21", "(", "91.3", "%", ")", "were", "ACR", "20", "%", "responders", ",", "18", "(", "78.3", "%", ")", "were", "ACR", "50", "%", ",", "and", "10", "(", "43.5", "%", ")", "were", "ACR", "70", "%", "responders", ".", "The", "treatment", "was", "not", "responsible", "for", "severe", "adverse", "events", ".", "Radiography", "showed", "a", "slow", "progression", "in", "the", "damage", "score", "and", "number", "of", "eroded", "joints", "in", "both", "treatment", "groups", ".", "CONCLUSION", "Stepping", "down", "to", "single", "agent", "maintenance", "therapy", "following", "6", "months", "of", "combination", "treatment", "with", "CSA", "and", "MTX", "in", "early", "RA", "was", "only", "successful", "with", "MTX", ".", "Because", "this", "treatment", "did", "not", "prevent", "some", "radiographic", "progression", ",", "other", "approaches", "(", "e.g", ".", ",", "step", "-", "up", "approach", ")", "may", "be", "more", "appropriate", "in", "early", "RA", "." ]

[ "Outcome_Physical", "Outcome_Other", "Participant_Condition", "Intervention_Pharmacological", "Outcome_Mortality", "Participant_Sample-size", "Outcome_Adverse-effects", "Intervention_Physical" ]

Xabi is a NOMBRE_SUJETO_ASISTENCIA, Ibarra Izaguirre is a NOMBRE_SUJETO_ASISTENCIA, 3762723 is a ID_SUJETO_ASISTENCIA, 43 57823189 63 is a ID_ASEGURAMIENTO, Villabona is a TERRITORIO, 20150 is a TERRITORIO, 19/05/1961 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 21/09/2013 is a FECHAS, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, 20 20 54816 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, arantxa.ambg@gmail.com is a CORREO_ELECTRONICO

380_task0

Sentence: Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com

[ "Nombre", ":", " ", "Xabi", ".", "\n", "Apellidos", ":", "Ibarra", "Izaguirre", ".", "\n", "NHC", ":", " ", "3762723", ".", "\n", "NASS", ":", "43", "57823189", "63", ".", "\n", "Domicilio", ":", "Calle", "el", "buen", "pastor", "66", ",", "1C.", "\n", "Localidad/", "Provincia", ":", "Villabona", ".", "\n", "CP", ":", "20150", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "19/05/1961", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/09/2013", ".", "\n", "Médico", ":", "Arantxa", "Andújar", "Mateos", "NºCol", ":", "20", "20", "54816", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "52", "años", ",", "240", "kg", "de", "peso", "e", "IMC", "de", "74", "kg", "/", "m2", ",", "que", "ingresó", "en", "el", "hospital", "con", "diagnóstico", "de", "ictus", "isquémico", ".", "Como", "antecedentes", "patológicos", "de", "interés", ",", "el", "paciente", "presentó", "en", "el", "pasado", "un", "tromboembolismo", "venoso", "profundo", ",", "razón", "por", "la", "cual", "le", "fue", "prescrita", "terapia", "anticoagulante", "domiciliaria", "con", "Rivaroxabán", ".", "\n", "Desde", "el", "Servicio", "de", "Urgencias", "se", "plantea", "la", "posibilidad", "de", "realizar", "al", "paciente", "un", "tratamiento", "fibrinolítico", "con", "alteplasa", ".", "Sin", "embargo", ",", "tras", "la", "exploración", "se", "desestimó", "dicha", "intervención", ",", "ya", "que", "el", "paciente", "se", "encontraba", "en", "estado", "límite", "del", "intervalo", "temporal", ",", "presentaba", "23", "puntos", "en", "la", "escala", "NIHSS", "(", "National", "Institute", "of", "Health", "Stroke", "Scale", ")", "y", "se", "desconocía", "la", "hora", "de", "la", "última", "toma", "de", "Rivaroxabán", ".", "\n", "Tras", "su", "ingreso", "en", "UCI", "para", "monitorización", "y", "vigilancia", "neurológica", ",", "se", "decidió", "iniciar", "tratamiento", "con", "enoxaparina", "como", "terapia", "anticoagulante", ".", "Para", "ello", ",", "el", "Servicio", "de", "Medicina", "Intensiva", "se", "puso", "en", "contacto", "con", "el", "Servicio", "de", "Farmacia", "con", "el", "fin", "de", "conocer", "la", "posología", "más", "adecuada", "dada", "la", "situación", "de", "obesidad", "extrema2", "(", "IMC", ">", "40", "kg", "/", "m2", ")", ".", "\n", "Por", "razones", "de", "seguridad", ",", "dada", "la", "escasez", "de", "datos", "al", "respecto", ",", "se", "decidió", "iniciar", "el", "tratamiento", "a", "dosis", "de", "0,7", "mg", "/", "kg/12", "h", "vía", "subcutánea", "(", "enoxaparina", "160", "mg/12", "h", ")", "para", "evitar", "sangrados", "y", "por", "ser", "la", "dosis", "máxima", "evaluada", "en", "diversos", "ensayos", "clínicos3", "-", "5", ".", "Además", ",", "se", "estableció", "la", "monitorización", "del", "factor", "anti", "-", "Xa", "para", "establecer", "la", "dosis", "final6", ".", "\n", "Transcurridas", "cuatro", "horas", "de", "la", "administración", "de", "la", "tercera", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "en", "sangre", "obtenida", "fue", "de", "0,37", "UI", "/", "mL.", "Al", "encontrarse", "entre", "0,35", "-", "0,49", "UI", "/", "mL", "se", "procedió", "a", "incrementar", "≈10", "%", "la", "dosis", "(", "170", "mg/12", "h", ")", ".", "Cuatro", "horas", "después", "de", "la", "siguiente", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "fue", "0,59", "UI", "/", "mL", ",", "y", "a", "las", "24", "horas", "de", "0,48", "UI", "/", "mL.", "A", "la", "vista", "de", "ese", "resultado", ",", "se", "incrementó", "la", "dosis", ",", "llegando", "a", "180", "mg/12", "h.", "Finalmente", ",", "la", "siguiente", "determinación", "obtuvo", "un", "valor", "de", "0,84", "UI", "/", "mL", ",", "situándonos", "dentro", "del", "rango", "terapéutico", "y", "fijando", "la", "dosis", "óptima", "para", "nuestro", "paciente", "en", "0,75", "mg", "/", "kg/12", "h.", "\n", "Remitido", "por", ":", "Dra", ".", "Arantxa", "Andújar", "Mateos", "Correo", "electrónico", ":", "arantxa.ambg@gmail.com", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Xabi is a NOMBRE_SUJETO_ASISTENCIA, Ibarra Izaguirre is a NOMBRE_SUJETO_ASISTENCIA, 3762723 is a ID_SUJETO_ASISTENCIA, 43 57823189 63 is a ID_ASEGURAMIENTO, Villabona is a TERRITORIO, 20150 is a TERRITORIO, 19/05/1961 is a FECHAS, España is a PAIS, 52 años is a EDAD_SUJETO_ASISTENCIA, 21/09/2013 is a FECHAS, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, 20 20 54816 is a ID_TITULACION_PERSONAL_SANITARIO, Varón is a SEXO_SUJETO_ASISTENCIA, 52 años is a EDAD_SUJETO_ASISTENCIA, Arantxa Andújar Mateos is a NOMBRE_PERSONAL_SANITARIO, arantxa.ambg@gmail.com is a CORREO_ELECTRONICO

380_task1

Sentence: Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com Instructions: please typing these entity words according to sentence: Xabi, Ibarra Izaguirre, 3762723, 43 57823189 63, Villabona, 20150, 19/05/1961, España, 52 años, 21/09/2013, Arantxa Andújar Mateos, 20 20 54816, Varón, 52 años, Arantxa Andújar Mateos, arantxa.ambg@gmail.com Options: TERRITORIO, SEXO_SUJETO_ASISTENCIA, ID_SUJETO_ASISTENCIA, FECHAS, CORREO_ELECTRONICO, PAIS, EDAD_SUJETO_ASISTENCIA, ID_ASEGURAMIENTO, ID_TITULACION_PERSONAL_SANITARIO, NOMBRE_SUJETO_ASISTENCIA, NOMBRE_PERSONAL_SANITARIO

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com

[ "Nombre", ":", " ", "Xabi", ".", "\n", "Apellidos", ":", "Ibarra", "Izaguirre", ".", "\n", "NHC", ":", " ", "3762723", ".", "\n", "NASS", ":", "43", "57823189", "63", ".", "\n", "Domicilio", ":", "Calle", "el", "buen", "pastor", "66", ",", "1C.", "\n", "Localidad/", "Provincia", ":", "Villabona", ".", "\n", "CP", ":", "20150", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "19/05/1961", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/09/2013", ".", "\n", "Médico", ":", "Arantxa", "Andújar", "Mateos", "NºCol", ":", "20", "20", "54816", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "52", "años", ",", "240", "kg", "de", "peso", "e", "IMC", "de", "74", "kg", "/", "m2", ",", "que", "ingresó", "en", "el", "hospital", "con", "diagnóstico", "de", "ictus", "isquémico", ".", "Como", "antecedentes", "patológicos", "de", "interés", ",", "el", "paciente", "presentó", "en", "el", "pasado", "un", "tromboembolismo", "venoso", "profundo", ",", "razón", "por", "la", "cual", "le", "fue", "prescrita", "terapia", "anticoagulante", "domiciliaria", "con", "Rivaroxabán", ".", "\n", "Desde", "el", "Servicio", "de", "Urgencias", "se", "plantea", "la", "posibilidad", "de", "realizar", "al", "paciente", "un", "tratamiento", "fibrinolítico", "con", "alteplasa", ".", "Sin", "embargo", ",", "tras", "la", "exploración", "se", "desestimó", "dicha", "intervención", ",", "ya", "que", "el", "paciente", "se", "encontraba", "en", "estado", "límite", "del", "intervalo", "temporal", ",", "presentaba", "23", "puntos", "en", "la", "escala", "NIHSS", "(", "National", "Institute", "of", "Health", "Stroke", "Scale", ")", "y", "se", "desconocía", "la", "hora", "de", "la", "última", "toma", "de", "Rivaroxabán", ".", "\n", "Tras", "su", "ingreso", "en", "UCI", "para", "monitorización", "y", "vigilancia", "neurológica", ",", "se", "decidió", "iniciar", "tratamiento", "con", "enoxaparina", "como", "terapia", "anticoagulante", ".", "Para", "ello", ",", "el", "Servicio", "de", "Medicina", "Intensiva", "se", "puso", "en", "contacto", "con", "el", "Servicio", "de", "Farmacia", "con", "el", "fin", "de", "conocer", "la", "posología", "más", "adecuada", "dada", "la", "situación", "de", "obesidad", "extrema2", "(", "IMC", ">", "40", "kg", "/", "m2", ")", ".", "\n", "Por", "razones", "de", "seguridad", ",", "dada", "la", "escasez", "de", "datos", "al", "respecto", ",", "se", "decidió", "iniciar", "el", "tratamiento", "a", "dosis", "de", "0,7", "mg", "/", "kg/12", "h", "vía", "subcutánea", "(", "enoxaparina", "160", "mg/12", "h", ")", "para", "evitar", "sangrados", "y", "por", "ser", "la", "dosis", "máxima", "evaluada", "en", "diversos", "ensayos", "clínicos3", "-", "5", ".", "Además", ",", "se", "estableció", "la", "monitorización", "del", "factor", "anti", "-", "Xa", "para", "establecer", "la", "dosis", "final6", ".", "\n", "Transcurridas", "cuatro", "horas", "de", "la", "administración", "de", "la", "tercera", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "en", "sangre", "obtenida", "fue", "de", "0,37", "UI", "/", "mL.", "Al", "encontrarse", "entre", "0,35", "-", "0,49", "UI", "/", "mL", "se", "procedió", "a", "incrementar", "≈10", "%", "la", "dosis", "(", "170", "mg/12", "h", ")", ".", "Cuatro", "horas", "después", "de", "la", "siguiente", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "fue", "0,59", "UI", "/", "mL", ",", "y", "a", "las", "24", "horas", "de", "0,48", "UI", "/", "mL.", "A", "la", "vista", "de", "ese", "resultado", ",", "se", "incrementó", "la", "dosis", ",", "llegando", "a", "180", "mg/12", "h.", "Finalmente", ",", "la", "siguiente", "determinación", "obtuvo", "un", "valor", "de", "0,84", "UI", "/", "mL", ",", "situándonos", "dentro", "del", "rango", "terapéutico", "y", "fijando", "la", "dosis", "óptima", "para", "nuestro", "paciente", "en", "0,75", "mg", "/", "kg/12", "h.", "\n", "Remitido", "por", ":", "Dra", ".", "Arantxa", "Andújar", "Mateos", "Correo", "electrónico", ":", "arantxa.ambg@gmail.com", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Xabi, Ibarra Izaguirre, 3762723, 43 57823189 63, Villabona, 20150, 19/05/1961, España, 52 años, 21/09/2013, Arantxa Andújar Mateos, 20 20 54816, Varón, 52 años, Arantxa Andújar Mateos, arantxa.ambg@gmail.com

380_task2

Sentence: Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-NOMBRE_SUJETO_ASISTENCIA", "I-NOMBRE_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "B-ID_SUJETO_ASISTENCIA", "O", "O", "O", "O", "B-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "I-ID_ASEGURAMIENTO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "B-TERRITORIO", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-PAIS", "O", "O", "O", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "B-FECHAS", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "B-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "I-ID_TITULACION_PERSONAL_SANITARIO", "O", "O", "O", "O", "O", "O", "O", "B-SEXO_SUJETO_ASISTENCIA", "O", "B-EDAD_SUJETO_ASISTENCIA", "I-EDAD_SUJETO_ASISTENCIA", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "I-NOMBRE_PERSONAL_SANITARIO", "O", "O", "O", "B-CORREO_ELECTRONICO", "O" ]

Nombre: Xabi. Apellidos: Ibarra Izaguirre. NHC: 3762723. NASS: 43 57823189 63. Domicilio: Calle el buen pastor 66, 1C. Localidad/ Provincia: Villabona. CP: 20150. Datos asistenciales. Fecha de nacimiento: 19/05/1961. País: España. Edad: 52 años Sexo: H. Fecha de Ingreso: 21/09/2013. Médico: Arantxa Andújar Mateos NºCol: 20 20 54816. Informe clínico del paciente: Varón de 52 años, 240 kg de peso e IMC de 74 kg/m2, que ingresó en el hospital con diagnóstico de ictus isquémico. Como antecedentes patológicos de interés, el paciente presentó en el pasado un tromboembolismo venoso profundo, razón por la cual le fue prescrita terapia anticoagulante domiciliaria con Rivaroxabán. Desde el Servicio de Urgencias se plantea la posibilidad de realizar al paciente un tratamiento fibrinolítico con alteplasa. Sin embargo, tras la exploración se desestimó dicha intervención, ya que el paciente se encontraba en estado límite del intervalo temporal, presentaba 23 puntos en la escala NIHSS (National Institute of Health Stroke Scale) y se desconocía la hora de la última toma de Rivaroxabán. Tras su ingreso en UCI para monitorización y vigilancia neurológica, se decidió iniciar tratamiento con enoxaparina como terapia anticoagulante. Para ello, el Servicio de Medicina Intensiva se puso en contacto con el Servicio de Farmacia con el fin de conocer la posología más adecuada dada la situación de obesidad extrema2 (IMC > 40 kg/m2). Por razones de seguridad, dada la escasez de datos al respecto, se decidió iniciar el tratamiento a dosis de 0,7 mg/kg/12 h vía subcutánea (enoxaparina 160 mg/12 h) para evitar sangrados y por ser la dosis máxima evaluada en diversos ensayos clínicos3-5. Además, se estableció la monitorización del factor anti-Xa para establecer la dosis final6. Transcurridas cuatro horas de la administración de la tercera dosis, la concentración de factor anti-Xa en sangre obtenida fue de 0,37 UI/mL. Al encontrarse entre 0,35-0,49 UI/mL se procedió a incrementar ≈10% la dosis (170 mg/12 h). Cuatro horas después de la siguiente dosis, la concentración de factor anti-Xa fue 0,59 UI/mL, y a las 24 horas de 0,48 UI/mL. A la vista de ese resultado, se incrementó la dosis, llegando a 180 mg/12 h. Finalmente, la siguiente determinación obtuvo un valor de 0,84 UI/mL, situándonos dentro del rango terapéutico y fijando la dosis óptima para nuestro paciente en 0,75 mg/kg/12 h. Remitido por: Dra. Arantxa Andújar Mateos Correo electrónico: arantxa.ambg@gmail.com

[ "Nombre", ":", " ", "Xabi", ".", "\n", "Apellidos", ":", "Ibarra", "Izaguirre", ".", "\n", "NHC", ":", " ", "3762723", ".", "\n", "NASS", ":", "43", "57823189", "63", ".", "\n", "Domicilio", ":", "Calle", "el", "buen", "pastor", "66", ",", "1C.", "\n", "Localidad/", "Provincia", ":", "Villabona", ".", "\n", "CP", ":", "20150", ".", "\n", "Datos", "asistenciales", ".", "\n", "Fecha", "de", "nacimiento", ":", "19/05/1961", ".", "\n", "País", ":", "España", ".", "\n", "Edad", ":", "52", "años", "Sexo", ":", "H.", "\n", "Fecha", "de", "Ingreso", ":", "21/09/2013", ".", "\n", "Médico", ":", "Arantxa", "Andújar", "Mateos", "NºCol", ":", "20", "20", "54816", ".", "\n", "Informe", "clínico", "del", "paciente", ":", "Varón", "de", "52", "años", ",", "240", "kg", "de", "peso", "e", "IMC", "de", "74", "kg", "/", "m2", ",", "que", "ingresó", "en", "el", "hospital", "con", "diagnóstico", "de", "ictus", "isquémico", ".", "Como", "antecedentes", "patológicos", "de", "interés", ",", "el", "paciente", "presentó", "en", "el", "pasado", "un", "tromboembolismo", "venoso", "profundo", ",", "razón", "por", "la", "cual", "le", "fue", "prescrita", "terapia", "anticoagulante", "domiciliaria", "con", "Rivaroxabán", ".", "\n", "Desde", "el", "Servicio", "de", "Urgencias", "se", "plantea", "la", "posibilidad", "de", "realizar", "al", "paciente", "un", "tratamiento", "fibrinolítico", "con", "alteplasa", ".", "Sin", "embargo", ",", "tras", "la", "exploración", "se", "desestimó", "dicha", "intervención", ",", "ya", "que", "el", "paciente", "se", "encontraba", "en", "estado", "límite", "del", "intervalo", "temporal", ",", "presentaba", "23", "puntos", "en", "la", "escala", "NIHSS", "(", "National", "Institute", "of", "Health", "Stroke", "Scale", ")", "y", "se", "desconocía", "la", "hora", "de", "la", "última", "toma", "de", "Rivaroxabán", ".", "\n", "Tras", "su", "ingreso", "en", "UCI", "para", "monitorización", "y", "vigilancia", "neurológica", ",", "se", "decidió", "iniciar", "tratamiento", "con", "enoxaparina", "como", "terapia", "anticoagulante", ".", "Para", "ello", ",", "el", "Servicio", "de", "Medicina", "Intensiva", "se", "puso", "en", "contacto", "con", "el", "Servicio", "de", "Farmacia", "con", "el", "fin", "de", "conocer", "la", "posología", "más", "adecuada", "dada", "la", "situación", "de", "obesidad", "extrema2", "(", "IMC", ">", "40", "kg", "/", "m2", ")", ".", "\n", "Por", "razones", "de", "seguridad", ",", "dada", "la", "escasez", "de", "datos", "al", "respecto", ",", "se", "decidió", "iniciar", "el", "tratamiento", "a", "dosis", "de", "0,7", "mg", "/", "kg/12", "h", "vía", "subcutánea", "(", "enoxaparina", "160", "mg/12", "h", ")", "para", "evitar", "sangrados", "y", "por", "ser", "la", "dosis", "máxima", "evaluada", "en", "diversos", "ensayos", "clínicos3", "-", "5", ".", "Además", ",", "se", "estableció", "la", "monitorización", "del", "factor", "anti", "-", "Xa", "para", "establecer", "la", "dosis", "final6", ".", "\n", "Transcurridas", "cuatro", "horas", "de", "la", "administración", "de", "la", "tercera", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "en", "sangre", "obtenida", "fue", "de", "0,37", "UI", "/", "mL.", "Al", "encontrarse", "entre", "0,35", "-", "0,49", "UI", "/", "mL", "se", "procedió", "a", "incrementar", "≈10", "%", "la", "dosis", "(", "170", "mg/12", "h", ")", ".", "Cuatro", "horas", "después", "de", "la", "siguiente", "dosis", ",", "la", "concentración", "de", "factor", "anti", "-", "Xa", "fue", "0,59", "UI", "/", "mL", ",", "y", "a", "las", "24", "horas", "de", "0,48", "UI", "/", "mL.", "A", "la", "vista", "de", "ese", "resultado", ",", "se", "incrementó", "la", "dosis", ",", "llegando", "a", "180", "mg/12", "h.", "Finalmente", ",", "la", "siguiente", "determinación", "obtuvo", "un", "valor", "de", "0,84", "UI", "/", "mL", ",", "situándonos", "dentro", "del", "rango", "terapéutico", "y", "fijando", "la", "dosis", "óptima", "para", "nuestro", "paciente", "en", "0,75", "mg", "/", "kg/12", "h.", "\n", "Remitido", "por", ":", "Dra", ".", "Arantxa", "Andújar", "Mateos", "Correo", "electrónico", ":", "arantxa.ambg@gmail.com", "\n" ]

[ "CALLE", "CORREO_ELECTRONICO", "NOMBRE_PERSONAL_SANITARIO", "NOMBRE_SUJETO_ASISTENCIA", "ID_ASEGURAMIENTO", "ID_TITULACION_PERSONAL_SANITARIO", "FECHAS", "TERRITORIO", "EDAD_SUJETO_ASISTENCIA", "ID_SUJETO_ASISTENCIA", "PAIS", "SEXO_SUJETO_ASISTENCIA" ]

Fazialisparese is an umlsterm, Therapiemassnahmen is an umlsterm, Uhrglasverbands is an umlsterm, Operationsmethode is an umlsterm, Patienten is an umlsterm, Goldimplantation is an umlsterm, Gesichtsbereich is an umlsterm, Goldimplantation is an umlsterm, Gesichtsfeldes is an umlsterm, Patienten is an umlsterm, Fazialisparese is an umlsterm, Goldimplantation is an umlsterm, Komplikationen is an umlsterm, Goldimplantats is an umlsterm, Goldimplantats is an umlsterm, Ausbildung is an umlsterm, Patienten is an umlsterm, Astigmatismus is an umlsterm, Goldimplantation is an umlsterm

HNO.90470262.ger.abstr_task0

Sentence: Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen .

[ "Die", "periphere", "Fazialisparese", "geht", "oft", "mit", "unvollstaendigem", "Lidschluss", "einher", "und", "kann", "zu", "einer", "Keratopathie", "unterschiedlichen", "Schweregrades", "bis", "hin", "zum", "Hornhautulkus", "fuehren", ".", "Die", "konservativen", "Therapiemassnahmen", "sind", "unbefriedigend", ",", "zudem", "stellt", "das", "Tragen", "eines", "Uhrglasverbands", "eine", "erhebliche", "kosmetische", "Beeintraechtigung", "dar", ".", "Zur", "Verbesserung", "des", "Lidschlusses", "gilt", "als", "klassische", "Operationsmethode", "die", "Tarsorrhapie", ",", "welche", "jedoch", "fuer", "den", "Patienten", "sowohl", "funktionelle", "als", "auch", "aesthetische", "Nachteile", "mit", "sich", "bringt", ".", "Als", "operative", "Alternative", "kommt", "die", "Goldimplantation", "zur", "Beschwerung", "des", "Oberlids", "zur", "Anwendung", ",", "ggf", ".", "in", "Kombination", "mit", "weiteren", "rehabilitativen", "Eingriffen", "im", "Gesichtsbereich", ".", "Durch", "die", "Goldimplantation", "wird", "ein", "kompletter", "Lidschluss", "ohne", "Beeintraechtigung", "des", "Gesichtsfeldes", "und", "ohne", "stoerenden", "kosmetischen", "Nebeneffekt", "ermoeglicht", ".", "Von", "Mai", "1994", "bis", "Januar", "1997", "wurden", "an", "der", "HNO", "-", "Klinik", "der", "Martin", "-", "Luther", "-", "Universitaet", "Halle", "-", "Wittenberg", "29", "Patienten", "mit", "peripherer", "Fazialisparese", "und", "Lagophthalmus", "mit", "einer", "Goldimplantation", "ins", "Oberlid", "versorgt", ".", "In", "allen", "Faellen", "war", "der", "Lidschluss", "postoperativ", "ausreichend", ",", "und", "es", "kam", "zu", "einer", "statistisch", "signifikanten", "Verminderung", "des", "Lagophthalmus", "und", "Verbesserung", "der", "Keratopathie", "mit", "Visusanstieg", ".", "Als", "Komplikationen", "wurden", "beobachtet", ":", "mechanische", "Ptosis", "(", "n=5", ")", ",", "deutliche", "Konturierung", "des", "Goldimplantats", "(", "n=5", ")", ",", "eine", "Extrusion", "des", "Goldimplantats", "(", "n=1", ")", "und", "ueberraschenderweise", "in", "mehreren", "Faellen", "die", "Ausbildung", "eines", "geringgradigen", "Hornhautastigmatismus", "(", "n=7", ")", ".", "Bei", "allen", "Patienten", "konnte", "der", "Astigmatismus", "durch", "das", "Anpassen", "von", "Zylinderglaesern", "korrigiert", "werden", ".", "Bei", "insgesamt", "sehr", "guten", "funktionellen", "Ergebnissen", "ist", "die", "Goldimplantation", "der", "aesthetisch", "stoerenden", "Tarsorrhapie", "ueberlegen", "." ]

[ "umlsterm" ]

Fazialisparese is an umlsterm, Therapiemassnahmen is an umlsterm, Uhrglasverbands is an umlsterm, Operationsmethode is an umlsterm, Patienten is an umlsterm, Goldimplantation is an umlsterm, Gesichtsbereich is an umlsterm, Goldimplantation is an umlsterm, Gesichtsfeldes is an umlsterm, Patienten is an umlsterm, Fazialisparese is an umlsterm, Goldimplantation is an umlsterm, Komplikationen is an umlsterm, Goldimplantats is an umlsterm, Goldimplantats is an umlsterm, Ausbildung is an umlsterm, Patienten is an umlsterm, Astigmatismus is an umlsterm, Goldimplantation is an umlsterm

HNO.90470262.ger.abstr_task1

Sentence: Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen . Instructions: please typing these entity words according to sentence: Fazialisparese, Therapiemassnahmen, Uhrglasverbands, Operationsmethode, Patienten, Goldimplantation, Gesichtsbereich, Goldimplantation, Gesichtsfeldes, Patienten, Fazialisparese, Goldimplantation, Komplikationen, Goldimplantats, Goldimplantats, Ausbildung, Patienten, Astigmatismus, Goldimplantation Options: umlsterm

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen .

[ "Die", "periphere", "Fazialisparese", "geht", "oft", "mit", "unvollstaendigem", "Lidschluss", "einher", "und", "kann", "zu", "einer", "Keratopathie", "unterschiedlichen", "Schweregrades", "bis", "hin", "zum", "Hornhautulkus", "fuehren", ".", "Die", "konservativen", "Therapiemassnahmen", "sind", "unbefriedigend", ",", "zudem", "stellt", "das", "Tragen", "eines", "Uhrglasverbands", "eine", "erhebliche", "kosmetische", "Beeintraechtigung", "dar", ".", "Zur", "Verbesserung", "des", "Lidschlusses", "gilt", "als", "klassische", "Operationsmethode", "die", "Tarsorrhapie", ",", "welche", "jedoch", "fuer", "den", "Patienten", "sowohl", "funktionelle", "als", "auch", "aesthetische", "Nachteile", "mit", "sich", "bringt", ".", "Als", "operative", "Alternative", "kommt", "die", "Goldimplantation", "zur", "Beschwerung", "des", "Oberlids", "zur", "Anwendung", ",", "ggf", ".", "in", "Kombination", "mit", "weiteren", "rehabilitativen", "Eingriffen", "im", "Gesichtsbereich", ".", "Durch", "die", "Goldimplantation", "wird", "ein", "kompletter", "Lidschluss", "ohne", "Beeintraechtigung", "des", "Gesichtsfeldes", "und", "ohne", "stoerenden", "kosmetischen", "Nebeneffekt", "ermoeglicht", ".", "Von", "Mai", "1994", "bis", "Januar", "1997", "wurden", "an", "der", "HNO", "-", "Klinik", "der", "Martin", "-", "Luther", "-", "Universitaet", "Halle", "-", "Wittenberg", "29", "Patienten", "mit", "peripherer", "Fazialisparese", "und", "Lagophthalmus", "mit", "einer", "Goldimplantation", "ins", "Oberlid", "versorgt", ".", "In", "allen", "Faellen", "war", "der", "Lidschluss", "postoperativ", "ausreichend", ",", "und", "es", "kam", "zu", "einer", "statistisch", "signifikanten", "Verminderung", "des", "Lagophthalmus", "und", "Verbesserung", "der", "Keratopathie", "mit", "Visusanstieg", ".", "Als", "Komplikationen", "wurden", "beobachtet", ":", "mechanische", "Ptosis", "(", "n=5", ")", ",", "deutliche", "Konturierung", "des", "Goldimplantats", "(", "n=5", ")", ",", "eine", "Extrusion", "des", "Goldimplantats", "(", "n=1", ")", "und", "ueberraschenderweise", "in", "mehreren", "Faellen", "die", "Ausbildung", "eines", "geringgradigen", "Hornhautastigmatismus", "(", "n=7", ")", ".", "Bei", "allen", "Patienten", "konnte", "der", "Astigmatismus", "durch", "das", "Anpassen", "von", "Zylinderglaesern", "korrigiert", "werden", ".", "Bei", "insgesamt", "sehr", "guten", "funktionellen", "Ergebnissen", "ist", "die", "Goldimplantation", "der", "aesthetisch", "stoerenden", "Tarsorrhapie", "ueberlegen", "." ]

[ "umlsterm" ]

Fazialisparese, Therapiemassnahmen, Uhrglasverbands, Operationsmethode, Patienten, Goldimplantation, Gesichtsbereich, Goldimplantation, Gesichtsfeldes, Patienten, Fazialisparese, Goldimplantation, Komplikationen, Goldimplantats, Goldimplantats, Ausbildung, Patienten, Astigmatismus, Goldimplantation

HNO.90470262.ger.abstr_task2

Sentence: Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen . Instructions: please extract entity words from the input sentence

[ "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O" ]

Die periphere Fazialisparese geht oft mit unvollstaendigem Lidschluss einher und kann zu einer Keratopathie unterschiedlichen Schweregrades bis hin zum Hornhautulkus fuehren . Die konservativen Therapiemassnahmen sind unbefriedigend , zudem stellt das Tragen eines Uhrglasverbands eine erhebliche kosmetische Beeintraechtigung dar . Zur Verbesserung des Lidschlusses gilt als klassische Operationsmethode die Tarsorrhapie , welche jedoch fuer den Patienten sowohl funktionelle als auch aesthetische Nachteile mit sich bringt . Als operative Alternative kommt die Goldimplantation zur Beschwerung des Oberlids zur Anwendung , ggf. in Kombination mit weiteren rehabilitativen Eingriffen im Gesichtsbereich . Durch die Goldimplantation wird ein kompletter Lidschluss ohne Beeintraechtigung des Gesichtsfeldes und ohne stoerenden kosmetischen Nebeneffekt ermoeglicht . Von Mai 1994 bis Januar 1997 wurden an der HNO-Klinik der Martin-Luther-Universitaet Halle-Wittenberg 29 Patienten mit peripherer Fazialisparese und Lagophthalmus mit einer Goldimplantation ins Oberlid versorgt . In allen Faellen war der Lidschluss postoperativ ausreichend , und es kam zu einer statistisch signifikanten Verminderung des Lagophthalmus und Verbesserung der Keratopathie mit Visusanstieg . Als Komplikationen wurden beobachtet : mechanische Ptosis ( n=5), deutliche Konturierung des Goldimplantats ( n=5), eine Extrusion des Goldimplantats ( n=1) und ueberraschenderweise in mehreren Faellen die Ausbildung eines geringgradigen Hornhautastigmatismus ( n=7). Bei allen Patienten konnte der Astigmatismus durch das Anpassen von Zylinderglaesern korrigiert werden . Bei insgesamt sehr guten funktionellen Ergebnissen ist die Goldimplantation der aesthetisch stoerenden Tarsorrhapie ueberlegen .

[ "Die", "periphere", "Fazialisparese", "geht", "oft", "mit", "unvollstaendigem", "Lidschluss", "einher", "und", "kann", "zu", "einer", "Keratopathie", "unterschiedlichen", "Schweregrades", "bis", "hin", "zum", "Hornhautulkus", "fuehren", ".", "Die", "konservativen", "Therapiemassnahmen", "sind", "unbefriedigend", ",", "zudem", "stellt", "das", "Tragen", "eines", "Uhrglasverbands", "eine", "erhebliche", "kosmetische", "Beeintraechtigung", "dar", ".", "Zur", "Verbesserung", "des", "Lidschlusses", "gilt", "als", "klassische", "Operationsmethode", "die", "Tarsorrhapie", ",", "welche", "jedoch", "fuer", "den", "Patienten", "sowohl", "funktionelle", "als", "auch", "aesthetische", "Nachteile", "mit", "sich", "bringt", ".", "Als", "operative", "Alternative", "kommt", "die", "Goldimplantation", "zur", "Beschwerung", "des", "Oberlids", "zur", "Anwendung", ",", "ggf", ".", "in", "Kombination", "mit", "weiteren", "rehabilitativen", "Eingriffen", "im", "Gesichtsbereich", ".", "Durch", "die", "Goldimplantation", "wird", "ein", "kompletter", "Lidschluss", "ohne", "Beeintraechtigung", "des", "Gesichtsfeldes", "und", "ohne", "stoerenden", "kosmetischen", "Nebeneffekt", "ermoeglicht", ".", "Von", "Mai", "1994", "bis", "Januar", "1997", "wurden", "an", "der", "HNO", "-", "Klinik", "der", "Martin", "-", "Luther", "-", "Universitaet", "Halle", "-", "Wittenberg", "29", "Patienten", "mit", "peripherer", "Fazialisparese", "und", "Lagophthalmus", "mit", "einer", "Goldimplantation", "ins", "Oberlid", "versorgt", ".", "In", "allen", "Faellen", "war", "der", "Lidschluss", "postoperativ", "ausreichend", ",", "und", "es", "kam", "zu", "einer", "statistisch", "signifikanten", "Verminderung", "des", "Lagophthalmus", "und", "Verbesserung", "der", "Keratopathie", "mit", "Visusanstieg", ".", "Als", "Komplikationen", "wurden", "beobachtet", ":", "mechanische", "Ptosis", "(", "n=5", ")", ",", "deutliche", "Konturierung", "des", "Goldimplantats", "(", "n=5", ")", ",", "eine", "Extrusion", "des", "Goldimplantats", "(", "n=1", ")", "und", "ueberraschenderweise", "in", "mehreren", "Faellen", "die", "Ausbildung", "eines", "geringgradigen", "Hornhautastigmatismus", "(", "n=7", ")", ".", "Bei", "allen", "Patienten", "konnte", "der", "Astigmatismus", "durch", "das", "Anpassen", "von", "Zylinderglaesern", "korrigiert", "werden", ".", "Bei", "insgesamt", "sehr", "guten", "funktionellen", "Ergebnissen", "ist", "die", "Goldimplantation", "der", "aesthetisch", "stoerenden", "Tarsorrhapie", "ueberlegen", "." ]

[ "umlsterm" ]

Less than 30 yrs is a Value, age is a Person, > 65 yrs is a Value, age is a Person, significant co - morbidities is a Scope, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia is a Scope

NCT02437084_exc_task0

Sentence: Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Person, Value

[ "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia.

[ "Less", "than", "30", "yrs", "of", "age", "or", ">", "65", "yrs", "of", "age", "\n", "Any", "significant", "co", "-", "morbidities", ",", "such", "as", "active", "heart", ",", "kidney", ",", "or", "liver", "diseases", ",", "accelerated", "or", "malignant", "hypertension", ",", "heart", "failure", ",", "severe", "anemia", ".", "\n" ]

[ "Scope", "Value", "Condition", "Qualifier", "Person" ]

Less than 30 yrs is a Value, age is a Person, > 65 yrs is a Value, age is a Person, significant co - morbidities is a Scope, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia is a Scope

NCT02437084_exc_task1

Sentence: Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia. Instructions: please typing these entity words according to sentence: Less than 30 yrs, age, > 65 yrs, age, significant co - morbidities, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia Options: Scope, Person, Value

[ "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia.

[ "Less", "than", "30", "yrs", "of", "age", "or", ">", "65", "yrs", "of", "age", "\n", "Any", "significant", "co", "-", "morbidities", ",", "such", "as", "active", "heart", ",", "kidney", ",", "or", "liver", "diseases", ",", "accelerated", "or", "malignant", "hypertension", ",", "heart", "failure", ",", "severe", "anemia", ".", "\n" ]

[ "Scope", "Value", "Condition", "Qualifier", "Person" ]

Less than 30 yrs, age, > 65 yrs, age, significant co - morbidities, active heart , kidney , or liver diseases , accelerated or malignant hypertension , heart failure , severe anemia

NCT02437084_exc_task2

Sentence: Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia. Instructions: please extract entity words from the input sentence

[ "B-Value", "I-Value", "I-Value", "I-Value", "O", "B-Person", "O", "B-Value", "I-Value", "I-Value", "O", "B-Person", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O" ]

Less than 30 yrs of age or > 65 yrs of age Any significant co-morbidities, such as active heart, kidney, or liver diseases, accelerated or malignant hypertension, heart failure, severe anemia.

[ "Less", "than", "30", "yrs", "of", "age", "or", ">", "65", "yrs", "of", "age", "\n", "Any", "significant", "co", "-", "morbidities", ",", "such", "as", "active", "heart", ",", "kidney", ",", "or", "liver", "diseases", ",", "accelerated", "or", "malignant", "hypertension", ",", "heart", "failure", ",", "severe", "anemia", ".", "\n" ]

[ "Scope", "Value", "Condition", "Qualifier", "Person" ]

Myokardinfarktregister is an umlsterm, Deutschland is an umlsterm, Register is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Dokumentation is an umlsterm, Infarkttherapie is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Krankenhaeusern is an umlsterm, Patienten is an umlsterm, maennlich is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, ASS is an umlsterm, ACE - Hemmer is an umlsterm, Gesamtmortalitaet is an umlsterm, Gesamtmortalitaet is an umlsterm, Krankenhaeusern is an umlsterm, Gebrauch is an umlsterm, Therapie is an umlsterm, Krankenhaeusern is an umlsterm

ZfuerKardiologie.90880857.ger.abstr_task0

Sentence: Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit .

[ "Das", "Myokardinfarktregister", "in", "Deutschland", "(", "MIR", ")", "ist", "ein", "multizentrisch", "und", "prospektiv", "angelegtes", "Register", "von", "konsekutiv", "eingeschlossenen", ",", "unselektierten", "Patienten", "mit", "akutem", "Myokardinfarkt", ".", "Ziel", "des", "MIR", "ist", "eine", "Dokumentation", "der", "Entscheidungs-", "und", "Verordnungspraxis", "einer", "optimierten", "Infarkttherapie", ",", "bestehend", "aus", "rekanalisierender", "Therapie", ",", "ASS", "Betablocker", "und", "ACE", "-", "Hemmer", "-", "Gabe", ".", ",", "Von", "12/96", "-", "5/98", "wurden", "bundesweit", "14598", "Patienten", "mit", "akutem", "Myokardinfarkt", "in", "217", "Krankenhaeusern", "eingeschlossen", ".", "Von", "diesen", "nahmen", "68", "Kliniken", "aus", "den", "neuen", "Bundeslaendern", "teil", ".", "65", "%", "der", "Patienten", "waren", "maennlich", ",", "das", "mittlere", "Alter", "betrug", "67", "Jahre", ".", "Die", "Praehospitalzeit", "lag", "im", "Median", "bei", "195", "min", ",", "das", "Erst", "-", "EKG", "war", "bei", "66", "%", "der", "Patienten", "diagnostisch", ".", "Eine", "rekanalisierende", "Therapie", "erhielten", "46,1", "%", "der", "Patienten", "(", "hospitale", "Thrombolyse", "36,2", "%", ";", "Primaer", "-", "PTCA", "9,9", "%", ")", ".", "Als", "Begleitmedikation", "in", "der", "Akutphase", "wurden", "verordnet", ":", "ASS", "bei", "90,3", "%", ",", "Betablocker", "bei", "53,8", "%", "und", "ACE", "-", "Hemmer", "bei", "52,5", "%", ".", "Die", "intrahospitale", "Gesamtmortalitaet", "betrug", "15,4", "%", ".", "Im", "Vergleich", "zeigte", "sich", "in", "kardiologischen", "Fachabteilungen", "eine", "niedrigere", "Gesamtmortalitaet", "(", "13,8", "%", ")", "gegenueber", "den", "Krankenhaeusern", "der", "Regelversorgung", "(", "16,1", "%", ")", ".", "Als", "moegliche", "Gruende", "fanden", "sich", "der", "haeufigere", "Gebrauch", "einer", "rekanalisierenden", "Therapie", "in", "Krankenhaeusern", "mit", "kardiologischer", "Fachabteilung", "(", "54,3", "%", "versus", "42,3", "%", ";", "p", "0,001", ")", "und", "das", "Vorhandensein", "eines", "Katheterlabors", "mit", "PTCA", "-", "Moeglichkeit", "." ]

[ "umlsterm" ]

Myokardinfarktregister is an umlsterm, Deutschland is an umlsterm, Register is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Dokumentation is an umlsterm, Infarkttherapie is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, Myokardinfarkt is an umlsterm, Krankenhaeusern is an umlsterm, Patienten is an umlsterm, maennlich is an umlsterm, Patienten is an umlsterm, Therapie is an umlsterm, Patienten is an umlsterm, ASS is an umlsterm, ACE - Hemmer is an umlsterm, Gesamtmortalitaet is an umlsterm, Gesamtmortalitaet is an umlsterm, Krankenhaeusern is an umlsterm, Gebrauch is an umlsterm, Therapie is an umlsterm, Krankenhaeusern is an umlsterm

ZfuerKardiologie.90880857.ger.abstr_task1

Sentence: Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit . Instructions: please typing these entity words according to sentence: Myokardinfarktregister, Deutschland, Register, Patienten, Myokardinfarkt, Dokumentation, Infarkttherapie, Therapie, Patienten, Myokardinfarkt, Krankenhaeusern, Patienten, maennlich, Patienten, Therapie, Patienten, ASS, ACE - Hemmer, Gesamtmortalitaet, Gesamtmortalitaet, Krankenhaeusern, Gebrauch, Therapie, Krankenhaeusern Options: umlsterm

[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit .

[ "Das", "Myokardinfarktregister", "in", "Deutschland", "(", "MIR", ")", "ist", "ein", "multizentrisch", "und", "prospektiv", "angelegtes", "Register", "von", "konsekutiv", "eingeschlossenen", ",", "unselektierten", "Patienten", "mit", "akutem", "Myokardinfarkt", ".", "Ziel", "des", "MIR", "ist", "eine", "Dokumentation", "der", "Entscheidungs-", "und", "Verordnungspraxis", "einer", "optimierten", "Infarkttherapie", ",", "bestehend", "aus", "rekanalisierender", "Therapie", ",", "ASS", "Betablocker", "und", "ACE", "-", "Hemmer", "-", "Gabe", ".", ",", "Von", "12/96", "-", "5/98", "wurden", "bundesweit", "14598", "Patienten", "mit", "akutem", "Myokardinfarkt", "in", "217", "Krankenhaeusern", "eingeschlossen", ".", "Von", "diesen", "nahmen", "68", "Kliniken", "aus", "den", "neuen", "Bundeslaendern", "teil", ".", "65", "%", "der", "Patienten", "waren", "maennlich", ",", "das", "mittlere", "Alter", "betrug", "67", "Jahre", ".", "Die", "Praehospitalzeit", "lag", "im", "Median", "bei", "195", "min", ",", "das", "Erst", "-", "EKG", "war", "bei", "66", "%", "der", "Patienten", "diagnostisch", ".", "Eine", "rekanalisierende", "Therapie", "erhielten", "46,1", "%", "der", "Patienten", "(", "hospitale", "Thrombolyse", "36,2", "%", ";", "Primaer", "-", "PTCA", "9,9", "%", ")", ".", "Als", "Begleitmedikation", "in", "der", "Akutphase", "wurden", "verordnet", ":", "ASS", "bei", "90,3", "%", ",", "Betablocker", "bei", "53,8", "%", "und", "ACE", "-", "Hemmer", "bei", "52,5", "%", ".", "Die", "intrahospitale", "Gesamtmortalitaet", "betrug", "15,4", "%", ".", "Im", "Vergleich", "zeigte", "sich", "in", "kardiologischen", "Fachabteilungen", "eine", "niedrigere", "Gesamtmortalitaet", "(", "13,8", "%", ")", "gegenueber", "den", "Krankenhaeusern", "der", "Regelversorgung", "(", "16,1", "%", ")", ".", "Als", "moegliche", "Gruende", "fanden", "sich", "der", "haeufigere", "Gebrauch", "einer", "rekanalisierenden", "Therapie", "in", "Krankenhaeusern", "mit", "kardiologischer", "Fachabteilung", "(", "54,3", "%", "versus", "42,3", "%", ";", "p", "0,001", ")", "und", "das", "Vorhandensein", "eines", "Katheterlabors", "mit", "PTCA", "-", "Moeglichkeit", "." ]

[ "umlsterm" ]

Myokardinfarktregister, Deutschland, Register, Patienten, Myokardinfarkt, Dokumentation, Infarkttherapie, Therapie, Patienten, Myokardinfarkt, Krankenhaeusern, Patienten, maennlich, Patienten, Therapie, Patienten, ASS, ACE - Hemmer, Gesamtmortalitaet, Gesamtmortalitaet, Krankenhaeusern, Gebrauch, Therapie, Krankenhaeusern

ZfuerKardiologie.90880857.ger.abstr_task2

Sentence: Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Das Myokardinfarktregister in Deutschland ( MIR ) ist ein multizentrisch und prospektiv angelegtes Register von konsekutiv eingeschlossenen , unselektierten Patienten mit akutem Myokardinfarkt . Ziel des MIR ist eine Dokumentation der Entscheidungs- und Verordnungspraxis einer optimierten Infarkttherapie , bestehend aus rekanalisierender Therapie , ASS Betablocker und ACE-Hemmer-Gabe . , Von 12/96-5/98 wurden bundesweit 14598 Patienten mit akutem Myokardinfarkt in 217 Krankenhaeusern eingeschlossen . Von diesen nahmen 68 Kliniken aus den neuen Bundeslaendern teil . 65% der Patienten waren maennlich , das mittlere Alter betrug 67 Jahre . Die Praehospitalzeit lag im Median bei 195 min , das Erst-EKG war bei 66% der Patienten diagnostisch . Eine rekanalisierende Therapie erhielten 46,1% der Patienten ( hospitale Thrombolyse 36,2% ; Primaer-PTCA 9,9% ) . Als Begleitmedikation in der Akutphase wurden verordnet : ASS bei 90,3% , Betablocker bei 53,8% und ACE-Hemmer bei 52,5% . Die intrahospitale Gesamtmortalitaet betrug 15,4% . Im Vergleich zeigte sich in kardiologischen Fachabteilungen eine niedrigere Gesamtmortalitaet ( 13,8% ) gegenueber den Krankenhaeusern der Regelversorgung ( 16,1% ) . Als moegliche Gruende fanden sich der haeufigere Gebrauch einer rekanalisierenden Therapie in Krankenhaeusern mit kardiologischer Fachabteilung ( 54,3% versus 42,3% ; p 0,001 ) und das Vorhandensein eines Katheterlabors mit PTCA-Moeglichkeit .

[ "Das", "Myokardinfarktregister", "in", "Deutschland", "(", "MIR", ")", "ist", "ein", "multizentrisch", "und", "prospektiv", "angelegtes", "Register", "von", "konsekutiv", "eingeschlossenen", ",", "unselektierten", "Patienten", "mit", "akutem", "Myokardinfarkt", ".", "Ziel", "des", "MIR", "ist", "eine", "Dokumentation", "der", "Entscheidungs-", "und", "Verordnungspraxis", "einer", "optimierten", "Infarkttherapie", ",", "bestehend", "aus", "rekanalisierender", "Therapie", ",", "ASS", "Betablocker", "und", "ACE", "-", "Hemmer", "-", "Gabe", ".", ",", "Von", "12/96", "-", "5/98", "wurden", "bundesweit", "14598", "Patienten", "mit", "akutem", "Myokardinfarkt", "in", "217", "Krankenhaeusern", "eingeschlossen", ".", "Von", "diesen", "nahmen", "68", "Kliniken", "aus", "den", "neuen", "Bundeslaendern", "teil", ".", "65", "%", "der", "Patienten", "waren", "maennlich", ",", "das", "mittlere", "Alter", "betrug", "67", "Jahre", ".", "Die", "Praehospitalzeit", "lag", "im", "Median", "bei", "195", "min", ",", "das", "Erst", "-", "EKG", "war", "bei", "66", "%", "der", "Patienten", "diagnostisch", ".", "Eine", "rekanalisierende", "Therapie", "erhielten", "46,1", "%", "der", "Patienten", "(", "hospitale", "Thrombolyse", "36,2", "%", ";", "Primaer", "-", "PTCA", "9,9", "%", ")", ".", "Als", "Begleitmedikation", "in", "der", "Akutphase", "wurden", "verordnet", ":", "ASS", "bei", "90,3", "%", ",", "Betablocker", "bei", "53,8", "%", "und", "ACE", "-", "Hemmer", "bei", "52,5", "%", ".", "Die", "intrahospitale", "Gesamtmortalitaet", "betrug", "15,4", "%", ".", "Im", "Vergleich", "zeigte", "sich", "in", "kardiologischen", "Fachabteilungen", "eine", "niedrigere", "Gesamtmortalitaet", "(", "13,8", "%", ")", "gegenueber", "den", "Krankenhaeusern", "der", "Regelversorgung", "(", "16,1", "%", ")", ".", "Als", "moegliche", "Gruende", "fanden", "sich", "der", "haeufigere", "Gebrauch", "einer", "rekanalisierenden", "Therapie", "in", "Krankenhaeusern", "mit", "kardiologischer", "Fachabteilung", "(", "54,3", "%", "versus", "42,3", "%", ";", "p", "0,001", ")", "und", "das", "Vorhandensein", "eines", "Katheterlabors", "mit", "PTCA", "-", "Moeglichkeit", "." ]

[ "umlsterm" ]

11beta - hydroxysteroid dehydrogenase type 2 is a Protein, mineralocorticoid ( MC ) receptor is a Protein, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein

15_task0

Sentence: Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side.

[ "Progesterone", "metabolism", "in", "the", "human", "kidney", "and", "inhibition", "of", "11beta", "-", "hydroxysteroid", "dehydrogenase", "type", "2", "by", "progesterone", "and", "its", "metabolites", ".", "\n", "Progesterone", "binds", "with", "high", "affinity", "to", "the", "mineralocorticoid", "(", "MC", ")", "receptor", ",", "but", "confers", "only", "very", "low", "agonistic", "MC", "activity", ".", "Therefore", ",", "progesterone", "is", "a", "potent", "MC", "antagonist", "in", "vitro", ".", "Although", "progesterone", "reaches", "up", "to", "100", "times", "higher", "plasma", "levels", "in", "late", "pregnancy", "than", "aldosterone", ",", "the", "in", "vivo", "MC", "antagonistic", "effect", "of", "progesterone", "seems", "to", "be", "relatively", "weak", ".", "One", "explanation", "for", "this", "phenomenon", "could", "be", "local", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", ",", "similar", "to", "the", "inactivation", "of", "cortisol", "to", "cortisone", "by", "the", "11beta", "-", "hydroxysteroid", "dehydrogenase", "(", "11beta", "-", "HSD", ")", "type", "2", ".", "We", "studied", "the", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", "in", "vitro", "and", "found", "reduction", "to", "20alpha", "-", "dihydro", "(", "DH)-progesterone", "as", "the", "main", "metabolite", ".", "Ring", "-", "A", "reduction", "to", "5alpha", "-", "DH", "-", "progesterone", ",", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", ",", "and", "3beta,5alpha", "-", "tetrahydro", "(", "TH)-progesterone", "was", "also", "documented", ".", "We", "further", "showed", "for", "the", "first", "time", "that", "17-hydroxylation", "of", "progesterone", "(", "17alpha", "-", "OH", "-", "progesterone", ",", "17alpha", "-", "OH", ",", "20alpha", "-", "DH", "-", "progesterone", ")", ",", "normally", "localized", "in", "the", "adrenals", "and", "the", "gonads", ",", "occurs", "in", "the", "human", "adult", "kidney", ".", "We", "found", "no", "formation", "of", "deoxycorticosterone", "from", "progesterone", "in", "the", "human", "adult", "kidney", ".", "Using", "human", "kidney", "cortex", "microsomes", ",", "we", "tested", "the", "inhibitory", "potency", "of", "progesterone", "and", "its", "metabolites", "on", "the", "11beta", "-", "HSD", "type", "2", ".", "The", "most", "potent", "inhibitor", "was", "progesterone", "itself", "(", "IC50", "=", "4.8", "x", "10(-8", ")", "mol", "/", "L", ")", ",", "followed", "by", "5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "=", "2.4", "x", "10(-7", ")", "mol", "/", "L", ")", ",", "20alpha", "-", "DH", "-", "progesterone", ",", "3beta,5alpha", "-", "TH", "-", "progesterone", ",", "17alpha", "-", "OH", "-", "progesterone", ",", "and", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "between", "7.7", "x", "10(-7", ")", "mol", "/", "L", "and", "1.3", "x", "10(-6", ")", "mol", "/", "L", ")", ".", "The", "least", "potent", "inhibitor", "was", "17alpha", "-", "OH,20alpha", "-", "DH", "-", "progesterone", ".", "In", "addition", "to", "progesterone", "metabolism", "by", "the", "kidney", ",", "the", "inhibition", "of", "11beta", "-", "HSD", "type", "2", "by", "progesterone", "and", "its", "metabolites", "could", "be", "a", "second", "explanation", "for", "the", "weak", "MC", "-", "antagonist", "activity", "of", "progesterone", "in", "vivo", ".", "Inhibition", "of", "11beta", "-", "HSD", "type", "2", "leads", "to", "an", "increase", "of", "intracellular", "cortisol", "in", "a", "way", "that", "the", "local", "equilibrium", "between", "the", "MC", "agonist", "cortisol", "and", "the", "antagonist", "progesterone", "is", "shifted", "to", "the", "agonist", "side", ".", "\n" ]

[ "Protein" ]

11beta - hydroxysteroid dehydrogenase type 2 is a Protein, mineralocorticoid ( MC ) receptor is a Protein, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein, 11beta - HSD type 2 is a Protein

15_task1

Sentence: Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side. Instructions: please typing these entity words according to sentence: 11beta - hydroxysteroid dehydrogenase type 2, mineralocorticoid ( MC ) receptor, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2, 11beta - HSD type 2, 11beta - HSD type 2, 11beta - HSD type 2 Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side.

[ "Progesterone", "metabolism", "in", "the", "human", "kidney", "and", "inhibition", "of", "11beta", "-", "hydroxysteroid", "dehydrogenase", "type", "2", "by", "progesterone", "and", "its", "metabolites", ".", "\n", "Progesterone", "binds", "with", "high", "affinity", "to", "the", "mineralocorticoid", "(", "MC", ")", "receptor", ",", "but", "confers", "only", "very", "low", "agonistic", "MC", "activity", ".", "Therefore", ",", "progesterone", "is", "a", "potent", "MC", "antagonist", "in", "vitro", ".", "Although", "progesterone", "reaches", "up", "to", "100", "times", "higher", "plasma", "levels", "in", "late", "pregnancy", "than", "aldosterone", ",", "the", "in", "vivo", "MC", "antagonistic", "effect", "of", "progesterone", "seems", "to", "be", "relatively", "weak", ".", "One", "explanation", "for", "this", "phenomenon", "could", "be", "local", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", ",", "similar", "to", "the", "inactivation", "of", "cortisol", "to", "cortisone", "by", "the", "11beta", "-", "hydroxysteroid", "dehydrogenase", "(", "11beta", "-", "HSD", ")", "type", "2", ".", "We", "studied", "the", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", "in", "vitro", "and", "found", "reduction", "to", "20alpha", "-", "dihydro", "(", "DH)-progesterone", "as", "the", "main", "metabolite", ".", "Ring", "-", "A", "reduction", "to", "5alpha", "-", "DH", "-", "progesterone", ",", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", ",", "and", "3beta,5alpha", "-", "tetrahydro", "(", "TH)-progesterone", "was", "also", "documented", ".", "We", "further", "showed", "for", "the", "first", "time", "that", "17-hydroxylation", "of", "progesterone", "(", "17alpha", "-", "OH", "-", "progesterone", ",", "17alpha", "-", "OH", ",", "20alpha", "-", "DH", "-", "progesterone", ")", ",", "normally", "localized", "in", "the", "adrenals", "and", "the", "gonads", ",", "occurs", "in", "the", "human", "adult", "kidney", ".", "We", "found", "no", "formation", "of", "deoxycorticosterone", "from", "progesterone", "in", "the", "human", "adult", "kidney", ".", "Using", "human", "kidney", "cortex", "microsomes", ",", "we", "tested", "the", "inhibitory", "potency", "of", "progesterone", "and", "its", "metabolites", "on", "the", "11beta", "-", "HSD", "type", "2", ".", "The", "most", "potent", "inhibitor", "was", "progesterone", "itself", "(", "IC50", "=", "4.8", "x", "10(-8", ")", "mol", "/", "L", ")", ",", "followed", "by", "5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "=", "2.4", "x", "10(-7", ")", "mol", "/", "L", ")", ",", "20alpha", "-", "DH", "-", "progesterone", ",", "3beta,5alpha", "-", "TH", "-", "progesterone", ",", "17alpha", "-", "OH", "-", "progesterone", ",", "and", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "between", "7.7", "x", "10(-7", ")", "mol", "/", "L", "and", "1.3", "x", "10(-6", ")", "mol", "/", "L", ")", ".", "The", "least", "potent", "inhibitor", "was", "17alpha", "-", "OH,20alpha", "-", "DH", "-", "progesterone", ".", "In", "addition", "to", "progesterone", "metabolism", "by", "the", "kidney", ",", "the", "inhibition", "of", "11beta", "-", "HSD", "type", "2", "by", "progesterone", "and", "its", "metabolites", "could", "be", "a", "second", "explanation", "for", "the", "weak", "MC", "-", "antagonist", "activity", "of", "progesterone", "in", "vivo", ".", "Inhibition", "of", "11beta", "-", "HSD", "type", "2", "leads", "to", "an", "increase", "of", "intracellular", "cortisol", "in", "a", "way", "that", "the", "local", "equilibrium", "between", "the", "MC", "agonist", "cortisol", "and", "the", "antagonist", "progesterone", "is", "shifted", "to", "the", "agonist", "side", ".", "\n" ]

[ "Protein" ]

11beta - hydroxysteroid dehydrogenase type 2, mineralocorticoid ( MC ) receptor, 11beta - hydroxysteroid dehydrogenase ( 11beta - HSD ) type 2, 11beta - HSD type 2, 11beta - HSD type 2, 11beta - HSD type 2

15_task2

Sentence: Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "I-Protein", "I-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Progesterone metabolism in the human kidney and inhibition of 11beta-hydroxysteroid dehydrogenase type 2 by progesterone and its metabolites. Progesterone binds with high affinity to the mineralocorticoid (MC) receptor, but confers only very low agonistic MC activity. Therefore, progesterone is a potent MC antagonist in vitro. Although progesterone reaches up to 100 times higher plasma levels in late pregnancy than aldosterone, the in vivo MC antagonistic effect of progesterone seems to be relatively weak. One explanation for this phenomenon could be local metabolism of progesterone in the human kidney, similar to the inactivation of cortisol to cortisone by the 11beta-hydroxysteroid dehydrogenase (11beta-HSD) type 2. We studied the metabolism of progesterone in the human kidney in vitro and found reduction to 20alpha-dihydro (DH)-progesterone as the main metabolite. Ring-A reduction to 5alpha-DH-progesterone, 20alpha-DH-5alpha-DH-progesterone, and 3beta,5alpha-tetrahydro (TH)-progesterone was also documented. We further showed for the first time that 17-hydroxylation of progesterone (17alpha-OH-progesterone, 17alpha-OH, 20alpha-DH-progesterone), normally localized in the adrenals and the gonads, occurs in the human adult kidney. We found no formation of deoxycorticosterone from progesterone in the human adult kidney. Using human kidney cortex microsomes, we tested the inhibitory potency of progesterone and its metabolites on the 11beta-HSD type 2. The most potent inhibitor was progesterone itself (IC50 = 4.8 x 10(-8) mol/L), followed by 5alpha-DH-progesterone (IC50 = 2.4 x 10(-7) mol/L), 20alpha-DH-progesterone, 3beta,5alpha-TH-progesterone, 17alpha-OH-progesterone, and 20alpha-DH-5alpha-DH-progesterone (IC50 between 7.7 x 10(-7) mol/L and 1.3 x 10(-6) mol/L). The least potent inhibitor was 17alpha-OH,20alpha-DH-progesterone. In addition to progesterone metabolism by the kidney, the inhibition of 11beta-HSD type 2 by progesterone and its metabolites could be a second explanation for the weak MC-antagonist activity of progesterone in vivo. Inhibition of 11beta-HSD type 2 leads to an increase of intracellular cortisol in a way that the local equilibrium between the MC agonist cortisol and the antagonist progesterone is shifted to the agonist side.

[ "Progesterone", "metabolism", "in", "the", "human", "kidney", "and", "inhibition", "of", "11beta", "-", "hydroxysteroid", "dehydrogenase", "type", "2", "by", "progesterone", "and", "its", "metabolites", ".", "\n", "Progesterone", "binds", "with", "high", "affinity", "to", "the", "mineralocorticoid", "(", "MC", ")", "receptor", ",", "but", "confers", "only", "very", "low", "agonistic", "MC", "activity", ".", "Therefore", ",", "progesterone", "is", "a", "potent", "MC", "antagonist", "in", "vitro", ".", "Although", "progesterone", "reaches", "up", "to", "100", "times", "higher", "plasma", "levels", "in", "late", "pregnancy", "than", "aldosterone", ",", "the", "in", "vivo", "MC", "antagonistic", "effect", "of", "progesterone", "seems", "to", "be", "relatively", "weak", ".", "One", "explanation", "for", "this", "phenomenon", "could", "be", "local", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", ",", "similar", "to", "the", "inactivation", "of", "cortisol", "to", "cortisone", "by", "the", "11beta", "-", "hydroxysteroid", "dehydrogenase", "(", "11beta", "-", "HSD", ")", "type", "2", ".", "We", "studied", "the", "metabolism", "of", "progesterone", "in", "the", "human", "kidney", "in", "vitro", "and", "found", "reduction", "to", "20alpha", "-", "dihydro", "(", "DH)-progesterone", "as", "the", "main", "metabolite", ".", "Ring", "-", "A", "reduction", "to", "5alpha", "-", "DH", "-", "progesterone", ",", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", ",", "and", "3beta,5alpha", "-", "tetrahydro", "(", "TH)-progesterone", "was", "also", "documented", ".", "We", "further", "showed", "for", "the", "first", "time", "that", "17-hydroxylation", "of", "progesterone", "(", "17alpha", "-", "OH", "-", "progesterone", ",", "17alpha", "-", "OH", ",", "20alpha", "-", "DH", "-", "progesterone", ")", ",", "normally", "localized", "in", "the", "adrenals", "and", "the", "gonads", ",", "occurs", "in", "the", "human", "adult", "kidney", ".", "We", "found", "no", "formation", "of", "deoxycorticosterone", "from", "progesterone", "in", "the", "human", "adult", "kidney", ".", "Using", "human", "kidney", "cortex", "microsomes", ",", "we", "tested", "the", "inhibitory", "potency", "of", "progesterone", "and", "its", "metabolites", "on", "the", "11beta", "-", "HSD", "type", "2", ".", "The", "most", "potent", "inhibitor", "was", "progesterone", "itself", "(", "IC50", "=", "4.8", "x", "10(-8", ")", "mol", "/", "L", ")", ",", "followed", "by", "5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "=", "2.4", "x", "10(-7", ")", "mol", "/", "L", ")", ",", "20alpha", "-", "DH", "-", "progesterone", ",", "3beta,5alpha", "-", "TH", "-", "progesterone", ",", "17alpha", "-", "OH", "-", "progesterone", ",", "and", "20alpha", "-", "DH-5alpha", "-", "DH", "-", "progesterone", "(", "IC50", "between", "7.7", "x", "10(-7", ")", "mol", "/", "L", "and", "1.3", "x", "10(-6", ")", "mol", "/", "L", ")", ".", "The", "least", "potent", "inhibitor", "was", "17alpha", "-", "OH,20alpha", "-", "DH", "-", "progesterone", ".", "In", "addition", "to", "progesterone", "metabolism", "by", "the", "kidney", ",", "the", "inhibition", "of", "11beta", "-", "HSD", "type", "2", "by", "progesterone", "and", "its", "metabolites", "could", "be", "a", "second", "explanation", "for", "the", "weak", "MC", "-", "antagonist", "activity", "of", "progesterone", "in", "vivo", ".", "Inhibition", "of", "11beta", "-", "HSD", "type", "2", "leads", "to", "an", "increase", "of", "intracellular", "cortisol", "in", "a", "way", "that", "the", "local", "equilibrium", "between", "the", "MC", "agonist", "cortisol", "and", "the", "antagonist", "progesterone", "is", "shifted", "to", "the", "agonist", "side", ".", "\n" ]

[ "Protein" ]

Klassifizierung is an umlsterm, perforierender Keratoplastik is an umlsterm, Klassifizierung is an umlsterm, Klassifizierung is an umlsterm

DerOpthalmologe.80950741.ger.abstr_task0

Sentence: Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren .

[ "Hintergrund", ":", "Die", "semiquantitative", "Klassifizierung", "der", "Hornhauttopographie", "nach", "perforierender", "Keratoplastik", "bietet", "die", "Moeglichkeit", ",", "neben", "dem", "keratometrischen", "oder", "topographischen", "Astigmatismusbetrag", "gebuendelt", "Information", "ueber", "die", "flaechige", "Brechkraftentwicklung", "der", "Hornhaut", "zu", "erhalten", ".", "Ziel", "der", "Studie", "war", ",", "den", "subjektiven", "semiquantitativen", "Prozess", "der", "Klassifizierung", "auf", "der", "Basis", "von", "Fourier", "-", "Koeffizienten", "zu", "objektivieren", "und", "mit", "der", "subjektiven", "Klassifizierung", "zu", "korrelieren", "." ]

[ "umlsterm" ]

Klassifizierung is an umlsterm, perforierender Keratoplastik is an umlsterm, Klassifizierung is an umlsterm, Klassifizierung is an umlsterm

DerOpthalmologe.80950741.ger.abstr_task1

Sentence: Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren . Instructions: please typing these entity words according to sentence: Klassifizierung, perforierender Keratoplastik, Klassifizierung, Klassifizierung Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren .

[ "Hintergrund", ":", "Die", "semiquantitative", "Klassifizierung", "der", "Hornhauttopographie", "nach", "perforierender", "Keratoplastik", "bietet", "die", "Moeglichkeit", ",", "neben", "dem", "keratometrischen", "oder", "topographischen", "Astigmatismusbetrag", "gebuendelt", "Information", "ueber", "die", "flaechige", "Brechkraftentwicklung", "der", "Hornhaut", "zu", "erhalten", ".", "Ziel", "der", "Studie", "war", ",", "den", "subjektiven", "semiquantitativen", "Prozess", "der", "Klassifizierung", "auf", "der", "Basis", "von", "Fourier", "-", "Koeffizienten", "zu", "objektivieren", "und", "mit", "der", "subjektiven", "Klassifizierung", "zu", "korrelieren", "." ]

[ "umlsterm" ]

Klassifizierung, perforierender Keratoplastik, Klassifizierung, Klassifizierung

DerOpthalmologe.80950741.ger.abstr_task2

Sentence: Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O" ]

Hintergrund : Die semiquantitative Klassifizierung der Hornhauttopographie nach perforierender Keratoplastik bietet die Moeglichkeit , neben dem keratometrischen oder topographischen Astigmatismusbetrag gebuendelt Information ueber die flaechige Brechkraftentwicklung der Hornhaut zu erhalten . Ziel der Studie war , den subjektiven semiquantitativen Prozess der Klassifizierung auf der Basis von Fourier-Koeffizienten zu objektivieren und mit der subjektiven Klassifizierung zu korrelieren .

[ "Hintergrund", ":", "Die", "semiquantitative", "Klassifizierung", "der", "Hornhauttopographie", "nach", "perforierender", "Keratoplastik", "bietet", "die", "Moeglichkeit", ",", "neben", "dem", "keratometrischen", "oder", "topographischen", "Astigmatismusbetrag", "gebuendelt", "Information", "ueber", "die", "flaechige", "Brechkraftentwicklung", "der", "Hornhaut", "zu", "erhalten", ".", "Ziel", "der", "Studie", "war", ",", "den", "subjektiven", "semiquantitativen", "Prozess", "der", "Klassifizierung", "auf", "der", "Basis", "von", "Fourier", "-", "Koeffizienten", "zu", "objektivieren", "und", "mit", "der", "subjektiven", "Klassifizierung", "zu", "korrelieren", "." ]

[ "umlsterm" ]

iliac crest bone graft harvesting is a Procedure, neurological deficits or peripheral neuropathy is a Scope, sciatic nerve is a Qualifier, Local infection is a Condition, Contraindication is a Condition, regional anesthesia is a Procedure, bleeding diathesis , coagulopathy is a Scope, Chronic pain is a Condition, oxycodone or equivalent is a Scope, Allergy is a Condition, local anesthetics is a Procedure, Pregnancy is a Condition

NCT02707874_exc_task0

Sentence: Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Scope, Condition, Procedure, Qualifier

[ "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O" ]

Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent

[ "Patients", "who", "undergo", "iliac", "crest", "bone", "graft", "harvesting", "as", "part", "of", "their", "surgery", "\n", "Preexisting", "neurological", "deficits", "or", "peripheral", "neuropathy", "in", "the", "distribution", "of", "the", "sciatic", "nerve", "\n", "Local", "infection", "\n", "Contraindication", "to", "regional", "anesthesia", "e.g", ".", "bleeding", "diathesis", ",", "coagulopathy", "\n", "Chronic", "pain", "disorders", "\n", "History", "of", "use", "of", "over", "30", "mg", "oxycodone", "or", "equivalent", "per", "day", "\n", "Allergy", "to", "local", "anesthetics", "\n", "History", "of", "significant", "psychiatric", "conditions", "that", "may", "affect", "patient", "assessment", "\n", "Pregnancy", "\n", "Inability", "to", "provide", "informed", "consent", "\n" ]

[ "Scope", "Procedure", "Condition", "Qualifier", "Multiplier", "Drug" ]

iliac crest bone graft harvesting is a Procedure, neurological deficits or peripheral neuropathy is a Scope, sciatic nerve is a Qualifier, Local infection is a Condition, Contraindication is a Condition, regional anesthesia is a Procedure, bleeding diathesis , coagulopathy is a Scope, Chronic pain is a Condition, oxycodone or equivalent is a Scope, Allergy is a Condition, local anesthetics is a Procedure, Pregnancy is a Condition

NCT02707874_exc_task1

Sentence: Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent Instructions: please typing these entity words according to sentence: iliac crest bone graft harvesting, neurological deficits or peripheral neuropathy, sciatic nerve, Local infection, Contraindication, regional anesthesia, bleeding diathesis , coagulopathy, Chronic pain, oxycodone or equivalent, Allergy, local anesthetics, Pregnancy Options: Scope, Condition, Procedure, Qualifier

[ "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O" ]

Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent

[ "Patients", "who", "undergo", "iliac", "crest", "bone", "graft", "harvesting", "as", "part", "of", "their", "surgery", "\n", "Preexisting", "neurological", "deficits", "or", "peripheral", "neuropathy", "in", "the", "distribution", "of", "the", "sciatic", "nerve", "\n", "Local", "infection", "\n", "Contraindication", "to", "regional", "anesthesia", "e.g", ".", "bleeding", "diathesis", ",", "coagulopathy", "\n", "Chronic", "pain", "disorders", "\n", "History", "of", "use", "of", "over", "30", "mg", "oxycodone", "or", "equivalent", "per", "day", "\n", "Allergy", "to", "local", "anesthetics", "\n", "History", "of", "significant", "psychiatric", "conditions", "that", "may", "affect", "patient", "assessment", "\n", "Pregnancy", "\n", "Inability", "to", "provide", "informed", "consent", "\n" ]

[ "Scope", "Procedure", "Condition", "Qualifier", "Multiplier", "Drug" ]

iliac crest bone graft harvesting, neurological deficits or peripheral neuropathy, sciatic nerve, Local infection, Contraindication, regional anesthesia, bleeding diathesis , coagulopathy, Chronic pain, oxycodone or equivalent, Allergy, local anesthetics, Pregnancy

NCT02707874_exc_task2

Sentence: Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "O", "O", "O", "O", "B-Qualifier", "I-Qualifier", "O", "B-Condition", "I-Condition", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "B-Scope", "I-Scope", "I-Scope", "I-Scope", "O", "B-Condition", "I-Condition", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Scope", "I-Scope", "I-Scope", "O", "O", "O", "B-Condition", "O", "B-Procedure", "I-Procedure", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Condition", "O", "O", "O", "O", "O", "O", "O" ]

Patients who undergo iliac crest bone graft harvesting as part of their surgery Preexisting neurological deficits or peripheral neuropathy in the distribution of the sciatic nerve Local infection Contraindication to regional anesthesia e.g. bleeding diathesis, coagulopathy Chronic pain disorders History of use of over 30mg oxycodone or equivalent per day Allergy to local anesthetics History of significant psychiatric conditions that may affect patient assessment Pregnancy Inability to provide informed consent

[ "Patients", "who", "undergo", "iliac", "crest", "bone", "graft", "harvesting", "as", "part", "of", "their", "surgery", "\n", "Preexisting", "neurological", "deficits", "or", "peripheral", "neuropathy", "in", "the", "distribution", "of", "the", "sciatic", "nerve", "\n", "Local", "infection", "\n", "Contraindication", "to", "regional", "anesthesia", "e.g", ".", "bleeding", "diathesis", ",", "coagulopathy", "\n", "Chronic", "pain", "disorders", "\n", "History", "of", "use", "of", "over", "30", "mg", "oxycodone", "or", "equivalent", "per", "day", "\n", "Allergy", "to", "local", "anesthetics", "\n", "History", "of", "significant", "psychiatric", "conditions", "that", "may", "affect", "patient", "assessment", "\n", "Pregnancy", "\n", "Inability", "to", "provide", "informed", "consent", "\n" ]

[ "Scope", "Procedure", "Condition", "Qualifier", "Multiplier", "Drug" ]

ECG is an umlsterm, ventricular tachycardia is an umlsterm, axis is an umlsterm, right is an umlsterm, bundle branch block is an umlsterm, echocardiogram is an umlsterm, heart is an umlsterm, verapamil is an umlsterm, tachycardia is an umlsterm, antiarrhythmic agents is an umlsterm, Sinus is an umlsterm, ECG is an umlsterm, findings is an umlsterm, verapamil - sensitive is an umlsterm, ventricular tachycardia is an umlsterm, children is an umlsterm

MonatsschriftKinderheilkunde.91471086.eng.abstr_task0

Sentence: The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children .

[ "The", "ECG", "of", "a", "15-year", "-", "old", "boy", "hospitalized", "for", "rhythm", "disturbances", "showed", "a", "sustained", "ventricular", "tachycardia", "(", "beat", "rate", "170", "to", "180/", "min", ")", "with", "left", "axis", "deviation", "and", "complete", "right", "bundle", "branch", "block", ".", "His", "echocardiogram", "showed", "a", "structurally", "normal", "heart", "with", "diminished", "left", "ventricular", "performance", ".", "Intravenous", "application", "of", "verapamil", "led", "to", "prompt", "termination", "of", "the", "tachycardia", ",", "after", "previous", "attempts", "with", "various", "other", "antiarrhythmic", "agents", "had", "failed", ".", "Sinus", "rhythm", "remained", "stable", ".", "ECG", "and", "echocardiographic", "changes", "returned", "to", "normal", ".", "Course", "and", "findings", "are", "characteristic", "of", "verapamil", "-", "sensitive", "idiopathic", "left", "ventricular", "tachycardia", ",", "an", "entity", "which", "so", "far", "has", "only", "rarely", "been", "observed", "in", "children", "." ]

[ "umlsterm" ]

ECG is an umlsterm, ventricular tachycardia is an umlsterm, axis is an umlsterm, right is an umlsterm, bundle branch block is an umlsterm, echocardiogram is an umlsterm, heart is an umlsterm, verapamil is an umlsterm, tachycardia is an umlsterm, antiarrhythmic agents is an umlsterm, Sinus is an umlsterm, ECG is an umlsterm, findings is an umlsterm, verapamil - sensitive is an umlsterm, ventricular tachycardia is an umlsterm, children is an umlsterm

MonatsschriftKinderheilkunde.91471086.eng.abstr_task1

Sentence: The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children . Instructions: please typing these entity words according to sentence: ECG, ventricular tachycardia, axis, right, bundle branch block, echocardiogram, heart, verapamil, tachycardia, antiarrhythmic agents, Sinus, ECG, findings, verapamil - sensitive, ventricular tachycardia, children Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children .

[ "The", "ECG", "of", "a", "15-year", "-", "old", "boy", "hospitalized", "for", "rhythm", "disturbances", "showed", "a", "sustained", "ventricular", "tachycardia", "(", "beat", "rate", "170", "to", "180/", "min", ")", "with", "left", "axis", "deviation", "and", "complete", "right", "bundle", "branch", "block", ".", "His", "echocardiogram", "showed", "a", "structurally", "normal", "heart", "with", "diminished", "left", "ventricular", "performance", ".", "Intravenous", "application", "of", "verapamil", "led", "to", "prompt", "termination", "of", "the", "tachycardia", ",", "after", "previous", "attempts", "with", "various", "other", "antiarrhythmic", "agents", "had", "failed", ".", "Sinus", "rhythm", "remained", "stable", ".", "ECG", "and", "echocardiographic", "changes", "returned", "to", "normal", ".", "Course", "and", "findings", "are", "characteristic", "of", "verapamil", "-", "sensitive", "idiopathic", "left", "ventricular", "tachycardia", ",", "an", "entity", "which", "so", "far", "has", "only", "rarely", "been", "observed", "in", "children", "." ]

[ "umlsterm" ]

ECG, ventricular tachycardia, axis, right, bundle branch block, echocardiogram, heart, verapamil, tachycardia, antiarrhythmic agents, Sinus, ECG, findings, verapamil - sensitive, ventricular tachycardia, children

MonatsschriftKinderheilkunde.91471086.eng.abstr_task2

Sentence: The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

The ECG of a 15-year-old boy hospitalized for rhythm disturbances showed a sustained ventricular tachycardia ( beat rate 170 to 180/ min ) with left axis deviation and complete right bundle branch block . His echocardiogram showed a structurally normal heart with diminished left ventricular performance . Intravenous application of verapamil led to prompt termination of the tachycardia , after previous attempts with various other antiarrhythmic agents had failed . Sinus rhythm remained stable . ECG and echocardiographic changes returned to normal . Course and findings are characteristic of verapamil-sensitive idiopathic left ventricular tachycardia , an entity which so far has only rarely been observed in children .

[ "The", "ECG", "of", "a", "15-year", "-", "old", "boy", "hospitalized", "for", "rhythm", "disturbances", "showed", "a", "sustained", "ventricular", "tachycardia", "(", "beat", "rate", "170", "to", "180/", "min", ")", "with", "left", "axis", "deviation", "and", "complete", "right", "bundle", "branch", "block", ".", "His", "echocardiogram", "showed", "a", "structurally", "normal", "heart", "with", "diminished", "left", "ventricular", "performance", ".", "Intravenous", "application", "of", "verapamil", "led", "to", "prompt", "termination", "of", "the", "tachycardia", ",", "after", "previous", "attempts", "with", "various", "other", "antiarrhythmic", "agents", "had", "failed", ".", "Sinus", "rhythm", "remained", "stable", ".", "ECG", "and", "echocardiographic", "changes", "returned", "to", "normal", ".", "Course", "and", "findings", "are", "characteristic", "of", "verapamil", "-", "sensitive", "idiopathic", "left", "ventricular", "tachycardia", ",", "an", "entity", "which", "so", "far", "has", "only", "rarely", "been", "observed", "in", "children", "." ]

[ "umlsterm" ]

alendronate is a compound, alkaline phosphatase is a protein, osteocalcin is a protein, CD44 is a protein

DS.d653_task0

Sentence: Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis.

[ "Osteogenic", "differentiation", "was", "enhanced", "after", "treatment", "with", "alendronate", "as", "confirmed", "by", "Alizarin", "Red", "S", "staining", ",", "elevated", "alkaline", "phosphatase", "activity", "and", "osteocalcin", "mRNA", "expression", ",", "a", "greater", "calcium", "peak", "by", "energy", "-", "dispersive", "xray", "spectrophotometry", ",", "and", "by", "immunofluorescence", "staining", "against", "CD44", "by", "flow", "cytometric", "analysis", "." ]

[ "protein", "compound" ]

alendronate is a compound, alkaline phosphatase is a protein, osteocalcin is a protein, CD44 is a protein

DS.d653_task1

Sentence: Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis. Instructions: please typing these entity words according to sentence: alendronate, alkaline phosphatase, osteocalcin, CD44 Options: compound, protein

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis.

[ "Osteogenic", "differentiation", "was", "enhanced", "after", "treatment", "with", "alendronate", "as", "confirmed", "by", "Alizarin", "Red", "S", "staining", ",", "elevated", "alkaline", "phosphatase", "activity", "and", "osteocalcin", "mRNA", "expression", ",", "a", "greater", "calcium", "peak", "by", "energy", "-", "dispersive", "xray", "spectrophotometry", ",", "and", "by", "immunofluorescence", "staining", "against", "CD44", "by", "flow", "cytometric", "analysis", "." ]

[ "protein", "compound" ]

alendronate, alkaline phosphatase, osteocalcin, CD44

DS.d653_task2

Sentence: Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "B-compound", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "I-protein", "O", "O", "B-protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-protein", "O", "O", "O", "O", "O" ]

Osteogenic differentiation was enhanced after treatment with alendronate as confirmed by Alizarin Red S staining, elevated alkaline phosphatase activity and osteocalcin mRNA expression, a greater calcium peak by energy-dispersive xray spectrophotometry, and by immunofluorescence staining against CD44 by flow cytometric analysis.

[ "Osteogenic", "differentiation", "was", "enhanced", "after", "treatment", "with", "alendronate", "as", "confirmed", "by", "Alizarin", "Red", "S", "staining", ",", "elevated", "alkaline", "phosphatase", "activity", "and", "osteocalcin", "mRNA", "expression", ",", "a", "greater", "calcium", "peak", "by", "energy", "-", "dispersive", "xray", "spectrophotometry", ",", "and", "by", "immunofluorescence", "staining", "against", "CD44", "by", "flow", "cytometric", "analysis", "." ]

[ "protein", "compound" ]

contrast is an umlsterm, myopia is an umlsterm, technique is an umlsterm, astigmatism is an umlsterm, techniques is an umlsterm, standard is an umlsterm

DerOpthalmologe.80950677.eng.abstr_task0

Sentence: Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) .

[ "Background", ":", "In", "contrast", "to", "the", "correction", "of", "simple", "myopia", "there", "is", "no", "widely", "accepted", "technique", "for", "the", "correction", "of", "myopic", "astigmatism", ".", "Currently", "two", "techniques", "are", "available", ":", "the", "photoastigmatic", "refractive", "keratectomy", "(", "PARK", ")", "and", "the", "combination", "of", "arcuate", "keratotomies", "with", "standard", "PRK", "(", "PRK", "-", "T", ")", "." ]

[ "umlsterm" ]

contrast is an umlsterm, myopia is an umlsterm, technique is an umlsterm, astigmatism is an umlsterm, techniques is an umlsterm, standard is an umlsterm

DerOpthalmologe.80950677.eng.abstr_task1

Sentence: Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) . Instructions: please typing these entity words according to sentence: contrast, myopia, technique, astigmatism, techniques, standard Options: umlsterm

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) .

[ "Background", ":", "In", "contrast", "to", "the", "correction", "of", "simple", "myopia", "there", "is", "no", "widely", "accepted", "technique", "for", "the", "correction", "of", "myopic", "astigmatism", ".", "Currently", "two", "techniques", "are", "available", ":", "the", "photoastigmatic", "refractive", "keratectomy", "(", "PARK", ")", "and", "the", "combination", "of", "arcuate", "keratotomies", "with", "standard", "PRK", "(", "PRK", "-", "T", ")", "." ]

[ "umlsterm" ]

contrast, myopia, technique, astigmatism, techniques, standard

DerOpthalmologe.80950677.eng.abstr_task2

Sentence: Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O" ]

Background : In contrast to the correction of simple myopia there is no widely accepted technique for the correction of myopic astigmatism . Currently two techniques are available : the photoastigmatic refractive keratectomy ( PARK ) and the combination of arcuate keratotomies with standard PRK ( PRK-T ) .

[ "Background", ":", "In", "contrast", "to", "the", "correction", "of", "simple", "myopia", "there", "is", "no", "widely", "accepted", "technique", "for", "the", "correction", "of", "myopic", "astigmatism", ".", "Currently", "two", "techniques", "are", "available", ":", "the", "photoastigmatic", "refractive", "keratectomy", "(", "PARK", ")", "and", "the", "combination", "of", "arcuate", "keratotomies", "with", "standard", "PRK", "(", "PRK", "-", "T", ")", "." ]

[ "umlsterm" ]

head is an umlsterm, pancreas is an umlsterm, procedure is an umlsterm, patients is an umlsterm, pain is an umlsterm, inflammation is an umlsterm, head is an umlsterm, pancreas is an umlsterm, bile duct obstruction is an umlsterm, pancreatic duct is an umlsterm, retropancreatic is an umlsterm, vessels is an umlsterm, patients is an umlsterm, operation is an umlsterm, operation is an umlsterm, need is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, patient is an umlsterm, relaparotomy is an umlsterm, bowel obstruction is an umlsterm, hospital is an umlsterm, patients is an umlsterm, diabetes is an umlsterm, head is an umlsterm, pancreas is an umlsterm, surgery is an umlsterm, procedure is an umlsterm, complications is an umlsterm, pancreatitis is an umlsterm, pain is an umlsterm, patients is an umlsterm

DerChirurg.70680364.eng.abstr_task0

Sentence: Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients .

[ "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "was", "developed", "25", "years", "ago", "by", "Beger", ".", "This", "procedure", "is", "indicated", "in", "patients", "suffering", "from", "chronic", "pain", "in", "combination", "with", "inflammation", "of", "the", "head", "of", "the", "pancreas", ",", "common", "bile", "duct", "obstruction", ",", "pancreatic", "duct", "obstruction", "and", "/", "or", "obstruction", "of", "the", "retropancreatic", "vessels", ".", "At", "the", "Inselspital", "in", "Berne", ",", "74", "patients", "underwent", "this", "operation", "between", "1993", "and", "1996", ".", "The", "median", "length", "of", "the", "operation", "was", "380", "min", ",", "with", "the", "need", "for", "transfusion", "in", "a", "median", "of", "0", "units", "(", "0", "-", "6", ")", ".", "There", "was", "no", "postoperative", "mortality", ".", "Total", "postoperative", "morbidity", "was", "13", "%", ".", "One", "patient", "needed", "relaparotomy", "on", "day", "17", "for", "small", "bowel", "obstruction", ".", "Median", "length", "of", "hospital", "stay", "was", "11", "days", ".", "Postoperatively", ",", "two", "patients", "developed", "diabetes", ".", "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "represents", "an", "organ", "-", "preserving", "principle", "of", "surgery", ".", "This", "procedure", "treats", "the", "complications", "of", "chronic", "pancreatitis", "and", "provides", "long", "-", "term", "pain", "relief", "in", "more", "than", "80", "%", "of", "patients", "." ]

[ "umlsterm" ]

head is an umlsterm, pancreas is an umlsterm, procedure is an umlsterm, patients is an umlsterm, pain is an umlsterm, inflammation is an umlsterm, head is an umlsterm, pancreas is an umlsterm, bile duct obstruction is an umlsterm, pancreatic duct is an umlsterm, retropancreatic is an umlsterm, vessels is an umlsterm, patients is an umlsterm, operation is an umlsterm, operation is an umlsterm, need is an umlsterm, postoperative is an umlsterm, mortality is an umlsterm, postoperative is an umlsterm, morbidity is an umlsterm, patient is an umlsterm, relaparotomy is an umlsterm, bowel obstruction is an umlsterm, hospital is an umlsterm, patients is an umlsterm, diabetes is an umlsterm, head is an umlsterm, pancreas is an umlsterm, surgery is an umlsterm, procedure is an umlsterm, complications is an umlsterm, pancreatitis is an umlsterm, pain is an umlsterm, patients is an umlsterm

DerChirurg.70680364.eng.abstr_task1

Sentence: Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients . Instructions: please typing these entity words according to sentence: head, pancreas, procedure, patients, pain, inflammation, head, pancreas, bile duct obstruction, pancreatic duct, retropancreatic, vessels, patients, operation, operation, need, postoperative, mortality, postoperative, morbidity, patient, relaparotomy, bowel obstruction, hospital, patients, diabetes, head, pancreas, surgery, procedure, complications, pancreatitis, pain, patients Options: umlsterm

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients .

[ "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "was", "developed", "25", "years", "ago", "by", "Beger", ".", "This", "procedure", "is", "indicated", "in", "patients", "suffering", "from", "chronic", "pain", "in", "combination", "with", "inflammation", "of", "the", "head", "of", "the", "pancreas", ",", "common", "bile", "duct", "obstruction", ",", "pancreatic", "duct", "obstruction", "and", "/", "or", "obstruction", "of", "the", "retropancreatic", "vessels", ".", "At", "the", "Inselspital", "in", "Berne", ",", "74", "patients", "underwent", "this", "operation", "between", "1993", "and", "1996", ".", "The", "median", "length", "of", "the", "operation", "was", "380", "min", ",", "with", "the", "need", "for", "transfusion", "in", "a", "median", "of", "0", "units", "(", "0", "-", "6", ")", ".", "There", "was", "no", "postoperative", "mortality", ".", "Total", "postoperative", "morbidity", "was", "13", "%", ".", "One", "patient", "needed", "relaparotomy", "on", "day", "17", "for", "small", "bowel", "obstruction", ".", "Median", "length", "of", "hospital", "stay", "was", "11", "days", ".", "Postoperatively", ",", "two", "patients", "developed", "diabetes", ".", "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "represents", "an", "organ", "-", "preserving", "principle", "of", "surgery", ".", "This", "procedure", "treats", "the", "complications", "of", "chronic", "pancreatitis", "and", "provides", "long", "-", "term", "pain", "relief", "in", "more", "than", "80", "%", "of", "patients", "." ]

[ "umlsterm" ]

head, pancreas, procedure, patients, pain, inflammation, head, pancreas, bile duct obstruction, pancreatic duct, retropancreatic, vessels, patients, operation, operation, need, postoperative, mortality, postoperative, morbidity, patient, relaparotomy, bowel obstruction, hospital, patients, diabetes, head, pancreas, surgery, procedure, complications, pancreatitis, pain, patients

DerChirurg.70680364.eng.abstr_task2

Sentence: Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O" ]

Duodenum-preserving resection of the head of the pancreas was developed 25 years ago by Beger . This procedure is indicated in patients suffering from chronic pain in combination with inflammation of the head of the pancreas , common bile duct obstruction , pancreatic duct obstruction and/or obstruction of the retropancreatic vessels . At the Inselspital in Berne , 74 patients underwent this operation between 1993 and 1996. The median length of the operation was 380 min , with the need for transfusion in a median of 0 units ( 0-6 ) . There was no postoperative mortality . Total postoperative morbidity was 13 % . One patient needed relaparotomy on day 17 for small bowel obstruction . Median length of hospital stay was 11 days . Postoperatively , two patients developed diabetes . Duodenum-preserving resection of the head of the pancreas represents an organ-preserving principle of surgery . This procedure treats the complications of chronic pancreatitis and provides long-term pain relief in more than 80 % of patients .

[ "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "was", "developed", "25", "years", "ago", "by", "Beger", ".", "This", "procedure", "is", "indicated", "in", "patients", "suffering", "from", "chronic", "pain", "in", "combination", "with", "inflammation", "of", "the", "head", "of", "the", "pancreas", ",", "common", "bile", "duct", "obstruction", ",", "pancreatic", "duct", "obstruction", "and", "/", "or", "obstruction", "of", "the", "retropancreatic", "vessels", ".", "At", "the", "Inselspital", "in", "Berne", ",", "74", "patients", "underwent", "this", "operation", "between", "1993", "and", "1996", ".", "The", "median", "length", "of", "the", "operation", "was", "380", "min", ",", "with", "the", "need", "for", "transfusion", "in", "a", "median", "of", "0", "units", "(", "0", "-", "6", ")", ".", "There", "was", "no", "postoperative", "mortality", ".", "Total", "postoperative", "morbidity", "was", "13", "%", ".", "One", "patient", "needed", "relaparotomy", "on", "day", "17", "for", "small", "bowel", "obstruction", ".", "Median", "length", "of", "hospital", "stay", "was", "11", "days", ".", "Postoperatively", ",", "two", "patients", "developed", "diabetes", ".", "Duodenum", "-", "preserving", "resection", "of", "the", "head", "of", "the", "pancreas", "represents", "an", "organ", "-", "preserving", "principle", "of", "surgery", ".", "This", "procedure", "treats", "the", "complications", "of", "chronic", "pancreatitis", "and", "provides", "long", "-", "term", "pain", "relief", "in", "more", "than", "80", "%", "of", "patients", "." ]

[ "umlsterm" ]

prostatectomy is an umlsterm, postoperative is an umlsterm, disorder is an umlsterm, technique is an umlsterm, erections is an umlsterm, sexual intercourse is an umlsterm, nerves is an umlsterm, injuries is an umlsterm, erectile dysfunction is an umlsterm, Alprostadil is an umlsterm, self - injection is an umlsterm, drugs is an umlsterm, administration is an umlsterm, alprostadil is an umlsterm, drug is an umlsterm, Sildenafil is an umlsterm, patients is an umlsterm, erections is an umlsterm, prostatectomy is an umlsterm, pressure is an umlsterm, devices is an umlsterm, penile prosthesis is an umlsterm, N. suralis is an umlsterm, transplantation is an umlsterm, prostatectomy is an umlsterm, erection is an umlsterm, future is an umlsterm

Reproduktionsmedizin.00160279.eng.abstr_task0

Sentence: Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future .

[ "Erectile", "failure", "after", "radical", "prostatectomy", "is", "a", "common", "postoperative", "disorder", ".", "However", ",", "nerve", "-", "sparing", "technique", "provides", "in", "about", "50", "-", "60", "%", "erections", "sufficient", "for", "sexual", "intercourse", ".", "Damage", "to", "the", "cavernous", "nerves", "or", "vascular", "injuries", "are", "responsible", "for", "erectile", "dysfunction", ".", "Alprostadil", "is", "most", "commonly", "used", "for", "self", "-", "injection", "monotherapy", "or", "in", "combination", "with", "other", "vasoactive", "drugs", ".", "Intraurethral", "administration", "of", "alprostadil", "failed", "to", "reproduce", "promising", "early", "results", ".", "The", "oral", "drug", "Sildenafil", "showed", "to", "be", "effective", "in", "patients", "with", "partial", "erections", ",", "however", ",", "it", "failed", "to", "work", "after", "non", "nerve", "-", "sparing", "radical", "prostatectomy", ".", "Negative", "pressure", "devices", "and", "penile", "prosthesis", "can", "be", "considered", "as", "alternative", "therpeutic", "options", ".", "Autologous", "N.", "suralis", "transplantation", "during", "radical", "prostatectomy", "might", "further", "improve", "erection", "rates", "in", "the", "near", "future", "." ]

[ "umlsterm" ]

prostatectomy is an umlsterm, postoperative is an umlsterm, disorder is an umlsterm, technique is an umlsterm, erections is an umlsterm, sexual intercourse is an umlsterm, nerves is an umlsterm, injuries is an umlsterm, erectile dysfunction is an umlsterm, Alprostadil is an umlsterm, self - injection is an umlsterm, drugs is an umlsterm, administration is an umlsterm, alprostadil is an umlsterm, drug is an umlsterm, Sildenafil is an umlsterm, patients is an umlsterm, erections is an umlsterm, prostatectomy is an umlsterm, pressure is an umlsterm, devices is an umlsterm, penile prosthesis is an umlsterm, N. suralis is an umlsterm, transplantation is an umlsterm, prostatectomy is an umlsterm, erection is an umlsterm, future is an umlsterm

Reproduktionsmedizin.00160279.eng.abstr_task1

Sentence: Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future . Instructions: please typing these entity words according to sentence: prostatectomy, postoperative, disorder, technique, erections, sexual intercourse, nerves, injuries, erectile dysfunction, Alprostadil, self - injection, drugs, administration, alprostadil, drug, Sildenafil, patients, erections, prostatectomy, pressure, devices, penile prosthesis, N. suralis, transplantation, prostatectomy, erection, future Options: umlsterm

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future .

[ "Erectile", "failure", "after", "radical", "prostatectomy", "is", "a", "common", "postoperative", "disorder", ".", "However", ",", "nerve", "-", "sparing", "technique", "provides", "in", "about", "50", "-", "60", "%", "erections", "sufficient", "for", "sexual", "intercourse", ".", "Damage", "to", "the", "cavernous", "nerves", "or", "vascular", "injuries", "are", "responsible", "for", "erectile", "dysfunction", ".", "Alprostadil", "is", "most", "commonly", "used", "for", "self", "-", "injection", "monotherapy", "or", "in", "combination", "with", "other", "vasoactive", "drugs", ".", "Intraurethral", "administration", "of", "alprostadil", "failed", "to", "reproduce", "promising", "early", "results", ".", "The", "oral", "drug", "Sildenafil", "showed", "to", "be", "effective", "in", "patients", "with", "partial", "erections", ",", "however", ",", "it", "failed", "to", "work", "after", "non", "nerve", "-", "sparing", "radical", "prostatectomy", ".", "Negative", "pressure", "devices", "and", "penile", "prosthesis", "can", "be", "considered", "as", "alternative", "therpeutic", "options", ".", "Autologous", "N.", "suralis", "transplantation", "during", "radical", "prostatectomy", "might", "further", "improve", "erection", "rates", "in", "the", "near", "future", "." ]

[ "umlsterm" ]

prostatectomy, postoperative, disorder, technique, erections, sexual intercourse, nerves, injuries, erectile dysfunction, Alprostadil, self - injection, drugs, administration, alprostadil, drug, Sildenafil, patients, erections, prostatectomy, pressure, devices, penile prosthesis, N. suralis, transplantation, prostatectomy, erection, future

Reproduktionsmedizin.00160279.eng.abstr_task2

Sentence: Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future . Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "B-umlsterm", "O", "O", "B-umlsterm", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "B-umlsterm", "O" ]

Erectile failure after radical prostatectomy is a common postoperative disorder . However , nerve-sparing technique provides in about 50-60 % erections sufficient for sexual intercourse . Damage to the cavernous nerves or vascular injuries are responsible for erectile dysfunction . Alprostadil is most commonly used for self-injection monotherapy or in combination with other vasoactive drugs . Intraurethral administration of alprostadil failed to reproduce promising early results . The oral drug Sildenafil showed to be effective in patients with partial erections , however , it failed to work after non nerve-sparing radical prostatectomy . Negative pressure devices and penile prosthesis can be considered as alternative therpeutic options . Autologous N. suralis transplantation during radical prostatectomy might further improve erection rates in the near future .

[ "Erectile", "failure", "after", "radical", "prostatectomy", "is", "a", "common", "postoperative", "disorder", ".", "However", ",", "nerve", "-", "sparing", "technique", "provides", "in", "about", "50", "-", "60", "%", "erections", "sufficient", "for", "sexual", "intercourse", ".", "Damage", "to", "the", "cavernous", "nerves", "or", "vascular", "injuries", "are", "responsible", "for", "erectile", "dysfunction", ".", "Alprostadil", "is", "most", "commonly", "used", "for", "self", "-", "injection", "monotherapy", "or", "in", "combination", "with", "other", "vasoactive", "drugs", ".", "Intraurethral", "administration", "of", "alprostadil", "failed", "to", "reproduce", "promising", "early", "results", ".", "The", "oral", "drug", "Sildenafil", "showed", "to", "be", "effective", "in", "patients", "with", "partial", "erections", ",", "however", ",", "it", "failed", "to", "work", "after", "non", "nerve", "-", "sparing", "radical", "prostatectomy", ".", "Negative", "pressure", "devices", "and", "penile", "prosthesis", "can", "be", "considered", "as", "alternative", "therpeutic", "options", ".", "Autologous", "N.", "suralis", "transplantation", "during", "radical", "prostatectomy", "might", "further", "improve", "erection", "rates", "in", "the", "near", "future", "." ]

[ "umlsterm" ]

tyrosinase is a Protein, tyrosine hydroxylase is a Protein, tyrosinase is a Protein, Tyrosine hydroxylase is a Protein

46_task0

Sentence: Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule.

[ "Hydroxylating", "activity", "of", "frog", "epidermis", "tyrosinase", ".", "\n", "Trypsin", "activated", "in", "a", "similar", "way", "both", "the", "tyrosine", "hydroxylase", "and", "the", "dopa", "-", "oxidasa", "activities", "of", "frog", "epidermis", "tyrosinase", ".", "Several", "electron", "donors", "reduced", "or", "eliminated", "the", "lag", "period", "for", "the", "hydroxylating", "enzyme", ".", "4", "x", "10(-5", ")", "M", "dopa", "was", "particularly", "effective", ",", "but", "without", "affecting", "the", "stationary", "activity", "after", "lag", "period", ".", "Tyrosine", "hydroxylase", "had", "KM", "=", "2.6", "X", "10(-3", ")", "M", "for", "tyrosine", "and", "2", "x", "10(-3", ")", "M", "dopa", "was", "a", "competitive", "inhibitor", "with", "Ki", "=", "5", "x", "10(-4", ")", "M.", "The", "enzyme", "was", "inactivated", "during", "its", "actuation", ".", "Data", "on", "thermal", "denaturation", "were", "similar", "to", "other", "obtained", "from", "dopa", "oxidase", ".", "Our", "results", "tend", "to", "confirm", "our", "previous", "hypothesis", "that", "the", "activatory", "process", "of", "the", "enzyme", "is", "accompanied", "by", "a", "spatial", "unfolding", "of", "the", "enzyme", "molecule", ".", "\n" ]

[ "Protein" ]

tyrosinase is a Protein, tyrosine hydroxylase is a Protein, tyrosinase is a Protein, Tyrosine hydroxylase is a Protein

46_task1

Sentence: Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule. Instructions: please typing these entity words according to sentence: tyrosinase, tyrosine hydroxylase, tyrosinase, Tyrosine hydroxylase Options: Protein

[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule.

[ "Hydroxylating", "activity", "of", "frog", "epidermis", "tyrosinase", ".", "\n", "Trypsin", "activated", "in", "a", "similar", "way", "both", "the", "tyrosine", "hydroxylase", "and", "the", "dopa", "-", "oxidasa", "activities", "of", "frog", "epidermis", "tyrosinase", ".", "Several", "electron", "donors", "reduced", "or", "eliminated", "the", "lag", "period", "for", "the", "hydroxylating", "enzyme", ".", "4", "x", "10(-5", ")", "M", "dopa", "was", "particularly", "effective", ",", "but", "without", "affecting", "the", "stationary", "activity", "after", "lag", "period", ".", "Tyrosine", "hydroxylase", "had", "KM", "=", "2.6", "X", "10(-3", ")", "M", "for", "tyrosine", "and", "2", "x", "10(-3", ")", "M", "dopa", "was", "a", "competitive", "inhibitor", "with", "Ki", "=", "5", "x", "10(-4", ")", "M.", "The", "enzyme", "was", "inactivated", "during", "its", "actuation", ".", "Data", "on", "thermal", "denaturation", "were", "similar", "to", "other", "obtained", "from", "dopa", "oxidase", ".", "Our", "results", "tend", "to", "confirm", "our", "previous", "hypothesis", "that", "the", "activatory", "process", "of", "the", "enzyme", "is", "accompanied", "by", "a", "spatial", "unfolding", "of", "the", "enzyme", "molecule", ".", "\n" ]

[ "Protein" ]

tyrosinase, tyrosine hydroxylase, tyrosinase, Tyrosine hydroxylase

46_task2

Sentence: Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "I-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Hydroxylating activity of frog epidermis tyrosinase. Trypsin activated in a similar way both the tyrosine hydroxylase and the dopa-oxidasa activities of frog epidermis tyrosinase. Several electron donors reduced or eliminated the lag period for the hydroxylating enzyme. 4 x 10(-5) M dopa was particularly effective, but without affecting the stationary activity after lag period. Tyrosine hydroxylase had KM = 2.6 X 10(-3) M for tyrosine and 2 x 10(-3) M dopa was a competitive inhibitor with Ki = 5 x 10(-4) M. The enzyme was inactivated during its actuation. Data on thermal denaturation were similar to other obtained from dopa oxidase. Our results tend to confirm our previous hypothesis that the activatory process of the enzyme is accompanied by a spatial unfolding of the enzyme molecule.

[ "Hydroxylating", "activity", "of", "frog", "epidermis", "tyrosinase", ".", "\n", "Trypsin", "activated", "in", "a", "similar", "way", "both", "the", "tyrosine", "hydroxylase", "and", "the", "dopa", "-", "oxidasa", "activities", "of", "frog", "epidermis", "tyrosinase", ".", "Several", "electron", "donors", "reduced", "or", "eliminated", "the", "lag", "period", "for", "the", "hydroxylating", "enzyme", ".", "4", "x", "10(-5", ")", "M", "dopa", "was", "particularly", "effective", ",", "but", "without", "affecting", "the", "stationary", "activity", "after", "lag", "period", ".", "Tyrosine", "hydroxylase", "had", "KM", "=", "2.6", "X", "10(-3", ")", "M", "for", "tyrosine", "and", "2", "x", "10(-3", ")", "M", "dopa", "was", "a", "competitive", "inhibitor", "with", "Ki", "=", "5", "x", "10(-4", ")", "M.", "The", "enzyme", "was", "inactivated", "during", "its", "actuation", ".", "Data", "on", "thermal", "denaturation", "were", "similar", "to", "other", "obtained", "from", "dopa", "oxidase", ".", "Our", "results", "tend", "to", "confirm", "our", "previous", "hypothesis", "that", "the", "activatory", "process", "of", "the", "enzyme", "is", "accompanied", "by", "a", "spatial", "unfolding", "of", "the", "enzyme", "molecule", ".", "\n" ]

[ "Protein" ]

ubiquitin is a Protein, ubiquitin is a Protein

313_task0

Sentence: Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination.

[ "Biochemical", "and", "biophysical", "analyses", "of", "Ras", "modification", "by", "ubiquitin", ".", "\n", "Ras", "proteins", "are", "small", "GTPases", "that", "play", "key", "roles", "in", "the", "regulation", "of", "several", "cellular", "processes", "such", "as", "growth", ",", "differentiation", ",", "and", "transformation", ".", "Although", "Ras", "signaling", "was", "thought", "to", "occur", "uniformly", "on", "the", "inner", "leaflet", "of", "the", "plasma", "membrane", ",", "a", "growing", "body", "of", "evidence", "indicates", "that", "Ras", "activation", "happens", "dynamically", "within", "defined", "plasma", "membrane", "microdomains", "and", "at", "other", "specific", "intracellular", "compartments", ",", "thus", "ensuring", "the", "generation", "of", "distinct", "signal", "outputs", ".", "Yet", "the", "mechanisms", "that", "control", "the", "spatiotemporal", "segregation", "of", "Ras", "proteins", "remain", "poorly", "characterized", ".", "We", "have", "recently", "shown", "that", "the", "differential", "modification", "of", "Ras", "proteins", "by", "ubiquitination", "is", "a", "crucial", "factor", "that", "controls", "Ras", "intracellular", "trafficking", "and", "signaling", "potential", ".", "To", "better", "understand", "the", "process", "of", "Ras", "ubiquitination", ",", "it", "is", "important", "to", "establish", "assays", "that", "not", "only", "provide", "information", "about", "the", "nature", "of", "the", "ubiquitin", "modification", "involved", ",", "but", "also", "enable", "the", "monitoring", "of", "the", "dynamics", "of", "this", "process", ".", "In", "this", "chapter", ",", "we", "will", "describe", "biochemical", "and", "biophysical", "methodologies", ",", "namely", "immunoprecipitation", ",", "nickel", "-", "chelate", "affinity", "chromatography", ",", "and", "bioluminescence", "resonance", "energy", "transfer", "(", "BRET", ")", ",", "for", "monitoring", "the", "ubiquitination", "of", "Ras", "proteins", ".", "Although", "the", "description", "focuses", "on", "Ras", ",", "the", "assays", "described", "can", "in", "principle", "be", "applied", "to", "the", "study", "of", "a", "range", "of", "proteins", "of", "interest", "that", "may", "be", "subject", "to", "ubiquitination", ",", "and", "the", "use", "of", "the", "different", "methods", "in", "parallel", "should", "provide", "new", "insights", "into", "the", "nature", "and", "dynamics", "of", "protein", "ubiquitination", ".", "\n" ]

[ "Protein" ]

ubiquitin is a Protein, ubiquitin is a Protein

313_task1

Sentence: Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination. Instructions: please typing these entity words according to sentence: ubiquitin, ubiquitin Options: Protein

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination.

[ "Biochemical", "and", "biophysical", "analyses", "of", "Ras", "modification", "by", "ubiquitin", ".", "\n", "Ras", "proteins", "are", "small", "GTPases", "that", "play", "key", "roles", "in", "the", "regulation", "of", "several", "cellular", "processes", "such", "as", "growth", ",", "differentiation", ",", "and", "transformation", ".", "Although", "Ras", "signaling", "was", "thought", "to", "occur", "uniformly", "on", "the", "inner", "leaflet", "of", "the", "plasma", "membrane", ",", "a", "growing", "body", "of", "evidence", "indicates", "that", "Ras", "activation", "happens", "dynamically", "within", "defined", "plasma", "membrane", "microdomains", "and", "at", "other", "specific", "intracellular", "compartments", ",", "thus", "ensuring", "the", "generation", "of", "distinct", "signal", "outputs", ".", "Yet", "the", "mechanisms", "that", "control", "the", "spatiotemporal", "segregation", "of", "Ras", "proteins", "remain", "poorly", "characterized", ".", "We", "have", "recently", "shown", "that", "the", "differential", "modification", "of", "Ras", "proteins", "by", "ubiquitination", "is", "a", "crucial", "factor", "that", "controls", "Ras", "intracellular", "trafficking", "and", "signaling", "potential", ".", "To", "better", "understand", "the", "process", "of", "Ras", "ubiquitination", ",", "it", "is", "important", "to", "establish", "assays", "that", "not", "only", "provide", "information", "about", "the", "nature", "of", "the", "ubiquitin", "modification", "involved", ",", "but", "also", "enable", "the", "monitoring", "of", "the", "dynamics", "of", "this", "process", ".", "In", "this", "chapter", ",", "we", "will", "describe", "biochemical", "and", "biophysical", "methodologies", ",", "namely", "immunoprecipitation", ",", "nickel", "-", "chelate", "affinity", "chromatography", ",", "and", "bioluminescence", "resonance", "energy", "transfer", "(", "BRET", ")", ",", "for", "monitoring", "the", "ubiquitination", "of", "Ras", "proteins", ".", "Although", "the", "description", "focuses", "on", "Ras", ",", "the", "assays", "described", "can", "in", "principle", "be", "applied", "to", "the", "study", "of", "a", "range", "of", "proteins", "of", "interest", "that", "may", "be", "subject", "to", "ubiquitination", ",", "and", "the", "use", "of", "the", "different", "methods", "in", "parallel", "should", "provide", "new", "insights", "into", "the", "nature", "and", "dynamics", "of", "protein", "ubiquitination", ".", "\n" ]

[ "Protein" ]

ubiquitin, ubiquitin

313_task2

Sentence: Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination. Instructions: please extract entity words from the input sentence

[ "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-Protein", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O" ]

Biochemical and biophysical analyses of Ras modification by ubiquitin. Ras proteins are small GTPases that play key roles in the regulation of several cellular processes such as growth, differentiation, and transformation. Although Ras signaling was thought to occur uniformly on the inner leaflet of the plasma membrane, a growing body of evidence indicates that Ras activation happens dynamically within defined plasma membrane microdomains and at other specific intracellular compartments, thus ensuring the generation of distinct signal outputs. Yet the mechanisms that control the spatiotemporal segregation of Ras proteins remain poorly characterized. We have recently shown that the differential modification of Ras proteins by ubiquitination is a crucial factor that controls Ras intracellular trafficking and signaling potential. To better understand the process of Ras ubiquitination, it is important to establish assays that not only provide information about the nature of the ubiquitin modification involved, but also enable the monitoring of the dynamics of this process. In this chapter, we will describe biochemical and biophysical methodologies, namely immunoprecipitation, nickel-chelate affinity chromatography, and bioluminescence resonance energy transfer (BRET), for monitoring the ubiquitination of Ras proteins. Although the description focuses on Ras, the assays described can in principle be applied to the study of a range of proteins of interest that may be subject to ubiquitination, and the use of the different methods in parallel should provide new insights into the nature and dynamics of protein ubiquitination.

[ "Biochemical", "and", "biophysical", "analyses", "of", "Ras", "modification", "by", "ubiquitin", ".", "\n", "Ras", "proteins", "are", "small", "GTPases", "that", "play", "key", "roles", "in", "the", "regulation", "of", "several", "cellular", "processes", "such", "as", "growth", ",", "differentiation", ",", "and", "transformation", ".", "Although", "Ras", "signaling", "was", "thought", "to", "occur", "uniformly", "on", "the", "inner", "leaflet", "of", "the", "plasma", "membrane", ",", "a", "growing", "body", "of", "evidence", "indicates", "that", "Ras", "activation", "happens", "dynamically", "within", "defined", "plasma", "membrane", "microdomains", "and", "at", "other", "specific", "intracellular", "compartments", ",", "thus", "ensuring", "the", "generation", "of", "distinct", "signal", "outputs", ".", "Yet", "the", "mechanisms", "that", "control", "the", "spatiotemporal", "segregation", "of", "Ras", "proteins", "remain", "poorly", "characterized", ".", "We", "have", "recently", "shown", "that", "the", "differential", "modification", "of", "Ras", "proteins", "by", "ubiquitination", "is", "a", "crucial", "factor", "that", "controls", "Ras", "intracellular", "trafficking", "and", "signaling", "potential", ".", "To", "better", "understand", "the", "process", "of", "Ras", "ubiquitination", ",", "it", "is", "important", "to", "establish", "assays", "that", "not", "only", "provide", "information", "about", "the", "nature", "of", "the", "ubiquitin", "modification", "involved", ",", "but", "also", "enable", "the", "monitoring", "of", "the", "dynamics", "of", "this", "process", ".", "In", "this", "chapter", ",", "we", "will", "describe", "biochemical", "and", "biophysical", "methodologies", ",", "namely", "immunoprecipitation", ",", "nickel", "-", "chelate", "affinity", "chromatography", ",", "and", "bioluminescence", "resonance", "energy", "transfer", "(", "BRET", ")", ",", "for", "monitoring", "the", "ubiquitination", "of", "Ras", "proteins", ".", "Although", "the", "description", "focuses", "on", "Ras", ",", "the", "assays", "described", "can", "in", "principle", "be", "applied", "to", "the", "study", "of", "a", "range", "of", "proteins", "of", "interest", "that", "may", "be", "subject", "to", "ubiquitination", ",", "and", "the", "use", "of", "the", "different", "methods", "in", "parallel", "should", "provide", "new", "insights", "into", "the", "nature", "and", "dynamics", "of", "protein", "ubiquitination", ".", "\n" ]

[ "Protein" ]

interactions is an umlsterm, agonists is an umlsterm, anaesthetics is an umlsterm, analgesics is an umlsterm, local anaesthetics is an umlsterm, pain therapy is an umlsterm, Laboratory is an umlsterm, animal is an umlsterm, research is an umlsterm, drug interactions is an umlsterm, molecular biology is an umlsterm, drug therapies is an umlsterm, local anaesthetic is an umlsterm, agonists is an umlsterm, peripheral nerve is an umlsterm, interaction is an umlsterm, local anaesthetics is an umlsterm, work is an umlsterm, interactions is an umlsterm, agonists is an umlsterm, opioids is an umlsterm, role is an umlsterm, spinal cord is an umlsterm

DerSchmerz.60100014.eng.abstr_task0

Sentence: The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception . Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]

The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception .

[ "The", "interactions", "of", "2-adrenoceptor", "agonists", "with", "anaesthetics", ",", "analgesics", "and", "local", "anaesthetics", "are", "not", "only", "of", "practical", "importance", "in", "many", "areas", "of", "anaesthesia", "and", "pain", "therapy", ",", "but", "also", "of", "significant", "theoretical", "interest", ".", "Laboratory", "investigations", "and", "animal", "research", "allow", "us", "to", "study", "the", "pharmacological", "mechanisms", "of", "these", "drug", "interactions", "by", "using", "the", "tools", "of", "molecular", "biology", ".", "This", "may", "lead", "to", "the", "establishment", "of", "a", "scientific", "basis", "allowing", "the", "definition", "of", "rational", "drug", "therapies", ".", "In", "the", "first", "part", "of", "this", "overview", ",", "recent", "data", "on", "local", "anaesthetic", "effects", "of", "2-adrenoceptor", "agonists", "on", "peripheral", "nerve", "conduction", "and", "their", "interaction", "with", "local", "anaesthetics", "are", "presented", ".", "Some", "important", "experimental", "work", "focusing", "on", "additive", "and", "synergistic", "spinal", "interactions", "of", "2-adrenoceptor", "agonists", "with", "opioids", "and", "some", "other", "agents", "are", "then", "discussed", ".", "Finally", ",", "there", "is", "a", "brief", "reference", "to", "the", "central", "role", "of", "the", "spinal", "cord", "in", "mediating", "and", "controlling", "nociception", "." ]

[ "umlsterm" ]

interactions is an umlsterm, agonists is an umlsterm, anaesthetics is an umlsterm, analgesics is an umlsterm, local anaesthetics is an umlsterm, pain therapy is an umlsterm, Laboratory is an umlsterm, animal is an umlsterm, research is an umlsterm, drug interactions is an umlsterm, molecular biology is an umlsterm, drug therapies is an umlsterm, local anaesthetic is an umlsterm, agonists is an umlsterm, peripheral nerve is an umlsterm, interaction is an umlsterm, local anaesthetics is an umlsterm, work is an umlsterm, interactions is an umlsterm, agonists is an umlsterm, opioids is an umlsterm, role is an umlsterm, spinal cord is an umlsterm

DerSchmerz.60100014.eng.abstr_task1

Sentence: The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception . Instructions: please typing these entity words according to sentence: interactions, agonists, anaesthetics, analgesics, local anaesthetics, pain therapy, Laboratory, animal, research, drug interactions, molecular biology, drug therapies, local anaesthetic, agonists, peripheral nerve, interaction, local anaesthetics, work, interactions, agonists, opioids, role, spinal cord Options: umlsterm

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]

The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception .

[ "The", "interactions", "of", "2-adrenoceptor", "agonists", "with", "anaesthetics", ",", "analgesics", "and", "local", "anaesthetics", "are", "not", "only", "of", "practical", "importance", "in", "many", "areas", "of", "anaesthesia", "and", "pain", "therapy", ",", "but", "also", "of", "significant", "theoretical", "interest", ".", "Laboratory", "investigations", "and", "animal", "research", "allow", "us", "to", "study", "the", "pharmacological", "mechanisms", "of", "these", "drug", "interactions", "by", "using", "the", "tools", "of", "molecular", "biology", ".", "This", "may", "lead", "to", "the", "establishment", "of", "a", "scientific", "basis", "allowing", "the", "definition", "of", "rational", "drug", "therapies", ".", "In", "the", "first", "part", "of", "this", "overview", ",", "recent", "data", "on", "local", "anaesthetic", "effects", "of", "2-adrenoceptor", "agonists", "on", "peripheral", "nerve", "conduction", "and", "their", "interaction", "with", "local", "anaesthetics", "are", "presented", ".", "Some", "important", "experimental", "work", "focusing", "on", "additive", "and", "synergistic", "spinal", "interactions", "of", "2-adrenoceptor", "agonists", "with", "opioids", "and", "some", "other", "agents", "are", "then", "discussed", ".", "Finally", ",", "there", "is", "a", "brief", "reference", "to", "the", "central", "role", "of", "the", "spinal", "cord", "in", "mediating", "and", "controlling", "nociception", "." ]

[ "umlsterm" ]

interactions, agonists, anaesthetics, analgesics, local anaesthetics, pain therapy, Laboratory, animal, research, drug interactions, molecular biology, drug therapies, local anaesthetic, agonists, peripheral nerve, interaction, local anaesthetics, work, interactions, agonists, opioids, role, spinal cord

DerSchmerz.60100014.eng.abstr_task2

Sentence: The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception . Instructions: please extract entity words from the input sentence

[ "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "B-umlsterm", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "O", "B-umlsterm", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "O", "B-umlsterm", "O", "O", "B-umlsterm", "I-umlsterm", "O", "O", "O", "O", "O", "O" ]

The interactions of 2-adrenoceptor agonists with anaesthetics , analgesics and local anaesthetics are not only of practical importance in many areas of anaesthesia and pain therapy , but also of significant theoretical interest . Laboratory investigations and animal research allow us to study the pharmacological mechanisms of these drug interactions by using the tools of molecular biology . This may lead to the establishment of a scientific basis allowing the definition of rational drug therapies . In the first part of this overview , recent data on local anaesthetic effects of 2-adrenoceptor agonists on peripheral nerve conduction and their interaction with local anaesthetics are presented . Some important experimental work focusing on additive and synergistic spinal interactions of 2-adrenoceptor agonists with opioids and some other agents are then discussed . Finally , there is a brief reference to the central role of the spinal cord in mediating and controlling nociception .

[ "The", "interactions", "of", "2-adrenoceptor", "agonists", "with", "anaesthetics", ",", "analgesics", "and", "local", "anaesthetics", "are", "not", "only", "of", "practical", "importance", "in", "many", "areas", "of", "anaesthesia", "and", "pain", "therapy", ",", "but", "also", "of", "significant", "theoretical", "interest", ".", "Laboratory", "investigations", "and", "animal", "research", "allow", "us", "to", "study", "the", "pharmacological", "mechanisms", "of", "these", "drug", "interactions", "by", "using", "the", "tools", "of", "molecular", "biology", ".", "This", "may", "lead", "to", "the", "establishment", "of", "a", "scientific", "basis", "allowing", "the", "definition", "of", "rational", "drug", "therapies", ".", "In", "the", "first", "part", "of", "this", "overview", ",", "recent", "data", "on", "local", "anaesthetic", "effects", "of", "2-adrenoceptor", "agonists", "on", "peripheral", "nerve", "conduction", "and", "their", "interaction", "with", "local", "anaesthetics", "are", "presented", ".", "Some", "important", "experimental", "work", "focusing", "on", "additive", "and", "synergistic", "spinal", "interactions", "of", "2-adrenoceptor", "agonists", "with", "opioids", "and", "some", "other", "agents", "are", "then", "discussed", ".", "Finally", ",", "there", "is", "a", "brief", "reference", "to", "the", "central", "role", "of", "the", "spinal", "cord", "in", "mediating", "and", "controlling", "nociception", "." ]

[ "umlsterm" ]

clozapine is a CHEMICAL, 5-hydroxytryptamine1C is a GENE-N, 5-hydroxytryptamine2 is a GENE-N

1403790_task0

Sentence: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Instructions: please extract entities and their types from the input sentence, all entity types are in options Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]

The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.

[ "The", "discriminative", "stimulus", "effects", "of", "clozapine", "in", "pigeons", ":", "involvement", "of", "5-hydroxytryptamine1C", "and", "5-hydroxytryptamine2", "receptors", "." ]

[ "CHEMICAL", "GENE-N" ]

clozapine is a CHEMICAL, 5-hydroxytryptamine1C is a GENE-N, 5-hydroxytryptamine2 is a GENE-N

1403790_task1

Sentence: The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors. Instructions: please typing these entity words according to sentence: clozapine, 5-hydroxytryptamine1C, 5-hydroxytryptamine2 Options: GENE-N, CHEMICAL

[ "O", "O", "O", "O", "O", "B-CHEMICAL", "O", "O", "O", "O", "O", "B-GENE-N", "O", "B-GENE-N", "O", "O" ]

The discriminative stimulus effects of clozapine in pigeons: involvement of 5-hydroxytryptamine1C and 5-hydroxytryptamine2 receptors.

[ "The", "discriminative", "stimulus", "effects", "of", "clozapine", "in", "pigeons", ":", "involvement", "of", "5-hydroxytryptamine1C", "and", "5-hydroxytryptamine2", "receptors", "." ]

[ "CHEMICAL", "GENE-N" ]